Piperidin-1-YL-n-pyridin-3-YL-2-oxoacetamide derivatives useful for the treatment of MTAP-deficient and / or MTA-accumulating cancers
Piperidin-1-YL-n-pyridin-3-YL-2-oxoacetamide derivatives address the lack of selectivity in PRMT5 inhibitors by binding to MTA in MTAP-deficient cancers, providing targeted therapy for MTAP-deleted tumor cells.
Patent Information
- Application Number
- CA3176912
- Authority / Receiving Office
- CA · CA
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-07-31
- Filing Date
- 2021-07-30
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2041-07-30
AI Technical Summary
Current PRMT5 inhibitors lack selectivity for MTAP-deleted cancer cell lines due to their mechanisms of action, which are either SAM-uncompetitive or SAM-competitive, failing to leverage the accumulation of MTA caused by MTAP-deletion.
Development of Piperidin-1-YL-n-pyridin-3-YL-2-oxoacetamide derivatives that bind in an MTA-uncompetitive, non-competitive, or mixed mode manner to target MTAP-deficient and/or MTA-accumulating cancers, potentially enhancing selectivity.
The proposed compounds demonstrate selective targeting of MTAP-deleted tumor cells by leveraging MTA accumulation, offering a potential therapeutic advantage over existing PRMT5 inhibitors.
Abstract
Description
<DP=1>²DEMANDE OU BREVET VOLUMINEUX²LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND ²PLUS D'UN TOME.²CECI EST LE TOME 1 DE 11²CONTENANT LES PAGES 1 A 279²NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des ²brevets²JUMBO APPLICATIONS / PATENTS²THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE THAN ONE ²VOLUME²THIS IS VOLUME 1 OF 11²CONTAINING PAGES 1 TO 279²NOTE: For additional volumes, please contact the Canadian Patent Office²NOM DU FICHIER / FILE NAME:²NOTE POUR LE TOME / VOLUME NOTE:²<DP=2>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²PIPERIDIN-1 -YL-N-PYRYDI NE-3-YL-2-0X0ACET AM IDE DERIVATIVES USEFUL FOR ²THE TREATMENT OF MTAP-DEFICIENT AND / OR MT A-ACCUMULATING CANCERS²Background of heinvention²100011 Cancer therapeutics can be broadly classified into two categories, ²cytotoxic and ²targeted therapies. While cytotoxic therapies are associated with widespread ²toxicities, ²targeted therapies have the advantage of selectively targeting the tumor cells ²that rely on the ²activity of their substrates. The clinical efficacy of targeted therapies has ²been demonstrated ²with. BCRJABL and EGFR inhibitors for the treatment of CML and non-small cell ²lung ²cancer, respectively. The success of these programs has furthered development ²of other ²therapies that specifically target amplified or mutation-activated oncogenes. ²The greater ²challenge is to develop selective therapies that target those tumors with loss-²of-function ²mutations or deletion of tumor suppressor genes, the loss of which obviate ²traditional ²strategies for molecular targeted therapeutics.²Efforts to characterize the cancer genome, led by groups like the Cancer ²Genome Atlas ²(TCGA), have made tremendous strides in elucidating the size and frequency of ²the deletion ²events that promote tumor growth by causing the loss of tumor suppressor ²genes. However, ²these events are often regional and cause the co-deletion of genes proximal to ²their intended ²targets. Though these passenger events are not known to cause a fitness ²advantage, they may ²cause collateral vulnerabilities that can be therapeutically leveraged. One ²example is the ²collateral vulnerability to PRMT5 inhibition conferred by loss of ²methylthioadenosine ²phosphorylase (MTAP), which is frequently co-deleted with the well-described ²tumor ²suppressor gene, CDKN2A (Kruykov et al., 2016; Madan et al., 2016 and Markarov ²et at., ²2016).²100021 Loss of CDKN2A occurs in ¨10-15% of all human cancers and with ²frequency in ²histologies such as malignant peripheral nerve sheath tumors, glioblastoma, ²mesothelioma, ²bladder urothelial carcinoma, esophageal squamous cell carcinoma, pancreatic ²adenocarcinoma, melanoma, non-small cell lung cancer, head and neck cancer and ²²cholangiosarcoma (Gao et al. Sci. Signal. 2013; Cerami et al. Cancer Discov. ²2012; and ²kkujon et al. Cell Reports 2016). Because of its proximity to CDKN2A on ²chromosome ²9p21, M14P is frequently included in the deletion. MTAP is a critical enzyme ²in the ²methionine salvage pathway, a six-step process that recycles methionine from ²the product of ²polyamine synthesis, methylthioadenosine (MTA). Loss of MTAP causes the ²accumulation ²of its substrate, MTA, which has been demonstrated by multiple groups to ²function as a²1²<DP=3>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²SAM-competitive PRMT5 inhibitor (Knoikov et al, 2016; Marjon et al, 2016 and²Markarov et al., 2016).²10003j PRMT5 is a type 11 arginine methyltransferase that regulates essential ²cellular ²functions, including the regulation of cell cycle progression, apoptosis and ²the DNA-damage ²response, by symmetrically dimethylating proteins involved in transcription ²and signaling ²(Koh, Bezzi and Guccione Curr Mod Bio Rep 2015 and Wu et al Nat Rev Drug ²Discovery ²2021). However, data from genome-wide genetic perturbation screens using shRNA ²has ²revealed a selective requirement for PRMT5 activity in MTAP-deleted cancer ²cell lines ²(Kruykov et al., 2016; Marjon et al., 2016 and Markarov et al., 2016). The ²accumulation of ²MTA caused by MTAP-deletion in these cell lines partially inhibits PRMT5, ²rendering those ²cells selectively sensitive to additional PRMT5²100041 PRMT5 inhibitors have been developed, yet they do not demonstrate ²selectivity for ²MTAP-deleted cancer cell lines. This lack of selectivity can be explained by ²the mechanisms ²of action of the inhibitors, as they are either SAM-uncompetitive or SAM-²competitive ²inhibitors and therefore, MTAP-agnostic (Katy kov et al., 2016; Marjon et al., ²2016 and ²Markarov et al., 2016) However, if a PRMT5 inhibitor were developed that ²leverages the ²accumulation of MTA by binding in an MTA-uncompetitive, non-competitive or ²mixed mode ²manner or in a MTA-cooperative binding manner, it could demonstrate ²selectivity for ²MTAP-deleted tumor cells.²Summary of the Invention²100051 in one aspect of the invention, provided is a compound of Formula (1) ²or a²pharmaceutically acceptable salt thereof;²wherein:²R2 R7²rõ1.1²H (Ram²R4 0 R6 Formula (1),²each R.' is independently selected from H, --D, halo, ---CN, ---Ct---C6 alkyl, ² heteroalkyl,²¨C1¨C6 haloakl, ¨C3¨C9 cycloalkyl, 3-10 membered heterocyclyl, ²heterocyclylalkyl,²heterofflylalkyl; arylalkyl, cycloalkylalkyl, ¨OR, 2²¨N(tal)s,²C(=0)Ral, ¨C(=0)0Ral, ¨²NRalC(=0)Ral, ---NRalC(=0)0Ral, ---C(=0)N(Ra1)2, ---0C(=0)N(Ral)2,-S(=0)Ral, --²-5(=0)2Ral,²¨SRal, ¨5(...0)(:...²NRa 1 r a 1,²K NRalS(...0)2Ral and ¨5(...0)2N(Ral)2.;²2²<DP=4>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²each Rs' is independently selected from halo, -CN, -CI-Co alkyl, -C1-C6 ²heteroalkyl, -CI-²C6 haloakl, haloalkoxy, -CS-C9 cycloalkyl, 3-10 membered heterocyclyl,²heterocyclylalkyl, heteroarylalkyl, arylak,r1, cycloalkylalkyl, --N(Ra2)2,--²-c())Ra2, ---²c(:=o)oRa2,-NRa2c(=o)Ra2,-NRa2c(=o)oRa2,-c(:=o)N(Ra2)2, --c(::.o)N(ORa2)(Ra2), ²- ²og=o)N(Ra2)2,-s(=o)Ra2, -s(=o)2Ra2,-siv2, -s(=o)(=NRa2)Ra2, -NRa2S(=0)2Ra2 and ²- ²S(=0)2N(Ra2)2;²each R3 is independently selected from H, ---D, halo, -CN, --CI-Co alkyl, -CI-²Co heteroalkyl, ²-CI-Co haloalkyl, -CS-C9 cycloalkyl, 3-10 membered heterocyclyl, ²heterocyclylalkyl, ²heteroarylalkyl, arylakl, cycloalkylalkyl, -0Ra3, -N(R3)2, -C(=0)e, -²C(=0)0Ra3, - ²NRat(=0)Ra3, -NRat(=0)0Ra3, -C(4))N(Ra3)2, -0C(=0)N(Ra3)2,-S(=0)Ra3, --²S(=0)2Ra3,²-SRa3, -S(:=0)(=NR83)Ra3, -NRa3S(:=0)2Ra3 and -S(=0)2N(Ra3)2;²each R4 is independently selected from H, -D, halo, -CN, -Ci-Co alkyl, -CI-Co ²heteroalkyl,²-CI-Co haloalkyl, -Cs-C9 cycloalkyl, 3-10 membered heterocyclyl, ²heterocyclylalkyl, ²heteroarylalkyl, arylalkyl, cycloalkylalkyl, --0Ra4, -N(R84)2, -C(=0)Ra4, -²C(=0)0Ra4, - ²NRa4C(=0)Ra4, -NR24C(=0)0Ra4, -C(=0)N(Ra4)2, -0C(=0)N(Ra4)2, -S(=0)Ra4, - ²S(=0)2Ra4, -SRa4, -S(=0)(=NRa4)Ra4, -NRa4S(=0)21V4 and -S(=20)2N(Ra4)2; ²each R6 is independently absent or selected from H, -D, halo, -CN, -Cl-C6 ²alkyl, -CI-Co ²heteroalkyl, -Ci-Co haloalkyl, -Cs-C to carbocyclyl, 3-10 membered ²heterocyclyl, ²heterocyclylalkyl, Co-Cio aryl, 5-10 member heteroaryl, heteroarylalkyl, ²arylalkyl, ²cycloalkylalkyl. -0Ra6, _N(Ra6)2, _c(=o)Ra6, -C(=0)0Ra6, -NRa6C(=0)Ra6, - ²NRa6C(=0)01V6, -C(=0)N(Ra6)2, -0C())N(Ra6)2,-S(=0)Ra6, -S(=0)21e6, -SRa6, - ²S(=0)(=NR26)11a6, -NRa6S(:=0)21106 and -S(=0)2N(Ra6)2, wherein each alkyl, ²carbocyclyl, ²heterocyclyl, cycloalkylalkyl, heterocyclylalkyl, aryl, heteroaryl, arylalkyl ²and ²heteroarylalkyl is optionally substituted at any available position; ²each R7 is independently absent or selected from H, -D, halo, -CN, -C1-Co ²alkyl, -Ci-Co ²hydroxyalkyl, -CI-Co haloalkyl, -C3-C9 cycloalk-yl, 3-10 membered ²heterocyclyl, 5-6-²membered monocyclic heteroatyl, heterocyclylalkyl, heteroarylallcyl, ²arylalkyl, ²cycloalkylalkyl, -01V7, -N(Ra7)2, --C(=0)Ra7, -C(=0)0Ra7, .44Ra7C(=0)Ra7, --²NRa7C(:=0)0R 7, -C(=0)N(Ra7)2, -0C(=0)N(R37)2,-S(=0)Ra7, -S(=0)2Ra7, -SR , - ²S(=0)(=NRa7)Ra7, -NRa7S(=0)2Ra7 and -S(=20)2N(Ra7)2;²each le is independently selected from H, -D, =0, halo, -CN, -CI-Co alkyl, -Ci-²Co ²heteroalkyl, -Ci-Co haloalkyl, -Cs-C9 cycloalkyl, 3-10 membered heterocyclyl, ²heterocyclylalkyl, heteroarylalkyl, arylalkyl, cycloalkylalkyl, -011a8, -²N(Ra8)2, -C(A))Ra8, -²3²<DP=5>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²C(...0)0Ra8, -NRa8C(..0)R8, -NRa8C(..0)01e8, -CII2C(...0)N(Ra8)2 -²C(...0)N(Ra8)2, -²OC(=0)N(Ra8)2, -CH2C()N(Ra8)2,-S(=0)Ra8, -S(=0)2W8, -S(=0)(=NR")Ras, - ²NRa8S(=0)2R9s and -S(=0)2N(Ra8)2 wherein two instances of R8 together with the ²atom or ²atoms to which they are attached can be taken together to form a 3-10 member ²cycloalkyl or ²heterocyclyl ring (e.g , a ring that together with the piperidine ring of ²Structure I can form a ²bridged, fused or Spiro bicyclic heterocyclic ring)²each Rai, Re, Ra3, Ra4, Ra6, R 7 and R 8 is independently selected from H, CI-²C6 alkyl, ---CI---²C6 heteroalkyl, C3-C9 cycloalkyl, 3-7 membered heterocyclyl, cycloalkylalkyl, ²heterocyclylalkyl, atyl, 5-6 membered heteroaryl, atylalkyl and heteroatylalk-²y1 wherein each ²alkyl, cycloalkyl, heterocyclyl, cycloalkylallcyl, heterocyclylalkyl, aryl, ²heterowyl, arylalkyl ²and heterowylalkyl is optionally substituted at any available position (e.g., ²substituted with 0, ²1, 2 or 3 instances of R.9, wherein each R9 is independently selected from =0, ²halo, -CN, - ²C1-C6 alkl, -Cl-C6 heteroalkyl, -CJ-C6 haloalkyl, -C3-C9 cycloalkyl, 3-10 ²membered ²heterocyclyl, C6-C10 aryl, 5-10 membered heteroaryl, cycloalkylak,r1, ²heterocycl,rlalkyl,²arylalkyl, heteromylalkyl, -ORb, -N(Rb)2, -C(=0)0Rb, -NRbC(...0)Rb, - ²NRbC(D)ORb, -C(=0)N(Rb)2, -0C(=0)N(Rb)2,-S()Rb, -S(0)2Rb, -SRb, - ²S(=0)(=NRb)Rb, -NRbS(=0)2Rb and -S(=0)2N(Rb)2, wherein each Rb is ²independently ²selected from H., -Cl-C6 alkyl (e.g., -Me, -Et, -Pr, -'Pr,-Bu, -13u, -sec-Bu, -²iso-Bu). and ²C3-C9 cycloalkyl. (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl); ²and ²nis0,1,2or3²provided that:²(i) when RI is H. R2 is not halo, -0Pr, -N(CII3)2 or -CF3;²(ii) when R.1 is ORal, R2 is not -0Ra2;²(iii) when RI is H and R2 is -CH3, R8 groups cannot be taken together to form ²a ring and R6 is ²not absent or H, and is not thiazolyl, furanyl or pyrroly1;²(iv) when R2 is Me, 11.' is not optionally substituted piperidine²(v) the compound is not:²(A) 5-(2-(5-methy1-2-(p-tolyppiperidin-1-1)-2-oxoacetamido)nicotinamide or any ²of its ²enantiomers or diastereomers; ²(B)2-(2-(4-(2H-tetrazol-5-yl)pheny1)-5-methylpiperidin.-1-y1)-N-(5,6-²dimethylpyriclin-3-y1)-²2-oxoacetamide or any of its enantiomers or diastereomers;²(C) 2-cyano-5-(2-(5-methyl-2-phenylpiperidin-1.11)-2-oxoacetamido)nicotinamide ²or any of ²its enantiomers or diastereomers.²4²<DP=6>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²[00061 In certain embodiments, R6 and R7 are not H and are in a !mins relative ²²configuration. In. some embodiments, 1(6 and R7 are not H and are in a cis ²relative ²configuration.²R7²r."(....1 8²100071 In some embodiments of Formula (I), the moiety represented as R8 ²is²selected from:²R7 R7 R7 R7²(N1 8 ²µN (R N ) _________________________________ (R8L²R6 R6 Re Re²R7²8,²y-i¨krµ²100081 In some embodiments of Formula (I) the moiety represented as R8 ²is²selected from:²R7 R7²I (R8)n \L"..)¨(R8 )n².sr²R6 and R6²R7²µN.²...²(00091 In other embodiments of Formula (I), the moiety represented as R8 ²is²selected from:²R7 R7²¨(R8)n ris1¨(R8)n²N²Re and R8²1001.01 In some embodiments, the compound is of Formula (Ia)²<DP=7>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²R2 R7²Ri²(R8L²R4 fie Formula (Ia).²100111 In other embodiments, the compound is of Formula (lb)²R7²RiR37²0²(R8)n²FZ4 H 6 R6 Formula (Tb).²100121 In some embodiments, the compound is of Formula (Ic)²2 R7²RI. R3²1-- 9 r²(R8)n²44 H Flo²Formula (lc).²100131 In other embodiments, the compound is of Formula (Td)²R2 R7²7²R1 R3²N²(R8L²R4 0 R Formula (Id).²1001.41 In some embodiments of Formula (I), (Ia), (Tb), (Ic) and (Id), each R8 ²is ²independently selected from H, ¨D, =0, halo, ¨CN, ¨Ci¨Cs alkyl, ¨C1¨C6 ²heteroalkyl, -CI-²Co haloalkyl, ¨C3¨C9 cycloakl, 3-10 membered heterocyclyl, heterocyclylalkyl, ²heteroarylalkyl, arylalkyl, cycloalkylalkyl, ¨OW8, ¨N(Ra8)2, ¨C(=0)1V8, -²C(=0)01V8, ¨ ²N-Rasc(=o)Ras.²0)01V8, ¨CI-T2C(=0)N(R 8)2 --C(=0)N(Ra8)2, ¨0C(=0)N(Ra8)2, ¨ ²CH2C(=0)N(Ra8)2, -S(=0)1V8, ¨S(0)211.a8, ¨SW8, ¨S(D)(=NRa8)Ras, ¨NRa8S(=0)2Ras ²and ²¨S(J)2N(Ra8)2.²10015j In some embodiments of Formula (I), (Ia), (lb), (Ic) and (Id); It' is ²selected from H, ²halo, ¨CN, ¨CI¨Cs alkyl, ¨Ci¨C6 heteroalkyl, ¨Ci¨Cs haloalkyl, ¨C3¨C9 ²cycloalkyl, 3-10²membered heterocyclyi, _N(Rai)2,²-LA 0)0Rai, ¨NRalC(=0)Ral, ¨ ²NRalC(=0)0Ral, ¨C(=0)N(Ral)2 and --0C(=0)N(Ra1)2. In some embodiments, RI is ²selected ²from H. halo, ¨CN, ¨C1¨C6 alkyl, ¨CI¨Cs haloalkyl, ¨OR' and ¨N(Ral)2. In some ²embodiments, RI is selected from H, ¨Cm¨Co alkyl, ¨CI¨Co haloalkyl, ¨0Ra1 and ²¨N(R.a1)2.²6²<DP=8>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²In further embodiments, each Rai is independently selected from H. -CI-Co ²alkyl (e.g., -Me,²-Et, -Pr, -'Pr,-"Bu, -13u, -sec-Bu, -iso-Bu) and -CI-Co haloalkyl (e.g., -²CHF2, -CF3). ²100161 In certain embodiments of Formula (I), (La), (Ib), (Ic) and (Id), RI is ²selected from ²H, -C1-C6 alkyl (e.g., -Me, -Et, -Pr, --113r,-"Bu, -'13u, -sec-Bu, -iso-Bu), -²C1-C6 alkyl (e.g.,²-CF3, -CHF2), -OH, -0-(C1-C6 alkyl) (e.g., -0Me, -0Et), -0-(C1-C6 haloakl) ²(e.g , - ²OCF 3, -OCHF2), -NI-h, -NH-(Ci-Co alkyl) (e.g, -NHMe) and -N-(CI-C6 akI)2 ²(e.g, ²NMe2). In some embodiments, RI is selected from H, --Me, -Et, ---CHF2, --0Me, -²-0Et, ---²OCHF2, -0CF3,-01-I and -NI-12. In further embodiments. RI is selected from FL, ²-Et, -0Me,²-0Et, -OCHF2, -0CF3 and-OH. In certain embodiments, le is selected from H and -²0Me. ²In some embodiments, RI is H. In other embodiments, RI is ---0Me.²100171 In certain embodiments. R1 is selected from H, -Me, -CHF2 and In ²further ²embodiments, RI is selected from -Me and -NH2. In certain embodiments. RI is -²Me. In ²other embodiments. RI is -NH2.²100181 In some embodiments of Formula (I), (la), (Ib), (Ic) and (Id), R2 is ²selected from ²halo, -CN, -CI-Co alkyl, -CI-Co heteroalkyl, -C1-C6 haloalkyl, -C1-C6 ²haloalkoxy, -C3-C9 ²cycloalkyl (e. g , cyclopropyl), 3-10 membered heterocyclyl (e.g., oxetanyl, ²tetrahydrofuranyl), -0Ra2, -N(R2)2, -C(=0)Ra2, -C())0Ra2, -NRa2C())Ra2, - ²NRa2C(...0)011a2, --C(:=0)N(Ra2)2, -C(:=0)N(ORa2)(Ra2) and -0C(...0)N(Ra2)2. ²In further ²embodiments, R2 is selected from halo, -CN, -CI-Co alkyl, -Ci-Co haloalkyl, -²Ci-Co ²haloalkoxy, -C3-C9 cycloalkyl (e.g., cyclopropyl), 3-6 membered heterocyclyl ²(e.g., ²oxetanyl, tetrahydrofuranyl), -0Ra2, -N(Ra2)2,-C(=O)N(ORa2)(Ra2), -C(=0)Ra2 ²and ---²C(...0)N(Ra2)2. In certain embodiments. R2 is selected from halo, -CI-Co ²alkyl, -Ci-Co ²haloalkyl, -CI-Co haloalkoxy, -C3-C9 cycloalkyl (e.g , cyclopropyl), 3-6 ²membered ²heterocyclyl (e.g., oxetanyl, tetrahydrofuranyl), -0Ra2, -C(D)Ra2 and -²C(=0)N(Ra2)2. In ²some embodiments, R2 is selected from halo, -Ci-Co alkyl, -C3-C9 cycloalkyl ²(e.g, ²cyclopropyl), 3-6 membered heterocyclyl (e.g., oxetanyl, tetrahydrofuranyl), -²Ci-Co ²haloalkyl, -CI-Co haloalkoxy, -OR', and -C(=0)N(Ra2)2. In further embodiments, ²each Ra2 ²is independently selected from H and ---CI---Co alkyl (e.g, --Me, --Et, --Pr, -²-)Pr,--"Bu, ²sec-Bu, -iso-Bu). In certain embodiments, R2 is selected from halo (e.g., -²Cl), -CI-Co alkyl ²(e.g , -Me, -Et, -Pr, -Tr,-"13u, -'13u, -sec-Bu, -iso-Bu), -C i-Co haloalk-yl ²(e.g , -CF3, ²CHF2), -C3-C9 cycloalkyl (e.g, cyclopropyl), 3-6 membered heterocyclyl (e.g., ²oxetanyl, ²tetrahydrofuranyl), -Ci-Co haloalkoxy (e.g., -OCF 3, -OCHF2), -0Me, -4(...0)H, ²- ²C(.---0)NHOH, and -C(=0)NH2. In further embodiments, R2 is selected from -Cl, -²Me, -Et,²7²<DP=9>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²-93r, -CF3, CH.F2, -OCHF2, -0CF3, cyclopropyl, -C(=0)NITOTI, -C(=0)I-T and - ²C(=0)NH2. In certain embodiments, R2 is selected from -C(=0)NH2 and -C(=0)H. ²In some ²embodiments, R2 is -C(=0)NH2. In certain embodiments; R2 is selected from --²Cl. -Me, -Et,²-CF3, -CHF2, -OCHF2, oxetan-3-²yl, tetrahydrofuran-3-yl, and cyclopropyl. In²further embodiments, R2 is selected from cyclopropyl, -Me and -Et.²100191 in some embodiments, RI is selected from H. -0Me, -0Et,-0CF3, -OCHF2, - ²²CHF2, -Me, -Et, -OH and -NH2 and R2 is selected from ---Cl, -Me, -Et, -Tr, -²CF3, -CHF2,²OCHF2, ²cyclopropyl, -C(=0)N1I2, and -C(=0)1-I, provided that when R2 is -Me, RI²is NH2.²In some embodiments, RI is selected from H, --CHF2, -Me and -NE2 and R2 is ²selected from²-Cl. -Me, -Et, -CF3, -OCHF2 ²and cyclopropyl, provided that when R2 is -Me, RI is²NI-12. In certain embodiments, RI is selected from -NF12 and -Me and R.2 is ²selected from - ²Me, and -Et. In further embodiments, RI is -NH2 and R2 is selected from ²cyclopropyl, -Me, ²and -Et.²In some embodiments R' is selected from H, -0Me, -0Et,-OCE3, -OCHF2, -Et and -²OH ²and R.2 is selected from -C(=0)NH2 and -C(D)H. In further embodiments, 11.' is ²selected ²from H and -0Me and R2 is -C(=0)NH2.²100201 In some embodiments of Formula (I), (Ia), (Tb), (Ic) and (Id), R3 is ²selected from H,²halo, -CN, alkyl, -CI-²C6 heteroalkyl, -Ci-C6 haloalkyl, -C3-C9 cycloalkyl, 3-10²membered heterocyclyl, -N(Ra3)2, -C(=0)Ra3, -C(=0)0Ra3, -NRa3C(=0)Ra3, - ²NRa3C(=0)01V3, -C(=0)N(Ra3)2 and --0C(=0)N(R93)2. In some embodiments, R3 is ²selected ²from FI, halo, -CN, -C1-C6 alkyl, -CI-C6 haloalkyl and -N(R)2. In further ²embodiments, ²Ra3 is selected from H and CI-C6 alkyl (e.g. -Me, -Et, -Pr, -Tr,-'113u, -93u, -²sec-Bu, -iso-²Bu). In certain embodiments, R3 is selected from -CI-Co alkyl (e.g , -Me, -Et, ²-Pr, -'Pr,-²Bu, -93u, -sec-Bu, -iso-Bu), -0-(CI-C6 ²alkyl) (e.g , -0Me), -N}{-(CI-C6²alkyl) (e.g , -NHMe) and -N-(CI-C6 alky1)2 (e.g, NMe2). In further ²embodiments, R3 is ²selected from H, -Me and -NH2. In certain embodiments, R3 is selected from H ²and -Me. In ²further embodiments, R3 is -Me.²100211 In some embodiments of Formula (I), (Ia), (Ib), (Ic) and (I.d), 124 is ²selected from FI, ²halo, -CN, -Ci-C6 alkyl, -Ci-C6 heteroalkyl, -CI-C6 haloalkyl, -C3-C9 ²cycloalkyl, 3-10 ²membered heterocyclyi, -0Ra4, _N(Ra4)2, _g=coRa4, -C(=0)0Ra4, -NRa4C()Ra4, - ²NW4C(=0)011a4, --C(=0)N(R24)2 and -0C(..0)N(Ra4)2. In some embodiments, R4 is ²selected ²from. H, halo, -CN, -Ci-C6 alkyl, -C1-C6 haloalkyl and -N(R4)2. In further ²embodiments,²8²<DP=10>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²each R04 is independently selected from H and -CI-C6 alkyl (e.g., -Me, -Et, -²Pr, -'13r,-"Bu, ²-'13u, -sec-Bu, -iso-Bu). In certain embodiments, R4 is selected from -C1-C6 ²alkyl (e.g , -²Me, -Et, -Pr; -13r,--nBu, 213u, --sec-Bu, -iso-Bu), -0-(Ci-C6 alkyl) (e.g., ²-0Me), ²Nth, -NH-(C1-C6 alkyl) (e.g., -NTIMe) and -N-(C1-C6 alky1)2 (e.g, NMe2). In ²further ²embodiments, R4 is H.²100221 in some embodiments of Formula (I), (lay, (Ib), (lc) and (id), each R6 ²is ²independently selected from H, ---D, halo; -CN; -C1-C6 alkyl, -C1-C6 ²heteroalkyl, -C1-C6 ²haloalkyl, -C3-Cio carbocyclyl, 3-10 membered heterocyclyl, heterocyclylalkyl, ²C6-C10 aryl, ²5-10 member heteroaryl, heteroarylalkyl, arylalkyl, cycloalkylalkyl, -0Ra6, ²_N(Rao)2, - ²C(=0)Ra6, -C(=0)0R86, -NRa6C(=(J)Ra6, -NRa6C(0)0Ra6, ---C:))N(Ra6)2, ²OC(=0)N(Ra6)2,-S(=0)Ra6, -s(=0)2Ra6. _sRa6, _s(,o)(:=NRa6)Ra6,²K. b( 0)2Ra6 and - ²S(=0)2N(Rn2, wherein each alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, ²cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl is ²substituted at any ²available position with 0, 1, 2 or 3 instances of Rw, wherein:²each Rw is independently selected from -D, -CN, halo, -C1-C6 alkyl, -CI-C6 ²heteroalkyl, -CI-C6 haloalkyl, -C3-C9 cycloalkyl, 3-10 membered heterocyclyl, ²C6-CIO aryl, ²5-10 membered heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, ²heteroarylalkyl,²heterocyclylalkoxy, _N(Rbio)2, _c(,0)-K610,²C(:=0)011b 1 , -NRb 1 C(=0)Rb 16,²0)0Rb16, -C(=0)N(Rbi )2, -0g=0)Rb10,²0)N(Rb16)2,-S(=0)Rb16, -²S(=0)2Rb16, -sew, -s(=o)(=NRbio)Rbio, -²N²0)2Rbw and -S(=0)2N(Rbw)2, wherein ²each alkyl, cycloalkyl, heteroalkyl, heterocyclyl, aryl, heteroaryl, ²cycloalkylalkyl, ²heterocyclylalkyl, heterocyclylalkoxy, arylalkyl and heteroarylalkyl of Rw is ²optionally ²substituted (e.g , substituted with 0, 1, 2 or 3 instances of -Me, -OH, C(=-²0)Me, - ²C(=0)NHMe, -NH2, -NHC(=0)Me or a combination thereof); ²each Rbi is independently H; -CI-C6 alkyl; -CI-C6 haloalkyl; -CI-²C6heteroalkyl substituted ²with 0 or 1 instance of =0; C3-C9 cycloalkyl; or 3-10 member heterocyclyl ²substituted with 0²or 1 instances of -Me or a combination thereof²100231 In some embodiments of Formula (I), (La), (Ib), (lc) and (Id), each R6 ²is²independently selected from -D, halo, -CN, -C1-C6 alkyl, -CI-C6 heteroalkyl,²haloalkyl, carbocyclyl, 3-10 membered heterocyclyl, heterocyclylalkyl, Co-²CI aiy, I, ²5-10 member heteroaryl, heteroarylalkyl, arylalkyl, cycloalkylalkyl, -01e6, -²N(Ra6)2, - ²c(::,o)R36, _c(:=0)0Ra6, _NRa6c(=0)Ra6,²K 0)0Ra6, -C(:=0)N(R36)2, -²0C(=0)N(Ra6)2,-S(=0)Ra6, -S(=0)21e6, -S(=0)(=NRa6)Rab, -NRa6S(=0)2Ra and -²9²<DP=11>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²S(=0)2N(Ra6)2, wherein each alkyl, carbocyclyl, heterocyclyl, aryl, ²heteroaryl, ²cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl is ²substituted at any ²available position with 0, 1, 2 or 3 instances of Rw, wherein: ²each RI is independently selected from -D, =0, -CN, halo, -C1-C6 alkyl, -CI-²C6 ²heteroalkyl, -C1-C6 haloalkyl, -C3-C9 cycloalkyl, 3-10 membered heterocyclyl, ²C6-Cto aryl, ²5-10 membered heteroaryl, cycloalkylalkyl, heterocyclylallcyl, arylalkyl, ²heteroarylalkyl, ²heterocyclylalkoxy, -OR²"10. 10, _N(-kb 10)2, _c(._-0)Rb 10, _C( =0)0Rb 10, _NRb 10c(4))Rb 10, ²NR / ) I C (::: 0)0Rb I , -C(=:0)N(Rb )2, -0C (:=0)Rb I , -OC (::::0)N(Rb 1 ²)2,-S(::::0)Rb I , - ²S(=0)2K2'4)10, _se 10, -s(=o)(=NRbio)Rbio,_NRbior,(=²0)2Rbl0 and -S(=0)2N(Rb0)2, wherein ²each alkyl, cycloalkyl, heteroalkyl, heterocyclyl, aryl, heteroaryl, ²cycloalkylalkyl, ²heterocyclylalkyl, heterocyclylalkoxy, arylalkyl and heteroarylalkyl of Rw is ²optionally ²substituted (e.g., substituted with 0, 1, 2 or 3 instances of -Me, -OH, ²C(D)Me, - ²C()N1-11\4e, -NH2, -NHC(=0)Me or a combination thereof); ²each Rbi is independently H; ---C1-C6 alkyl; ---C1-C6 haloalkyl; ---C1---²C6heteroalkyl substituted ²with 0 or 1 instance of =0; C3-C9 cycloalkyl; or 3-10 member heterocyclyl ²substituted with 0²or 1 instances of -Me or a combination thereof²100241 In some embodiments of Formula (I), (la), (lb), (lc) and (Id), each le ²is ²independently selected from H, halo, -CN, -C1-C6 alkyl, -Ci-C6 heteroalkyl, -²Ci-C6 ²haloalk-yl, -C3-Cto carbocyclyl, 3-10 membered heterocyclyl, ²heterocyclylalkyl, C6-C to aryl, ²5-10 member heterofflyl, heteroarylalkyl, arylalkyl, cycloalkylalkyl, ORa6, -²N(Ra6)2, - ²C(=0)1V6, ---C(=0)0e, ---NIV6C(=0)1V6, ---NIV6C(=0)01V6, ---C(=0)N(Ra6)2, ---²0C(:=0)N(R06)2,-S(:=0)Ra6, -S(:=0)2Ra6, -SW , -S(:=0)(:=NRa6)R06, -²NRa6S(=0)21126 and - ²S(=0)2N(W6)2, wherein each alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, ²²cycloallcylalk-yl, heterocyclylalkyl, arylalkyl and heteroarylalkyl is ²substituted at any ²available position with 0, 1, 2 or 3 instances of RI , wherein:²each le is independently selected from -D, -CN, halo, -C1-C6 alkyl, -CI-Co ²²heteroalkyl, -C1-C6 haloalkyl, -C3-C9 cycloak,l, 3-10 membered heterocyclyl, ²C6-Cio aryl, ²5-10 membered heterowyl, cvcloalkylalkyl, heterocyclylalkyl, arylalkyl, ²heteroarylalkyl,²heterocyclylalkoxy, -N(Rbw)2, -C(=0)Rbl , -C(:=0)0Rbio, _NRbioc(::,o)Rbio, ²_ ²NRbtAio-(,_ 0)0Rbla, -C(43)N(R.b0)2, -0C(=0)1kbm, -0C(=0)N(Rb1 )2,-S(=0)Rbla, -² ²S(=0)2Rbi0, _sRb10, _S(=0)(=Nr10)..µK1110,²NRbit'S(=0)2Rbm and -S(=0)2N(Rb"))2, wherein²each alkyl, cycloalkyl, heteroalkyl, heterocyclyl, aryl, heteroatyl, ²cycloalkylalkyl, ²heterocyclylalkyl, heterocyclylalkoxy, atylalkyi and heteroarylalkyl. of R") ²is optionally²<DP=12>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²substituted (e.g., substituted with 0, 1, 2 or 3 instances of-Me, -0T-I, ²C(...0)Me, - ²C(=0)NHMe, -NI-I2, -NHC(43)Me or a combination thereof); ²each Rbla is independently H; .-CI¨Co alkyl; -C1-C6 haloalkyl: -Ci-²Coheteroalkyl substituted ²with 0 or 1 instance of =0; C3-C9 cycloalkyl; or 3-10 member heterocyclyl ²substituted with 0²or =! instances of -Me or a combination thereof.²100251 in some embodiments, each le is independently selected from H and -CI-²Co alkyl²(e.g., -Me, -Et, -Pr, -'Pr,--nBu, --sec-Bu,²In some embodiments of Formula (I), (Ia), (lb), (lc) and (Id), each R6 is ²independently²selected from H, -Ci-Co alkyl, -C1-C6 heteroalkyl, -Ci-Co haloalkyl, ²carbocyclyl, ²3-10 membered heterocyclyl, heterocyclylalkyl, Co-Cio atyl, 5-10 member ²heteroaryl, ²heteroarylalkyl, arylalkyl and cycloalkylaikyl, wherein each alkyl, ²cycloalkyl, heterocyclyl, ²cycloalkylalkyl, heterocyclylalkyl, aryl, heteroaryl, arylalkyl and ²heteroarylalkyl is optionally ²substituted at any available position.²100261 In some embodiments, each R6 is independently selected from -CI-Co ²alkyl, -Ct-Co ²heteroalkyl, -C1-C6 haloalkyl, -C3-C10 carbocyclyl, 3-10 membered ²heterocyclyl, ²heterocyclylalkyl, Co-Cio aryl, 5-10 member heteroary, I, heteroarylalkyl, ²arylalkyl and ²cycloallcylalk-yl, wherein each alkyl, cycloalkyl; heterocyclyl, cycloaklalk-²yl, ²heterocyclylalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl is ²optionally substituted at ²any available position.²In some embodiments, each R6 is independently selected from H, -Ci-Co alkyl, -²CI-Co²heteroalkyl, haloalkyl, -C3-Clo carbocyclyl, 3-10 membered heterocyclyl, ²heterocyclylalkyl, Co-Cio aryl, 5-10 member heteroaryl, heteroarylalkyl, ²arylalkyl and ²cycloalkylalkyl, wherein each alkyl, cycloalkyl, heterocyclyl, cycloalkyla141, ²²heterocyclylalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl is ²substituted at any ²available position with 0, 1, 2 or 3 instances of RI wherein:²each RI is independently selected from -D, -CN, halo, -CI-Co alkyl, -Ci-Co²heteroalkyl, haloalkyl, -C3-C9 cycloallcyl, 3-10 membered heterocyclyl, Co-²Clo aryl, ²5-10 membered heteroatyl, cycloak,rlalk-y1; arylalkyl, heteroarylalkyl, ²heterocyclylalkoxy,²heterocyclylalkyl, - Rm. bio)2, _c (õ:0)Rbio, _c(::õ0)0Rbio. ²_NRbioc(õ:0)Rbio, _²0)0Rbla, -C(43)N(R.b0)2, -0C(=0)Rbla, -0C(=0)N(Rbl0)2,-S(=0)Rbla, -²S(=0)2Rbi0, _S(=0)(=Nrio)Rbio,²-NRblaS(=0)2Rbla an a 0)2N(Rbla)2, wherein²each alkyl, cycloalkyl, heteroalkyl, heterocyclyl, aryl, heteroaryl, ²cycloalkylalkyl, ²heterocyclylalkyl, arylalkyl and heteroarylalkyl of R.') is optionally ²substituted (e.g, with 0,²11²<DP=13>²CA 03176912 2022-09-23²WO 2022 / 026892 PCT / US2021 / 044004²1, 2, 3, 4, or 5 instances of -Me, -Et, -'Pr, cyclopropyl, oxetan-3-yl, --(Mt ²...0, -F, -0Me, - ²CH2CH2F, -CH2CHF2, -CH2CH2CF3, -C(=0)Me, -N(Me)2, -CH2N(CH3)2, - ²CH2N(CH3)CH2CH3, -N('Pr)(Et), -N('Pr)(Me), --N(E02, -N(CH3)(Et), -NHC(=0)Me, ²or a ²combination thereof); and²each el is independently selected from H; -Ci-Co alkyl; -Ci-Co haloalkyl; -Ci-²Co ²heteroalkyl substituted with 0 or 1 instance of `,:); C3-C9 cycloalk-yl, and a ²3-10 member ²heterocyclyl substituted with 0 or 1 instances of =0, -Me or a combination ²thereof ²100271 In some embodiments of Formula (I), (la), (Ib), (Ic) and (Id), each R6 ²is ²independently selected from H, -C1-C6 alk-yl, -Ci-Cs heteroalkyl, -Ci-Co ²haloalkyl, -C3-C to ²carbocyclyl, 3-10 membered heterocyclyl, heterocyclylalkyl, C6-Cio aryl, 5-10 ²member ²heteroaryl, heteroarylalkyl, arylalkyl and cycloalkylalkyl, wherein each ²alkyl, cycloalkyl, ²heterocyclyl, cycloalkylalkyl, heterocyclylalkyl, aryl, heteroatyl, arylakl ²and ²heterofflylalkyl is optionally substituted at any available position. In ²certain embodiments, ²each R6 is independently selected from H, -Ci-C6 alkyl, -Ci-C6 heteroalkyl,²haloalkyl, -C3-Cio carbocyclyl, 3-10 membered heterocyclyl, heterocyclylalkyl, ²Co-Cio aryl, ²5-10 member heterowy, I, heteroarylalk-yl, arylalkyl and cycloalkylalkyl, ²wherein each alkyl, ²cycloallcyl, heterocyclyl, cycloalkyla141, heterocyclylalkyl, aryl, ²heteroaryl, atylalkyl and ²heterouylalkyl is substituted at any available position with 0, 1, 2 or 3 ²instances of R' ²wherein:²each RI is independently selected from -D, -CN, halo, -Ci-Co alkyl, -C i-²C6²heteroalkyl, ²haloalkyl, -C3-C9 cycloallcyl, 3-10 membered heterocyclyl, C6-Clo aryl,²5-10 membered heteroaryl, cycloalkylaikyl, atylalkyl, heteroarylalkyl, ²heterocyclylalkoxy,²heterocyclylalkyl, - RN( bio)2, _c (21)Ro, -C (0)0R , _NRbioc (=o)Rbio. _ ²Neloc (=o)oRbio, _c(=0)N(Rbi0)2, -0C(=0)Rbio, _0c(=0)N(Rbio)2,..s(=0)Rbi0, _²s(=0)2Rb10, . __Ksb10²K. S(=0)(=²NRb10)Rb10, NRb10,,²0)2Rbi and-S(=0)2N(Rw)2, wherein²each alkyl, cydoalkyl, heteroalkyl, heterocyclyl, aryl, heteroaryl,²heterocyclylalkyl, wylalk-y1 and heterofflylalkyl of Rm is optionally ²substituted (e.g, with 0,²1, 2, 3, 4, or 5 instances of --Me, -Et, ²cyclopropyi, oxetan-3-y1, -OH, =0, --F, -0Me, -²CH2CH2F, -CH2CHF2, -0-12C1-12CF3, -N(Me)2, -CH2N(CF13)2, - ²CH2N(CH3)CH2CH3, -N('Pr)(Et), -N('Pr)(Me), -N(Et)2, -N(CH3)(Et), -NHC(=0)Me, ²or a ²combination thereof); and²12²<DP=14>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²each Rbi is independently selected from H; ¨CI--C6 alkyl; ¨CI¨C6 haloalkyl; ²¨CI¨C6²heteroalkyl substituted with 0 or 1 instance of C3¨C9 cycloalkyl; and a 3-²10 member²heterocyclyl substituted with 0 or 1 instances of =0, ¨Me or a combination ²thereof.²In some embodiments, each R6 is independently selected from H, ¨CI¨C6 alkyl ²(e.g., ¨Me, ¨²Et, ¨Pr, ¨'13r, -'13u, sec-Bu, ¨C3¨Cio monocyclic or bicyclic carbocyclyl ²(e.g., ²cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, ²bicyclo[1.1.1]pentan-yl, ²4,5,6,7-tetrahydro-1H-indazolyl, spiro[3.31heptanyl), 3-10 membered mono or ²bicyclic ²heterocyclyl (e.g., oxetanyl, azepanyl, piperidinyl, pyrorolidinyl, ²tetrahydrofuranyl,²tetrahydropyranyl, 1,2-dihydropyridinyl, morpholinyl, C6¨Cio ²mono or bicyclic²aryl (e.g., phenyl, naphthyl, 1,2,3,4-tetrahydronaphthalenyl, 2,3-dihydro-1H-²indenyl, 1,2,3,4 ²tetrahydroquinolinyl, 1,2 dihydroquinolinyl, 1,2-dihydroisoquinolinyl, 1,2,3,4 ²²tetrahydroisoquinolinyl, chromanyl, indolinyl, 3,4-dihydro-2H-²benzo[b][1,4]oxazinyl, 2,3-²dihydrobenzofuranyl, benzo[d] [ 1,3] dioxolyl, 2,3-dihydro-1H-²benzo[d]imidazoly1), 5-6 ²member monocyclic heteroaryl (e.g., thiophenyl, thiazolyl, pyrazolyl, ²imidazolyl, oxazolyl, ²pyridinyl, pyrimidinyl), 8-10 member bicyclic heteroaryl (e.g., ²benzo[dlisothiazolyl, indolyl, ²benzofuranyl, 1H-indazolyl, 2H-indazolyl, benzo[b]thiophenyl, quinolinyl, 1,5-²naphthyridinyl, 1,2-dihydro-1,5-naphthyridinyl, 1,2,3,4-tetrahydro-1,8-²naphthyridinyl, ²isoquinolinyl, benzo[d]imidazolyl, benzo[d]thiazolyl, benzo [d] oxazolyl, ²[1,2,4]triazolo[4,3-²a]pyridinyl, imidazo[1,2-a]pyridinyl, imidazo[1,5-a]pyridinyl, 1H-pyrazolo[4,3-²b]pyridinyl), ²1H-pyrazolo[3,4-b]pyridinyl, 1H-thieno[2,3-c]pyrazolyl, 1H-thieno[3,2-²c]pyrazolyl, ²thiazolo[5,4-blpyridiny1) wherein each alkyl, carbocyclyl, heterocyclyl, aryl ²and heteroaryl is ²optionally substituted (e.g., substituted with 0, 1, 2 or 3 instances of R In ²some ²embodiments, each R6 is independently selected from ¨Ci¨Co alkyl (e.g., ¨Me, ²¨Et, ¨Pr, ¨Tr,²sec-Bu, ¨Su), ¨C3-00 monocyclic or bicyclic carbocyclyl (e.g, cyclopropyl, ²cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, bicyclo[1.1.1]pentan-yl, ²4,5,6,7-tetrahydro-²1H-indazolyl, spiro[3.3]heptanyl), 3-10 membered mono or bicyclic heterocyclyl ²(e.g., ²oxetanyl, azepanyl, piperidinyl, pyrorolidinyl, tetrahydrofuranyl, ²tetrahydropyranyl, 1,2-²dihydropyridinyl, morpholinyl, isoindolinyl), C6--Cio mono or bicyclic aryl ²(e.g., phenyl, ²naphthyl, 1,2,3,4-tetrahydronaphthalenyl, 2,3-dihydro-IFI-indenyl, 1,2,3,4 ²tetrahydroquinolinyl, 1,2 dihydroquinolinyl, 1,2-dihydroisoquinolinyl, 1,2,3,4 ²²tetrahydroisoquinolinyl, chromamõ,I, indolinyl, isoindolinyl, 3,4-dihydro-2H-²benzo[b][1,4]oxazinyl, 2,3-dihydrobenzofura.nyl, benzo [d][ 1,3] dioxolyl, 2,3-²dihydro-1H-²benzo[d]imidazoly1), 5-6 member monocyclic heteroaryl (e.g , thiophenyl, ²thiazolyl,²13²<DP=15>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²pyrazolyl, imidazolyl, oxazolyl, pyridinyl, pyrimidinyl), 8-10 member bicyclic ²heteroaql ²(e.g , benzo[d]isothiazolyl, indolyl, benzofuranyl, 1H-indazolyl, 2H-²indazolyl, ²benzo[b]thiophenyl, quinoliny1,1,5-naphthyridinyl, 1,2-dihydro-1,5-²naphthyridinyl, 1,2,3,4-²tetrahydro-1,8-naphthyridinyl, isoquinolinyl, benzo[d]imidazolyl, ²benzo[d]thiazolyl, ²benzo[d]oxazolyl, [1,2,4]triazolo[4,3-c]pyridinyl, imidazo[1,2-cdpyridinyl, ²imidazo[1,5-²a] pyridinyl, 1H-pyrazolo[4,3-b]pyridinyl), 1H-pyrazolo[3,4-b]pyridinyl, 1H-²thieno[2,3-²c]pyrazolyl, 1H-thieno[3,2-c]pyrazolyl, thiazolo[5,4-h]pyridinyl) wherein each ²alkyl, ²carbocyclyl, heterocyclyl, aryl and heteroaryl is optionally substituted ²(e.g., substituted with ²0, 1, 2 or 3 instances of RE)).²In certain embodiments, each R6 is an 8-10 member bicyclic heteroaryl (e.g., ²indolyl,²benzofuranyl, 2H-indazolyl, benzo[b]thiophenyl, quinolinyl, 1,5-²naphthyridinyl, 1,2-dihydro-1,5-naphthyridin.yl, 1,2,3,4-tetrahydro-1,8-²n.aphthyridinyl, ²imidazo[1,2-a]pyridinyl, imidazo[1,5-a]pyridinyl, isoquinolinyl, ²benzo[d]imidazolyl, ²benzo[althiazoly1; benzo[d]isothiazolyl, benzo [d] oxazolyl, ²[1,2,4]triazolo[4,3-a]pyridinyl, ²imidazo[1,2-cdpyridinyl, 1H-pyrazolo[4,3-b]pyridinyl),1H- pyrazolo[3,4-²14yridinyl, 1H-²thieno[2,3-c]pyrazolyl, 1.H-thieno[3,2-c]pyrazolyl, thiazolo[5,4-b]pyridinyl, ²1,2,3,4-²tetrahydro-1,8-naphthyridinyl) wherein the bicyclic heteroatyl is optionally ²substituted (e.g., ²substituted with 0, 1, 2 or 3 instances of R16),In some embodiments, each R6 ²is independently²selected from H. -Me, -Tr, see-Bu, cyclobutyl, cyclopentyl, cyclohexyl, ²bicyclo[1.1.1]pentan-l-yl, spiro[3.3]heptan-2-yl, 4,5,6,7-tetrahydro-1H-²indazol-6-yl, ²piperidin-4-yl, piperidin-3-yl, pyrrolidin-3-yl, 1,2-dihydropyridin-4-yl, ²phenyl, naphthalen-2-²yl, 1,2,3,4-tetrahydroquinolin-6-yl, 1,2,3,4-tetrahydronaphthalen-6-yl, ²chroman-6-yl, 1,5-²naphthyridin-6-yl, 1,2,3,4-tetrahydro-1,8-naphthyridin-6-yl, 2,3-dihydro-1H-²inden-5-yl, ²indolin-5-yl, indolin-4-yl, 2,3-dihydro-1H-benzo[d]imidazol-511, 2,3-²dihydrobenzofuran-5-²yl, 2,3-dihydrobenzofuran-6-yl, benzo[d][1,3] dioxo1-5-y1], isoindolin-5-yl, ²isoindolin-611, ²3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl, 1,2-dihydroquinolin-6-yl, 1,2-²dihydroisoquinolin-²7-yl, thiophen-2-yl, thiophen-3-yl, thiazol-4-yl, thiazol-5-yl, pyrazol-l-²yl, ²pyrazol-5-yl, pyrazol-3-yl, pyrazol-4-yl, pyridin-2-yl, pyridin-3-yl, pyridin-²4-yl, pyriinidin-5-²yl, indo1-4-yl, indo1-5-yl, benzofuran-5-yl, benzofuran-6-yl, 1 / 1 indazol-5-²yl, 111 indazol-4-²yl, 2H-indazol-6-yl, 2H-indazol-5-yl, benzo[b]thiophen-3-yl, benzo[b]thiophen-²5-yl, ²quinolin-6-yl, quinoline-3-yl, isoquinolin-6-yl, benzo[d]imidazo-5-yl, 1H-²benzo[d]irnidazol-²4-yl, benzo[c / Ithiazol-5-yl, benzo[d]thiazol-6-yl, benzo[d]thiazol-4-yl, ²benzo[d]isothiazol-5-²yl, benzo[d]oxazol-4-yl, benzo[d]oxazol-5-yl, [1,2,4]triazolo[4,3-a]pyridin-6-²yl, imidazo[1,2-²14²<DP=16>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²alpyridin-6-yl, imidazo[1,2-a]pyridin-7-yl, pyrazolo[4,3-²b]pyridin-6-yl, 1H-pyrazolo[3,4-b]pyridin-5-yl, 1H-pyrazolo[3,4-b]pyridin-5-0, ²1H-²PYrazolo4,3-bipyridin-5-yl, 1H-pyrazolo[4,3-bilpyridin-6-yl, 1H-thieno[2,3-²clpyrazol-5-yl, ²1H-thieno[3,2-cipyrazol-5-yl, thiazolo[5,4-b]pyridin-6-y1), each optionally ²substituted (e.g., ²substituted with 0, 1, 2 or 3 instances of RI ).²In some embodiments, each le is independently selected from -Me, -Tr, -13u, ²see-Bu, ²cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[1.1.11pentan-1-yl, ²spiro[3.31heptan-2-yl, 4,5,6,7-²tetrahydro-1H-inda-zol-6-ylõ piperidin-4-yl, piperidin-3-yl, pyrrolidin-3-yl, ²1,2-²dihydropyridin-411, phenyl, naphthalen-2-yl, 1,2,3,4 tetrahydroquinolin-6-yl, ²1,2,3,4-²tetrahydronaphthalen-6-yl, chroman-6-yl, 1,5-naphthyridin-6-yl, 1,2,3,4-²tetrahydro-1,8-²naphthyridin-6-yl, 2,3-dihydro-1H-inden-5-yl, indolin-5-yl, indolin-4-yl, 2,3-²dihydro-1H-²benzo[d]imidazol-5-yl, 2,3-dihydrobenzofuran-5-yl, 2,3-dihydrobenzofuran-6-yl, ²²benzo[d][1,3] dioxo1-5-y1], isoindolin-5-yl, isoindolin-6-yl, 3,4-dihydro-2H-²benzo[b][1,41oxazin-7-yl, 1,2-dihydroquinolin-6-yl, 1,2-dihydroisoquinolin-7-²yl, thiophen-2-²yl, thiophen-3-yl, thiazol-2-yl, thiazol-411, thiazol-5-yl, pyrazol-1-yl, ²pyrazol-5-yl, pyrazol-²3-yl, pyrazol-4-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-5-yl, ²indo1-4-yl, indo1-²5-yl, benzofuran-5-yl, benzofuran-6-yl, 1H indazol-5-yl, 1H indazol-4-yl, 2H-²indazol-6-yl, ²2H-indazol-5-yl, benzo[b]thiophen-3-yl, benzo[b]thiophen-5-yl, quinolin-611, ²quinoline-3-²yl, isoquinolin-6-yl, benzo[d]imidazo-5-yl, 1H-benzo[d]imidazol.-4-0, ²benzo[d]thiazol-5-yl, ²benzo[d]thiazol-6-yl, benzo[d]thiazol-4-yl, benzo[d]isothiazol-5-4, ²benzo[d]oxazol-4-yl, ²benzo[d]oxazo1-5-yl, [ 1,2,4]triazolo[4,3-alpyridin-6-yl, imidazol 1,2-²alpyridin-6-yl,²imidazo[1,2-alpyridin-7-yl, pyrazolo[4,3-b]pyridin-6-yl, 1H-²pyrazolo[3,4-b]pyridin-5-yl, 1H-pyrazolo[3,4-b]pyridin-5-yl, 1H-pyrazolo[4,3-²b]pyridin-5-yl, ²1H-pyrazolo[4,3-b]pyridin-6-õ,1, 1H-thieno[2,3-c]pyrazol-5-yl, 1H-thieno[3,2-²c]pyrazol-5-yl, ²thiazolo[5,4-b]pyridin-6-y1), each optionally substituted (e.g., substituted ²with 0, 1, 2 or 3 ²instances of R.1 ).²100281 in some embodiments, R6 is selected from optionally substituted phenyl, ²pyridin-2-²yl, pyridin-4-yl, and pyrimidin-5-y1 (e.g., substituted with 0, 1, 2 ²or 3 instances ²of 111 ). In some embodiments, R6 is selected from phenyl, pyridin-2-yl, ²pyridin-3-yl, ²pyridin-4-yl, pyrimidin-5-y1 and phenyl substituted with one instance of R").²100291 In some embodiments, R6 is selected from:²<DP=17>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004² ()%²'1Y² R10 R10 R19 R" . In further embodiments, R6 is²100301 In some embodiments, R6 is optionally substituted phenyl (e.g., ²substituted with 0, 1,²o²2 or 3 instances of R' ). In certain embodiments, R6 is R".²In some embodiments, 116 is selected from optionally substituted bicyclic ²heteroaryl (e.g., ²substituted with 0, 1, 2 or 3 instances of RP). In further embodiments, R6 is ²selected from ²optionally substituted 1H-indazol-5-yl, 2H-indazol-5-yl, benzo[dlisothiazol-5-²yl, ²benzo[d]thiazol-5-yl, benzo[b]thiophen-5-yl, benzo[d]oxazol-4-yl, ²benzo[ci]oxazol-5-yl, ²quinoline-7-yl, 1H-thieno[2,3-c]pyrazol-5-yl, imidazo[1,2-a]pyridin-7-yl, and ²imidazo[1,5-²a]pyridin-6-yl, (e.g., substituted with 0, 1, 2 or 3 instances of R' ).²Rl N-R10²100311 In some embodiments. R6 is "Lt- N or²Rio²gel '141². In further embodiments,²100321 In certain embodiments of the invention, RI is independently selected ²from --D, =0, ²halo (e.g., F, Cl, Br), -CN, -CI-C6 alkyl (e.g., -Me, -Et, -Pr, -iPr, -sec-Bu, ²-tBu, ²CH2(CH3)(iPr)), -C1--C6 heteroallcyl (e.g., -CH(CH3)(NMe2), -²CH2CH2N(Me)(oxetan-3-²-CH2CH(CH3)(NMe2), --CH20H, -CH(OH)(CH3), -C(OH)(CH3)2, -CH2NH2), ²CI-C6 haloalkyl (e.g., -CHF2, -CH2CF3, -CF3), -C3-C9 cycloalkyl (e.g., ²cyclopropyl, ²cyclobutyl, cyclopentyl, cyclohexyl), 3-10 membered ²heterocycly1(e.g.,tetrahydrofuranyl, ²tetrahydropyranyl, oxetanyl, morpholinyl, pyrolidinyl, piperidinyl, piperidin-²2-onyl, ²piperazinyl, piperazin-2-only, azetidinyl, decahydro-1,6-naphthyridinyl, 2-²azaspiro[3.31heptanyl, 5-oxa-2,8-diazaspiro[3.5]nonanyl, 8-²azabicyclo[3.2.1joctanyl, 2-²azabicyclo[2.2.2]octanyl, 3-azabicyclo[3.2.0]heptanyl, 3-²azabicyclo[3.1.1]heptanyl, 3-²azabicyclo[3.1.0]hexanyl, 2-azabicyclo[2.1.1]hexamõ,1, 1-²azabicyclo[2.2.1]heptanyl, 3-²azabicyclo13.2.01heptanyl, 2,9-di azaspiro[5.51undecanyl, ²bicyclo[1.1.11pentanyl, ²octahydrocyclopenta[c]pyrrolyl, decahydro-1,6-naphthyridinyl, octahydro-1H-²pyrrolo[3,4-²c]pyridinyl, decahydro-2,7-naphthyridinyl, 2,9-diazaspiro[5.5]undecanyl), 5-10 ²membered²16²<DP=18>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²heteroaryl (e.g., pyridinyl, imidazo[1,2-a]pyridinyl, imidazolyl, pyrazolyl, ²thiazolyl, ²thiophenyl), cycloalkylalk-yl (e.g. -CH2-cyclopropyl), heterocyclylalkyl ²(e.g., -CH2-²morpholinyl, --(CH2)2-pyrolidinyl -(CH2)2-pyrolidinyl --CH2-imidazolyl, --CH2-²pyrazoly1, ²CH2-1,2,4-triazolyl, -CIT2-morpholinyl, -(CIT2)2-morpholinyl), ²heterocyclylalkoxy (e.g., - ²0-(CH2)2-pyrolidinyl, -0-CH2-piperidinyl, -0-CH2-oxetanyl, -0-CH2-²tetrahydrofuranyl, - ²0-CH2-tetrahydropyranyl), heteroarylalkyl (e.g., -CH2-triazolyl, -CH2-²imidazolyl, -CH2-²pyrazolyl), -ORb10 (e.g., -OH, -0Me, OEt, -0-tetrahydrofuranyl, -0-²tetrahydropyran-4-y1,²-0CF3, -OCHF2), -N(Rbl. 0)2, (e.g., -NH2, -NTIRb10, -NHMe, -NMe2, -NICIT2CF3, -² ²NH-oxetan-3-yl, -NH-(N-Me-2-oxo-pyrolidin-3-y1), -NRWOC(=0)Rb 1 0 (e.g., - ²NHC(=0)Me), -C(=0)N(Rb10)2, (e.g., --C(=0)N112, C(=0)NHMe), -0C(=0)Rb1 0 ²(e.g., ²OC(:=0)Me), -S(=0)Rb10 (e.g., -S02Me), -NRblOS(=0)2Rb10 (e.g., NFISO2Me) and - ²²S(=0)2N(Rb10)2 (e.g., SO2NH2, SO2NHMe), wherein each alkyl, cycloakl, ²heterocyclyl, ²aryl, heterowyl, cycloalkylalkyl, heterocyclylalkyl, atylalk-y1 and ²heteroatylalk-y1 is optionally ²substituted (e.g., with 0, 1, 2, 3, 4, or 5 instances of -Me, --Et, --iPr, ²cyclopropyl, oxetan-3-yl,²-OH, =0, -F, -0Me, -CH2CII2F, -CIT2CHF2, -CH2CT12CF3, -C(=0)Me, -N(Me)2, - ²CH2N(CH3)2, -CH2N(CH3)CH2CH3, -N(iPr)(Et), -N(iPr)(Me), -N(Et)2, -N(CH3)(Et), -² ²NHC(=0)Me, or a combination thereof); and wherein:²each Rbl is independently selected from H, -C alkyl, ²(e.g., -Me, -Et, -Pr, -'Pr, -sec-Bu,²-Su), -C1-C6 haloalk-yl (e.g , -CF 3, -CHF2, -CH2CF.3), -CI-C6heteroalkyl ²substituted with ²o or 1 instances of =0 (e.g, -CH2CH2NMe2, -CH2C()NMe2, -CH(CH3)CH2NMe2, - ²CH(CH3)C(=0)NMe2), C3-C9 cycloalkyl and 3-10 member heterocyclyl (e.g. ²tetrahydrofuran-3-yl, tetrahydropyran-4-yl, oxetan-3-yl, N-Me-2-oxo-pyrolidin-²3-yl, ²piperidin-4-y1) substituted with 0 or 1 instances of =0, -Me or a combination ²thereof. ²In certain embodiments, each Rb' is independently selected from H, -Me, -Et, -²Pr, -Tr, -²sec-Bu, -CF3, -CHF2., -Cl2CF3, -CH2CH2NMe2, -CTI2C(=0)NMe2, - ²CH(CH3)CH2NMe2, -CH(CH3)C(=0)NMe2), tetrahydrofuran-3-yl, tetrahydropyran-4-²yl, ²oxetan-4-y1 and N-Me-2-oxo-pyrolidin-311.²100331 In some embodiments, each RI is independently selected from the group ²consisting²of-D,:-=0. -OH, -F, -Cl. -Br, -CN, -Me, -Et, -Pr, -Tr, -sec-Bu, -0Me, -0Et, ²-²CHF2, -CH2CF3, -CF3, -OCHF2, -CH2OH, -CH(OH)(CH3), -CH20Me, - ²C(OH)(CH3)2, -CH2NH2, -CH(CH3)(NMe2), -CH2CH(CH3)(NMe2), -CH2(CH3)(1Pr), ²-NIMe, -NITCH2CF3, -NMe2, cyclopropyl, cyclobutyl, cyclopentyl,²cyclohexyl, thiazol-2-yl, thiazol-5-yl, thiophen-2-yl, tetrahydrofuran-3-yl, ²tetrahydropyran-²17²<DP=19>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²411, oxetan-3-yl, morpholin-2-yl, -CH2-morpholin-4-yl, -(CIT2)2-morpholin-4-²yl,²2-vi, 1H-pyrazol-5-yl, 1H-imidazol-4-yl, imidazo[1,2-a]pyridin-7-yl, pyrolidin-²l-yl, ²pyrolidin-3-yl, piperidin-4-yl, piperidin-3-yl, piperidin-2-one-4-yl, ²piperazin-4-yl, piperazin-²4-yl, piperazin-2-on-5-y1 pyridine-4-yl, pyridine-3-yl, pyrazol-l-yl, pyrazol-²3-yl, pyrazol-4-²yl, pyrazol-5-yl, 1H-pyrazol-5-yl, azetidin-3-yl, -(CH2)2-pyrolidin-1-y1 -²(CH2)2-pyrolidin-2-²yl -CH2-imidazol-1-yl, -CH2-pyrazol-1-yl, -CH2-cyclopropyl, - ²0(CH2)2NMe2, -0-tetrahydrofuran-3-yl, -0-tetrahydropyran-4-yl, -0-(N-Me-2-oxo-²pyrolidin-3-y1), -0-(CH2)2-pyrolidin-2-y1 -0-CH2-piperidin-4-y1 -0-012-oxetan-²3-yl, - ²NCH3-piperidin-4-y1 -NH-oxetan-3-yl, -NH-(N-Me-2-oxo-pyrolidin-3-y1), ²decahydro-1,6-²naphthyridin-6-yl, 2-azaspiro[3.31heptan-6-yl, 5-oxa-2,8-diazaspiro[3.51nonan-²8-yl, ²azabicyclo[3.2.1 joctan-3-yl, 2-azabicyclo[2.2.2Joctan-4-yl, 3-²azabicyclor3.2.0Theptan-6-²yl, 3-azabicyclo[3.1.1]heptan-1-yl, 3-azabicyclo[3.1.0]iexan-6-yl, 1-²azabicyclo[2.2.1]heptan-²4-yl, 3-azabicyclo[3.2.0]heptan-6-yl, 2-azabicyclo[2.1.1]hexan-4-yl, 2,9-²diazaspiro[5.5]undecane-9-yl, bicyclo[1.1.11pentan-2-yl, ²octahydrocyclopentalc]pyrrol-5-²yl, decahydro-1,6-naphthyridin-6-yl, octahydro-1H-pyrrolo[3,4-c]pyridine-5-yl, ²decahydro-²2,7-naphthyridin-2-yl, 2,9-diazaspiro[5.5]undecan-2-yl, -NHC(=0)Me, - ²NHCH2C(=0)NMe2, -NHCH(CH3)C()NMe2, -C(=0)NH2, C(3)NHMe, -0C(=0)Me, - ²SO2Me, -NHSO2Me,- SO2NH2 and -S02MIMe, wherein each -0Me, -0Et, -Me, -Et, -Fr,²cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuran-3-yl, oxetan-²3-yl, ²pyrolidin-l-yl, pyrolidin-3-yl, piperidin-4-yl, piperidin-3-yl, piperidin-2-²one-4-y1 piperazin-²4-yl, pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, thiazol-2-yl, ²thiophen-2-yl, -CH2-²cyclopropyl, -CH2-morpholin-4-yl, -(CIT2)2-morpholin-4-yl, -morpholin-2-yl, --²(CH2)2-²pyrolidin-1-yl, -CH2-1,2,4-triazol-1-y1 -CH2-imidazol-1-yl, imidazol-2-y1,-CH2-²pyrazol-1-²yl, -OCH2-piperidin-4-yl, azetidin-3-yl, 2-azaspiro[3.3]heptan-6-yl, 2-methy1-²5-oxa-2,8-²diazaspiro[3.511nonan-8-yl, 8-azabicyclo[3.2.1]octan-3-yl, and decahydro-1,6-²naph thyridin-6-²yl; and wherein²each RI can be independently substituted with 0, 1, 2, 3, 4, or 5 instances ²of -Me, -Et, -'Pr, ²cyclopropyl, oxetan-3-yl, -OH, =0, -F, --0Me, --CH2CH2F, -CH2CHF2, -CH2CH2CF3, ²- ²C(=0)Me, -N(Me)2, -CH2N(CT13)2, -CH2N(CII3)CH2CI-T3,Pr)(Et), -N('Pr)(Me), - ²N(Et)2, -N(CH3)(Et), -NHC(=0)Me, or a combination thereof.²100341 In some embodiments, is optionally substituted 3-6 membered ²monocyclic ²heteterocyclyl or optionally substituted 6-10 membered bicyclic ²heteterocyclyl. In further ²embodiments, RI is -D, -Cl, -F, -Me, -CH2-0H,²18²<DP=20>²CA 03176912 2022-09-23²WO 2022 / 026892 PCT / US2021 / 044004²N =-1, ², ²CCi ).<1 .)<,F 4....k-911² I.' N ....-'10., , 41.NIJ²(N. H F)N) KINN- N ." 0²N '²C F3 'r² F '1' 1², ,²,²NVN²NH²e.,.NO i a²I " / ²' -,s" e=-"'"`===²,' N² N) N....NI-' 1,,,0,0 ,-,- ) \''N²i 1 1 H -'fs'y A V²,,,L, 6²N,,s. , -";Y'' -+' ²,²r=-"."*"=. : r:q.,1 , N².'' NI' Cis) .,,,,-0.N.....- ,...---,..Nõ, N²,.=.- 0,²0 m ..,-) 0 N ,- / - 6²6 N ' i'j:1 N.: \---- ''' N '''..N..`) 0 N ..,- 0N ...--²,L ''''N ''..= 7 N².--)=., I²' .²'²----k-) psi / l'I-... , ².n,õ 41A1V ''.7 ..._r_,...1 / 6²)---0 ''''''' -14 N N²- ²n ---- i 1²µ-` '-.,õõ:....5) N ,e2,-.......õ,õ, ².".1,t². ,²0 1 ir 'N -1 4.- ..,.²1 L.,.. N ik-,--- \ ,N ,..., .,,, ....õ .--²"cl < > I N²\\-,,, >`" I -NI"' 0 6 1 0², , , ,²0 --.,-, ,5.² L --. --(.,²---- 0 N r N N²) ..--.. 0²==-.. r-2' C 7))²--0 \---N²(õ,...,õ..0 L-0) 'Nu"' 1 Ce -1---e7²\ \²t ....4,.. ..-.;,.., ,²N²(6 'T²( µ.) ="=,:0,. ,²u²) i / ²r ², --.<-----;õ .,Nj õNõ²N N².i.< ----------------------------------------------- ²sc's '4²)."...ciss, I:bN N. N...,....õõ N õ.., P44²N² \ i², -------------------------------------------------------- ²\² / ²19²<DP=21>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²7N.²\²I²41,tfa, .(VVV²sAA,v²(6 5²N¨²²r--²2 \ Y²rN²\ / / .pr-1;²N¨²²N , c (!)²N ( F.> / ²N¨²²=AftnI Pr4;.1 I Pi; F or²100351 In some embodiments of Formula (I), (la), (lb), (Ic) and (Id), each R7 ²is ²independently selected from H, halo (e.g., F. Cl), -CN, -CI-C6 alk-yl (e.g , -²Me, -Et, -Pr, - ²Tr, -sec-Bu, -Su), 5-membered heteroaryl (e.g., pyrazolyl), -CI---C6 haloalkyl ²(e.g, -CF3, - ²CHF2, -012CF3), -CI-C6 hydroxyalkyl (e.g., -CH2OH), -C3-C9 cycloalkyl (e.g.,²cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl), (e.g, -OH, -0Me, -²OCHF2), - ²N(12a7)2 and -C(=0)N(Ra7)2 (e.g, -C(=0)NH2, -C(3)NHMe). In further ²embodiments, ²each Ra7 is independently selected from H and ---Cl---C6 alkyl (e.g., --Me, -²Et, --Pr, --'Pr,---Bu,²-sec-Bu, -iso-Bu). In some embodiments, each R7 is independently selected from ²H and ²methyl. In certain embodiments, each R7 is H. In other embodiments, each R7 is ²methyl. ²100361 in some embodiments of Formula (I), (la), (Ib), (lc) and (id), each le ²is ²independently selected from H, ---D, halo (e.g., --F, --CI), ---CN, ---Cl---C6 ²alkyl (e.g., --Me, -Et, - ²Pr, -Tr, -sec-Bu, -Su), arylakl, (e.g., benzyl), -C(=0)Ra8 (e.g., -C(=0)Me, -²C(=0)Et,-²C(=0)Pr, -C()'Pr), -N(Ra8)2 (e.g., -NHMe, NH2, NMe2), -NRa8C(=0)Ras (e.g., - ²NHC(=0)Me), ---CH2C(=0)N(Ra8)2 (e.g., ---CH2C())NH2) and -OR' (e.g., ---OH, --²0Me, ²O'Pr, -0CF3). In further embodiments, each II" is independently selected from -²CF3,and²-CI-C6 alkyl (e.g , -Me, -Et, -Pr, -'Pr,-"Bu, -sec-Bu, -iso-Bu). ²In some²embodiments, each R8 is independently selected from H, -D, -F, -Me, -Et, -CN, -²0Me, - ²&Pr, --OFC3, benzyl, --NHC(=0)Me, ---NMe2, ---CH2C(=0)NH2, ---C(=0)'Pr and --²OH. In ²certain embodiments, each R8 is independently selected from H, -D, -F, -Me, -²Et and -CN. ²In further embodiments, each R8 is independently selected from H, -D, -F and -²Me.²<DP=22>²CA 03176912 2022-09-23²WO 2022 / 026892 PCT / US2021 / 044004²100371 In some embodiments of Formula (I), (la), (lb), (Ic) and (Id), n is 0. ²In other²embodiments, n is I. In certain embodiments, n is 2. In other embodiments, n ²is 3.²In some embodiments of Formula (I), (la), (lb), (lc) and (Id), the moiety ²represented as²R7²(LI 8²XN.,r7-(R )11²R6 is selected from:²(R8),1-2²R7 Ix²²R7²r\c5) R7²AN R6 NN \ y= ,,NryiNN .,,,NilyNN A.N,r,²(R8)n-2 R6 R6 (R8)n-2 R6², , ,²n-2(R8)²\ S,,²R7²FAD²r.²A.NI)Y-Nly- (R8)6-2 '1. N²ca"(R8)fi.2 \N .,..( XN²(R862²R6 R6 R6 R6², , ,² r137<Ds R7²g²rym XN ,T>,N ____________________________________ (R8)n-2²AN,,),,,,,..,) (R8)n-2²Re (R8)n-2 R6²and R6². . ²,²100381 In some embodiments of Formula (I), (la), (lb), (Ic) and (Id), the ²moiety represented ²R7²i'll a²'31 / 4a.N y)-(R )1'²as R6 is selected from:²ii6 (R6)n.2 R6 (R8)11-2 R6 (R8)n-2 fie (R8)31-2², =²"214371,.,,..,NN V1571yNN²R6 (R8)n.2 R6 <R862²,²21²<DP=23>²CA 03176912 2022-09-23²WO 2022 / 026892 PCT / US2021 / 044004²I -²ri²xN.._;x.² ' :- N - ' I N² R6 (R8)n-2 R6 (R8)n-2 R6 '(R8)n-2 R6 N(R8)n-2²(R8)n-2 (R8)n--2 (R8)n-2 (R8).2²\². \²õ\\.:.²r \,... 6....r\--..²: \ ,²).õ.1.....) .N.N AN y=-= ;12.4.N ..,.:".."²R6 R6 R6 , R6 ,²(R8)n-2 (R8)n-2 (R8)n-2 (R6)11-2².:\r,....--. ..µ30 .....r....... ,AN y) VI;²R6 , R6 , Re , R6 ,²R7 R7 R7 R7²ri.1.0.....)1'1 ( )² __________ (Re) 2 m (R8)²"1 / 4,..N,....,..3=,,,.....õ-) n== '3, ,,,,......")=õ,.......) ²(R8)n-2 IN..........õ..1 / 4,, .-- / n -2 µ,... N...............3,,..) .R8. ²n-2²R7 R7 R7 R7² ____________ i poe 8 )²1 , go 8 µ ______ ( p 8 ) ,u1'1Y4'') (R )²c = - / n-2 ...µN ,......,,,,s,µ%.....,..1 k r'. in-2 :ALN ².......,,..1. ,,,....õ...) %. - / n-2 .,...ttri 2 ,,,,......õ / ,, ¨8 , ²n -2²,²r-----,,) .--,...õ---) õ²:32z.N.;>,, r 1 8 r''{-N\I ,R8,²-IR )n-2 ,2_ N .4\40.)¨ , ¨ in-2 \N __ _(R8)n2².-.)..,1 / ²r\) ( )²8, n-2²and²100391 In some of the above embodiments wherein the piperidine is part of a ²larger ring, n ²is 2. In some embodiments, each R6 and R7 is independently selected from H and ²¨CH3. In ²further embodiments, R6 is H. In other embodiments. R6 is ---CH3. In certain ²embodiments, ²R7 is H. In certain embodiments, R7 is ¨CH3.²100401 In some embodiments, the compounds of Formula (I), (la), (lb), (lc) and ²(Id) are ²selected from Table I.²100411 In one aspect, provided is a pharmaceutical composition comprising a ²compound of²Formula (I), (la), (lb), (Ic) and (Id) as defined herein and a ²pharmaceutically acceptable²22²<DP=24>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²carrier. In some embodiments, the pharmaceutical composition further comprises ²a second ²therapeutic agent.²10042j In one aspect, provided is a method of treating an MTAP-deficient ²and / or an MTA-²accumulating disease in a subject in need thereof by administering to the ²subject a ²therapeutically effective amotmt of a c or a pharmaceutically acceptable ²composition thereof. ²In some embodiments, the compound or composition is administered in ²combination with a ²second therapeutic agent.²100431 In some embodiments, the disease is a proliferating disease. In one ²embodiment, the ²disease is an MTAP-deficient and / or MTA-accumulating cancer. In certain ²embodiments, ²the cancer is glioblastoma, malignant peripheral nerve sheath tumors (MPNST), ²esophageal ²cancer (e.g., esophageal squamous cell carcinoma or esophageal ²adenocarcinoma), bladder ²cancer (e.g., bladder urothelial carcinoma), pancreatic cancer (e.g., ²pancreatic ²adenocarcinoma), mesothelioma, melanoma, non-small cell lung cancer (NSCLC; ²e.g, lung ²squamous or lung adenocarcinoma), astrocytoma, undifferentiated pleiomorphic ²sarcoma, ²diffuse large B-cell lymphoma (DLBCL), leukemia, head and neck cancer, stomach ²²adenocarcinoma, myxofibrosarcoma, cholarmiosarcorna, cancer of the brain, ²stomach, ²kidney, breast, endometrium, urinary tract, liver, soft tissue, pleura and ²large intestine or ²sarcoma.²100441 In one aspect, provided is a method of treating a cancer in a subject ²in need thereof ²comprising the steps of:²a) assessing the level of MTAP and / or MTA in a test sample obtained from said ²subject, ²wherein the MTA level can be assessed directly (e.g., by ELISA or LC-MS / MS) or ²indirectly ²(e.g , by SDMA-modified protein ELISA or IHC, or by RNA splicing);²b) comparing the test sample with a reference, wherein MTAP deficiency and / or ²MTA ²accumulation in said test sample compared to the reference indicates the ²cancer in said ²subject will respond to therapeutic treatment with a PRMT5 inhibitor; and²c) administering a therapeutically effective amount of a compound of Formula ²(I), (la), (lb), ²(lc) and (Id) as defined herein or a pharmaceutical composition thereof to the ²subject ²identified in step b).²Brief description of the drawings²100451 FIG. I. Frequency of MTAP homozygous deletion in cell lines ²representing ²exemplary cancers according to The Cancer Genome Atlas (TCGA).²23²<DP=25>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²100461 FIG. 2. Combination of AG-270, a MAT2A inhibitor, with an exemplar ²MTAP"-²selective PRMT5 inhibitor in a 7-day viability assay in the MTAP-null SW1573 ²cancer cell ²line demonstrates enhanced cellular viability defects²100471 FIG. 3. Combination of AG-270, a MAT2A inhibitor effect is synergistic ²according ²to the HSA. model, where the synergy score quantifies the exess of the highest ²single ²compound response²100481 FIG. 4. Combination of AMG-510; a KRASG12C inhibitor, with an exemplar ²MTAP"-selective PRMT5 inhibitor in a 7-day viability assay in the MTAP-null ²SW1573 ²cancer cell line demonstrates enhanced cellular viability defects.²100491 FIG. 5. Combination of MAPK1 / MAPK3 inhibitors (exemplified by ²ulixertinib and ²5CH772984), with an exemplar MTAP"-selective PRMT5 inhibitor in a 7-day ²viability ²assay in the MTAP-null SW1573 cancer cell line demonstrates enhanced cellular ²viability ²defect.²100501 FIG. 6. Combination of MEK inhibitors (exemplified by trametinib); with ²an ²exemplar MTAP-selective PRMT5 inhibitor in a 7-day viability assay in the MTAP-²null ²SWI.573 cancer cell line demonstrates enhanced cellular viability' defects.²100511 FIG. 7. Combination of CDK4 / 6 inhibitors (exemplified by palbociclib ²and ²abetnaciclib), with an exemplar MTAP"1-selective PRMT5 inhibitor in a 7-day ²viability ²assay in the MTAP-null AlOID cancer cell line demonstrates enhanced cellular ²viability' ²defects.²Definitions²ATIAP²100521 "MTAP" as used herein refers to methylthioadenosine phosphorylase, an ²enzyme in ²the methionine salvage pathway, also known as S-methyl-5'-thioadenosine ²phosphotylase; ²also known as BDMF; DMSFH; DMSMFH; LGMBF; MSAP; and c86fus. External IDs: ²OMIM: 156540 MGI: 1914152 HomoloGene:1838 chEMBL: 4941 GeneCards: MTAP ²Gene; Entrez 4507; RefSeq (mRNA): NM_002451; location: Chr 9: 21.8-21.93 Mb. ²By ²"wild-type" MTAP is meant that encoded by NM 002451 or having the same amino ²acid ²sequence (NP 002442). (Schmid et al. Oncogene 2000, 19, pp 5747-54).²24²<DP=26>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²As used herein, the term "MTAP-deficient","MTAP-deficiency","MTAP-null" and ²the like ²refer to cells (including, but not limited to, cancer cells, cell lines, ²tissues, tissue types, ²tumors, etc.) that have a significant reduction in post-translational ²modification, production, ²expression, level, stability and / or activity of MTAP relative to that in a ²control, e.g., reference ²or normal or non-cancerous cells. The reduction can be at least about 20%, ²30%, 40%, 50%, ²60%, 70%, 80% or 90%. In some embodiments, the reduction is at least 20%. In ²some ²embodiments, the reduction is at least 50%. The terms "MTAP-deficient and / or ²MTA ²accumulating", "MTAP-deficient and / or MTA-accumulating", MTAP deficient and / or ²MTA ²upregulated" and the like, regarding a cell or cells, etc., indicate that the ²cell or cells, etc., ²either are deficient in MTAP and / or overproduce or accumulate MTA. MTAP-²deficient cells ²include those wherein the MTAP gene has been mutated, deleted, or ²transcriptionally ²silenced. As a non-limiting example, MTAP-deficient cells can have a ²homozygous deletion. ²MTAP knockdown is not lethal. In some embodiments, the MTAP-deficient cells ²are also ²CDKN2A-deficient. The MTAP deficiency can be detected using any reagent or ²technique ²known in the art, for example: immunohistochemistry utilizing an antibody to ²MTAP, and / or ²genornic sequencing, and / or nucleic acid hybridization and / or amplification ²utilizing at least ²one probe or primer comprising a sequence of at least 12 contiguous ²nucleotides (nt) of the ²sequence of MTAP, wherein the primer is no longer than about 30 nt.²
[0053] An "MTAP-deficiency-related" or "MTAP-deficiency" or "MTAP deficient" ²disease (for example, a proliferating disease, e.g, a cancer) or a disease ²(for example, a ²proliferating disease, e.g., a cancer)"associated with MTAP deficiency" or a ²disease (for ²example, a proliferating disease, e.g., a cancer) "characterized by MTAP ²deficiency" and the ²like refer to an ailment (for example, a proliferating disease, e.g., a ²cancer) wherein a ²significant number of cells are MTAP-deficient. For example, in a MTAP-²deficiency-related ²disease, one or more disease cells can have a significantly reduced post-²translational ²modification, production, expression, level, stability and / or activity of ²MTAP. Examples of ²MTAP-deficiency-related diseases include, but are not limited to, cancers, ²including but not ²limited to: glioblastoma, malignant peripheral nerve sheath tumors (MPNST), ²esophageal ²cancer (e.g., esophageal squamous cell carcinoma or esophageal ²adenocarcinoma), bladder ²cancer (e.g , bladder urothelial carcinoma), pancreatic cancer (e.g , ²pancreatic ²adenocarcinoma), mesothelioma, melanoma, non-small cell lung cancer (NSCLC; ²e.g., lung ²squamous or lung adenocarcinoma), astrocytoma, undifferentiated pleiomorphic ²sarcoma, ²diffuse large B-cell lymphoma (DLI3CL), leukemia, head and neck cancer, ²stomach²<DP=27>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²adenocarcinoma, myxofibrosarcoma, cholangiosarcoma, cancer of the brain, ²stomach, ²kidney, breast, endometrium, urinary tract, liver, soft tissue, pleura and ²large intestine or ²sarcoma (See FIG. 1). In a patient afflicted with a MTAP-deficiency-related ²disease, it is ²possible that some disease cells (e.g., cancer cells) can be MTAP-deficient ²while others are ²not. Similarly, some disease cells may be MTA-accumulating while others are ²not. ²Thus, the present disclosure encompasses methods of treatment involving ²diseases of these ²tissues, or any other tissues, wherein the proliferation of MTAP-deficient ²and / or MTA-²accumulating cells can be inhibited by administration of a PRMT5 inhibitor.²Some cancer cells which are MTAP-deficient are also deficient in CDKN2A; the ²post-²translational modification, production, expression, level, stability and / or ²activity of the ²CDKN2A gene or its product are decreased in these cells. The genes for MTAP ²and ²CDKN2A are in close proximity on chromosome 9p21; MTAP is located ²approximately 100 ²kb telomeric to CDKN2A. Many cancer cell types harbor CDKN2A / MTAP loss (loss ²of ²both genes). Thus, in some embodiments, a MTAP-deficient cell is also ²deficient in ²CDKN2A.²MTA and MTA accumulation ²100541 By "MTA" is meant the PRMT5 inhibitor also known as methyl-²thioadenosine, 5-²methy1-5'-thioadenosine, [51deoxy-5'-(methylthio)-fl-D-ribofuranosyl] adenine, ²5'-methyl-²thioadenosine, 5'-deoxy, 5'-methyl thioadenosine, and the like. MTA ²selectively inhibits ²PRMT5 methyltransferase activity. MTA is the sole known catabolic substrate ²for MTAP. ²The terms "MTA accumulating", "MTA overproducing", "MTA upregulated" and the ²like ²refer to cells (including, but not limited to, cancer cells, cell lines, ²tissues, tissue types, ²tumors, etc.) that have a significantly increased production, level and / or ²stability of MTA. ²MTA-accumulating cells include those wherein the cells comprise at least about ²20%, 30%, ²40%, 50%, 60%, 70%, 80%, 90%, 100%, or greater than 100%, higher production, ²level ²and / or stability of MTA than that in normal or non-cancerous cells. In some ²embodiments, ²MTA-accumulating cells include those wherein the cells comprise at least 20% ²higher ²production, level and / or stability of MTA than that in normal or non-cancerous ²cells. In ²some embodiments, MTA-accumulating cells include those wherein the cells ²comprise at ²least 50% higher production, level and / or stability of MTA than that in normal ²or non-²cancerous cells. Determination of MTA accumulation in test samples (e.g., ²cells such as ²cancer cells being tested for MTA accumulation) and reference samples, and ²other cells,²26²<DP=28>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²tissues, samples, etc., can be performed using any method known in the art. ²Such methods ²for detecting MTA include, as a non-limiting example, liquid ²chromatography¨electrospray ²ionization¨tandem mass spectrometry (LC-ESI-MS / MS), as described in Stevens et ²al. J. ²Chromatogr. A. 2010, 1217, pp 3282-3288; and Kirovski et al. Am. .1. Pathol. ²2011, 178, ²pp 1145-1152; and references cited therein. Loss of MTAP is associated with ²accumulation ²of MTA (Williams-Ashman et al. Biochem. Pharm. 1982, 31, pp 277-288; and Limm ²et al. ²Eur. J. Cancer. 2013, 49, Issue 6.²100551 An "MTA-accumulation-related", "MTA-accumulation", "MTA-accumulating", ²"MTA overproducing", "MTA upregulated" disease (for example, a proliferating ²disease, ²e.g, a cancer) or a disease (for example, a proliferating disease, e.g., a ²cancer) "associated ²with MTA accumulation" or a disease (for example, a proliferating disease, ²e.g., a cancer) ²"characterized by MTA accumulation" and the like refer to an ailment (for ²example, a ²proliferating disease, e.g, a cancer) wherein a significant number of cells ²are MTA ²accumulating. Examples of MTA-accumulating diseases include, but are not ²limited to, ²cancers, including but not limited to: glioblastoma, malignant peripheral ²nerve sheath tumors ²(MPNST), esophageal cancer (e.g, esophageal squamous cell carcinoma or ²esophageal ²adenocarcinoma), bladder cancer (e.g., bladder urothelial carcinoma), ²pancreatic cancer (e.g., ²pancreatic adenocarcinoma), mesothelioma, melanoma, non-small cell lung cancer ²(NSCLC; ²e.g., lung squamous or lung adenocarcinoma), astrocytoma, undifferentiated ²pleiomorphic ²sarcoma, diffuse large B-cell lymphoma (DLBCL), leukemia, head and neck ²cancer, stomach ²adenocarcinoma, myxofibrosarcoma, cholangiosarcoma, cancer of the brain, ²stomach, ²kidney, breast, endometrium, urinary tract, liver, soft tissue, pleura and ²large intestine or ²sarcoma (See FIG. I). In a patient afflicted with a MTAP-deficiency-related ²disease, it is ²possible that some disease cells (e.g., cancer cells) can be MTAP-deficient ²while others are ²not.²In a patient having or having been diagnosed with an MTA-accumulating disease, ²some cells ²may be MTA-accumulating while others are not.²100561 Anincrease in therapeutic window between normal cells and MTAP-²deleted / MTA ²accumulating cells could be achieved by using an inhibitor that binds PRMT5²tificompetitively with MTA. As used herein, "uncompetitive binding" and ²"uncompetitive ²inhibition" and "cooperative binding" and "cooperative inhibition" (e.g, MTA-²uncompetitive ²binding, MTA-uncompetitive inhibition, MTA-cooperative binding, MTA-²cooperative ²inhibition) refers to binding of an. inhibitor to a protein (e.g., PRMT5) that ²is increased in the²27²<DP=29>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²presence of a co-factor (e.g., MTA) over the binding of the same inhibitor in ²the absence of ²the co-factor. The PRMT5 inhibitors known in the art are generally either SAM ²(5-²adenosylmethionine) uncompetitive or SAM competitive. As the concentration of ²SAM in ²wild-type and MTAP-null cells is similar, these inhibitors are expected to ²bind with similar ²potency to both cell types. By contrast, an MTA-cooperative (and either SAM ²competitive or ²showing enhanced cooperativity with MTA relative to SAM) inhibitor would bind ²with ²apparent greater potency in the presence of high concentrations of MTA and ²would therefore ²result in preferential inhibition of PRMT5 in MTA-accumulating cells relative ²to normal ²cells.²10057j As described further herein, a cancer cell, a cancer type, or a subject ²with cancer, is ²"PRMT5 inhibitor sensitive," sensitive to treatment with PRMT5 inhibitors," ²sensitive to ²PRMT5 therapeutic inhibition," or described in similar terms if it is amenable ²to treatment ²with a PRMT5 inhibitor, e.g., due to its MTAP deficiency and / or MTA ²accumulation ²character.²PRAM²100581 "PRMT5" as used herein is the gene or protein Protein Arginine ²Methyltransferase ²5, also known as HRMT1L5; IBP72; JIM; SKBI; or SKB IHs External IDs: OMIM: ²604045, MGI: 1351645, HomoloGene: 4454, ChEMBL: 1795116, GeneCards: PRMT5 ²Gene; EC number 2.1.1.125. Ensembl ENSG00000100462; UniProt 014744; Entrez ²Gene ²ID: 10419; RefSeq (mRNA): NM_001039619. The mouse homolog is NM 013768. ²Methyltransferases such as PRMT5 catalyze the transfer of one to three methyl ²groups from. ²the co-factor S-adenosylmethionine (also known as SAM or AdoMet) to lysine or ²arginine ²residues of histone proteins. Arginine methylation is carried out by 9 ²different protein ²arginine methyltransferases (PRMT) in humans. Three types of methylarginine ²species exist: ²(1) Monomethylarginine (MMA); (2) Asymmetric dimethyl arginine (Al)MA), which ²is ²produced by Type I methyl transferases (PRMT1, PRMT2, PRMT3, CALM 1, PRMT6 and ²²PRMT8); and (3) Symmetrical dimethylarginine (SDMA), which is produced by Type ²II ²methyl transferases (PRMT5 and PRM.T7). PRMTI and PRMT5 are the major ²asymmetric ²and symmetric arginine methyltransferases, respectively. PRMT5 promotes ²symmetric ²dimethylation on histones at H3R8 and H4R3 (H4R3me2). Symmetric methylation of ²H4R3 ²is associated with transcriptional repression and can act as a binding site ²for DNMT3A. Loss ²of PRMT5 results in reduced DNMT3A binding and gene activation. Tumor ²suppressor gene²28²<DP=30>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²ST7 and chemokines RNATES, IP10, CXCL 11 are targeted and silenced by PRMT5. ²WO ²2011 / 079236.²100591 Additional substrates include E2F1, p53, EGFR and CRAF. PRMT5 is part ²of a ²multi-protein complex comprising the co-regulatory factor WDR77 (also known as ²MEP50, a ²CDK4 substrate) during Gl. / S transition. Phosphorylation increases PRMT5 / WDR77 ²²activity. WDR77 is the non-catalytic component of the complex and mediates ²interactions ²with binding partners and substrates. PRMT5 can also interact with pICIn or ²RioK1 adaptor ²proteins in a mutually exclusive fashion to modulate complex composition and ²substrate ²specificity.²100601 PRMT5 has either a positive or negative effect on its substrates by ²arginine ²methylation when interacting with a number of complexes and is involved in a ²variety of ²cellular processes, including RNA processing, signal transduction, ²transcriptional regulation, ²and germ cell development. PRMT5 is a major pro-survival factor regulating ²elF4E ²expression and p53 translation. PRMT5 triggers p53-dependent apoptosis and ²sensitized ²various cancer cells to Tumor necrosis factor (TNF)-related apoptosis-inducing ²ligand ²(TRAIL) without affecting TRAIL resistance in non-transformed cells.²100611 The term "PRMT5 inhibitor" refers to any compound capable of inhibiting ²the ²production, level, activity, expression or presence of PRMT5. These include, ²as non-limiting ²examples, any compound inhibiting the transcription of the gene, the ²maturation of RNA, the ²translation of rriRNA, the posttranslational modification of the protein, the ²enzymatic activity ²of the protein, the interaction of same with a substrate, etc. The term also ²refers to any agent ²that inhibits the cellular function of the PRMT5 protein, either by ATP-²competitive inhibition ²of the active site, allosteric modulation of the protein structure, disruption ²of protein-protein ²interactions, or by inhibiting the transcription, translation, post-²translational modification, or ²stability of PRMT5 protein.²100621 In some embodiments, a PRMT5 inhibitor competes with another compound, ²protein or other molecule which interacts with PRMT5 and is necessary for ²PRMT5 function. ²As a non-limiting example, a PRMT5 inhibitor can compete with the co-factor 5-²adenosylmethionine (also known as SAM or AdoMet).²In some embodiments, the PRMT5 inhibitor is uncompetitive with MTA. In further ²²embodiments, the PRMT5 inhibitor is uncompetitive with miA and competitive ²with SAM.²29²<DP=31>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²In some embodiments, the PRMT5 inhibitor is uncompetitive with MTA and ²uncompetitive ²with SAM but binds with a higher degree of potency for the MTA complex ²relative to the ²SAM complex.²Chemical Definitions ²100631 Definitions of specific functional groups and chemical terms are ²described in more ²detail below. The chemical elements are identified in accordance with the ²Periodic Table of ²the Elements, CAS version, Handbook of Chemistry and Physics, 75th Ed., inside ²cover, and ²specific functional groups are generally defined as described therein. ²Additionally, general ²principles of organic chemistry, as well as specific functional moieties and ²reactivity, are ²described in Thomas Sorrell, Organic Chemistry, University Science Books, ²Sausalito, 1999; ²Smith and March, March Advanced Organic Chemistry, 5th Edition, John Wiley & ²Sons, ²Inc., New York, 2001; Larock, Comprehensive Organic Transformations, VCH ²Publishers, ²Inc., New York, 1989; and Carruthers, Some Modern Methods of Organic ²Synthesis, 31. ²Edition, Cambridge University Press, Cambridge, 1987.²100641 Compounds described herein can comprise one or more asymmetric centers, ²and ²thus can exist in various isomeric forms, e.g., enantiomers and / or ²diastereomers. For ²example, the compounds described herein can be in the form of an individual ²enantiomer, ²diastereomer or geometric isomer, or can be in the form of a mixture of ²stereoisomers, ²including racemic mixtures and mixtures enriched in one or more stereoisomer. ²Isomers can ²be isolated from mixtures by methods known to those skilled in the art, ²including chiral high-²pressure liquid chromatography (HPLC) and the formation and crystallization of ²chiral salts; ²or preferred isomers can be prepared by asymmetric syntheses. See, for ²example, Jacques et²Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); ²Wilen ²et al., Tetrahedron 33:2725 (1977); Eliel, Stereochemistry of Carbon Compounds ²(McGraw¨²Hill, NY, 1962); and Wilen, Tables of Resolving Agents and Optical Resolutions ²p. 268 (E.L. ²Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972). The invention ²additionally ²encompasses compounds described herein as individual isomers substantially ²free of other ²isomers, and alternatively, as mixtures of various isomers.²100651 The "enantiomeric excess" ("e.e.") or "% enantiomeric excess" ("%e.e.") ²of a ²composition as used herein refers to an excess of one enantiomer relative to ²the other ²enantiomer present in the composition. For example, a composition can contain ²90% of one ²enantiomer, e.g., the S enantiomer, and 10% of the other enantiomer, i.e., the ²R enantiomer.²<DP=32>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²e. e. = (90-10) / 100 = 80%.²100661 Thus, a composition containing 90% of one enantiomer and 10% of the ²other ²enantiomer is said to have an enantiomeric excess of 80%.²[00671 The "diastereomeric excess" ("d.e.") or 44) / 0 diastereomeric excess" ²("%d.e.") of a ²composition as used herein refers to an excess of one diastereomer relative to ²one or more ²different diastereomers present in the composition. For example, a composition ²can contain ²90% of one diastereomer, and 10% of one or more different diastereomers.²d.e. = (90-10) / 100 = 80%.²[00681 Thus, a composition containing 90% of one diastereomers and 10% of one ²or more ²different diastereomers is said to have a diastereomeric excess of 80%.²In an alternative embodiment, compounds described herein may also comprise one ²or more ²isotopic substitutions. For example, hydrogen may be 2H (D or deuterium) or 3H ²(T or ²tritium); carbon may be, for example, '3C or 14C; oxygen may be, for example, ²180; nitrogen ²may be, for example, '51µ1, and the like. In other embodiments, a particular ²isotope (e.g., 3H,²13C, 14C, 18,-% or -- 15²N) can represent at least 1%, at least 5%, at least 10%, at least 15%, at ²least ²20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at ²least 50%, at least ²60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at ²least 90%, at least ²95%, at least 99%, or at least 99.9% of the total isotopic abundance of an ²element that ²occupies a specific site of the compound.²100691 in a formula, is a single bond where the stereochemistly of the ²moieties ²immediately attached thereto is not specified.²When a range of values is listed, it is intended to encompass each value and ²sub-range within ²the range. For example, "C1--6 alkyl" is intended to encompass, Ci, C2, C3, ²C.4, C5, C6, C1--6, ²C1--5, CJ.-4. C1-3, C1-2, C2--6, C2-5, C2--4, C2--3, C3--6, C3-5, C3--4, C4--²6, C4--5, and C5--6 alkyl. ²The following terms are intended to have the meanings presented therewith ²below and are ²useful in understanding the description and intended scope of the present ²invention. When ²describing the invention, which may include compounds, pharmaceutical ²compositions ²containing such compounds and methods of using such compounds and ²compositions, the ²following terms, if present, have the following meanings unless otherwise ²indicated. It ²should also be understood that when described herein any of the moieties ²defined forth below ²may be substituted with a variety of substituents, and that the respective ²definitions are ²intended to include such substituted moieties within their scope as set out ²below. Unless ²otherwise stated, the term "substituted" is to be defined as set out below. It ²should be further²31²<DP=33>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²understood that the terms "groups" and "radicals" can be considered ²interchangeable when ²used herein. The articles "a" and "an" may be used herein to refer to one or ²to more than one ²(i.e. at least one) of the grammatical objects of the article. By way of ²example "an analogue" ²means one analogue or more than one analogue.²100701 The term "unsaturated bond" refers to a double or triple bond.²100711 The term "unsaturated" or "partially unsaturated" refers to a moiety ²that includes at ²least one double or triple bond.²100721 The term "saturated" refers to a moiety that does not contain a double ²or triple bond, ²i.e., the moiety only contains single bonds.²Affixing the suffix "-ene" to a group indicates the group is a divalent ²moiety; e.g, ak,rlene is ²the divalent moiety of alkyl, alkenylene is the divalent moiety of alkenyl, ²alkynylene is the ²divalent moiety of alkynyl, heteroalkylene is the divalent moiety of ²heteroalkyl, ²heteroalkenylene is the divalent moiety of heteroalkenyl, heteroalkynylene is ²the divalent ²moiety of heteroalkynyl, carbocyclylene is the divalent moiety of carbocyclyl; ²²heterocyclylene is the divalent moiety of heterocyclyl, atylene is the ²divalent moiety of aryl, ²and hetermuylene is the divalent moiety of heteroaryl.²100731 The term "azido" refers to the radical ¨N3.²"Aliphatic" refers to an alkyl, alkenylõ alkynyl, or carbocyclyl group, as ²defined herein. ²"Cycloalkyla141" refers to an alkyl radical in which the alkyl group is ²substituted with. a ²cycloalk-yl group. Typical cycloalkylalkyl groups include, but are not limited ²to, ²cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, ²cycloheptylmethyl, cyclooctylmethyl, cyclopropylethyl, cyclobutylethyl, ²cyclopentylethyl, ²cyclohexylethyl, cycloheptylethyl, and cyclooctylethyl, and the like.²100741 "Heterocyclylalkyl" refers to an alkyl radical in which the alkyl group ²is substituted ²with a heterocyclyl group. Typical heterocyclylalkyl groups include, but are ²not limited to, ²pyrrolidinylmethyl, piperidinylmethyl, piperazinylmethyl, morpholinylmethyl, ²pyrrolidinylethyl, piperidinylethyl, piperazinylethyl, morpholinylethyl, and ²the like. ²"Aralk-yl" or "m,rlalk-y1" is a subset of alkyl and aryl, as defined herein, ²and refers to an ²optionally substituted alkyl group substituted by an optionally substituted ²atyl group. ²"Alkyl" refers to a radical of a straight¨chain or branched saturated ²hydrocarbon group ²having from 1 to 20 carbon atoms ("C i.-.20 alkyl"). In some embodiments, an ²alkyl group has ²1 to 12 carbon atoms ("C1-12 alkyl"). In some embodiments, an alkyl group has ²1 to 10 ²carbon atoms ("Ci--10 alkyl"). In. some embodiments, an alkyl group has 1 to 9 ²carbon atoms²32²<DP=34>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²(-C1-9 alkyl"). In some embodiments, an alkyl group has Ito 8 carbon atoms ²("Ci-s alkyl"). ²In some embodiments, an alkyl group has I to 7 carbon atoms ("Ci--7 alkyl"). ²In some ²embodiments, an alkyl group has 1 to 6 carbon atoms ("CI-6 alkyl", also ²referred to herein as ²"lower alkyl"). In some embodiments, an alkyl group has 1 to 5 carbon atoms ²("C1-5 alkyl"). ²In some embodiments, an alkyl group has 1 to 4 carbon atoms ("CI.-4 alkyl"). ²In some ²embodiments, an alkyl group has 1 to 3 carbon atoms ("Cl--3 alkyl"). In some ²embodiments, ²an alkyl group has I to 2 carbon atoms ("C1-2 alkyl"). In some embodiments, an ²alkyl group ²has 1 carbon atom ("CI alkyl"). In some embodiments, an alkyl group has 2 to 6 ²carbon ²atoms ("C2--6a1ky1"). Examples of CI-6 alkyl groups include methyl (CI), ethyl ²(C2), n-propyl ²(C3), isopropyl (C3), n--butyl (C4), tert-butyl (C4), sec-butyl (C4), iso-²butyl (C4), n-pentyl ²(Cs), 3-penta.nyl (Cs), amyl (Cs), neopentyl (Cs), 3-methyl-2-butanyl (Cs), ²tertiary amyl ²(Cs), and n-hexyl (Co). Additional examples of alkyl groups include n-heptyl ²(C7), n-octyl ²(Cs) and the like. Unless otherwise specified, each instance of an alkyl group ²is²independently optionally substituted; i.e., unsubstituted (an "unsubstituted ²alkyl") or ²substituted (a "substituted alkyl") with one or more substituents; e.g., for ²instance from I to 5 ²substituents, I to 3 substituents, or I substituent. In certain embodiments, ²the alkyl group is ²unsubstituted CI-10 alkyl (e.g., -CH3). In certain embodiments, the alkyl ²group is substituted ²Ci-io alkyl. Common alkyl abbreviations include Me (-CH3), Et (-012CH3), Pr (-²CH(CH3)2), "Pr (-CH2CH2CH3), "Bu (-CH2CH2CH2CH3), or 'Bu (-CH2CH(CH3)2).²[00751 "Allcylene" refers to an alkyl group wherein two hydrogens are removed ²to provide ²a divalent radical, and which may be substituted or unsubstituted. ²Unsubstituted alkylene ²groups include, but are not limited to, methylene (-CH2-), ethylene (-CH2CT12-²), propylene (-²CH2CH2CH2-), butylene (-CH2CH2CH2CH2-), pentylene (-CH2CH2CH2CH2CH2-), ²hexylene ²(-CH2CH2CH2CH2CH2CH2-), and the like. Exemplary substituted alkylene groups, ²e.g, ²substituted with one or more alkyl (methyl) groups, include but are not ²limited to, substituted ²methylene (-CH(CH3)-, (-C(CH3)2-), substituted ethylene (-CH(CH3)CH2-,-²CH2CH(CH3)-, ²-C(CH3)2CH2-,-CH2C(CH3)2-), substituted propylene (-CH(CH3)CH2CH2-, - ²CH2CH(CH3)CH2-, -CH2CH2CH(CH3)-, --C(CH3)2CH2CH2-, --CH2C(CH3)2CH2-, ²CH2CH2C(CH3)2-), and the like. When a range or number of carbons is provided ²for a ²particular alkylene group, it is understood that the range or number refers to ²the range or ²number of carbons in the linear carbon divalent chain. Alkylene groups may be ²substituted or ²unsubstituted with one or more substituents as described herein.²33²<DP=35>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²
[0076] "Alkenyl" refers to a radical of a straight-chain or branched ²hydrocarbon group ²having from 2 to 20 carbon atoms, one or more carbon-carbon double bonds (e.g ², 1, 2, 3, or ²4 carbon-carbon double bonds), and optionally one or more carbon-carbon triple ²bonds (e.g., ²1, 2, 3, or 4 carbon-carbon triple bonds) ("C2-20 alkenyl"). In certain ²embodiments, alkenyl ²does not contain any triple bonds. In some embodiments, an alkenyl group has 2 ²to 10 ²carbon atoms ("C2-10 alkenyl"). In some embodiments, an alkenyl group has 2 to ²9 carbon ²atoms ('.C2-9 alkenyl"). In some embodiments, an alkenyl group has 2 to 8 ²carbon atoms ²("C2-8 alkenyl"). In some embodiments, an alkenyl group has 2 to 7 carbon ²atoms ("C2-7 ²alkenyl"). In some embodiments, an alkenyl group has 2 to 6 carbon atoms ('C2-²6 alkenyl"). ²In some embodiments, an alkenyl group has 2 to 5 carbon atoms ('-C2-5 ²alkenyl"). In some ²embodiments, an alkenyl group has 2 to 4 carbon atoms ("C2-4 alkenyl"). In ²some ²embodiments, an alkenyl group has 2 to 3 carbon atoms ("C2-3 alkenyl"). In ²some ²embodiments, an alkenyl group has 2 carbon atoms ("C2 alkenyl"). The one or ²more carbon-²carbon double bonds can be internal (such as in 2-butenyl) or terminal (such ²as in 1-buteny1). ²Examples of C2-4 alkenyl groups include ethenyl (C2), 1-propenyl (C3), 2-²propenyl (C3), 1-²butenyl (C4), 2-butenyl (C4), butadienyl (C4), and the like. Examples of C2--6 ²alkenyl groups ²include the aforementioned C2-4 alkenyl groups as well as pentenyl (C5), ²pentadienyl (C5), ²hexenyl (C6), and the like. Additional examples of alkenyl include heptenyl ²(C7), octenyl ²(Cs), octatrienyl (Cs), and the like. Unless otherwise specified, each ²instance of an alkenyl ²group is independently optionally substituted, i.e., unsubstituted (an ²"unsubstituted alkenyl") ²or substituted (a "substituted alkenyl") with one or more substituents e.g., ²for instance from 1 ²to 5 substituents, 1 to 3 substituents, or 1 substituent. In certain ²embodiments, the alkenyl ²group is unsubstituted C2-10 alkenyl. In certain embodiments, the alkenyl ²group is substituted ²C2-10 alkenyl.²100771 "Alkynyl" refers to a radical of a straight-chain or branched ²hydrocarbon group ²having from 2 to 20 carbon atoms, one or more carbon-carbon triple bonds (e.g ², 1, 2, 3, or 4 ²carbon-carbon triple bonds), and optionally one or more carbon-carbon double ²bonds (e.g., ²1, 2, 3, or 4 carbon-carbon double bonds) ('C2-20 alkynyl"). In certain ²embodiments, alkynyl ²does not contain any double bonds. In some embodiments, an alkynyl group has 2 ²to 10 ²carbon atoms ("C2.. .lo alkynyl"). In some embodiments, an alkynyl group has 2 ²to 9 carbon ²atoms ("C2-9 alkynyl"). In some embodiments, an alkynyl group has 2 to 8 ²carbon atoms ²("C2-s alkynyl"). In some embodiments, an alkynyl group has 2 to 7 carbon ²atoms ("C2-7 ²alkynyl"). In some embodiments, an alkynyl group has 2 to 6 carbon atoms ("C2-²6 alkynyl").²34²<DP=36>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²In some embodiments, an alkynyl group has 2 to 5 carbon atoms ("C2-5 ²alkynyl"). In some ²embodiments, an alkynyl group has 2 to 4 carbon atoms ("C2.-4 alkynyl"). In ²some ²embodiments, an alkynyl group has 2 to 3 carbon atoms ("C2-3 alkynyl"). In ²some ²embodiments, an alkynyl group has 2 carbon atoms ("C2 alkynyl"). The one or ²more carbon-²carbon triple bonds can be internal (such as in 2-butynyl) or terminal (such ²as in 1-butyny1). ²Examples of C2-4 alkynyl groups include, without limitation, ethynyl (C2), 1-²propynyl (C3), ²2-propynyl (C3), 1-butynyl (C4), 2-butynyl (C4), and the like. Examples of C2-²6 alkenyl ²groups include the aforementioned C2-4 alkynyl groups as well as pentynyl ²(Cs), hexynyl ²(C6), and the like. Additional examples of alkynyl include heptynyl (C7), ²octynyl (C8), and ²the like. Unless otherwise specified, each instance of an alkynyl group is ²independently ²optionally substituted, i.e., unsubstituted (an "unsubstituted alkynyl") or ²substituted (a ²"substituted alkynyl") with one or more substituents; e.g., for instance from ²1 to 5 ²substituents, 1 to 3 substituents, or 1 substituent. In certain embodiments, ²the alkynyl group ²is unsubstituted C2-10 alkynyl. In certain embodiments, the alkynyl group is ²substituted C2-10 ²alkynyl.²100781 The term "heteroalkyl," as used herein, refers to an alkyl group, as ²defined herein, ²which further comprises 1 or more (e.g, 1, 2, 3, or 4) heteroatoms (e.g, ²oxygen, sulfur, ²nitrogen, boron, silicon, phosphorus) within the parent chain, wherein the one ²or more ²heteroatoms is inserted between adjacent carbon atoms within the parent carbon ²chain and / or ²one or more heteroatoms is inserted between a carbon atom and the parent ²molecule, i.e., ²between the point of attachment. In certain embodiments, a heteroalkyl group ²refers to a ²saturated group having from 1 to 10 carbon atoms and 1, 2, 3, or 4 heteroatoms ²("heteroCi-io ²alkyl"). In some embodiments, a heteroalkyl group is a saturated group having ²1 to 9 carbon ²atoms and 1, 2, 3, or 4 heteroatoms ("heteroC1-9 alkyl"). In some embodiments, ²a heteroalkyl ²group is a saturated group having I to 8 carbon atoms and I, 2, 3, or 4 ²heteroatoms ²("h.eteroCi-,s alkyl"). In some embodiments, a heteroalkyl group is a ²saturated group having 1 ²to 7 carbon atoms and 1, 2, 3, or 4 heteroatoms ("heteroCi.--7 alkyl"). In ²some embodiments, a ²heteroalkyl group is a group having 1 to 6 carbon atoms and 1, 2, or 3 ²heteroatoms ²("heteroCi-6 alkyl"). In some embodiments, a heteroalkyl group is a saturated ²group having 1 ²to 5 carbon atoms and 1 or 2 heteroatoms ("heteroCi--5 alkyl"). In some ²embodiments, a ²heteroalkyl group is a saturated group having 1 to 4 carbon atoms and 1 or 2 ²heteroatoms ²("heteroCi4 alkyl"). In some embodiments, a heteroalkyl group is a saturated ²group having 1 ²to 3 carbon atoms and 1 heteroatom ("heteroC1.-.3 alkyl"). In some ²embodiments, a²<DP=37>²CA 03176912 2022-09-23² WO 2022 / 026892 PCT / US2021 / 044004²heteroalkyl group is a saturated group having 1 to 2 carbon atoms and 1 ²heteroatom ²("heteroCi--2 alkyl"). In some embodiments, a heteroalkyl group is a saturated ²group having I ²carbon atom and 1 heteroatom ("heteroCi alkyl"). In some embodiments, a ²heteroalkyl group ²is a saturated group having 2 to 6 carbon atoms and I or 2 heteroatoms ²("heteroC2-6alkyl"). ²Unless otherwise specified, each instance of a heteroalkyl group is ²independently ²unsubstituted (an "unsubstituted heteroalkyl") or substituted (a "substituted ²heteroalkyl") ²with one or more substituents. In certain embodiments, the heteroalkyl group ²is an ²unsubstituted heteroCi-io alkyl. In certain embodiments, the heteroalkyl group ²is a ²substituted heteroCi -.io alkyl. Exemplary heteroalkyl groups include: -CI-²120H, -CH2OCH.3, ²-CH2NH2, ---CH2NH(CH3), -CH2N(CH3)2, ---CH2CFI20H, ---CH2CH2OCH3, ---²CF1.2CH2NH2, ²CII2CH2NH(CH3), -CH2CTI2N(CH:02.²100791 "Aryl" refers to a radical of a monocyclic or polycyclic (e.g., ²bicyclic or tricyclic) ²411+2 aromatic ring system (e.g, having 6, 10, or 14 it electrons shared in a ²cyclic array) ²having 6-14 ring carbon atoms and zero heteroatoms provided in the aromatic ²ring system ²("C6-14 aryl"). In some embodiments, an aryl group has six ring carbon atoms ²("C6my1"; ²e.g., phenyl). In some embodiments, an aryl group has ten ring carbon atoms ²("Cio aryl"; ²e.g, naphthyl such as 1-naphthyl and 2-naphthyl). In some embodiments, an aryl ²group has ²fourteen ring carbon atoms ("C14 aryl"; e.g, anthracyl). "Aryl" also includes ²ring systems ²wherein the aryl ring, as defined above, is fused with one or more carbocyclyl ²or heterocyclyl ²groups wherein the radical or point of attachment is on the aryl ring, and in ²such instances, ²the number of carbon atoms continue to designate the number of carbon atoms in ²the atyl ring ²system. Particularly aryl groups include phenyl, naphthyl, indenyl, and ²tetrahydronaphthyl. ²Unless otherwise specified, each instance of an aryl group is independently ²optionally ²substituted, i.e., unsubstituted (an "unsubstituted aryl") or substituted (a ²"substituted aryl") ²with one or more subsfituents. In certain embodiments, the aryl group is ²unsubstituted C6-I4 ²aryl. In certain embodiments, the aryl group is substituted C6-14 aryl.²100801 in certain embodiments, an aryl group is substituted with one or more ²of groups ²selected from halo, Ci-C8 alkyl, Ci---C8 haloalkyl, cyano, hydroxy, Ci-C8 ²alkoxy, and amino. ²100811 Examples of representative substituted aryls include the following² R88 --R88 R58²=R57 and²\ R57 =²36²<DP=38>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²wherein one of R56 and R5' may be hydrogen and at least one of R56 and R5' is ²each ²independently selected from CI-C8 alkyl, Ci-Cs haloalkyl, 440 membered ²heterocyclyl,²alkanoyl, alkoxy, ²heteroaryloxy, alkylamino, arylatnino, heterowylamino, NR58C0R59,²NR58S0R59NR58S02R59, COOalkyl, COOmyl, CONR"R", CONR"OR", NR"R", ²S02NR58R59, S-alkyl, SOalkyl, SO2alkyl, Saryl, SOaryl, SO2aryl; or R56 and R57 ²may be ²joined to form a cyclic ring (saturated or unsaturated) from 5 to 8 atoms, ²optionally ²containing one or more heteroatoms selected from the group N, 0, or S. R6' and ²R61 are ²independently hydrogen, Ci-Cs alkyl, CI-C4haloalkyl, C3-C10 cycloalkyl, 4-10 ²membered ²heterocyclyl, C6-Cio aryl, substituted C6-Cio aiyl, 5-10 membered heteroaryl, ²or substituted ²5-10 membered heteroaryl.²"Fused aryl" refers to an aryl having two of its ring carbons in common with a ²second aryl or ²heteroaryl ring or with a au-bocycly1 or heterocyclyl²100821 "Heteroaryl" refers to a radical of a 5-10 membered monocyclic or ²bicyclic 4n+2 ²aromatic ring system (e.g., having 6 or 10 It electrons shared in a cyclic ²array) having ring ²carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, ²wherein each ²heteroatom is independently selected from nitrogen, oxygen and sulfur ("5-10 ²membered ²heteroaryl"). In heteroaryl groups that contain one or more nitrogen atoms, ²the point of ²attachment can be a carbon or nitrogen atom, as valency permits. Heteroaryl ²bicyclic ring ²systems can include one or more heteroatoms in one or both rings. "Heteroaryl" ²includes ²ring systems wherein the heteroaryl ring, as defined above, is fused with one ²or more ²carbocyclyl or heterocyclyl groups wherein the point of attachment is on the ²heteroaryl ring, ²and in such instances, the number of ring members continue to designate the ²number of ring ²members in the heteroaryl ring system. "Heteroaryl" also includes ring systems ²wherein the ²heteroaryl ring, as defined above, is fused with one or more aryl groups ²wherein the point of ²attachment is either on the aryl or heteroaryl ring, and in such instances, ²the number of ring ²members designates the number of rim members in the fused (aryl / heteroaryl) ²ring system. ²Bicyclic heteroaryl groups wherein one ring does not contain a heteroatom ²(e.g, indolyl, ²quinolinyl, carbazolyl; and the like) the point of attachment can be on either ²ring; i.e.. either ²the ring bearing a heteroatom (e.g., 2-indoly1) or the ring that does not ²contain a heteroatom ²(e.g, 5-indoly1).²100831 In some embodiments, a heteroaly1 group is a 5-10 membered aromatic ²ring system ²having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ²ring system, ²wherein each heteroatom is independently selected from nitrogen, oxygen, and ²sulfur ("5-10²37²<DP=39>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²membered heteroaryl"). In some embodiments, a heteroaryl group is a 5-8 ²membered ²aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms ²provided in the ²aromatic ring system, wherein each heteroatom is independently selected from ²nitrogen, ²oxygen, and sulfur ("5-8 membered heteroaryl"). In some embodiments, a ²heteroaryl group ²is a 5-6 membered aromatic ring system having ring carbon atoms and 1-4 rim ²heteroatoms ²provided in the aromatic ring system, wherein each heteroatom is independently ²selected ²from nitrogen, oxygen, and sulfur ("5-6 membered heteroaryl"). In some ²embodiments, the ²5-6 membered heteroaryl has 1-3 ring heteroatoms selected from nitrogen, ²oxygen, and ²sulfur. In some embodiments, the 5-6 membered heteroaryl has 1-2 ring ²heteroatoms ²selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 ²membered ²heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur. ²Unless ²otherwise specified, each instance of a heteroaryl group is independently ²optionally ²substituted, i.e., unsubstituted (an "unsubstituted heteroaryl") or ²substituted (a "substituted ²heteroaryl") with one or more substituents. In certain embodiments, the ²heteroaryl group is ²unsubstituted 5-14 membered heteroaryl. In certain embodiments, the heteroaryl ²group is ²substituted 5-14 membered heteroaryl. In some embodiments, a heteroaryl group ²is a ²bicyclic 8-12 membered aromatic ring system having ring carbon atoms and 1-6 ²ring ²heteroatoms provided in the aromatic ring system, wherein each heteroatom is ²independently ²selected from nitrogen, oxygen, and sulfur ("8-12 membered bicyclic ²heteroaryl"). In some ²embodiments, a heteroaryl group is an 8-10 membered bicyclic aromatic ring ²system having ²ring carbon atoms and 1-6 ring heteroatoms provided in the aromatic ring ²system, wherein ²each heteroatom is independently selected from nitrogen, oxygen, and sulfur ²("8-10 ²membered bicyclic heteroaryl"). In some embodiments, a heteroaryl group is a 9-²10 ²membered bicyclic aromatic ring system having ring carbon atoms and 1-6 ring ²heteroatoms ²provided in the aromatic ring system, wherein each heteroatom is independently ²selected ²from nitrogen, oxygen, and sulfur ("9-10 membered bicyclic heteroaryl"). ²Unless otherwise ²specified, each instance of a heteroaryl group is independently unsubstituted ²(an ²"unsubstituted heteroaryl") or substituted (a "substituted heteroaryl") with ²one or more ²substituents. In certain embodiments, the heteroaryl group is an unsubstituted ²5-14 ²membered heteroaryl. In certain embodiments, the heteroaryl group is a ²substituted 5-14 ²membered heteroaryl.²100841 Exemplary 5-membered heteroaryl groups containing one heteroatom ²include, ²without limitation, pyrrolyl, furanyl and thiophenyl. Exemplary 5-membered ²heteroaryl²38²<DP=40>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²groups containing two heteroatoms include, without limitation, imidazolyl, ²pyrazolyl, ²oxazolyl, isox.azolyl, thiazolyl, and isothiazolyl. Exemplary 5-membered ²heteroaryl groups ²containing three heteroatoms include, without limitation, triazolyl, ²oxadiazolyl, and ²thiadiazolyl. Exemplary 5-membered heteroaryl groups containing four ²heteroatoms include, ²without limitation, letrazolyl. Exemplary 6-membered heteroaryl groups ²containing one ²heteroatom include, without limitation, pyridinyl. Exempla*, 6-membered ²heteroaryl groups ²containing two heteroatoms include, without limitation, pyridazinyl, ²pyrimidinyl, and ²pyrazinyl. Exemplary 6-membered heteroaryl groups containing three or four ²heteroatoms ²include, without limitation, triazinyl and tetrazinyl, respectively. Exemplary ²7-membered ²heteroaryl groups containing one heteroatom include, without limitation, ²azepinyl, oxepinyl, ²and thiepinyl. Exemplary 5,6-bicyclic heteroaryl groups include, without ²limitation, indolyl, ²isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, ²benzofuranyl, ²benzoisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, ²benzoxadiazolyl, ²benzthiazolyl, benzisothiazolyl, benzthiadiazolyl, indolizinyl, and purinyl. ²Exemplary 6,6--²bicyclic heteroaryl groups include, without limitation, naphthyridinylõ ²pteridinyl, quinolinyl, ²isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl.²100851 Examples of representative heteroaryls include the following:²11:71²lc? -(f..-N)²N."²\N%²N² ___________________________________ N I²wherein each Z is selected from carbonyl, N. NV, 0, and S; and R65 is ²independently ²hydrogen, CI-C8 alkyl, C3-Cio cycloalkyl, 4-10 membered heterocyclyl, C6-Cio ²aryl, and 5-²membered heteroaryl.²
[0086] In the structures described herein, a substituent attached to a ²polycyclic (e.g., ²bicyclic or tricyclic) cycloalkyl, heterocyclyl, an or heteroaryl with a bond ²that spans two or²39²<DP=41>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²more rings is understood to mean that the substituent can be attached at any ²position in each ²of the rings.²"Heteroaralkyl" or "heteroatylallcyl" is a subset of "alkyl" and refers to an ²alkyl group ²substituted by a heteroaryl group, wherein the point of attachment is on the ²alkyl moiety. ²The term "carbocyclyl" or "carbocyclic" refers to a radical of a non-aromatic ²monocyclic, ²bicyclic, or tricyclic or polycyclic hydrocarbon ring system having from 3 to ²14 ring carbon ²atoms ("C3-14 carbocyclyl") and zero heteroatoms in the non-aromatic ring ²system. ²Carbocyclyl groups include fully saturated ring systems (e.g., cycloalkyls), ²and partially ²saturated ring systems. In some embodiments, a carbocyclyl group has 3 to 10 ²ring carbon ²atoms ("C3-10 carbocyclyl"). In some embodiments, a carbocyclyl group has 3 to ²8 ring ²carbon atoms ("C3-8 carbocyclyl"). In some embodiments, a carbocyclyl group ²has 3 to 7 ²ring carbon atoms ("C3-7 carbocyclyl"). In some embodiments, a carbocyclyl ²group has 3 to ²6 ring carbon atoms ("C3-6 carbocyclyl'). In some embodiments, a carbocyclyl ²group has 4 ²to 6 ring carbon atoms ("C4-6 carbocyclyl"). In some embodiments, a ²carbocyclyl group has ²to 6 ring carbon atoms ("C5-6 carbocyclyl"). In some embodiments, a ²carbocyclyl group ²has 5 to 10 ring carbon atoms ("C5-10 carbocyclyl"). Exemplary C3-6 ²carbocyclyl groups ²include, without limitation, cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl ²(C4), ²cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), ²cyclohexenyl (C6), ²cyclohexadienyl (Co), and the like. Exemplary C34 carbocyclyl groups include, ²without ²limitation, the aforementioned C3-6 carbocyclyl groups as well as cycloheptyl ²(C7), ²cycloheptenyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), cyclooctyl ²(Cs), ²cyclooctenyl (Cs), bicyclo[2.2.1jheptanyl (C7), bicyclo[2.2.2]octanyl (Cs), ²and the like. ²Exemplary C3-10 carbocyclyl groups include, without limitation, the ²aforementioned C3-8 ²carbocyclyl groups as well as cyclononyl (C9), cyclononenyl (C9), cyclodecyl ²(Cm), ²cyclodecenyl (C to), octahydro-1H-indenyl (C9), decahydronaphthalenyl (Cm), ²spiro[4.5]decanyl (C10), and the like.²100871 As the foregoing examples illustrate, in certain embodiments, the ²carbocyclyl group ²is either monocyclic ("monocyclic carbocyclyl") or polycyclic (e.g., ²containing a fused, ²bridged or spiro ring system such as a bicyclic system ("bicyclic ²carbocyclyl") or tricyclic ²system ("tricyclic carbocyclyl")) and can be saturated or can contain one or ²more carbon-²carbon double or triple bonds. "Carbocycly1" also includes ring systems ²wherein the ²carbocyclyl ring, as defined above, is fused with one or more aryl or ²heteroaryl groups ²wherein the point of attachment is on the carbocyclyl ring, and in such ²instances, the number²<DP=42>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²of carbons continue to designate the number of carbons in the carbocydic ring ²system. ²Unless otherwise specified, each instance of a carbocyclyl group is ²independently ²unsubstituted (an "unsubstituted carbocyclyl") or substituted (a "substituted ²carbocyclyl") ²with one or more subsfituents. In certain embodiments, the carbocyclyl group ²is an ²unsubstituted C3-14 carbocyclyl. In certain embodiments, the carbocyclyl group ²is a ²substituted C3-14 carbocyclyl.²100881 The term "cycloalkyl" as employed herein includes saturated cyclic, ²bicyclic, ²tricyclic, or polycyclic hydrocarbon groups having 3 to 14 carbons containing ²the indicated ²number of rings and carbon atoms (for example a C3-C14 monocyclic, C4-C14 ²bicyclic, C5-²Cl4tricyclic, or C6-C14 polycyclic cycloalkyl). In some embodiments ²"cycloalkyl" is a ²monocyclic cycloalkyl. In some embodiments, a monocyclic cycloalkyl has 3-14 ²ring carbon ²atoms. ("C3-14 monocyclic cycloalkyl"). In some embodiments, a monocyclic ²cycloalkyl ²group has 3 to 10 ring carbon atoms ("C3-10 monocyclic cycloalkyl"). In some ²embodiments, ²a monocyclic cycloalkyl group has 3 to 8 ring carbon atoms ("C34 monocyclic ²cycloakr1"). ²In some embodiments, a monocyclic cycloalkyl group has 3 to 6 ring carbon ²atoms ("C3-6 ²monocyclic cycloalkyl"). In some embodiments, a monocyclic cycloalkyl group ²has 4 to 6 ²ring carbon atoms ("C4-6 monocyclic cycloalkyl'). In some embodiments, a ²monocyclic ²cycloalkyl group has 5 to 6 ring carbon atoms ("C5-6 monocyclic cycloalkyl"). ²In some ²embodiments, a monocyclic cycloalkyl group has 5 to 10 ring carbon atoms ("C5-²10 ²monocyclic cycloalkyl"). Examples of monocyclic C5-6 cycloalkyl groups include ²²cyclopentyl (C5) and cyclohexyl (C5). Examples of C3-6 cycloakl groups include ²the ²aforementioned C5-6 cycloalkyl groups as well as cyclopropyl (C3) and ²cyclobutyl (C4). ²Examples of C3-8 cycloalkyl groups include the aforementioned C3-6 cycloalkyl ²groups as ²well as cycloheptyl (C7) and cyclooctyl (C8).²100891 In some embodiments "cycloalkyl" is a bicyclic cycloalkyl. In some ²embodiments, ²a bicyclic cycloalkyl. has 444 ring carbon atoms. ("C4-14 bicyclic ²cycloalkyl"). In some ²embodiments, a bicyclic cycloalkyl group has 4 to 12 ring carbon atoms ("C4-12 ²bicyclic ²cycloalkyl"). In some embodiments, a bicyclic cycloalkyl group has 4 to 10 ²ring carbon ²atoms ("C4-lo bicyclic cycloalkyl"). In some embodiments, a bicyclic ²cycloalkyl group has 5 ²to 10 ring carbon atoms ("C5-10 bicyclic cycloalkyl"). In. some embodiments, a ²bicyclic ²cycloalkyl group has 6 to 10 ring carbon atoms ("C6-10 bicyclic cycloalkyl"). ²In some ²embodiments, a bicyclic cycloalkyl group has 8 to 10 ring carbon atoms ("Cs-io ²bicyclic ²cycloalkyl"). In some embodiments, a bicyclic cycloalkyl group has 7 to 9 ring ²carbon atoms²41²<DP=43>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²("C7-9 bicyclic cycloalkyl"). Examples of bicyclic cycloalkyls include ²bicyclo[1.1.0]butane ²(C4), bicyclo[1.1.1]pentane (C5), spiro[2.2] pentane (C5), ²bicyclo[2.1.0]pentane (C5), ²bicyclo[2.1.1]hexane (C6), bicyclo[3.1.01hexane (C6), spiro[2.31 hexane (C6), ²bicyclo[2.2.1]heptane (norbornane) (C7), bicyclo[3.2.01heptane (C7), ²bicyclo[3.1.1]heptane ²(C7), bicyclo[3.1.1]heptane (C7), bicyclo[4.1.0]heptane (C7), spiro[2.4] ²heptane (C7), Spiro ²[3.3] heptane (C7), bicyclo[2.2.2]octane (Cs), bicyclo[4.1.1]octane ²(Cs)octahydropentalene ²(Cs), bicyclo[3.2.11octane (Cs), bicyclo[4.2.01octane (Cs), spiro[2.51octane ²(Cs), ²spiro[3.4]octane (Cs), bicyclo[3.3.1]nonane (C9), octahydro-IT-I-indene (C9), ²bicydo[4.2.1]nonarie (C9), spiro[3.5]nonane (C9), spiro[4.4]nonane (C9), ²bicyclo[3.3.2]decane (Cio), bicrclo[4.3.11decane (Cm), spiro1;4.51decane ²(C10), ²bicyclo[3.3.3]undecane (C11), decahydronaphthalene (C io), ²bicyclo[4.3.21undecane (CIO, ²spiro[5.5]undecane (Cii) and bicyclo[4.3.3]dodecane (C12).²In some embodiments "cycloalkyl" is a tricyclic cycloalkyl. In some ²embodiments, a ²tricyclic cycloalkyl has 6-14 ring carbon atoms. ("C6-14 tricyclic ²cycloalkyl"). In some ²embodiments, a tricyclic cycloalkyl group has 8 to 12 ring carbon atoms ("Cs-²12 tricyclic ²cycloalkyl"). In some embodiments, a tricyclic cycloalkyl group has 10 to 12 ²ring carbon ²atoms ("C10-12 tricyclic cycloalkyl. Examples of tricyclic cycloallcyls ²include adamantine ²(C12).²100901 Unless otherwise specified, each instance of a cycloalkyl group is ²independently ²unsubstituted (an "unsubstituted cycloalkyl") or substituted (a "substituted ²cycloalkyl") with ²one or more substituents. In certain embodiments, the cycloalkyl group is an ²unsubstituted ²C3-14 cycloalkyl. In certain embodiments, the cycloalkyl group is a ²substituted C3-14 ²cycloalkyl²"Heterocycly1" or "heterocyclic" refers to a radical of a 3¨ to 10¨membered ²non¨aromatic ²ring system having ring carbon atoms and 1 to 4 ring heteroatoms, wherein each ²heteroatom ²is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, ²and silicon ("3-²membered heterocyclyl"). In heterocyclyl groups that contain one or more ²nitrogen ²atoms, the point of attachment can be a carbon or nitrogen atom, as valency ²permits. A ²heterocyclyl group can either be monocyclic ("monocyclic heterocyclyl") or a ²fused, bridged ²or Spiro ring system such as a bicyclic system ("bicyclic heterocyclyl"), and ²can be saturated ²or can be partially unsaturated. Heterocydyl bicyclic ring systems can include ²one or more ²heteroatoms in one or both rings. "Heterocycly1" also includes ring systems ²wherein the ²heterocyclyl ring, as defined above, is fused with one or more carbocyclyl ²groups wherein the²42²<DP=44>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²point of attachment is either on the carbocyclyl or heterocyclyl ring, or ring ²systems wherein ²the heterocyclyl ring, as defined above, is fused with one or more aryl or ²heteroaryl groups, ²wherein the point of attachment is on the heterocyclyl ring, and in such ²instances, the number ²of ring members continue to designate the number of ring members in the ²heterocyclyl ring ²system. Unless otherwise specified, each instance of heterocyclyl is ²independently optionally ²substituted, i.e., unsubstituted (an "unsubstituted heterocyclyl") or ²substituted (a "substituted ²heterocyclyl") with one or more substituents. In certain embodiments; the ²heterocyclyl group ²is unsubstituted 3-10 membered heterocyclyl. In certain embodiments, the ²heterocyclyl ²group is substituted 3-10 membered heterocyclyl.²10091j In some embodiments; a heterocyclyl group is a 5-10 membered non-²aromatic ring ²system having ring carbon atoms and 1-4 ring heteroatoms, wherein each ²heteroatom is ²independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and ²silicon ("5-10 ²membered heterocyclyl"). In some embodiments, a heterocyclyl group is a 5-8 ²membered ²non--aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, ²wherein each ²heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5-8 ²membered ²heterocyclyl"). In some embodiments, a heterocyclyl group is a 5-6 membered ²non-aromatic ²ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each ²heteroatom is ²independently selected from nitrogen, oxygen, and sulfur ("5-6 membered ²heterocyclyl"). In ²some embodiments, the 5-6 membered heterocyclyl has 1-3 ring heteroatoms ²selected from ²nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered ²heterocyclyl has 1-2 ²ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some ²embodiments, the 5-6 ²membered heterocyclyl has one ring heteroatom selected from nitrogen, oxygen, ²and sulfur. ²100921 Exemplary' 3-membered heterocyclyl groups containing one heteroatom ²include, ²without limitation, aziridinyl, oxiranyl, thiorenyl. Exemplary 4-membered ²heterocyclyl ²groups containing one heteroatom include, without limitation, azetidinyl, ²oxetanyl and ²thietanyl. Exemplary 5-membered heterocyclyl groups containing one heteroatom ²include, ²without limitation, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, ²dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl and pyrroly1-2,5---dione. ²Exemplary 5---²membered heterocyclyl groups containing two heteroatoms include, without ²limitation, ²dioxolanyl, oxasulfuranyl, disulfuranyl, and oxazolidin-2-one. Exemplary 5-²membered ²heterocyclyl groups containing three heteroatoms include, without limitation, ²triazolinyl, ²oxadiazolinyl, and thiadiazolinyl. Exemplary 6-membered heterocyclyl groups ²containing ²one heteroatom include, without limitation, piperidinyl, tetrahydropyranyl, ²dihydropyridinyl,²43²<DP=45>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²and thianyl. Exemplary 6¨membered heterocyclyl groups containing two ²heteroatoms ²include, without limitation, piperazinyl, morpholinyl, dithianyl, dioxanyl. ²Exemplary 6¨²membered heterocyclyl groups containing two heteroatoms include, without ²limitation, ²triazinanyl. Exemplary 7¨membered heterocyclyl groups containing one ²heteroatom include, ²without limitation, azepanyl, oxepanyl and thiepanyl. Exemplary 8¨membered ²heterocyclyl ²groups containing one heteroatom include, without limitation, azocanyl, ²oxecanyl and ²thiocanyl. Exemplary 5-membered heterocyclyl groups fused to a C6 aryl ring ²(also referred ²to herein as a 5,6-bicyclic heterocyclic ring) include, without limitation, ²indolinyl. ²isoindolinyl; dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinonyl, and ²the like. ²Exemplary bicyclic heterocyclyl groups include, without limitation, indolinyl, ²isoindolinyl, ²dihydrobenzofuranyl, dihydrobenzothienyl, tetrahydrobenzothienyl, ²tetrahydrobenzofuranyl, ²tetrahydroindolyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, ²decahydroquinolinyl, ²decahydroisoquinolinyl, octahydrochromenyl, octahydroisochromenyl; ²decahydronaphthyridinyl, decahydro-1,8-naphthyddinyl, octahydropyrrolo[3,2-²bipyrrole, ²indolinyl, phthalimidyl, naphthalimidyl, chromanyl, chromenyl, 1H-²benzole][1,41diazepinyl, ²1,4,5,7-tetrahydropyrano[3,4-b]pyrrolyl, 5,6-dihydro-4H-furo[3,2-b]py-n-olyl, ²6,7-dih.ydro-²5H-furo[3,2-b]pyranyl; 5,7-dihydro-4H-thieno[2,3-c]pyranyl, 2,3-dihydro-1H-²pyrrolo[2,3-²b]lpyridinyl, 2,3-dihydrofuro[2,3-b]pyridinyl, 4,5,6,7-tetrahydro-ITI-²pyrrolo[2,3-61pyridinyl, ²4,5,6,7-tetrahydrofuro[3,2-c]pyridinyl, 4,5,6,7-tetrahydrothien.o[3,2-²b]pyridinyl, 1 ,2,3,4-²tetrahydro-1,6-naphthyridinyl, and the like. Exemplary 6-membered heterocyclyl ²groups ²fused to an aryl ring (also referred to herein as a 6,6-bicyclic heterocyclic ²ring) include, ²without limitation, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and the ²like. ²"Nitrogen-containing heterocyclyl" group means a 4¨ to 7¨ membered non-²aromatic cyclic ²group containing at least one nitrogen atom, for example, but without ²limitation, morpholine, ²piperidine (e.g., 2-piperidinyl, 3-piperidinyl and 4-piperidinyl), pyrrolidine ²(e.g., 2-²pyrrolidinyl and 3-pyrrolidinyl), azetidine, pynrolidone, imidazoline, ²imidazolidinone, 2-²pyrazoline, pyrazolidine, piperazine; and N-alkyl piperazines such as N-methyl ²piperazine. ²Particular examples include azetidine, piperidone and piperazone.²100931 "Hetero" when used to describe a compound or a group present on a ²compound ²means that one or more carbon atoms in the compound or group have been ²replaced by a ²nitrogen, oxygen, or sulfur heteroatom. Hetero may be applied to any of the ²hydrocarbyl ²groups described above such as alkyl, e.g., heteroalkyl, cycloalkyl, e.g., ²heterocyclyl,²44²<DP=46>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²e.g., heteroaryl, cycloalkenyl, e.g., cycloheteroalkenyl, and the like having ²from I to 5, and ²particularly from 1 to 3 heteroatoms.²100941 "Ac,r1" refers to a radical -C(=0)e, where R2() is hydrogen, ²substituted or ²unsubstitued alkyl, substituted or unsubstitued alkenyl, substituted or ²unsubstitued alkynyl, ²substituted or unsubstitued carbocyclyl, substituted or unsubstituted ²heterocyclyl, substituted ²or unsubstituted aryl, or substituted or unsubstitued heteroaryl, as defined ²herein. "Alkanoyl" ²is an acyl group wherein IV is a group other than hydrogen. Representative ²acyl groups ²include, but are not limited to, formyl (-CHO), acetyl (-C(...0)CH3), ²cyclohexylcarbonyl, ²cyclohexylmethylcarbonyl, benzoyl (--C()Ph), benzylcarbonyl (-D)CH2Ph), --C())-²²C1----(38 alkyl, -C(=0)-(CH2)t(C6--Cio aly1), -C(=0)-(CH2)K5-10 membered ²heteroaryl), ²C(..0)-(CH2)t(C3-C10 cycloalkyl), and -C(..0)-(CH2)K4-1. 0 membered ²heterocyclyl), wherein ²t is an integer from 0 to 4. In certain embodiments, R.21 is CI-C8 alkyl, ²substituted with halo ²or hydroxy; or C3-Cio cycloalkyl, 4-10 membered heterocyclyl, C6-Cio aiyl, ²mylalk-yl, 5-10 ²membered heteroaryl or heterom,rlalk-yl, each of which is substituted with ²unsubstituted CI-²C4 alkyl, halo, unsubstituted Ci-C4 alkoxy, unsubstituted Ci-C4 haloalkyl, ²unsubstituted²Ci-²Ci hydroxyalkyl, or unsubstituted CI-C4 h.aloalkoxy or hydroxy.²100951 The term aminoallcyl refers to a substituted alkyl group wherein one or ²more of the²hydrogen atoms are independently replaced by an group.²100961 The term hydroxyalkyl refers to a substituted alkyl group wherein one ²or more of the ²hydrogen atoms are independently replaced by an -OH group.²100971 The terms "alkylamino" and "dialkylamino" refer to -NH(alkyl) and-²N(alkyl)2 ²radicals respectively. In some embodiments the alkylamino is a---NH(Ci---C4 ²alkyl). In some ²embodiments the alkylamino is methylamino, ethylamino, propylamino, ²isopropylamino, n-²butylamino, iso-butylamino, sec-butylamino or tert-butylarnino. In some ²embodiments the ²dialkylamino is ---N(Cr-C6 alky1)2. In some embodiments the dialkylamino is a ²dimethylamino, a methylethylamino, a diethylamino, a methylpropylamino, a ²methylisopropylamino, a methylbutylamino, a methylisobutylamino or a ²methyltertbutylamino.²100981 The term "aryloxy" refers to an -0-aryl radical. In some embodiments ²the aryloxy ²group is phenoxy.²100991 The term "haloalkoxy" refers to alkoxy structures that are substituted ²with one or ²more halo groups or with combinations thereof. For example, the term ²"fluoroalkoxy"²<DP=47>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²includes haloalkoxy groups, in which the halo is fluorine. In some embodiments ²haloalkoxy ²groups are difluoromethoxy and trifluoromethoxy.²101001 "Mkoxy" refers to the group -00 where R29 is substituted or ²unsubstituted alkyl, ²substituted or unsubstitued alkenyl, substituted or unsubstitued alkynyl, ²substituted or ²unsubstitued carbocyclyl, substituted or unsubstituted heterocyclyl, ²substituted or ²unsubstituted aryl, or substituted or unsubstitued heteroaryl. Particular ²alkoxy groups are ²methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, see-butoxy, n-²pentoxy, n-²hexoxy, and 1,2-dimethylbutoxy. Particular alkoxy groups are lower alkoxy, ²i.e. with ²between 1 and 6 carbon atoms. Further particular alkoxy groups have between 1 ²and 4 ²carbon atoms.²In certain embodiments. R29 is a group that has I or more substituents, for ²instance from I to ²substituents, and particularly from Ito 3 substituents, in particular 1 ²substituent, selected ²from the group consisting of amino, substituted amino, C6-Cio atyl, arylox-y, ²carboxyl, cyano. ²C3-C10 cycloalkyl, 4-10 membered heterocyclyl, halogen, 5-10 membered ²heteroaryl, ²hydroxyl, nitro, thioalkoxy, thioatyloxy, thiol, alkyl-S(0)-, aryl-S(0)-, ²alkyl-S(0)2- and ²aryl-S(0)2-. Exemplary 'substituted alkoxy' groups include, but are not ²limited to, -0-²(CH2)t(C6-Cio aiy1), -0-(CH2)t(5-10 membered heteroaryl), -0-(CH2)t(C3-Cio ²and -0--(CH2)t(4-10 membered heterocyclyl), wherein t is an integer from 0 to ²4 and any ²aryl, heteroaryl, cycloalkyl or heterocyclyl groups present, may themselves be ²substituted by²unsubstituted Ci-C4 alkyl, halo, unsubstituted alkoxy, unsubstituted Ci-C4 ²haloalkyl, ²unsubstituted Cl--=C4 hydroxyalkyl, or unsubstituted CI-C4 haloalkoxy or ²hydroxy. Particular ²exemplary 'substituted alkoxy' groups are -0CF3, -00-12CF3, -OCH2Ph, -OCH2-²cyclopropyl, -OCH2CH2OH, and -OCH2CH2NMe2.²101011 "Amino" refers to the radical -NH2.²101021 "Oxo group" refers to -C(:=0)-.²101031 "Substituted amino" refers to an amino group of the formula-N(0)2 ²wherein R38 is ²hydrogen, substituted or unsubstituted alkyl, substituted or unsubstitued ²alkenyl, substituted ²or unsubstitued alkynyl, substituted or unsubstitued carbocyclyl, substituted ²or unsubstituted ²heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstitued ²heteroaryl, or an ²amino protecting group, wherein at least one of R38 is not a hydrogen. In ²certain ²embodiments, each R38 is independently selected from hydrogen. Ci-Cs alkyl, C3-²C8 alkenyl, ²C3-C8 alkynyl, C6-Cio aryl, 5-10 membered heteroaryl, 4-10 membered ²heterocyclyl, or C3-²CIO cycloalk-yl; or CI-C8 alkyl, substituted with halo or hydroxy; C3-C8 ²alkenyl, substituted²46²<DP=48>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²with halo or hydroxy; C3¨C8 alkynyl, substituted with halo or hydroxy, or -²(CH2)t(C6¨C10 ²aryl), -(CH2)t(5-10 membered heteroaryl), -(CH2)t(C3¨C10 cycloalkyl), or -²(CH2)t(4-10 ²membered heterocyclyl), wherein t is an integer between 0 and 8, each of which ²is substituted ²by unsubstituted Ci¨C4 alkyl, halo, unsubstituted C1--C4 alkoxy, unsubstituted ²C1--C4 ²haloalk-yl, unsubstituted Ci¨C4 hydroxyalkyl, or unsubstituted Ci¨C4 ²haJoalkoxy or hydroxy; ²or both R38 groups are joined to form an alkylene group.²101041 Exemplary "substituted amino" groups include, but are not limited to, --²NR39-Ci--Cs ²alkyl, ¨NR39-(CH2)t(C6¨C10 aryl), ¨NR39-(CH2)t(5-10 membered heteroaryl), ²¨NR39-²(CH2)t(C3¨C10 cycloalky,1), and ¨NR39-(CH2)t(4-10 membered heterocyclyl), ²wherein t is an ²integer from 0 to 4, for instance 1 or 2, each R39 independently represents H ²or Ci--Cs alkyl; ²and any alkyl groups present, may themselves be substituted by halo, ²substituted or ²unsubstituted amino, or hydroxy; and any aryl, heteroaryl, cycloakl, or ²heterocyclyl groups ²present, may themselves be substituted by unsubstituted C1--C4 alkyl, halo. ²unsubstituted²Ci¨²²C4 alkoxy, unsubstituted CI¨Ca haloalkyl, unsubstituted Cl--C4 hydroxyalkyl, ²or²unsubstituted C ²haloalkoxy or hydroxy. For the avoidance of doubt the term 'substituted²amino' includes the groups alkylamino, substituted alk-ylamino, ²alkylarylamino, substituted ²alky, larylarnino, arylamino, substituted arylamino, dialkylarnino, and ²substituted dialk-ylamino ²as defined below. Substituted amino encompasses both monosubstituted amino and ²²disubstituted amino groups.²101051 in certain embodiments, the substituent present on the nitrogen atom is ²a nitrogen ²protecting group (also referred to herein as an "amino protecting group"). ²Nitrogen ²protecting groups include, but are not limited to, ---01-1, --OR. ¨N(R")2,²¨C(=0)N(Wc)2, ¨CO2Raa, ¨SO2Raa, ¨C(=NRix)Raa, ¨C(=NR")0Raa, ¨C(=NRc`)N(R")2,²¨SO2N(Rcc)2, ¨SO2Rcc, ¨S020Rcc, ¨SORaa, ¨C(=S)N(R")2, ¨C(=0)SR", ¨C(=S)SR", ¨C ²1-²alkyl (e.g., aralkyl, heteroaralkyl), ---C2-io alkenyl, alkynyl, heteroCi-²io alkyl, ²heteroC2-lo alkenyl, heteroC2-io alkynyl, C3-10 carbocyclyl, 3-14 membered ²heterocyclyl, C6-14 ²aryl, and 5-14 membered heteroaryl groups, wherein each alkyl, alkenyl, ²alkynyl, heteroalkyl, ²heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aralkyl, aryl, and ²heteroaryl is ²independently substituted with 0, 1, 2, 3, 4, or 5 Rdd groups, and wherein ²Raa, Rbb, R" and Rdd ²are as defined herein. Nitrogen protecting groups are well known in the art ²and include those ²described in detail in Protecting Groups in Organic Synthesis, T. W. Greene ²and P. G. M. ²Wuts, 3rd edition, John Wiley & Sons, 1999, incorporated herein by reference.²47²<DP=49>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²each instance of 12" is, independently, selected from -Ci-io alkyl, --Ci-io ²perhaloalkyl, -C2-lo ²alkenyl, -C2-io alkynyl, heteroCi-io alkyl, heteroC2-io alkenyl, heteroC2-io ²alkynyl, C3-10 ²carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered ²heteromyl, or two ²It" groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered ²heteroaryl ²ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, ²heteroalkynyl, ²carbocyclyl, heterocyclyl, my!, and heteroaryl is independently substituted ²with 0,1, 2, 3, 4, ²or 5 Rdd groups;²each instance of Rbb is, independently, selected from hydrogen, -OR", --²N(R")2, --CN,²-C(=0)R", -C(=0)N(R"-)2, -CO2R", -SO2R", -C(=NR")0R", -C(=NR")N(R")2,²-SO2N(Rcc)2, -SO2R", -S020R", -C(=S)N(R")2, -C(=0)SR", -C(=S)SR",²--P(:=0)(OR")2, -P(...0)(N(R")2)2, --Ci-io alkyl, -Ci-io perhaloalkyl, -C2-io ²alkenyl, -C2-io alkynyl, heteroCi-io alkyl, heteroC2-io alkenyl, heteroC2-io ²alkynyl, C3-10 ²carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered ²heteromyl, or two ²Rbb groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered ²heteromyl ²ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, ²heteroalkynyl, ²carbocyclyl, heterocyclyl, my!, and heteroaryl is independently substituted ²with 0, 1, 2, 3, 4, ²or 5 Rdd groups; wherein X- is a counterion.²each instance of Re' is, independently, selected from hydrogen, -Ci-to alkyl, -²-Ci-io ²perhaloalkyl, -C2-lo alkenyl, -C2-io alkynyl, heteroCi-io alkyl, heteroC2-io ²alkenyl, heteroC2-io ²alkynyl, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 my!, and 5-14 ²membered ²heteroaryl, or two R" groups are joined to form a 3-14 membered heterocyclyl ²or 5-14 ²membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, ²heteroalkenyl, ²heteroalkynyl, carbocyclyl, heterocyclyl, my!, and heteroaryl is independently ²substituted ²with 0, 1, 2, 3, 4, or 5 Rdd groups;²each instance of Rdd is, independently, selected from halogen, -CN, -NO2, -N3, ²--S02H,²-S03H, -OH, -OR", -0N(117)2, -N(R)2, -N(Rff)34X-, -N(ORee)R.ff, -SH, -SR", -²SSR",²-C(=0)R", -CO2H, -0O211", -0C()Ree, -0CO2Ree, -C(=0)N(Rff)2, -0C(=0)N(Rff)2, ²-NRITC(=0)R", -NRIICO2Ree, -NRffC(=0)N(Rff)2; -C(=NRIT)ORee, -0C(=NRI)Ree, ²-0C(:=NRff)OR", -C(...NRff)N(Rff)2, --0C(..NRff)N(Rff)2, -²NRffC(...NRff)N(Rff)2, ²-NOSO2R", -S021\1(102, -S0211, -S020R", -0S02R", -S(=0)Ree, -Si(R)3,²-0Si(R")3, -C(=S)N(Rff)2, -C(=0)SRee, -C(=S)SR", -SC(=S)SRee, -K=0)(OR")2, ²-P(...0)(R")2, -013(...0)(Ree)2, -013(..0)(0R")2, -C1-6 alkyl, --CI-6 ²perhaloalkyl, -C2-6 ²alkenyl, -C2-6 alkynyl, heteroCi-6a1ky1, heteroC2-6a1keny1, heteroC2-6alkynyl, ²C3-10²48²<DP=50>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²carbocyclyl, 3-10 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl, ²wherein ²each alkyl, alkenyl, alkynyl, heteroakl, heteroalkenyl, heteroalkynyl, ²carbocyclyl, ²heterocyclyl, aryl, and heteroaly1 is independently substituted with 0, 1, 2, ²3, 4, or 5 Rgg ²groups, or two geminal Rdd substituents can be joined to form =0 or =S; ²wherein X is a ²counterion;²each instance of Ree is, independently, selected from -C1-6 alkyl, -C1-6 ²perhaloalkyl, -C2-6 ²alkenyl, -C2-6 alkynyl, heteroC1-6 alkyl, heteroC2-6alkenyl, heteroC2-6 ²alkynyl, C3-10 ²carbocyclyl, C6-1k) aryl, 3-10 membered heterocyclyl, and 3-10 membered ²heteroaryl, wherein ²each alkyl, alkenyl, alk-ynyl, heteroalk-yl, heteroalkenyl, heteroallcynyl, ²carbocyclyl, ²heterocyclyl, aryl, and heteroaly1 is independently substituted with 0, 1, 2, ²3, 4, or 5 Rgg ²groups;²each instance of Rff is, independently, selected from hydrogen, -C1-6 alkyl, -²C1-6 ²perhaloalkyl, -C2-6 alkenyl, -C2-6 alkynyl, heteroCi-6alkyl, heteroC2-²6alkenyl, heteroC2-²6a1kyny1, C3-10 carbocyclyl, 3-10 membered heterocyclyl, C6-lo aryl and 5-10 ²membered ²heteroaryl, or two Rff groups are joined to form a 3-10 membered heterocyclyl ²or 5-10 ²membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, ²heteroalkenyl, ²heteroallcynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is ²independently substituted ²with 0, 1, 2, 3, 4, or 5 RU groups; and²each instance of RU is, independently, halogen, --CN, -NO2, -N3, -S02H, -S03H, ²-OH,²-00-6 alkyl, -0N(C1-6 allcy1)2, N(C1-6 -N(CI-6 alky1)3+X-, -NH(C1-6 ²allcy1)2+X-, ²-NH2(C1-6 alkyl) 1)C, -NH3+X-, -N(00-6 alkyl)(C1-6 alkyl), -N(OH)(Ci-6 alkyl), ²-NH(OH), ²--SH, -SC1-6 alkyl, --SS(C1-6 alkyl), --C(=0)(C1-6 alkyl), --COAL -0O2(C1-6 ²alkyl),²-0C(=0)(C1-6 alkyl), -00O2(C1-6 alkyl), -C(43)NH2, -C(=0)N(C1-6 alky1)2,²-0C()NH(C1-6 alkyl), -NHC(=0)(C1-6 -N(CI-6 alkyl)g=0)(C1-6 alkyl), ²-NtICO2(C1-6 alkyl), --NTIC(:=0)N(C1-6 alky1)2, -NHC(=0)N1-1.(Ct alkyl), -M-²IC(=0)N1-1.2, ²--C(=NH)0(C1-6 alkyl), -0C(=NH)(C1-6 alkyl), -0C(=NH)OCI-6 alkyl, -C(=NH)N(C1-²6²alk-y1)2, -C(=NH)NH(C1-6 -²C(=NH)NH2, -0C(=NH)N(C1-6 alky1)2, -0C(NH)NH(Ci-²6 alk)'l), -0C(NH)NH2, -NHC(NH)N(C1-6 allcy1)2, -NHC(=NH)NH2, -NHS02(CI ²alkyl), ²--SO2N(C1-6 alky1)2, -SO2NII(C 1-6 alkyl), --SO2N1-12. --S02C 1-6 alkyl, --²S020C1-6 alkyl,²-0S02C1-6 alkyl, -SOC1-6 alkyl, -Si(C1-6 alky1)3, --0Si(C1-o alkyl); -²C(=S)N(CI-6 alky1)2,²-C(=S)NH(C1-6 alkyl), -C(=S)NH2, -C(=0)S(C1-6 alkyl), -C(=5)SC1-6 alkyl, -²SC(S)SCI-6 ²alkyl, -P(:=0)(0C1-6 alky1)2, --13(=0)(C1-6 alky1)2, --0P(=0)(Ci-6 alky1)2, -²0P(=0)(0C1-6 ²alky1)2, -C1-6 alkyl, -CI-6 perhaloalkyl, -C2-6 alkenyl, -C2-6 alkynyl, ²heteroCi-6alk-yl,²49²<DP=51>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²heteroC2.6a1keny1, heteroC2.6a1kyny1, C3-10 carbocyclyl, C6-10 aryl, 3-10 ²membered ²heterocyclyl, 5-10 membered heteroaryl; or two geminal Rgg substituents can be ²joined to ²form =0 or =S; wherein X- is a counterion.²101061 For example, nitrogen protecting groups such as amide groups (e.g., ²¨C(=0)R") ²include, but are not limited to, formamide, acetamide, chloroacetamide, ²trichloroacetamide, ²trifluoroacetarnide, phenylacetarnide, 3-phenylpropanamide, picolinamide, 3-²pyridylcarboxamide, N-benzoylphenylalanyl derivative, benzamide, p-²phenylbenzamide, o-²nitrophenylacetamide, o-nitrophenoxyacetamide, acetoacetamide, (N'-²dithiobenzyloxyacylamino)acetamide, 3-(p-hydroxyphenyl)propanamide, 3-(o-²nitrophenyppropanatnide, 2-methyl-2-(o-nitrophenoxy)propanamide, 2-methy1-2-(o-²²phenylazophenoxy)propanamide, 4-chlorobutanamide, 3-methyl-3-nitrobutanamide, ²o-²nitrocinnamide, N-acetylm.ethionine derivative, o-nitrobenzamide and o-²(benzoyloxymethyl)benzarnide.²101071 Nitrogen protecting groups such as carbamate groups (e.g., ¨C(=0)0Raa) ²include; ²but are not limited to, methyl carbamate, ethyl carbamate, 9-fluorenylmethyl ²carbamate ²(Fmoc), 9-(2-sulfo)fluorenylm.ethyl carbamate, 942,7-dibromogluorenylmethyl ²carbam.ate, ²2,7-di-t-butyl-[9-(10,10-dioxo-10,10,10,10-tetrahydrothioxanthyl)]methyl ²carbamate (DED-²Tmoc), 4-methoxyphenacyl carbamate (Phenoc), 2,2,2-trichloroethyl carbamate ²(Troc), 2-²trimethylsilylethyl carbamate (Teoc), 2-phenylethyl carbamate (hZ), 1-(1-²adamanty1)-1-²methylethyl carbamate (Adpoc), 1,1-dimethy1-2-haloethyl carbamate, 1,1-²dimethy1-2,2-²dibromoethyl carbamate (DB-t-B0C), 1,1-dimethy1-2,2,2-trichloroethyl carbamate ²²(TCBOC), 1-methyl-1-(4-biphenylyl)ethyl carbamate (Bpoc), 1-(3,5-di-1-²butylpheny1)-1-²methylethyl carbamate (t-Bumeoc), 2-(2'¨ and 4'-pyridyl)ethyl carbamate ²(Pyoc), 2-(N,N-²dicyclohexylcarboxarnido)ethyl carbamate, t-butyl carbamate (BOC or Boc), 1-²adamantyl ²carbamate (Adoc), vinyl carbamate (Voc), ally' carbamate (Alloc), 1-²isopropylally1 ²carbamate (Ipaoc), cinnamyl carbamate (Coc), 4-nitrocinnamyl. carbamate (Noc), ²8-quinoly1 ²carbamate, N-hydroxypiperidinyl carbamate, alkyldithio carbamate, benzyl ²carbamate (Cbz), ²p-methoxybenzyl carbamate (Moz), p-nitobenzyl carbamate, p-bromobenzyl ²carbamate, p-²chlorobenzyl carbamate, 2,4-dichlorobenzyl carbamate, 4-methylsulfinylbenzyl ²carbamate ²(Msz), 9-anthrylmethyl carbamate, diphenylmethyl carbamate, 2-methylthioethyl ²carbamate, ²2-methylsulfonylethyl carbamate, 2-(p-toluenesulfonyl)ethyl carbamate,²dithia.nyl)jmethyl carbamate (Dmoc), 4-methylthiophenyl carbamate (Mtpc), 2,4-²dimethylthiophenyl carbamate (Bmpc), 2-phosphonioethyl carbamate (Peoc), 2-²<DP=52>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²triphenylphosphonioisopropyl carbamate (Ppoc), 1,1-dimethy1-2-cyanoethyl ²carbamate, m-²chloro-p-acyloxybenzyl carbamate, p-(dihydroxyboryl)benzyl carbamate, 5-²benzisoxazolylmethyl carbamate, 2-(trifluoromethyl)-6-chromonylmethyl ²carbamate (Tcroc), ²m-nitrophenyl carbamate, 3,5-dimethoxybenzyl carbamate, o-nitrobenzyl ²carbamate, 3,4-²dimethoxy-6-nitrobenzyl carbamate, phenyl (o-nitrophenyl)m.ethyl carbamate, t-²amyl ²carbamate, S-benzyl thiocarbamate, p-cyanobenzyl carbamate, cyclobutyl ²carbamate, ²cyclohexyl carbamate, cyclopentyl carbamate, cyclopropylmethyl carbamate, p-²decyloxybenzyl carbamate, 2,2-dimethoxyacylvinyl carbamate, o-(N,N-²dimethylcarboxarnido)benzyl carbamate, 1,1-dimethy1-3-(N,N-²dimethylcarboxamido)propyl ²carbamate, 1,1-dimethylpropynyl carbamate, di(2-pyridyl)methyl carbamate, 2-²furanylmethyl ²carbamate, 2-iodoethyl carbamate, isobornyl carbamate, isobutyl carbamate, ²isonicotinyl ²carbamate, p-(p'-methoxyphenylazo)benzyl carbamate, 1-methylcyclobutyl ²carbamate, 1-²methylcyclohexyl carbamate, 1-methyl-l-cyclopropylmethyl carbamate, I-methyl-²143,5-²dimethoxyphenyl)ethyl carbamate, 1-methyl-1-(p-phenylazophenypethyl carbamate, ²1-²methyl-l-phenylethyl carbamate, 1-methy1-1.-(4-pyridypethyl carbamate, phenyl ²carbamate, ²p-(phenylazo)benzyl carbamate, 2,4,6-tri-t-butylphenyl carbamate, 4-²(trimethylarnmonturn)benzyl carbamate, and 2,4,6-trimethylbenzyl carbamate.²101081 Nitrogen protecting groups such as sulfonamide groups (e.g., ---²S(...0)211') include, ²but are not limited to, p-toluenesulfonamide (Ts), benzenesulfonamide, 2,3,6-²trimethy1-4-²methoxybenzenesulfonamide (Mtr), 2,4,6-trimethoxybenzenesulfonamide (Mtb), 2,6-²²dimethy1-4-methoxybenzenesulfonamide (Pine), 2,3,5,6-tetramethy1-4-²methoxybenzenesulfonamide (Mte), 4-methoxybenzenesulfonamide (Mbs), 2,4,6-²trimethylbenzenesulfonamide (Mts), 2,6-dimethoxy-4-methylbenzenesulfonamide ²(iMds), ²2,2,5,7,8-pentamethylchroman-6-sulfonamide (Pmc), methanesulfonarnide (Ms),13-²trimethylsilyletha.nesulfonamide (SES), 9-anthracenesulfonamide, 4-(4',8'-²dimethoxyriaphthylmethyl)benzenesulfonamide (DNMBS), benzylsulfonamide, ²trifluoromethylsulfonamide, and phenacylsulfonarnide.²Other nitrogen protecting groups include, but are not limited to, ²phenothiazinyl-(10)-acyl ²derivative, N'-p-toluenesulfonylaminoacyl derivative, N'-phenylaminothioacyl ²derivative, N-²benzoylphenylalanyl derivative, N-acetylmethionine derivative, 4,5-dipheny1-3-²oxazolin-2-²one, N-phthahrnide, N-dithiasuccinirnide (Dts), N-2,3-diphemõ,lmaleimide, N-²2,5-²dimethylpyrrole, N-1,1,4,4-tetramethyldisilylazacyclopentane adduct (STABASE), ²5-²substituted 1,3-dimethy1-1,3,5-triazacyclohexan-2-one, 5-substituted 1,3-²dibenzy1-1,3,5-²51²<DP=53>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²triazacyclohexan-2-one, 1-substituted 3,5-dinitro-4-pyridone, N-methylamine, N-²allylamine, ²N424trimethylsilypethoxylmethylamine (SEM), N-3-acetoxypropylamine, N-(1-²isopropy1-²4-nitro-2-oxo-3-pyroolin-3-yl)amine, quaternary ammonium salts, N-benzylamine, ²N-di(4-²methoxyphenypmethylainine, N-5-dibenzosuberylamine, N-triphenylmethylamine ²(Tr), N-²[(4-methoxyphenyl)diphenylmethyl]amine (MMTr), N-9-phenylfluorenylamine ²(Ph.F), N-²2,7-dichloro-9-fluorenylmethylenearnine, N-ferrocenylmethylarnino (Fon), N-2-²picolylamino N' -oxide, N-1,1-dimethylthiomethyleneamine, N-benyylideneamine, ²N-p-²methoxybenzylideneamine, N-diphenylmethyleneamine, N-[(2-²pyridypmesitylimethyleneamine, N-(N',N'-dimethylarninomethylene)amine, N,N'-²isopropylidenediamine, N-p-nitrobenzylideneamine, N-salicylideneamine, N-5-²chlorosalicylideneamine, N-(5-chloro-2-hydroxyphenyl)phenylmethyleneamine, N-²cyclohexylideneamine, N-(5,5-dimethy1-3-oxo-l-cyclohexenyl)amine, N-borane ²derivative, ²N-diphenylborinic acid derivative, N4phenyl(pentaacylchrornitun¨ or ²tungsten)acyl]arnine, ²N-copper chelate, N-zinc chelate, N-nitroamine, N-nitrosoamine, amine N-oxide, ²²diphenylphosphinamide (Dpp), dimethylthiophosphinamide (Mpt), ²diphenylthiophosphinamide (Ppt), dialkyl phosphoramidates, dibenzyl ²phosph.oramidate, ²diphenyl phosphorarnidate, benzenesulfenamide, o-nitrobenzenesulfenamide ²(Nps), 2,4-²dini trobenzenesulfenamide, pentachlorobenzenesulfenamide, 2-nitro-4-²methoxybenzenesulfenamide, triphenylmethylsulfenarnide, and 3-²nitropyridinesulfenamide²(NPYs).²10109] In certain embodiments, the substituent present on an oxygen atom is an ²oxygen ²protecting group (also referred to herein as an "hydroxyl protecting group"). ²Oxygen ²protecting groups include, but are not limited to, ¨Raa, ¨N(R)2, ¨C(=0)SRaa, ²¨C(=0)11.8a,²¨CO2Raa, ¨q=0)N(Rbb)2, ¨C(=NRbb)Raa, ¨C(=NRbb)0Raa, ¨C(=NRbb)N(Rbb)2, ²¨S(=0)Raa, ²¨SO2R", ¨Si(R)3, ¨P(Rcc)2, ---P(R")31X-,----P(OR")2, ---P(OR")34X-,²¨P(A))(OR")2, and ¨P(.---0)(N(Rbb)2)2, wherein Raa, Rbb, and R" are as defined ²herein. ²Oxygen protecting groups are well known in the art and include those described ²in detail in ²Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3rd ²edition, ²John Wiley & Sons, 1999, incorporated herein by reference.²101101 Exemplary' oxygen protecting groups include, but are not limited to, ²methyl, ²methoxymethyl (MOM), methylthiomethyl (MTM), t-butylthiomethyl, ²(phenyldimethylsilypmethoxymethyl (SMOM), benzyloxymethyl (BOM), p-²methoxybenzyloxymethyl (PMBM), (4-methoxyphenoxy)methyl (p-AOM), ²guaiacolmethyl²52²<DP=54>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²(GUM), 1-butoxymethyl, 4-pentenyloxymethyl (POM), siloxymethyl, 2-²methoxyethoxymethyl (MEM), 2,2,2-trichloroethoxymethyl, bis(2-²chloroethoxy)methyl, 2-²(trimethylsilyl)ethoxymethyl (SEMOR), tetrahydropyranyl (THP), 3-²bromotetrahydropyranyl, tetrahydrothiopyranyl, 1-methoxycyclohexyl, 4-²methoxytetrahydropyranyl (MTHP), 4-methoxytetrahydrothiopyranyl, 4-²methoxytetrahydrothiopyranyl S,S-dioxide, 1-[(2-chloro-4-metkõ,l)phenyl]-4-²methoxypiperidin-4-y1 (CTMP), 1,4-dioxan-2-yl, tetrahydrofuranyl, ²tetrahydrothiofuranyl, ²2,3,3a,4,5,6,7,7a-octahydro-7,8,8-trimethyl-4,7-methanobenzofuran-211, 1-²ethoxyethyl, I-²(2-chloroethoxy)ethyl, 1-methyl-1-methoxyethyl, 1-methyl-1-benzyloxyethyl, 1-²methyl-l-²benzyloxy-2-fluoroethyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, ²24phenylselenypethyl, t-²butyl, allyl, p-chlorophenyl, p-methoxyphenyl, 2,4-dinitrophenyl, benzyl (Bn), ²p-²methoxybenzyl, 3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-²halobenzyl, 2,6-²dichlorobenzyl, p-cyanobenzyl, p-phenylbenzyl, 2-picolyl, 4-picolyl, 3-methyl-²2-picoly1 N-²oxido, diphenylmethyl, p,p'-dinitrobenzhydryl, 5-dibenzosubetyl, ²triphenylmethyl, a-²naphthyldiphenylmethyl, p-methoxyphenyldiphenylmethyl, di(p-²methoxyphenyl)phenylmethyl, tri(p-methoxyphenyl)methyl, 444'-²bromophenacyloxyphenyl)diphenylmethyl, 4,4',4"-tris(4,5-²dichlorophthalimidophenyl)methyl, 4,4',4"-tris(levuhnoyloxyphenypinethyl, ²4,41,41'-²tris(benzoyloxyphenypmethyl, 3-(imidazol-1-yObis(41,4"-dimethoxyphenyl)methyl, ²1,1-²bis(4-methox,pheny1)-1'-pyrenylmethyl, 9-anthryl, 9-(9-phenyl)xanthenyl, 949-²pheny1-10-²oxo)anthryl, 1,3-benzodithiolan-2-yl, benzisothiazolyl S,S-dioxido, ²trimethylsilyl (TMS), ²triethylsilyl (TES), triisopropylsilyl (TIPS), dimethylisopropylsilyl (IPDMS), ²²diethylisopropylsilyl (DEIPS), dimethylthexylsilyl, t-butyldimethylsilyl ²(TBDMS), t-²butyldiphenylsilyl (TBDPS), tribenzylsilyl, tri-p-xylylsilyl, triphenylsilyl,²diphenylmethylsily1 (DPMS), t-butylmethoxyphenylsilyl (TBMPS), formate, ²benzoylformate, ²acetate, chloroacetate, dichloroacetate, trichloroacetate, trifluoroacetate, ²methoxyacetate, ²triphenylmethox-yacetate, phenoxyacetate, p-chlorophenoxyacetate, 3-²phenylpropionate, 4-²oxopentanoate (levulinate), 4,4-(ethylenedithio)pentanoate ²(levulinoyldithioacetal), pivaloate, ²adamantoate, croton ate, 4-methoxycrotonate, benzoate, p-phenylbenzoate, 2,4,6-²²trimethylbenzoate (mesitoate), methyl carbonate, 9-fluorenylmethyl carbonate ²(Fmoc), ethyl ²carbonate, 2,2,2-trichloroethyl carbonate (Troc), 24trimethylsilypethyl ²carbonate (TMSEC), ²24phenylsulfonyl) ethyl carbonate (Psec), 2-(triphenylphosphonio) ethyl ²carbonate (Peoc), ²isobutyl carbonate, vinyl carbonate, allyl carbonate, t-butyl carbonate (BOC ²or Boc), p-²53²<DP=55>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²nitrophenyl carbonate, benzyl carbonate, p-methoxybenzyl carbonate, 3,4-²dimethoxybenzyl ²carbonate, o-nitrobenzyl carbonate, p-nitrobenzyl carbonate, S-benzyl ²thiocarbonate, 4-²ethoxy-1 -napththyl carbonate, methyl dithiocarbonate, 2-iodobenzoate, 4-²azidobutyrate, 4-²nitro-4-methylpentanoate, o-(dibromomethyl)benzoate, 2-formylbenzenesulfonate, ²2-²(methylthi omethoxy)ethyl, 4-(methylthiomethoxy)butyrate, 2-²(methylthiomethoxymethypbenzoate, 2,6-dichloro-4-methylphenoxyacetate, 2,6-²dichloro-4-²(I,1,3,3-tetramethylbutyl)phenoxyacetate, 2,4-bis(1,1-²dimethylpropyl)phenoxyacetate, ²chlorodiphenylacetate, isobutyrate, monosuccinoate, (E)-2-methyl-2-butenoate, ²o-²(methoxyacyl)benzoate, a-naphthoate, nitrate, alkyl N,N,N',N'-²tetramethylphosphorodiamidate, alkyl N-phenylcarbamate, borate, ²dimethylphosphinothioyl, ²alkyl 2,4-dinitrophenylsulfenate, sulfate, metha.nesulfonate (mesylate), ²benzylsulfonate, and ²tosylate (Ts).²101111 in certain embodiments, the substituent present on a sulfur atom is a ²sulfur²protecting group (also referred to as a "thiol protecting group"). Sulfur ²protecting groups²include, but are not limited to, ---N(Rbb)2, C(....0)SRaa, C(...0)Ra3, ---²CO2Raa,²¨C(=0)N(Rbb)2, ¨C(=NRbb)R", ¨C(=NRbb)Olkaa, ¨C(=NRbb)N(Rbb)2, ¨S(=0)Raa, ²¨SO2Raa,²¨Si(Raa)3, ¨P(Rc92, ¨P(11.")3+X-, ¨P(OR)2, ¨P(ORcc):31X7, ¨P(4:)(Raa)2, ²¨P(=0)(OR")2, ²and ¨P(...0)(N(Rbb)2)2, wherein IV", leb, and R" are as defined herein. Sulfur ²protecting ²groups are well known in the art and include those described in detail in ²Protecting Groups in ²Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3 edition, 'John Wiley & ²Sons, ²1999, incorporated herein by reference.²101121 The term "leaving group" is given its ordinary meaning in the art of ²synthetic ²organic chemistry and refers to an atom or a group capable of being displaced ²by a ²nucleophile. Examples of suitable leaving groups include, but are not limited ²to, halogen ²(such as F, Cl, Br, or I (iodine)), alkoxycarbonyloxy, aryloxycarbonyloxy, ²alkanesulfonyloxy, ²arenesulfonyloxy, alkyl-carbonyloxy (e.g, acetoxy), arylcarbonyloxy, aryloxy. ²methoxy, ²N,O-dimethylhydroxõ,larnino, pixyl, and haloformates. In certain embodiments, ²the leaving ²group is halogen, alkanesulfonyloxy, arenesulfonyloxy, diazonium, alkyl ²diazenes, atyl ²diazenes, alkyl triazenes, aryl triazenes, nitro, alkyl nitrate, aryl nitrate, ²alkyl phosphate, aryl ²phosphate, alkyl carbonyl oxy, aryl carbonyl oxy, alkoxcarbonyl oxy, ²aryoxcarbonyl oxy ²ammonia, alkyl amines, aryl arnines, hydroxyl group, alk-ylox, group, or ²atyloxy. In some ²cases, the leaving group is a sulfonic acid ester, such as toluenesulfonate ²(tosylate, ¨0Ts), ²methanesulfonate (mesylate, ¨OMs),p-bromobenzenesulfonyloxy (brosylate, ¨0Bs), ²¨²54²<DP=56>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²OS(...0)2(CF2)3CF3 (nonaflate, ¨ONO, or trifluoromethanesulfonate (triflate, ²¨0TO. In ²some cases, the leaving group is a brosylate, such as p-²bromobenzenesulfonyloxy. In some ²cases, the leaving group is a nosylate, such as 2-nitrobenzenesulfonyloxy. In ²some ²embodiments, the leaving group is a sulfonate-containing group. In some ²embodiments, the ²leaving group is a tosylate group. The leaving group may also be a ²phosphineoxide (e.g , ²formed during a Mitsunobu reaction) or an internal leaving group such as an ²epoxide or ²cyclic sulfate. Other non-limiting examples of leaving groups are water, ²ammonia, alcohols, ²ether moieties, thioether moieties, zinc halides, magnesium moieties, ²diazonium salts, and ²copper moieties.²10113j "Carbon," refers to the radical .--q=0)0H.²101141 "Cyrano" refers to the radical ¨CN.²1011.51 -Halo" or "halogen" refers to fluor (F), chloro (Cl), bromo (Br), and ²iodo (1). In ²certain embodiments, the halo group is either fluoro or chloro.²101161 "Haloalkyl" refers to an alkyl radical in which the alkyl group is ²substituted with ²one or more halogens. Typical haloalkyl groups include, but are not limited ²to, ²trifluoromethyl (¨CF3), difluorom.ethyl (¨CHF2), fluoromethyl (¨CH2F), ²chloromethyl (¨²CH2C1), dichloromethyl (¨CHCl2), tribromomethyl (¨CH2Br), and the like.²1011.71 "Hydroxy" refers to the radical ¨OH.²1011.81 "Nitro" refers to the radical ¨NO2.²101191 "Thioketo" refers to the group =S.²101201 Alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and ²heteroaryl groups, as ²defined herein, are optionally substituted (e.g., "substituted" or ²"unsubstituted" alkyl, ²"substituted" or "unsubstituted" alkenyl, "substituted" or "unsubstituted" ²alkynyl, ²"substituted" or "unsubstituted" carbocyclyl, "substituted" or "unsubstituted" ²heterocyclyl, ²"substituted" or "unsubstituted" aryl or "substituted" or "unsubstituted" ²heterowyl group). In ²general, the term "substituted", whether preceded by the term "optionally" or ²not, means that ²at least one hydrogen present on a group (e.g., a carbon or nitrogen atom) is ²replaced with a ²permissible substituent, e.g., a substituent which upon substitution results ²in a stable ²compound, e.g., a compound which does not spontaneously undergo transformation ²such as ²by rearrangement, cyclization, elimination, or other reaction. Unless ²otherwise indicated, a ²"substituted" group has a substituent at one or more substitutable positions ²of the group, and ²when more than one position in any given structure is substituted, the ²substituent is either the ²same or different at each position. The term. "substituted" is contemplated to ²include²<DP=57>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²substitution with all permissible substituents of organic compounds, any of ²the substituents ²described herein that results in the formation of a stable compound. The ²present invention ²contemplates any and all such combinations in order to arrive at a stable ²compound. For ²purposes of this invention, heteroatoms such as nitrogen may have hydrogen ²substituents ²and / or any suitable substituent as described herein which satisfy the ²valencies of the ²heteroatoms and results in the formation of a stable moiety.²101211 Exemplary carbon atom substituents include, but are not limited to, ²halogen, -CN; -²NO2, -N3, -S02H, -S03H, -OR", -ON(R)2, -N(R)2, -N(R)3X, -N(OR")Rbb,²SH, -SR", -SSR", -C(C)R", -CO2H, -CHO, -C(OR)2, -CO2R", -0C(=0)R", -²0CO21taa, -C())N(Rbb)2; -0C(=o)N(Rbb)2, _NRbb,Q=0\²NRbbCO21taa, -²NRbbC(=0)N(Rbb)2.²-C(=NRbb)12", -C(=²NRbb)o-aa,²OC(::NRbb)Raa, -0C(=NRbb)ORaa, -²c(=NR)iNbbv.,(Th².kbb)2, -0C(=NRbb)N(Rbb)2, -NRbbC(=NRbb)N(Rbb)2, -C(.3)1=1RbbSO2R", -²NRbbSO2Raa, -SO2N(Rbb)2, -SO2R", -S020Raa, -0502Raa, -S(=0)R",-S(J)(=NRbb)R", -² ²0S(=0)rea, ---S1(R")3, -0S1(R)3-C(=S)N(Rb)2; -C(=0)SRaa, -C(=S)SR", -²SC(=S)SRaa, - ²SC(.4))SRaa, -0C(=0)SR", -SC(0)OR, -SC(:=0)Raa, -P(:=0)2R23, -0P(=0)2Ra2, - ²P(=0)(R")2, -0P(=0)(R")2, -0P(=0)(OR")2, -P(=0)2N(Rbb)2, -0P(=0)2N(Rbb)2, - ²P(=0)(NRbb)2, -0P(=0)(NRbb)2, -NRbbP(=0)(OR")2, -NRbbP(=0)(NRbb)2, -P(R)2. - ²P(R)3. -0P(R")2, -0P(R")3, -B(R")2, -B(OR)2, -I3R"(OR"), Ci-lo alkyl, Ci-io ²haloalkyl, ²C2.-.10 alkenyl, C2--10 alkynyl, C3-10 carbocyclyl, 3-14 membered ²heterocyclyl, C6-14 aryl, and ²5-14 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, ²heterocyclyl, ²aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rdd ²groups; or two ²geminal hydrogens on a carbon atom are replaced with the group =0, =S, ²=NN(Rbb)2,²=NNRibbc()=0,-aa, =²NNRbbC(=0)0Raa, =NNRbbS(=0)2R", =NR. or =NOR";²each instance of Raa is, independently, selected from Ci-io alkyl, C1.-.10 ²haloalkyl, C2.-.10 ²alkenyl, C2-10 alkynyl, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 ²aryl, and 5-14 ²membered heteroaryl, or two Ra groups are joined to form a 3-14 membered ²heterocyclyl or ²5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, ²carbocyclyl, ²heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, ²3, 4, or 5 Rdd ²groups;²each instance of Rbb is, independently, selected from hydrogen, -OH, -OR, -²N(R)2, -CN, ²-C(=0)R", -C()N(R")2, -CO2R", -SO2Raa, -C(=NR")0Raa, -C(=NR")N(R")2, -²S02N(R")2, -S0211, -S020R", -C(=S)N(R")2, -C(=0)SR", -C(=S)SR", - ²P(=0)2R", -P(=0)(R")2, -P(=0)2N(Rcc)2, -P(=0)(NRcc)2, Ci...io alkyl, Ci-io ²haloalkyl, C2-.10²56²<DP=58>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²alkenyl, C2-10 alkynyl, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 ²aryl, and 5-14 ²membered heteroaryl, or two Rbb groups are joined to form a 3-14 membered ²heterocyclyl or ²5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, ²carbocyclyl, ²heterocyclyl, atyl, and heteroaryl is independently substituted with 0, 1, 2, ²3, 4, or 5 Rdd ²groups;²each instance of R" is, independently, selected from hydrogen, Ci-to alkyl, Ci-²to haloalkyl, ²C2-to alkenyl, C2-I0 alkynyl, C3-to carbocyclyl, 3-14 membered heterocyclyl, ²C6-I4 aryl, and ²5-14 membered heteroaryl, or two R." groups are joined to form a 3-14 membered ²²heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, ²alkynyl, ²carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted ²with 0, 1, 2, 3, 4, ²or 5 Rdd groups;²each instance of Rdd is, independently, selected from halogen, -CN, -NO2, -N3, ²-S02H, - ²SOH, -OH, -OR", -0N(Rff)2, -N(R)2, -N(Rff)3+X--, -N(OR)R, -SR, -SR", -SSR", - ²C(=0)Ree, -CO2H, -CO2R", -0C(=0)Ree, -00O2R", -C(=0)N(Rff)2, -0C(=0)N(Rff)2, - ²²NRffC(...0)R", -NRffCO2Ree, -NRffq=0)N(Rff)2, -C(...NRff)0Ree, -0C(...NRff)R", ²- ²0C(=NRff)0Ree, -C(=NRff)N(Rff)2, -0C(=NlIff)N(Rff)2, -NRffC(=NRff)N(Rff)2,-²NRffS0211", ²-SO2N(Rff)2, -SO2R", -S020R", -0S02R", -S(=0)R", -Si(R)3, -0Si(R")3, -²C(...S)N(Rff)2, -C(:=0)SR", -SC(...S)SR", -P(...0)(R")2, -²0P(=0)(Ree)2, -0P(3)(0R")2, C I -6 alkyl, C haloakl, C2--6 alkenyl. C2.-6 ²alkynyl, C3-10 ²carbocyclyl, 3-10 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl, ²wherein ²each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, atyl, and heteroaryl ²is independently ²substituted with 0, 1, 2, 3, 4, or 5 Rgg groups, or two geminal Rdd ²substituents can be joined to ²form =0 or =S;²each instance of It" is, independently, selected from C1.-6 alkyl, C1.-6 ²haloallcyl, C2-6²C2-6 alkynyl, C3-10 carbocyclyl, C6-10 aryl, 3-10 membered heterocyclyl, and 3-²10 membered ²heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, ²my], and ²heteroffly1 is independently substituted with 0, 1, 2, 3, 4, or 5 Rgg groups; ²each instance of le is, independently, selected from hydrogen, C1-6 alkyl, C1-²6 haloallcyl, C2-6 ²alkenyl, C2-6 alkynyl, C3-10 carbocyclyl, 3-10 membered heterocyclyl, C6-10 ²aryl and 5-10 ²membered heteroaryl, or two Rff groups are joined to form a 3-14 membered ²heterocyclyl or ²5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, ²carbocyclyl, ²heterocyclyl, atyl, and heteroaryl is independently substituted with 0, 1, 2, ²3, 4, or 5 Rgg ²groups; and²57²<DP=59>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²each instance of Rgg is, independently, halogen, -CN, -NO2, -N3, -S02FT, -²S0311, -OFT, - ²OC1-6 alkyl, -01\1(C1-6 alky1)2, -N(Ci.-6 alky1)2, -N(Ci.-6 alky1)3+X.-, -²NH(C1-6 alky1)2+X--, - ²NH2(C1-6 alkyl) +X-, -NH3+X-, -N(0C1-6 alicyl)(Ci-6 alkyl), -N(OH)(C1-6 ²alkyl), -NH(OH), ²-SF!. -SCI-6 alkyl, -SS(C1-6 alkyl), -C(=0)(C1-6 alkyl), -0O2I-T, -0O2(C1-6 ²alkyl), - ²0C(=0)(C1-6 alkyl), -00O2(C1-6 alkyl), -C(=0)NH2, -C(=0)N(C1.-6 alky1)2, - ²OC(=0)NH(C1-6 alkyl), -NHC(=0)(C1-6 alkyl), -N(C1-6 ak,,I)C(=0)(0.-6 alkyl), - ²²NHCO2(C1-6 alkyl), -NHC(=0)N(C1-6 alky1)2, --NHC(=0)NH(C1-6 alkyl), -²NHC(=0)NH2, - ²C(=MI)0(C1-6 alkyl),-OC(:=NH)(C1-6 alkyl), -0C(=NI-T)0C1-6 alkyl, -C,(=N1-²1)N(C1-6 ²allcy1)2, -C(=NH)NH(C1.-6 alkyl), -C(=NH)NH2, -0C(=NH)N(C1-6 alky1)2, - ²OC(NH)NH(C1-6 alkyl), -0C(NH)N112, -NHC(NH)N(Ci-6 alk-y1)2, -NHC(=NH)NH2, - ²NITS02(C1-6 alkyl), -502N(C1-6 alky1)2, -SO2N1-1(C1-6 alkyl), -SO2N112,-S02C1-²6 alkyl, - ²S020C1-6 alkyl, -0502C1-6 alkyl, -S0C1-6 alkyl, -Si(C1-6 alky1)3, -0Si(C1-6 ²alky1)3 -²C(=S)N(C1-6 alk-y1)2õ C(=S)NH(C1-6 alkyl), C(=S)NH2, -C(1)S(C1-6 -C(=S)SCi.-²6 ²alkyl, --SC(=S)SCI-6 alkyl, -P(=0)2(CI-6 alkyl), -P(=0)(C1-6 ak,r1)2, -²0P())(C1-6 alky1)2, --²01?(:=0)(0C1-6 alky1)2, C1-6 alkyl, C1_6 haloalkyl, C2-6 alkenyl, C2-6 ²alkynyl, C3-10 ²carbocyclyl, C6-10 aryl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl; ²or two ²geminal Rgg substituents can be joined to form =0 or =S; wherein X- is a ²counterion. ²101221 A "counterion" or "anionic counterion" is a negatively charged group ²associated ²with a cationic quaternary amino group in order to maintain electronic ²neutrality. Exemplary ²counterions include halide ions (e.g, F, Cl-, Br, r), NO3--, 004-, OH--, H2PO4-²', HSO4-, ²SO4-25u1f0nate ions (e.g., methansulfonate, trifluoromethanesulfonate, p-²toluenesulfonate, ²benzenesulfonate, 10-camphor sulfonate, naphthalene-2-sulfonate, naphthalene-l-²sulfonic ²acid-5-sulfonate, ethan-l-sulfonic acid-2-sulfonate, and the like), and ²carboxyl ate ions ²(e.g, acetate, ethanoate, propanoate, benzoate, glycerate, lactate, tartrate, ²glycolate, and the ²like).²Nitrogen atoms can be substituted or unsubstituted as valency permits, and ²include primary, ²secondary, tertiary, and quartemary nitrogen atoms. Exemplary nitrogen atom ²substitutents ²include, but are not limited to; hydrogen, -OH, -01kaa; -N(R")2, -CN, ²C(=0)N(R")2, -CO2Raa, -SO2Raa, -C(=NRbb)R", -((=4\111.")0Raa, -C(=NR")N(R")2, -² ²SO2N(R")2, -S02R", -S020R", -SORaa, -C(=S)N(R")2, -C(=0)SR", -C(=S)SR", - ²P(0)2R, -P(=0)(Raa)2õ -P(=0)2N(11")2., -P(=0)(NR")2, C1-10 alkyl, Ci-io ²haloakl, C2-10 ²alkenyl, C2-10 alkynyl, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 ²aryl, and 5-14 ²membered heteroaryl, or two R" groups attached to a nitrogen atom are joined ²to form a 3-14²58²<DP=60>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, ²alkenyl, ²alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently ²substituted with 0, 1, ²2, 3, 4, or 5 Rdd groups, and wherein R", Rbb, R": and Rdd are as defined ²above.²These and other exemplary substituents are described in more detail in the ²Detailed ²Description, Examples, and Claims. The invention is not intended to be limited ²in any ²manner by the above exemplary listing of substituents.²Other definitions ²10123j As used herein, the term "salt" refers to any and all salts and ²encompasses ²pharmaceutically acceptable salts.²101241 The term "pharmaceutically acceptable salt" refers to those salts which ²are, within ²the scope of sound medical judgment, suitable for use in contact with the ²tissues of humans ²and lower animals without undue toxicity, irritation, allergic response and ²the like, and are ²commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable ²salts are well ²known in the art. For example, Berge et al., describes pharmaceutically ²acceptable salts in ²detail in J. Pharmaceutical Sciences (1977) 66:1-19. Pharmaceutically ²acceptable salts of ²the compounds of this invention include those derived from suitable inorganic ²and organic ²acids and bases. Examples of pharmaceutically acceptable, nontoxic acid ²addition salts are ²salts of an amino group formed with inorganic acids such as hydrochloric acid, ²hydrobromic ²acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids ²such as acetic ²acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or ²malonic acid or by ²using other methods used in the art such as ion excharme. Other ²pharmaceutically acceptable ²salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, ²benzoate, bisulfate, ²borate, butyrate, camphorate, camphorsulfonate, citrate, ²cyclopentanepropionate, digluconate, ²dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, ²glycerophosphate, ²gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-²ethanesulfonate, ²lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, ²methanesulfonate, 2-²naphthalenesulfonate, nicotin ate, nitrate, oleate, oxalate, palmitate, ²pamoate, pectinate, ²persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, ²stearate, succinate, ²sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate ²salts, and the like. ²Pharmaceutically acceptable salts derived from appropriate bases include ²alkali metal, ²alkaline earth metal, ammonium and1sr(C1-4alky1)4 salts. Representative alkali ²or alkaline ²earth metal salts include sodium, lithium, potassium, calcium, magnesium, and ²the like.²59²<DP=61>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²Further pharmaceutically acceptable salts include, when appropriate, nontoxic ²ammonium, ²quatemaiy, ammonium, and amine cations formed using counterions such as ²halide, ²hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate, ²and aryl sulfonate. ²101251 A "subject" to which administration is contemplated includes, but is ²not limited to, ²humans (i.e., a male or female of any age group, e.g, a pediatric subject ²(e.g., infant, child, ²adolescent) or adult subject (e.g., young adult, middle¨aged adult or senior ²adult)) and / or a ²non-human animal, e.g., a mammal such as primates (e.g., cynomologus monkeys, ²rhesus ²monkeys), cattle, pigs, horses, sheep, goats, rodents, cats, and / or dogs. In ²certain ²embodiments, the subject is a human. In certain embodiments, the subject is a ²non-human ²animal. The terms "human," "patient," and "subject" are used interchangeably ²herein. ²101261 Disease, disorder, and condition are used interchangeably herein.²101271 As used herein, and unless otherwise specified, the terms "treat," ²"treating" and ²"treatment" contemplate an action that occurs while a subject is suffering ²from the specified ²disease, disorder or condition, which reduces the severity of the disease, ²disorder or²condition, or retards or slows the progression of the disease, disorder or ²condition ²("therapeutic treatment"), and also contemplates an action that occurs before ²a subject begins ²to suffer from the specified disease, disorder or condition ("prophylactic ²treatment"). ²101281 In general, the "effective amount" of a compound refers to an amount ²sufficient to ²elicit the desired biological response. As will be appreciated by those of ²ordinary skill in this ²art, the effective amount of a compound of the invention may vary depending on ²such factors ²as the desired biological endpoint, the pharmacokinetics of the compound, the ²disease being ²treated, the mode of administration, and the age, health, and condition of the ²subject. An ²effective amount encompasses therapeutic and prophylactic treatment.²101291 As used herein, and unless otherwise specified, a "therapeutically ²effective amount" ²of a compound is an amount sufficient to provide a therapeutic benefit in the ²treatment of a ²disease, disorder or condition, or to delay or minimize one or more symptoms ²associated with ²the disease, disorder or condition. A therapeutically effective amount of a ²compound means ²an amount of therapeutic agent, alone or in combination with other therapies, ²which provides ²a therapeutic benefit in the treatment of the disease, disorder or condition. ²The term ²"therapeutically effective amount" can encompass an amount that improves ²overall therapy, ²reduces or avoids symptoms or causes of disease or condition, or enhances the ²therapeutic ²efficacy of another therapeutic agent.²<DP=62>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²[01301 As used herein, and unless otherwise specified, a "prophylactically ²effective ²amount" of a compound is an amount sufficient to prevent a disease, disorder ²or condition, or ²one or more symptoms associated with the disease, disorder or condition, or ²prevent its ²recurrence. A prophylactically effective amount of a compound means an amount ²of a ²therapeutic agent, alone or in combination with other agents, which provides a ²prophylactic ²benefit in the prevention of the disease, disorder or condition. The term ²"prophylactically ²effective amount" can encompass an amount that improves overall prophylaxis or ²enhances ²the prophylactic efficacy of another prophylactic agent.²Detailed Description of Certain Embodiments of the Invention²101311 As generally described herein, the present invention provides compounds ²(e.g., ²compounds of Formula (I), (la), (lb), (lc) and (Id) or compounds of Table 1, ²or ²pharmaceutically acceptable salts thereof) that are MTA-uncompetitive PRMT5 ²inhibitors ²useful for treating proliferating disorders (e.g., cancers) associated with ²MTAP deficiencies ²and / or MTA accumulation.²101321 in some embodiments, the present invention provides compounds (e.g., ²compounds ²of Formula (I), (Ia), (lb), (Ic) and (Id) or compounds of Table 1, or ²pharmaceutically ²acceptable salts thereof) that are MTA-uncompetitive, non-competitive or mixed ²mode ²PRMT5 inhibitor or an MTA cooperative binding agent useful for treating ²proliferating ²disorders (e.g, cancers) associated with MTAP deficiencies and / or MTA ²accumulation.²C'ompounds ²10133j In one aspect, provided herein are compounds or pharmaceutically ²acceptable salts ²thereof according to Formula (I) wherein:²R2 R7²R1kR30²NNllN ²(R8)²R4 0 R6 Formula (I),²each R.' is independently selected from H, -D, halo, -CN, -C1-C6 alkyl, -C ²heteroalkyl, ²-Ci-C6 haloalk-yl, -C3-C9 cycloalkyl, 3-10 membered heterocyclyl, ²heterocyclylallcyl, ²heterowylallcyl, arylalkyl, cycloalkylallcyl, -0Ral, -N(Ra1)2, -C(=0)Ral, -²C(=0)0Ral,²61²<DP=63>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²NRa I c (:=0)Ra _N.-.K a 1,-, (:::²0)0Ra I, -C(::::0)N(R2 1)2, -0C (:=0)N(Ra )2,-S(=0)Ra 1, -²S(=0)2Ra -SRa -S (=0)(=NRa I )Ra I, -NRa I Sfr-40)2Ra I and -S(20)21=1(Ral)2;²each R2 is independently selected from halo, --CN, alkyl; -²C1-C6 heteroalkyl, -Cl---C6²haloalkyl, -C1-C6 haloalkoxy, -C3-C9 cycloalkyl, 3-10 membered heterocyclyl, ²heterocyclylalkyl, heteroarylalkyl, arylalkyl, cycloalkylalkyl, -011a2, -²N(R)2, -C(A))Ra2, - ²C())012.a2, -NRa2C(=0)Ra2, -NRa2C())0Ra2, -C(=0)N(Ra2)2, -C(=0)N(OR8-2)(Ra2), -² ²0C(=0)N(Ra2)2,-S(=0)R82, -S(=0)2Ra2, ---se,---s(=o)(=NRa2)Ra2, -NRa2S(=0)2Ra2 ²and - ²S(=0)2N(R02)2;²each R.3 is independently selected from H, -D, halo, -CN, -CI-Co alkyl, -C1-C6 ²heteroalkyl, ²-CI-Co haloalkyl, -C3-C9 cycloallcyl, 3-10 membered heterocyclyl, ²heterocyclylalkyl, ²heteroarylalkyl, arylalkyl, cycloalkylalkyl, -0Ra3, -N(Ra3)2, -C(=0)Ra3, -²C(=0)01133, - ²NRa3C(=0)Ra3, -NRa3C(=0)0Ra3, -CK9N(R03)2, -0C(=0)N(R33)2,-S(=0)R03, -²S(=0)21e,²-SRa3, -S(=0)(=NRa3)Ra3, -NRa3SKO2R83 and -S(=0)2N(Ra3)2;²each R4 is independently selected from H, -D, halo, -CN, -CI-Co alkyl, -Ci-Co ²heteroalkyl,²-CI-Co haloalkyl, -C3-C9 cycloalkyl, 3-10 membered heterocyclyl, ²heterocyclylalkyl, ²heteroarylalkyl, arylalkyl, cycloalkylalkyl, _oRa4, _N(ta4)2, _c(-,0)Ra4, -²Q=0)0Ra4, - ²NRa4C(=0)Ra4, -NR94g=0)0Ra4, -20)N (Ra4)2, -0q=0)N(Ra4)2, -S(=0)Ra4, - ²S(=0)2Ra4, -SRa4,²NRa4)Ra4.²K Zi( 0)2Ra4 and -S(=0)2N(Ra4)2; ²each R6 is independently absent or selected from H, -D, halo, -CN, -C f-Co ²alkyl, -C1-Co ²heteroalkyl, -C1-C6 haloalkyl, -C3-Cm carbocyclyl, 3-10 membered heterocyclyl, ²²heterocyclylalkyl, Co-C fo aryl, 5-10 member heteroaryl, heteroarylalkyl,²cycloalkylalkyl, -0Ra6, -N(Ra6)2, -C(:=0)01226, -NRa6C(=0)Ra6, - ²NRa6C(=0)0Ra6, -C(=0)N(Ra6)2, -0C(20)N(Ra6)2,-S(=0)Ra6, -S(=0)2Ra6, -SRa6, - ²S(=0)(=NRa6)R96, -NRa6S(=0)2Ra6 and -S(0)2N(Rao)2, wherein each alkyl, ²carbocyclyl, ²heterocyclyl, cycloalkylalkyl, heterocyclylalkyl, aryl, heteroaryl, arylalkyl ²and ²heteroarylalkyl is optionally substituted at any available position; ²each R7 is independently absent or selected from H, -D, halo, -CN, -C f-Co ²alkyl, -C1-Co ²hydroxyalkyl, -Ci-Co haloalkyl. -C3-C9 cycloakl, 3-10 membered heterocyclyl, 5-²6-²membered monocyclic heteroafyl, heterocyclylalkyl, heteroarylalkyl,²cycloalkylalkyl, -0Ra7, -N(R), -C(:=0)01227, -NRa7C(:=0)Ra7, - ²NRa7C(=0)0Ra7, -C(=0)N(Ra7)2, -0C(3)N(Ra7)2,-S(=0)Ra7, -S(=0)2Ra7, -SRa7, - ²S(=0)(=NRa7)R97, ---NRa7S(=0)2R97 and -S(=0)2N(Ra7)2;²62²<DP=64>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²each 118 is independently selected from T-T, -D, =0, halo, -CN, -CI-C6 alkyl, -²C1-C6 ²heteroalkyl, -CI-C6 haloalkyl, -C3-C9 cycloalkyl, 3-10 membered heterocyclyl, ²heterocyclylalkyl, heteroarylalkyl, arylak,r1, cycloalkylallcyl,²-NR38C(=0)R38, -NRa8C(...0)01138, -CH2C(:=0)N(Ra8)2 -C(...0)N(Ra8)2, - ²0C(=0)N(Ra8)2, -CH2C(=0)N(Ra8)2,-S(=0)Ra8, -S(=0)21e8, -SR", -²S(=0)(=NR.a8)Ra8, - ²NeS(=0)21e8 and -S(=0)2N(Ra8)2 wherein two instances of le together with the ²atom or ²atoms to which they are attached can be taken together to form a 3-10 member ²cycloak,r1 or ²heterocyclyl ring (e.g., a ring that together with the piperidine ring of ²Structure T can form a ²bridged, fused or Spiro bicyclic heterocyclic ring)²each lel, Ra2, Ra3; Ra4,²K Ra7 and Ras is independently selected from H, (31.---C6 ²alkyl, -CI¨²C6 heteroalkyl, C3-C9 cycloalkyl, 3-7 membered heterocyclyl, cycloalkylalkyl, ²heterocyclylalk-yl, aryl, 5-6 membered heterowyl, arylalkyl and ²heteroarylalkyl wherein each²cycloalkyl, heterocyclyl, cycloalk-ylalkyl, heterocycly1a141, aryl, ²heteroalyl, arylalkyl ²and heteroarylalk-yl is optionally substituted at any available position (e.g, ²substituted with 0, ²1, 2 or 3 instances of R9, wherein each R9 is independently selected from =0, ²halo, -CN, - ²Ci-Co alkyl, -Ci-Co heteroalkyl, -C1-C6 haloalk-yl, -C3-C9 cycloalkyl, 3-10 ²membered ²heterocyclyl, Co-Cio aryl, 5-10 membered heteroaryl, cycloalk-ylalkyl, ²heterocycly1a141,²arylalk-yl, heteroarylalkyl, -ORb, -N(Rb)2, -C(...0)0Rb, -NRbC(:=0)Rb, - ²NRbC(---0)0Rb, -C(=0)N(Rb)2, -0C(=0)N(Rb)2,-S(=::))Rb, -S(=:20)2Rb, -SRb, - ²S(=0)(=NRb)Rb, -NRbS(=0)2Rb and -S(=0)2N(Rb)2, wherein each 11" is ²independently²selected from -Ci-C6 alkyl (e.g , -Me, -Et, -Pr, -)Pr,-"Bu, ---sec-Bu,--iso-²Bu).and²C3-C9 cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl); and²nis0,1,2or3²provided that:²when R1 is H, R2 is not halo, -0Pr, -N(CI-13)2 or -CF3;²when RI is OR", R2 is not -OR',²when RI is H and R2 is -CH3, R8 groups cannot be taken together to form a ring ²and le) is not²absent or H, and is not thiazolyl, furanyl or pyrrolyl;²when R2 is Me, RI is not optionally substituted piperidine²the compound is not:²5-(2-(5-methy1-2-(p-tolyl)piperidin-1-y1)-2-oxoacetamido)nicotinamide or any ²of its²enantiomers or diastereomers²63²<DP=65>²CA 03176912 2022-09-23²WO 2022 / 026892 PCT / US2021 / 044004²2-(2-(4-(2H-tetrazol-5-yl)pheny1)-5-methylpiperidin-l-y1)-N-(5,6-²dimethylpyridin-3-y1)-2-²oxoacetamide²2-cyano-5-(2-(5-methy1-2-phenylpi peri din- l -y1)-2-oxoacetatni ²do)nicotinatni de.²101341 In some embodiments, R6 is absent (e.g., if a Spiro ring formed by two ²R8 groups is²attached to the atom that would otherwise bear R6).²101351 in some embodiments, R7 is absent (e.g, if a spiro ring formed by two ²R8 groups is²attached to the atom that would otherwise bear R7).²101361 In certain embodiments, R6 and R7 are not H and are in a trans relative²configuration. In other embodiments, R6 and R7 are not H and are in a cis ²relative²configuration.²R7²101371 In some embodiments, the moiety represented as R6 in Formula (I) ²is²selected from:²R7 R7 R7 R7²rs-1²tR8) ¨(R) (1)¨(R8) N ) n .1.N n n²y²Re s R6 R6 Re , wherein R6, R7, R8 and n are²as described herein.²R7²101381 In certain embodiments, the moiety represented as R6 is selected ²from:²R7 R7²r""LI²¨(R8)²n²R6 and R6²R7²r'L.s1²:401 y) (R8)n²101391 In other embodiments, the moiety represented as R6 is selected ²from:²64²<DP=66>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004² E.R7 R7²rkl `12, / DN `x14.17¨µ's%²R6 and R6²101401 In some embodiments of the invention, the compound of Formula (I) is of ²Formula²(la)² R2 R7² RI, ,3.²1 0 r²N²N²H (R² R4 0 Fe Formula (la),²\ herein IV, R2, R3, R4, R6, R7, R8 and n are as described herein.²101411 In some embodiments of the invention, the compound of Formula (I) is of ²Formula²(lb)² R2 R7²R1²NLN,IL R8)² 144 a R6 Formula (Ib),²wherein. RI, R2, R3, R4, R6, R7, R8 and n are as described herein.²10142j In some embodiments of the invention, the compound of Formula (I) is of ²Formula²(Ic)² R2 R7²R'²r_²H (R8L² Fk4 0 Re Formula (lc),²wherein IV, R2, R3, R4, 6²K, R7, R8 and n are as described herein.²101431 In some embodiments of the invention, the compound of Formula (I) is of ²Formula²(Id)² R2 RT²W² '1 I iv 1 -;µ.1²N²(ReL²H 0 -F-I8 Formula (Id),²wherein IV, R2, R3, R4, R6, R7, R8 and n are as described herein.²<DP=67>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²[01441 In some embodiments of Formula (I), (lay, (Ib), (Ic) and (Id), when R2 ²is Me, R1 is ²not H.²101451 As generally defined herein, each R1 is independently selected from H, ²halo, -CN, - ²CI-Cs alkyl, -C1-C6 heteroalkyl, -CI-Co haloalkyl, -C3-C9 cycloalkyl, 3-10 ²membered²heterocyclyl, heterocyclylalk-yl, heteroarylalkyl, atylakl, cycloalkylalkyl, ² -N(Ra1)2, ²-C(=0)11a1, -C(=0)0e, -NRa1C(=0)Rai, -NRa1C(=0)011a1, -C(0)N(Rai)2, - ²0C(=0)N(Rai)2,_s(=o)Rai, -S(=0)212.", -SR", -S(=0)(=NRal)Ral, -NRa1S(=0)2Ral ²and - ²S(...0)2N(Ral)2, wherein RI is as defined herein.²101461 In some embodiments, 10 is selected from H, halo, -CN, -C1-C6 alkyl, -²CI-Cs ²heteroalkyl, -Ct-C6 haloalkyl, -C3--C9 cycloalkyl, 3-10 membered heterocyclyl, ²OR1,--²N(Rai)2, -C(...0)Rai, _c(,,,o)oRai, _NRaic(,,,o)Rai, -NeC(...0)0Ral, -²C(...0)N(Ral)2 and - ²0C(=0)N(Ra1)2. In further embodiments, R1 is selected from H, halo, -CN, -Ci-²Cs alkyl, - ²CI-Cs haloalkyl, -OR and _N(Rai)2.²101471 In certain embodiments, R1 is selected from H, -CI-Cs alkyl, -Ci-Cs ²haloalkyl, ²ORE' and -N(Ra1)2 wherein Ral is as defined herein. In further embodiments, ²each Ra1 is ²independently selected from H, -C1-C6 alkyl (e.g., -Me, -Et, -Pr, -Tr,-"Bu, -²13u, -sec-Bu, ²-iso-Bu) and -Ci-Cs haloalkyl (e.g., -CHF2,²101481 In some embodiments, R1 is selected from H, -CI-Cs alkyl (e.g., -Me, -²Et, -Pr, - ²Pr,-"Bu, -'Bu, -sec-Bu, -iso-Bu), -CI-Co haloalkyl (e.g., -CF 3, -CHF2), -OH, -²0-(Ci-Cs ²alk-yl) (e.g , -0Me, -0Et), -0-(C i-Cs haloalkyl) (e.g , -0CF3, -OCHF2), -NH, -²NH-(C ²C6 alkyl) (e.g , -NHMe) and N -(Ci C6 alky1)2 (e.g, NMe2). In certain ²embodiments, R1 is ²selected from H, -Me, -Et, -CHF2, -0Me, -0Et, -OCHF2, -0CF3,-OH and -NI-12. In ²²further embodiments, 111 is selected from H, -Et, -0Me, -0Et, -OCHF2, -0CF3 ²and -OH. ²101491 In some embodiments, R.1 is selected from H and -0Me.²101501 In other embodiments, R1 is selected from H, -Me, -CHF2 and -NI-12. In ²further ²embodiments, R1 is selected from -Me and -NH2.²101511 in some embodiments, R1 is H. In some embodiments R1 is -D.²101521 In certain embodiments, It1 is halo (e.g., fluor , chloro, bromo, ²iodo). In further ²embodiments, R1 is -Cl. In some embodiments, R1 is -F. In some embodiments, R1 ²is -Br. ²In some embodiments, 10 is -I.²101531 In some embodiments, R.1 is -CN.²101541 In certain embodiments, R1 is -CI-Cs alkyl. In further embodiments, R1 ²is -Me. In ²some embodiments. R1 is -Et. In some embodiments R1 is -Pr or -iPr.²66²<DP=68>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²[01551 In some embodiments, RI is -C1-C6 heteroalkyl. In further embodiments, ²RI is ²methoxymethyl (-CH2OCH3). In some embodiments, IV is hydroxymethyl (-CH2OH). ²In ²some embodiments, RI is aminomethyl (e.g.,-CH2NH2, -CH2NHCH3, -CH2N(CH3)2. ²In some embodiments, le is -CI-C6 haloalkyl. In further embodiments, RI is²trifluoromethyl (-CF3). In other embodiments, RI is difluoromethyl (-CHF2).²101561 in some embodiments, RI is -C3-C9 carbocydyl (e.g., cyclopropyl, ²cyclobutyl, ²cyclopentyl, cyclohexyl). In some embodiments, RI is cyclopropyl. In some ²embodiments ²RI is cyclobutyl. In some embodiments, RI is cyclopentyl. In some embodiments, ²RI is ²cyclohexyl.²In some embodiments, RI is 3-10 membered heterocycly! (e.g., oxetanyl, ²tetrahydropyranyl, ²tetrahydrofuranyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, ²morpholinyl, azepanyl). ²In some embodiments, RI is oxetanyl. In some embodiments, RI is ²tetrahydropyranyl. In ²some embodiments, RI is tetrahydrofuranyl. In some embodiments, RI is ²azetidinyl. In some ²embodiments, RI is pyrrolidinyl. In some embodiments, RI is piperidinyl. In ²some ²embodiments, RI is piperazinyl. In some embodiments, RI is morpholinyl. In ²some ²embodiments, RI is azepanyl.²(01571 In some embodiments RI is cycloalky, lalkyl (e.g, cyclopropylmethyl, ²cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cycloheptylmethyl). In ²some ²embodiments, RI is heterocyclylalkyl (e.g., oxetanylmethyl, aziridinylmethyl, ²tetrahydrofuranylmethyl, pyrolidinylmethyl, tetrahydropyranylmethyl, ²piperidinylmethyl, ²piperazinylmethyl, morpholinylmethyl, azepanylmethyl).²101581 In some embodiments, RI is arylalkyl. In some embodiments, RI is ²benzyl. ²In some embodiments, RI is heteroatylalkyl (e.g., pyridinylmethyl, ²thiazolylmethyl, ²triazolylmethyl, pyrazolylmethyl).²101591 In some embodiments, RI is -OR (e.g., hydroxy (-OH), inethoxy, ²difluoromethoxy ²(-0CHF2), trifluoromethoxy (-0CF3), ethoxy, propoxy, isopropoxy, ²cyclopropyloxy, ²cyclobutyloxy). In some embodiments, RI is hydroxy. In some embodiments, RI is ²methoxy. ²In some embodiments, RI is ethoxy. In some embodiments, RI is propoxy. In some ²²embodiments, RI is isopropoxy. In some embodiments RI is dilluoromethoxy. (-²OCTIF2). ²In some embodiments, RI is trifluoromethoxy (-0CF3).²(01601 In some embodiments, RI is -N(R1)2 (e.g, -NH2, -NHRal, -N(CH3)RaI). In ²some²embodiments, RI is In some embodiments, RI is -NHRal (e.g, -NIIMe, -NHEt, - ²²N'HPr, -NHiPr, -NHcyclopropyl, -NHcyclobuty1). In some embodiments, RI is -²N(CH3)Ral²67²<DP=69>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²(e.g., -NMe2, -N(CH3)Et, -N(CII3)Pr, -N(CI-1.3)1Pr, -N(CH3)cyclopropyl, - ²N(CH3)cyclobuty1).²In some embodiments, RI is -C(:=0)Ral or -C(=0)0Ral. In some embodiments, RI ²is - ²C(=0)R3l wherein WI is as described herein. In some embodiments. RI is -²C(...0)alkyl. In ²some embodiments, RI is -C(0)CH3, -C(0)cyclopropyl, -C(0)cyclobutyl, -C(0)!Bu, ²- ²C(0)113r, -C(0)Pr, -C(0)113u, or -C())0Me. In some embodiments, R.' is acetyl ²(-²C(=0)Me). In some embodiments; RI is -C(=0)0R21. In some embodiments. RI is - ²COOH. In some embodiments, 11' is COOMe.²101611 In some embodiments, R' is -NRalg=0)Ral. In certain embodiments, RI is -² ²NHC(=0)Ral (e.g, NHC(=0)Me; NHC(=0)Et; NHC(=0)Pr, NHC(=0)IPr, NHC())Bu; ²NITC(...0)11u, NHC(...0)Cyclopropyl, NITC(...0)Cyclobuty1). In some ²embodiments, RI is - ²N(CH3)C(=O)Ral (e.g., N(CH3)C(=0)Me, N(CH3)C(=0)Et, N(CH3)C(20)Pr, ²N(CH3)C(C)IPr, N(CH3)C(0)Bu, N(CH3)C(=0)43u, N(CH3)C(=0)Cyclopropyl, ²N(CH3)C(Cyclobuty1).²In some embodiments. RI is -NR"C(:=0)012al. In certain embodiments, RI is - ²NHC(=0)0Ral (e.g., NH.C(=0)0Me, NHC(=0)0Et, NHC(20)0Pr, NHC(=0)0IPr, ²NHC(=0)0Bu, NHC(=0)0113u, NHC(=0)0Cyclopropyl, NHC(=0)0Cyc1obuty1). In some ²embodiments. RI is -N(CH3)C(...0)0Ral (e.g., N(C113)C(:=0)0Me, ²N(CH3)C(...0)0Et, ²N(CH3)C(D)0Pr, N(CH3)C(=0)011r, N(CH3)C(=0)0Bu, N(CH3)C(=0)09Bu, ²N(CH3)C(0)0Cyclopropyl, N(CH3)C(=0)0Qõ,clobuty1).²101621 In some embodiments. RI is -C(=0)N(Ral)2(e.g,---C(=0)NH2, -C(=0)NHRal, -² ²C(...0)N(CH3)Ral). In some embodiments, RI is -C(...0)NH2. In certain ²embodiments, RI is ²-C(=0)NHRai (e.g., -C(20)NHMe, -C(=0)NHEt, -C(=0)NHPr, -C(=0)NHIPr, - ²C(=0)NHBu, -C()NH'Bu, -C(=0)NHCyclopropyl, -C()NHCyclobuty1). In certain ²embodiments, RI is -C(...0)N(C113)Ral (e.g,-C(...0)NMe2, -C(...0)N(CI-1.3)Et, -² ²C(=0)N(CH3)Pr, -C(=0)N(CH3)113r, -C(=0)N(CH3)Bu, -C(=0)N(CH3)Su, - ²C()N(CH3)Cyclopropyl, -C()N(CH3)Cyclobuty1).²In some embodiments, RI is -0C(=0)N(Ra1)2. In certain embodiments, RI is²OC(...0)NFIRal (e.g., -0C(...0)N1IMe, -0C(=0)NTIEt, -0C(...0)NHPr, -²0C(...0)N1fPr, - ²OC(=0)NHBu, -0C(=0)NHiBu, -0C(=0)NHCyclopropyl, -0C(=0)NHCyclobuty1). In ²certain embodiments, R.' is -0C(=0)N(CH3)Ral (e.g, -0C(=0)NMe2, -²0C(=0)N(CH3)Et, - ²0C(...0)N(C113)Pr, -0C(...0)N(CH3)113r, -0C(...0)N(CH3)Bu, -0C(=0)N(CH3)Su, - ²OC(=0)N(CH3)Cyclopropyl, -0C(=0)N(CH3)Cyclobuty1).²68²<DP=70>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²
[0163] In some embodiments. RI is -S(=0)Ral. In certain embodiments. RI is -²S(=0)alkyl ²(e.g, -S(=0)Me, -S(=0)Et, -S(=0)Pr, -S(=0)'Pr). In certain embodiments, RI is -² ²S(=0)cycloak,r1 (e.g., -S(=0)cyclopropyl, -S(=0)cyclobutyl, -S(=0)cyclopentyl, ²- ²S(:=0)cyclohexyl).²101641 In some embodiments, RI is -S(=0)2R.a1. In certain embodiments, RI is - ²²S(=0)2alk-y1 (e.g., -S(=0)2Me, -S(=0)2Et, -S(=0)2Pr, -S(=0)2113r). In certain ²embodiments,²RI is -S(=0)2cyc1oalkyI (e.g., -S(=0)2cyclopropyl, -S(=0)2cyclobutyl, -²S(0)2crclopentyl, - ²S(=0)2cyc1ohexy1). In some embodiments, RI is S(=0)2aryl (e.g., ²S(:=0)2pheny1). ²101651 In some embodiments. RI is -SRal. In certain embodiments, RI is -Salk-²yl (e.g., - ²SMe, -SEt, -SPr, -SIPr). In certain embodiments, RI is -Scycloalkyl (e.g., -²Scyclopropyl, - ²Scyclobutyl, -Scyclopentyl, -Scyclohexyl). In certain embodiments, RI is -²Saryl (e.g., ²Sphenyl).²In some embodiments, RI is -S(=0)(=NIV)Ral. In certain embodiments, RI is - ²S(=0)(=NH)Ral (e.g., -S(4))(=NH)Me, -S(=0)(=NH)Et, -S(=0)(=N1-1)13r, -²S(=0)(=NH)1Pr, - ²S(=0)(=NH)Bu, -S(=0)(=NH)Su, -S(:=0)(=NH)Cyclopropyl, -S(=0)(=NH)Cyclobuty1). ²In ²some embodiments, RI is -S(=-0)(=NCH3)Ral (e.g., -S(20)(=NCH3)Me, -²S(43)(=NCH3)Et, - ²S(=0)(=NCH3)Pr, -S(=0)(=NCH30r, -S(=0)(=NCH3)Bu, -S(=0)(=NCH3)tBu, - ²S(:=0)(=NCI13)Cyclopropyl, -S(:=0)(=NCH3)Cyclobuty1).²
[0166] In some embodiments, RI is -NRalS(0)2Ral. In certain embodiments, RI is ²- ²NHS(=0)2allcyl (e.g , -NHS(=0)2Me, -NHS(=0)2Et, -NHS())2Pr, -NHS(=0)2'Pr). In ²certain embodiments, RI is -NHS(=0)2cycloalky1 (e.g., -NHS(=0)2cyclopropy1, ²NTIS(=0)2cyclobutyl, -NIIS(=0)2cyc1openty1, -NITS(=0)2cyc1ohexy1). In certain ²embodiments, RI is -N(CH3)S(=0)2alkyl (e.g., -N(CH3)S(=0)2Me, -N(CH3)S(=0)2Et, ²- ²N(CH3)S()2Pr, -N(CH3)S(:))21Pr). In certain embodiments, R1 is - ²N(CH3)S(=0)2cycloalkyl (e.g., -N(CH3)S(=0)2cyclopropyl, -²N(CH3)S(=0)2cyclobutyl, - ²N(CH3)S(D)2cyclopentyl, -N(CH3)S(=0)2cyc1ohexy1).²
[0167] in some embodiments, RI is -S(=0)2N(Ral)2. (e.g, -S(=0)2NH2, -²S(=0)2NHRai, - ²S(=0)2N(CH3)Ra1). In some embodiments, RI is -S(=0)2NH2. In some embodiments. ²RI is - ²S(=0)2NHRaI (e.g., -S(=0)2NHMe, -S(:=0)2NHEt, -S(=0)2NHPr, -S(=0)2N11:13r, - ²S(=0)2NHcyc1opropyl, -S(=-0)2NHcyclobuty1). In some embodiments, RI is - ²S(=0)2N(CH3)Ra1 (e.g, -S(20)2NMe2, -S(=0)2N(CH3)Et, -S()2N(CH3)Pr, - ²S(=0)2N(CH3)1Pr, -S(=0)2N(CH3)cyclopropyl, -S(=0)2N(CH3)cyclobuty1).²69²<DP=71>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²
[0168] As generally defined herein, each R2 is independently selected from ²halo, -CN, - ²Ci-C6 alkyl, -Ci-C6 heteroalkyl, -C1-C6 haloalkyl, -C1-C6 haloalkoxy, -C3-C9 ²cycloalkyl, ²3-6 membered heterocyclyl, heterocyclylalkyl, heteroarylalkyl, arylalkyl, ²cycloakrIalk-yl,²-N(R)2. -C(:=0)Ra2, -C(:=0)0Ra2, -NRa2C(:=0)Ra2, -NRa2q=0)0Ra2, - ²C(=0)N(Ra2)2, -C(=0)N(ORa2)(R02), -0C(=.0)N(Ra2)2,-S(=0)R02, -S(=D)2Ra2, -²SR.a2, - ²S(=0)(=NRa2)Ra2, -NRa2S(=0)2Ra2 and -S(=D)2N(Ra-2)2, wherein Ra-2 is as ²defined herein.²101691 In some embodiments, R2 is selected from halo, --CN, alkyl, --C1-C6²heteroalkyl, -C1-C6 haloalkyl, -C1-C6 haloalkoxy, -C3-C9 cycloalkyl (e.g., ²cyclopropyl), 3-6²membered heterocyclyl (e.g, oxetanyl, tetrahydrofuranyl), -N(V-2)2, -²C(=D)Ra2, - ²C(=0)0Ra2, --²NRa2C(=0)Ra2, --NRa2C())0Ra2, --C(=0)N(Ra2)2, --C(=0)N(ORa2)(Ra2), ²OC(=0)N(Ra2)2.²101701 In certain embodiments, R2 is selected from halo, -CN, -CI-C6 alkyl, -²Ci-C6 ²haloalkyl, -Ci-C6 haloalkoxy, -C3-C9 cycloalkyl (e.g., cyclopropyl), 3-6 ²membered ²heterocyclyl (e.g, oxetanyl, tetrahydrofuranyl), -0Ra2, --N(R)2, -²C(=0)N(ORa2)(Ra2),-²C(=0)Ra2 and -C(=O)N(Ra2)2.²101711 In some embodiments. R2 is selected from halo, -Ci-C6 alkyl, -Ci-C6 ²haloalkyl, - ²CI-C6 haloalkoxy, -C3-C9 cycloalkyl (e.g, cyclopropyl), 3-6 membered ²heterocyclyl (e.g,²oxetanyl, tetrahydrofuranyl), --C(=0)Rie and -C(:=0)N(Ra2)2.²101721 In some embodiments, R2 is selected from halo, -CI-C6 alkyl, -CI-C6 ²haloalkyl, - ²CI-C6 haloalkoxy, -C3-C9 cycloalkyl (e.g, cyclopropyl), 3-6 membered ²heterocyclyl (e.g., ²oxetanyl, tetrahydrofuranyl), -OR', and -C(=0)N(Ra2)2, wherein each It' is as ²described ²herein. In further embodiments, each Ra2 is independently selected from H and -²Ci-C6 alkyl ²(e.g , -Me, -Et, -Pr, -Pr,-Bu, -fl3u, -sec-Bu, -iso-Bu).²101731 In certain embodiments, R2 is selected from halo (e.g., -Cl), -CI-C6 ²alkyl (e.g., - ²Me, -Et, -Pr, -'Pr,-"Bu. -'13u, -sec-Bu, -iso-Bu), -CI-Co haloalkyl (e.g., -²CF3, CHF 2), -CI-²Co haloalkoxy (e.g., -OCF 3, -OCHF 2) -C3-C9 cycloalkyl (e.g., cyclopropyl), 3-²6 membered²heterocyclyl e.g,( oxetanyl, ²tetrahydrofuranyl),-OR a2 (e.g , -0Me), -C(=0)NHOH, -²C(=0)H, and --C(=0)NH2. In further embodiments. R2 is selected from -CI, --Me, ²-Et, ²-CF3, -CHF2, -OCHE?, -0CF3, cyclopropyl, -0Me, oxetan-3-yl, tetrahydrofuran-²311, - ²C(=0)NHOH, -C(D)H and -C(0)NH2.²101741 In some embodiments, R2 is selected from -C(=0)NH2 and -C(0)H.²<DP=72>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²In some embodiments, R2 is selected from -CI, -Me, -Et, -Tr, --CF3, CHF2, -²OCHF2, - ²OCF3, and cyclopropyl. In further embodiments, R2 is selected from ²cyclopropyl, -Me and - ²Et.²In certain embodiments, R2 is halo (e.g., fluoro, chloro, bromo, iodo). In ²further ²embodiments, R2 is -Cl. In some embodiments, R2 is -F. In some embodiments, R2 ²is -Br. ²In some embodiments, R2 is -I.²101751 In some embodiments. R2 is ---CN.²101761 In certain embodiments, R2 is -C1--C6 alkyl. In further embodiments. R2 ²is -Me. In ²some embodiments, R2 is -Et. In some embodiments R2 is -Pr or -iPr.²In some embodiments, R2 is --CI-C6 heteroalkyl. In further embodiments. R2 is ²methoxymethyl (-CI-T2OCH3). In some embodiments, R2 is hydroxymethyl (-CH2OH). ²In ²some embodiments, R2 is aminomethyl (e.g.,-CH2NH2, -CH2NHCH3, -CH2N(CH3)2. ²101771 in some embodiments, R2 is -C1--C6 haloalkyl. In further embodiments, ²R2 is ²trifluoromethyl (---CF3). In other embodiments, R2 is difluoromethyl (---²CHF2).²In some embodiments, R2 is -CI-C6 haloalkoxy. In further embodiments, R2 is ²trifluoromethoxy (-0CF3), In other embodiments, R2 is difluoromethoxy (-²0CHF2). ²In some embodiments, R2 is -C3-C9 carbocyclyl (e.g., cyclopropyl, cyclobutyl, ²cyclopentyl, ²cyclohexyl). In some embodiments, R2 is cyclopropyl. In some embodiments R2 is ²²cyclobutyl. In some embodiments, R2 is cyclopentyl. In some embodiments, R2 is ²²cyclohexi.²In some embodiments, le is 3-6 membered heterocyclyl (e.g, oxetanyl, ²tetrahydropyranyl, ²tetrahydrofuranyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, ²morpholinyl, azepanyl). ²In some embodiments, R2 is oxetanyl. In some embodiments, R2 is ²tetrahydropyranyl. In ²some embodiments, R2 is tetrahydrofuranyl. In some embodiments, R2 is ²azetidinyl. In some ²embodiments, R2 is pyrrolidinyl. In some embodiments, R2 is piperidinyl. In ²some ²embodiments, R2 is piperazinyl. In some embodiments, R2 is morpholinyl. In ²some ²embodiments, R2 is azepanyl.²101781 In some embodiments R2 is cycloaklalkyl (e.g., cyclopropylmethyl, ²cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cycloheptylmethyl). In ²some ²embodiments, R2 is heterocyclylalkyl. (e.g., oxetanylm.ethyl, ²aziridinylmethyl, ²tetrahydrofuranylmethyl, pyrolidinylmethyl, tetrahydropyranylmethyl, ²piperidinylmethyl, ²piperazinylmethyl, morpholinylmethyl, azepanylmethyl).²101791 In some embodiments, R2 is arylalkyl. In some embodiments, R2 is ²benzyl.²71²<DP=73>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²[01801 In some embodiments, R2 is heteroarylalkyl (e.g., pyridinylmethyl, ²thiazolylmethyl, ²triazolylmethyl, pyrazolylmethyl).²[01811 In some embodiments; R2 is =0R2 (e.g, hydroxy (-OH), methoxy, ethoxy, ²propoxy, isopropoxy, cyclopropyloxy, cyclobutyloxy). In some embodiments, R2 ²is hydroxy. ²In some embodiments, R2 is methoxy. In some embodiments. R2 is ethoxy. In some ²²embodiments, R2 is propoxy. In some embodiments, R2 is isopropoxy.²101821 In some embodiments, R2 is ---N(R)2 (e.g., ---NH2, .--NHRa2, .--²N(CH3)Ra2). In some ²embodiments, R2 is -NH2. In some embodiments, R2 is -1\THRa2 (e.g., -NIiMe, -²NHEt, - ²NHPr, -NHIPr, -NHcyclopropyl, -NHcyclobuty1). In some embodiments, R2 is -²N(CH3)Ra2 ²(e.g., ---"We2, -N(CH3)Et, -N(CH3)Pr, -N(CH3)1Pr, ---N(CH3)cyclopropyl, - ²N(CH3)cyclobuty1).²In some embodiments, R2 is -C(=0)1,02 or -C(43)0112. In some embodiments, R2 ²is - ²C(4))1(a2 wherein e is as described herein. In some embodiments, R2 is -²C(=0)alkyl. In ²some embodiments, R2 is -C(0)CH3, -C(0)cyclopropyl, -C(0)cyclobutyl, -C(0)13u, ²- ²C(0)Pr, -C(0)Pr, -C(0)13u, or -C(=0)0Me. In some embodiments, R2 is acetyl (-²C(=0)Me). In some embodiments, R2 is -C(=0)0R8-2. In some embodiments, R2 is - ²²COOH. In some embodiments, R2 is COOMe.²[01831 In some embodiments, R2 is -NR82C(=0)Ra2. In certain embodiments, R2 is ²- ²N'HC(=0)Ra2 (e.g., NHC(00)Me, N'HC(=0)Et, NHC(=0)Pr, NHC(=0)'Pr, NHC()13u, ²NHC(=0)13u, NHC(D)Cyclopropyl, NHC(=0)Cyclobuty1). In some embodiments, R2 is -² ²N(CH3)C())Ra2 (e.g., N(CH3)C(=0)Me, N(CH3)C(=0)Et, N(CH3)C(=0)Pr, ²N(CH3)C(=0)'13r, N(CH3)C(=0)13u, N(CII3)Ce=0Mu, N(CTI3)C(=0)Cyclopropyl, ²N(CH3)C(D)Cyclobuty1).²[01841 In some embodiments, R2 is -NRa2C(=0)0Ra2. In certain embodiments, R2 ²is - ²NITC(=0)012a2 (e.g., NFIC(=0)0Me, NTIC(=0)0Et, NliC(:=0)0Pr, NFIC(=0)0iPr, ²N'HC(=0)0Bu, NHC(=0)013u, NHC(=0)0Cyclopropyl, N1-IC(=0)0Cyc1obuty1). In some ²embodiments, R2 is -N(CH3)C(=0)011a2 (e.g., N(CH3)C(4))0Me, N(CH3)C(=0)0Et, ²N(CH3)C(4))0Pr, N(CH3)C(=0)0'Pr, N(CH3)C(=0)013u, N(CH3)C(=0)0I3u, ²N(CH3)C(=0)0Cyclopropyl, N(CII3)C(=0)0Cyclobuty1).²101851 In some embodiments. R2 is -C(=0)N(Ra2)2 (e.g , -C(=0)NH2, -C(=0)NHRa2, ²- ²C(=0)N(CH3)Ra2). In some embodiments, R2 is -C())NH2. In certain embodiments, ²R2 is ²-C(=0)NtIll.92 (e.g., -C(:=0)NIIMe, -C(=0)NtIEt, -C(=0)NtIPr, -C(=0)NtI'Pr, - ²C(=0)NHBu, -C(0)NH'13u, -C(=0)NHCyclopropyl, -C(=0)NHCyc1obuty1). In certain²72²<DP=74>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²embodiments, R2 is -C(...0)N(CH3)Ra2 (e.g., -C(...0)NMe2, -C(:=0)N(CH3)Et, - ²C(=0)N(CH3)Pr, -C(=0)N(CH3)113r, -C(=0)N(CH3)Bu, -C(3)N(CH3)'3u, - ²C(=0)N(CH3)Cyclopropyl, -C(=0)N(CH3)Cyclobuty1).²In some embodiments, R2 is -C(...0)N(ORa2)(11 2). In certain embodiments. R2 ²is - ²C(=0)NH(ORa2) (e.g., -C(=0)NHOH, -C(=0)NHOMe). In some embodiments, R2 is - ²C()NHOH.²101861 In some embodiments, R2 is -0C(=0)N(Ra2)2. In certain embodiments. R2 ²is -²0C(...0)NFIRa2 (e.g., -0C(...0)NTIMe, -0C(...0)NHEt, -0C(...0)NHPr, -²OC(=0)NHBu, -0C(=0)NWI3u, -0C(=0)NHCyclopropyl, -0C()NHCyclobuty1). In ²certain embodiments, R2 is -0C(=0)N(CH3)Ra2 (e.g., --0C(=0)NMe2, -²0C(=0)N(CH3)Et, - ²0C(...0)N(C113)Pr, -0C(...0)N(CH3)113r, -0C(...0)N(CH3)Bu, -0C(...0)N(CH3)f3u, ²- ²0C(=0)N(CH3)Cyclopropyl, -0C(=0)N(CH3)Cyclobuty1).²101871 In some embodiments, R2 is -S(=0)11a2. In certain embodiments, R2 is -²S()allcyl ²(e.g., -S(::0)Me, -S(=0)Et, -S(=0)Pr, -S(=0)Pr). In certain embodiments, R2 is ²- ²S(...0)cyc1oalky1 (e.g., -S(....0)cyc1opropyl, -S(...0)cyclobutyl, -²S(...0)cyclopenty1, - ²S(=0)cyclohexyl).²101881 In some embodiments, R2 is -S(=0)2Ra2. In certain embodiments, R2 is -²S(...0)2alkyl (e.g., -S(...0)2Me, -S(=0)2Pr, ²-S(...0)21Pr). In certain embodiments,²R2 is -S(=0)2cycloalk-y1 (e.g , -S(=0)2cyclopropyl, -S(3)2cyclobutyl, -²S(=0)2cyclopentyl, - ²S(=0)2cyc1ohexy1). In some embodiments, R2 is S())2aryl (e.g., S(=0)2pheny1).²101891 In some embodiments, R2 is --se. In certain embodiments, R2 is -Salkyl ²(e.g., - ²SMe, -SEt, -SPr, -S'Pr). In certain embodiments. R2 is -Scycloalkyl (e.g., -²Scyclopropyl, ²Scyclobutyl, -Scyclopentyl, -Scyclohexyl). In certain embodiments, R2 is -²Saryl (e.g., ²Sphemõ,I).²In some embodiments, R2 is -S(=0)(=NRa2)Ra2. In certain embodiments, R2 is - ²S(=0)(=NH)Ra2 (e.g , -S(D)(=NH)Me, -S(=0)(=NH)Et, -S(=0)(=NH)Pr, -²S(=0)(=NH)iPr, - ²S(=0)(=NH)Bu, -S(=0)(=NH)tBu, -S(=0)(=NH)Cyclopropyl, -S(=0)(=NH)Cyclobuty1). ²In ²some embodiments, R2 is -S(=0)(=NCH3)Ra2 (e.g , -S())(=NCH3)Me, -²S(=0)(=NCH3)Et, - ²S(=0)(=NCT13)Pr, -S(...0)(...NCI-T3)iPr, -S(=0)(=NCT13)Bu, -S(...0)(=NCH3)Su, -² ²S(=0)(=NCH3)Cyclopropyl, -S(=0)(=NCH3)Cyclobuty1).²101901 In some embodiments, R2 is -NRa2S(=0)2Ra2. In certain embodiments. R2 ²is - ²NITS(...0)2alkyl (e.g., -NIIS(...0)2Me, -1\11IS(...0)2Et, -NITS(...0)2Pr, ..4I-²IS(...0)2130. In ²certain embodiments, R2 is -NHS(=0)2cycloalkyl (e.g., -NHS(=0)2cyc1opropy1, -²73²<DP=75>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²NHS(:=0)2cyclobutyl, -NHS(=0)2cyc10penty1, -NTIS(=0)2cyclohexyl). In certain ²embodiments, R2 is -N(CH3)S(=0)2alkyl (e.g., -N(CH3)S(=0)2Me, -N(CH3)S(=0)2Et, ²- ²N(CH3)S())2Pr, --N(CH3)S())2'Pr). In certain embodiments, R2 is ²N(CH3)S(=0)2cyc10a1ky1 (e.g., -N(CH3)S(-0)2cyc10pr0py1, -²N(CH3)S(=0)2cyc10buty1, - ²N(CH3)S(D)2cyclopentyl, -N(CH3)S(=0)2cyclohexyl).²101911 in some embodiments, R2 is -S(=0)2N(Ra2)2. (e.g, -S(=0)2NH2, -²S(=0)2NHIV12, - ²S(=0)2N(CH3)e). In some embodiments, R2 is -S(=0)2NH2. In some embodiments. R2 ²is - ²S(=0)2NHRa2 (e.g., -S(=0)2NEIMe, -S(=0)2NHEt, -S(=0)2NI-1.Pr, -S(=0)2NH'Pr, - ²S(=0)2NHcyclopropyl, -S())2NHcyclobuty1). In some embodiments, R2 is - ²S(=0)2N(CH3)1e2 (e.g, -S())2NMe2, -S(=0)2N(CH3)Et, -S(=0)2N(CH3)Pr, - ²S(:=0)2N(CH3)113r, -S(=0)2N(CH3)cyclopropyl, -S(=0)2N(CH3)cyclobuty1).²101921 Some embodiments of Formula (I), (Ia), (lb), (Ic) and (Id) feature ²certain ²combinations of 10 and R2. In one embodiment, RI is selected from H, -0Me, -²0Et,-0CF3,²-OCHF2, --CHF2, -Me, -Et, --OH and --NH2 and R2 is selected from -CI, -Me, -²Et, -²CF3, -CHF2, -OCHE?, cyclopropyl, -C(=0)NH2, and -CC=0)H, provided that when R2 ²is - ²Me, RI is NH2. In one embodiment. R' is selected from H, -CHF2, -Me and -NH2 ²and R2 is ²selected from -Cl. -Me, -Et, -CF3, -CHF2, -OCHF2 and cyclopropyl, provided ²that when R2 ²is -Me, le is NH2. In a further embodiment, RI is selected from -NI-T2 and -Me ²and R2 is ²selected from -Me, and -Et. In one emboniment, RI is -NH2 and R2 is selected ²from. -Me or ²-Et. In another embodiment, le is selected from H, -0Me, -0Et,-0CF3, -OCHF2, -²Et and - ²OH and le is selected from -C(=0)NH2 and -C(=0)H. In a further embodiment, RI ²is ²selected from H and -0Me and R2 is -C(=0)N1i2.²101931 As generally described herein, each R3 is independently selected from ²H, -D, halo, -²CN, -Ci-C6 alkyl, -Ci-C6 heteroallcyl, -C3-C9 ²cycloalk-yl, 3-10 membered²heterocyclyl, heterocyclylalk-yl, heteroarylalkyl, arylalkyl, cycloalkylalkyl, ²-OR , -N(Ra3)2, ²-C(=0)R03, -C(=0)0R.a3, -NRa3C(=0)Ra3, -NRa3C(D)ORa3, -C(0)N(R03)2, -²0C(=0)N(Ra3)2,-S(=0)1e3, -S(=0)21V3, -²s(=o)(=NRa3)Ra3, -NIV3S(=0)2Ra3 and -²S(=0)2N(Ra3)2, wherein It' is as described herein.²101941 In some embodiments, R3 is selected from 1-1, halo, -CN, -(31-C6 alkyl, ²-C1-C6 ²heteroalkyl, -CI-C6 haloalkyl, -C3-C9 cycloalkyl, 3-10 membered heterocyclyl, -²0R3, - ²N(Ra3)2, -C(ORa3, -C()ORa3, -NRa3C()Ra3, -NRa3C())0R93, -C(=0)N(Ra3)2 and - ²OC(=0)N(R93)2.²74²<DP=76>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²
[0195] In certain embodiments, R3 is selected from H, halo, -CN, -CI-C6 alkyl, ²-C1-C6 ²haJoalkyl and -N(Ra3)2 wherein Ra3 is as described herein. In further ²embodiments, Ra3 is²selected from H and CI---C6 alkyl (e.g., ---Me, ---Et, --Pr, ---IPr,---"Bu, ²-sec-Bu, --iso-Bu). In²some embodiments. R3 is selected from -CI-C6 alkyl (e.g., -Me, -Et, -Pr, -²'13r,-"Bu, -²sec-Bu, -iso-Bu), -OH, akl) (e.g , -0Me), -NH2, -NH-(CI-C6 alkyl) (e.g., ²NHMe) and -N-(Cl-C6 alk-y1)2 (e.g, NMe2). In further embodiments, R3 is ²selected from H, ²---Me and ---NH2. In certain embodiments, R3 is selected from H and ---Me.²101961 In some embodiments. R3 is H. In some embodiments R3 is -D.²In certain embodiments, R3 is halo (e.g, fluoro, chloro, bromo, iodo). In ²further ²embodiments, R3 is ---Cl. In some embodiments, R3 is --F. In some embodiments, ²R3 is --Br. ²In some embodiments, R3 is -1-²101971 In some embodiments, R3 is -CN.²101981 in certain embodiments, R3 is -CJ-C6 alkyl. In further embodiments, R3 ²is -Me. In ²some embodiments, R3 is ---Et. In some embodiments R3 is ---Pr or ---iPr.²In some embodiments. R3 is heteroalkyl. In further embodiments, R3 is ²methoxymethyl (-CH2OCH3). In some embodiments. R3 is hydroxymethyl (-CH2OH). ²In ²some embodiments, R3 is aminomethyl (e.g. ,-CH2NH2, -CH2NHCH3, -CH2N(CH3)2. ²101.991 In some embodiments, R3 is -CI-C6 haloalkyl. In further embodiments, ²R3 is ²trifluoromethyl (-CF3). In other embodiments, R3 is clifluoromethyl (-CHF2).²102001 in some embodiments, R3 is -C-C9 carbocydyl (e.g., cyclopropyl, ²cyclobutyl, ²cyclopentyl, cyclohexyl). In some embodiments, R3 is cyclopropyl. In some ²embodiments ²R3 is cyclobutyl. In some embodiments, R3 is cyclopentyl. In some embodiments, ²R3 is ²cyclohexyl.²102011 In some embodiments, R3 is 3-10 membered heterocõ,c1y1 (e.g , oxetanyl, ²²tetrahydropyranyl, tetrahydrofuranyl, azetidinyl, pyrrolidinyl, piperidinyl, ²piperazinyl, ²morpholinyl, azepanyl). In some embodiments, R3 is oxetanyl. In some ²embodiments, R3 is ²tetrahydropyranyl. In some embodiments, R3 is tetrahydrofuranyl. In some ²embodiments, R3 ²is azetidinyl. In some embodiments, R3 is pyrrolidinyl. In some embodiments. ²R3 is ²piperidinyl. In some embodiments, R3 is piperazinyl. In some embodiments, R3 ²is ²moipholinyl. In some embodiments, R3 is azepanyl.²102021 In some embodiments R3 is cycloallcylalkyl (e.g , cyclopropylmethyl, ²cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cycloheptylmethyl). In ²some ²embodiments, R3 is heterocyclylalkyl (e.g., oxetanylmethyl, aziridinylmethyl,²<DP=77>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²tetrahydrofuranylmethyl, pyrolidinylmethyl, tetrabydropyranylmethyl, ²piperidinylmethyl, ²piperazinylmethyl, morpholinylmethyl, azepanylmethyl).²102031 In some embodiments, R3 is aiyialkyl. In some embodiments, R3 is ²benzyl. ²In some embodiments, R3 is heteroarylalkyl (e.g., pyridinylmethyl, ²thiazolylmethyl, ²triazolylmethyl, pyrazolylmethyl).²102041 in some embodiments, R3 is -OR' (e.g., hydroxy (-0H), methoxy, ²difluoromethoxy ²(-0CHF2), trifluoromethoxy (-0CF3), ethoxy, propoxy, isopropoxy, ²cyclopropyloxy, ²cyclobutyloxy). In some embodiments, R3 is hydroxy. In some embodiments, R3 is ²methoxy. ²In some embodiments, R3 is ethoxy. In some embodiments, R3 is propox-y. In ²some ²embodiments, R3 is isopropoxy. In some embodiments R3 is difluoromethoxy. (-²0CHF2). ²In some embodiments, R3 is trifluoromethoxy (-0CF3).²102051 In some embodiments, R3 is -N(103)2 (e.g., -NH2, -NHRa3, -N(CH3)103). ²In some ²embodiments, R3 is -NH2. In some embodiments, R3 is -NHRa3 (e.g, -NHMe, -NHEt, ²-²N1-1Pr, -NHcyclopropyl, -NHcyc1obuty1). In some embodiments, R3 is -²N(CH3)Ra3 ²(e.g., -NMe2, -N(CII3)Et, -N(CI-1.3)Pr, -N(CT13)Tr, -N(CI-13)cyclopropyl, - ²N(CH3)cyclobuty1).²In some embodiments, R3 is -C(=0)Ra3or -C(=0)0Ra3. In some embodiments, R3 is -² ²C(:=0)1133 wherein Ra3 is as described herein. In some embodiments, R3 is -²C(...0)alkyl. In ²some embodiments, R3 is -C(0)CH3, -C(0)cyclopropyl, -C(0)cyclobutyl, -C(0)!Bu, ²- ²C(0)113r, -C(0)Pr, -C(0)113u, or -C())0Me. In some embodiments, R3 is acetyl (-²²C(=0)Me). In some embodiments, R3 is -C(=0)01V3. In some embodiments, R3 is - ²COOH. In some embodiments. R3 is COOMe.²102061 In some embodiments. R3 is -NRa3C(=0)Ra3. In certain embodiments, R3 is ²- ²NHC(=0)Ra3 (e.g, NHC(=0)Me, NHC(=0)Et, NHC()Pr, NHC(=0)iPr, NHC(20)Bu, ²NITC(...0)11u, NHC(...0)Cyclopropyl, NFIC(...0)Cyclobuty1). In some ²embodiments, R3 is - ²N(CH3)C(=3)Ra3 (e.g., N(CH3)C(=0)Me, N(CH3)C(=0)Et, N(CH3)C()Pr, ²N(CH3)CKOIPr, N(CH3)C(0)Bu, N(CH3)C(=0)43u, N(CH3)C(=0)Cyclopropyl, ²N(CH3)C(Cyclobuty1).²102071 In some embodiments. R3 is -NR"C(=0)011". In certain embodiments, R3 is ²- ²NHC(=0)011a3 (e.g., NH.C(=0)0Me, NHC(=0)0Et, NHC(20)0Pr, NHC(=0)0IPr, ²NHC(=0)0Bu, NHC(=0)0113u, NHC(=0)0Cyclopropyl, NHC(=0)0Cyc1obuty1). In some ²embodiments. R3 is -N(CH3)C(...0)0Ra3 (e.g., N(C113)C(=0)0Me, ²N(CH3)C(...0)0Et,²76²<DP=78>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²N(CI-1.3)C(...0)0Pr, N(CH3)C(...0)0'Pr, N(CI-I3)C(=3)0Bu, N(CI-²1.3)C(...0)013u, ²N(CH3)CK90Cyclopropyl, N(CH3)¶=0)0Cyclobuty1).²102081 In some embodiments, R3 is -C(=0)N(Ra3)2(e.g., --C(=0)NH2, --²C(=0)NHRa3, - ²C(:=0)N(CI-I3)e). In some embodiments. R3 is -C(...0)N1I2. In certain ²embodiments, R3 is ²-C(=0)NHR6 (e.g., -C(=D)NHMe, -C(00)NHEt, -C(00)NHPr, -C(00)NH'Pr, - ²C()NHBu, -C(=0)NWI3u, -C(=0)NHCyclopropyl, -C(=0)NHCyclobuty1). In certain ²embodiments, R3 is -C(=0)N(CH3)R33 (e.g., --C(=0)NMe2, -C(=0)N(CH3)Et, ²C(...0)N(CH3)Pr, -C(...0)N(CTI3) / Pr, -C(=0)N(CT-I3)Bu, -C(=0)N(CI-T3)!Bu, - ²C(=0)N(CH3)Cyclopropyl, -C(=0)N(CH3)Cyclobuty1).²102091 In some embodiments, R3 is -0C(=0)N(Ra3)2. In certain embodiments, R3 ²is ²0Q...0)1\111Ra' (e.g., -0C(...0)NHMe, -0C(...0)N1-1Et, -0C(:=0)NI-IPr, -²0C(...0)NITPr, - ²0C(=0)NHI3u, -0C(=0)NITI3u, -0C(=0)NHCyclopropyl, -0C(=0)NHCyclobuty1). In ²certain embodiments, R3 is -0C()N(CH3)12.a3 (e.g., -0C(=0)NMe2, -²0C(=0)N(CH3)Et, - ²OC(=0)N(CH3)Pr, -0C(=0)N(CH3)11r, -0C(=0)N(CH3)1311, -0C(=0)N(CH3)t3u, - ²0C(...0)N(CI-1.3)Cyclopropyl, -0C(:=0)N(CH3)Cyclobuty1).²102101 In some embodiments, R3 is -S(=0)Ra3. In certain embodiments, R3 is -²S(=0)alkyl ²(e.g , -S(=0)Me, -S(=0)Et, -S(=0)Pr, -S(=0)1Pr). In certain embodiments, R3 is ²- ²S(...0)cycloalkyl (e.g., -S(...0)cyclopropyl, -S('=0)cyclobutyl, -²S(...0)cyclopentyl, - ²S(=0)cyclohexy1).²102111 in some embodiments, R3 is -S(=0)211a3. In certain embodiments, R3 is - ²²S(=0)2alkyl (e.g., -S(=0)2Me, -S(=0)2Et, -S(=0)2Pr, -S(=0)2!Pr). In certain ²embodiments, ²R3 is -S(...0)2cycloalkyl (e.g., -S(...0)2cyclopropyl, -S(...0)2cyc10buty1, -²S(...0)2cyclopentyl, - ²S(=0)2cyclohexyl). In some embodiments, R3 is S(=D)2aryl (e.g , S(=0)2pheny1).²102121 In some embodiments, R3 is ¨SRa3. In certain embodiments, R3 is -Salk-²yl (e.g., - ²SMe, -SEt, -SPr, -S113r). In certain embodiments, R3 is -Scycloalkyl (e.g., -²Scyclopropyl, ²Scyclobutyl, -Scyclopentyl, -Scyclohexyl). In certain embodiments, R3 is -²Saryl (e.g., ²Spheny1).²102131 In some embodiments. R3 is -S(=0)(=NRa3)Ra3. In certain embodiments. R3 ²is - ²S(=0)(=NT)R 3 (e.g., -S(...0)(=NI-I)Me, -S(:=0)(...N11)Et, -S(...0)(=NH)Pr, -²S(=0)(...NE)ift, - ²S(=0)(=NH)Bu, -S(=0)(=N1013u, -S(=0)(=NH)Cyclopropyl, -S(=0)(=NH)Cyclobuty1). ²In ²some embodiments, R3 is -S()(=NCH3)1e3 (e.g., -S())(=NCH3)Me, -S(=0)(=NCH3)Et, ²- ²S(...0)(...NCI-T3)Pr, -S(...0)(=NCT-I3)iPr, -S(...0)(=NCI-T3)Bu, -S(...0)(=NCI-²1.3)Su, - ²S(=0)(=NCH3)Cyclopropyl, -S(=-0)(=NCH3)Cyclobuty1).²77²<DP=79>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²WU] In some embodiments. R3 is -NR23S(=0)2Ra3. In certain embodiments, R3 is - ²²NHS(=0)2a1ky1 (e.g., -NH.S(=0)2Me, -NHS(=0)2Et, -NHS(D)2Pr, -NHS(=0)2.'Pr). In ²²certain embodiments, R3 is -NHS(=0)2cycloalkyl (e.g, -NHS(=0)2cyclopropyl, - ²NITS(=0)2cyc10buty1, -NITS(=0)2cyclopentyl, -NFIS(=0)2cyc10hexy1). In certain ²embodiments, R3 is -N(CH3)S(=0)2a1ky1 (e.g., -N(CH3)S(=0)2Me, -N(CH3)S(=0)2Et, ²- ²N(CH3)S(=0)2Pr, -N(CH3)S())2.113r). In certain embodiments, R3 is - ²N(CH3)S(=0)2cycloalkyl (e.g., -N(CH3)S(=0)2cyclopropyl, -²N(CH3)S(=0)2cyclobutyl, - ²N(CH3)S('=0)2cyc10pen1y1, -N(CH3)S(=0)2cyclohexyl).²102151 In some embodiments, R3 is -S(=0)2N(Ra3)2. (e.g., -S(=0)2NH2, -²S(=0)2NHR83, - ²S(=0)2N(CH3)1e3). In some embodiments, R3 is -S(=0)2NH2. In some embodiments; ²R3 is - ²S(=0)2N1IRa3 (e.g , -S(:=0)2NHMe, -S(=0)2NHEt, -S(=0)2NEIPr, -S(=0)2N1-1113r, -² ²S(=0)2NHcyclopropyl, -S(=0)2NHcyclobuty1). In some embodiments, R3 is - ²S(=0)2N(CH3)1e3 (e.g., -S())2NMe2, -S(=0)2N(CH3)Et, -S(=0)2N(CH3)Pr, - ²S(=0)2N(CH3):13r, -S(=0)2N(CH3)cyclopropyl, -S(=0)2N(CH3)cyclobuty1).²102161 As generally described herein, each 11.4 is independently selected from ²H, -D, halo, - ²CN, -CI-C6 alkyl, -Ci-Co heteroalkyl, -CI-C6 haloalkyl, -C3-C9 cycloalkyl, 340 ²mem.bered²heterocyclyl, heterocyclylalkyl, heteroarylalkyl, arylalkyl, cycloalkylalkyl, ² -N(Ra4)2, ²-g=0)R34, -C(=0)01134, ANTRa4c(::::0)Ra4, _NRa4c(:=0)0Ra4, -C(:=0)N(R34)2, - ²0C(=0)N(Ra4)2, -S(D)Ra4, -S(0)2Ra4, -SR", -S(=0)(=NRa4)R04, -NRa4S(=0)2R." and ²- ²S(=0)2N(Ra4)2, wherein each Ra4 is as described herein.²102171 In certain embodiments, R4 is selected from H, halo, -CN, -Cl-C6 alkyl, ²-C1-C6 ²heteroalkyl, -C1-C6 haloalkyl, -C3-C9 cycloalkyl, 3-10 membered heterocyclyl, -²0R'4, - ²N(R84)2, -C(=o)R34, -C(=0)0R84, -NW4C(=0)1V4, -NRa4CK901V4, -C(=0)N(12a4)2 and ²- ²0C(=0)N(114)2.²1021.81 In some embodiments, R4 is selected from H, halo, -CN, -C1-C6 alkyl, -²CI-C6 ²haloalk-yl and -N(R04)2, wherein each R." is as described herein. In further ²embodiments, ²each le is independently selected from H and -Ci-C6 alkyl (e.g., -Me, -Et, -²Pr, -Pr,-Bu, ²tBu,---sec-Bu, ---iso-Bu). In some embodiments. R4 is selected from -Ci-C6 ²alkyl (e.g., -Me, ²-Et, -Pr, -'Pr,-nBu, -'Bu, -sec-Bu, -iso-Bu), -OH, -0-(C1-C6 alkyl) (e.g., -²0Me), -N1I2, - ²NH-(CI-C6 alkyl) (e.g., -NHMe) and -N-(Ci-Co alky1)2 (e.g, NMe2).²102191 In some embodiments, R4 is H. In some embodiments R4 is -D.²78²<DP=80>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²
[0220] In certain embodiments, R4 is halo (e.g., fluoro, chloro, bromo, iodo). ²In further ²embodiments, R4 is -Cl. In some embodiments, R4 is -F. In some embodiments, R4 ²is -Br. ²In some embodiments, R4 is -I.²
[0221] In some embodiments, R4 is -CN.²In certain embodiments, le is -CI-C6 alkyl. In further embodiments, R4 is -Me. ²In some ²embodiments, R4 is -Et. In some embodiments 114 is -Pr or -iPr.²102221 In some embodiments. R4 is -CI-C6 heteroalkyl. In further embodiments, ²R4 is ²methoxymethyl (-0120CH3). In some embodiments, R4 is hydroxymethyl (-CH20}I). ²In ²some embodiments, R4 is aminomethyl (e.g ,-CH2NH2, -CH2NHCH3, -CH2N(CH3)2. ²10223j In some embodiments; R4 is -CI-C6 haloakrl. In further embodiments, R4 ²is ²trifluoromethyl (-CF3). In other embodiments, R4 is difluoromethyl (-01F2).²In some embodiments, R4 is -C3-C9 carbocyclyl (e.g., cyclopropyl, cyclobutyl, ²cyclopentyl, ²cyclohexõ,1). In some embodiments, R4 is cyclopropyl. In some embodiments R4 ²is ²cyclobutyl. In some embodiments, R4 is cyclopentyl. In some embodiments; R4 is ²²cyclohexyl.²In some embodiments, R4 is 3-10 membered heterocyclyl (e.g., oxetanyl, ²tetrahydropyranyl, ²tetrahydrofuranyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, ²morpholinyl, azepamõ,1). ²In some embodiments, R4 is oxetanyl. In some embodiments, R4 is ²tetrahydropyra.nyl. In ²some embodiments. R4 is tetrahydrofuranyl. In some embodiments, R4 is ²azetidinyl. In some ²embodiments, R4 is pyrrolidinyl. In some embodiments, R4 is piperidinyl. In ²some ²embodiments, R4 is piperazinyl. In some embodiments, R4 is morpholinyl. In ²some ²embodiments, le is azepanyl.²102241 In some embodiments R4 is cycloalkylalkyl (e.g., cyclopropylmethyl, ²cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cycloheptylmethyl). In ²some ²embodiments. R4 is heterocyclylalkyl (e.g., oxetanylmethyl, aziridinylmethyl, ²tetrahydrofuranylmethyl, pyrolidinylmethyl, tetrahydropyranylmethyl, ²piperidinylmethyl, ²piperazinylmethyl, morpholinylmethyl, azepanylmethyl).²In some embodiments, R4 is arylalkyl. In some embodiments, R4 is benzyl.²In some embodiments. R4 is heterowylalkyl (e.g., pyridinylmethyl, ²thiazolylmethyl, ²triazolylmethyl, pyrazolylmethyl).²102251 In some embodiments, R4 is -0Ra4 (e.g. hydroxy (-OH), methoxy, ²difluoromethoxy ²(-0CHF2), trifluoromethoxy (-0CF3), ethoxy, propoxy, isopropoxy, ²cyclopropyloxy, ²cyclobutyloxy). In some embodiments, R4 is hydroxy. In some embodiments, R4 is ²methoxy.²79²<DP=81>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²In some embodiments, R4 is ethoxy. In some embodiments, R4 is propoxy. In some ²²embodiments, R4 is isopropoxy. In some embodiments R4 is difluorom.ethoxy. (-²0CHF2). ²In some embodiments, R4 is trifluoromethoxy (-0CF3).²102261 In some embodiments, R4 is ¨N(11")2 (e.g., ¨NI-12, ¨N(CT13)Ra4). In ²some ²embodiments, R4 is ¨NH2. In some embodiments, R4 is ¨NHR" (e.g, ¨NHMe, ¨NHEt, ²¨ ²NHPr, ¨NH'Pr, ¨NHcyclopropyl, ¨NHcyclobuty1). In some embodiments, R4 is ²¨N(CH3)11" ²(e.g., --NMe2, ---N(CH3)Et, .--N(CH3)Pr, ---N(CH3YPr, --N(CH3)cyclopropyl, ---²N(CH3)cyclobuty1).²In some embodiments, R4 is ¨C(=0)Ra4 or ¨C(=0)0Ra4. In some embodiments, R4 is ²¨ ²C(=0)R" wherein Ra4 is as described herein. In some embodiments, R4 is ---²C(=0)allcyl. In ²some embodiments. R4 is ¨C(0)CH3, -C(0)cyclopropyl, -C(0)cyclobutyl, -C(0)Su, -² ²C(0) / Pr, -C(0)Pr, -C(OYBu, or ¨C(0)0Me. In some embodiments, R4 is acetyl (¨²C()Me). In some embodiments, R4 is ¨C(=0)0R". In some embodiments, R4 is ¨ ²COOH. In some embodiments, R4 is COOMe.²102271 In some embodiments. R4 is ¨NR"C(=0)1124. In certain embodiments, 114 ²is ¨ ²NHC(=0)Ra4 (e.g, NHC(=0)Me, NHC(=0)Et, NHC(=0)Pr, NHC(=0)13r, NHC(0)Bu, ²NHC(=O)tBu, NHC())Cyclopropyl, NHC(=0)Cyclobuty1). In some embodiments, R4 is ²¨ ²N(CH3)C(...0)1124 (e.g., N(CH3)C(...0)Me, N(CH3)C(=0)Et, N(CT13)C(...0)Pr, ²N(CH3)C(Pr, N(CH3)C()Bu, N(CH3)C(=O)tBu, N(CH3)C(=0)Cyclopropyl, ²N(CH3)C(0)Cyclobuty1).²In some embodiments, 12.4 is --NR"C(=0)0Ra4. In certain embodiments, R4 is ---²NTIC(=0)0R" (e.g., NFIC(...0)0Me, NFIC(...0)0Et, NHC(...0)0Pr, NHC(:=0)0'Pr, ²NHC(=0)0Bu, NHC(43)0tBu, NHC(=0)0Cyclopropyl, NHC(=0)0Cyclobuty1). In some ²embodiments, R4 is ¨N(CH3)C(=0)0R" (e.g, N(CH3)C(=0)0Me, N(CH3)C(=0)0Et, ²N(CH3)C(...0)0Pr, N(CH3)C(...0)0'Pr, N(CH3)C(...0)013u, N(CH3)C(=0)0Su, ²N(CH3)C(0)0Cyclopropyl, N(CH3)C(=0)0Cyclobuty1).²102281 in some embodiments, R4 is ¨C(=0)N(R")2(e.g, ¨C(=0)NH2, ¨C(=0)NHR4, ¨ ²C(=0)N(CH3)R"). In some embodiments, R4 is ---C())NH2. In certain embodiments. ²R4 is ²¨C(...0)NHR" (e.g, ¨C(...0)NHMe, ¨C(...0)NHEt, ¨C(...0)NHPr, ¨C(...0)NEPPr, ¨ ²C(=0)NHBu, ¨C(=0)NH1Bu, ¨C(=0)NHCyclopropyl, ¨C(=0)NHCyclobuty1). In certain ²embodiments, R4 is ¨C(=0)N(CH3)Ra4 (e.g, ¨C(=0)NMe2, ¨C(=0)N(CH3)Et, ¨ ²C(=0)N(CH3)Pr, ¨C(...0)N(CH3)'Pr, ¨C(...0)N(CH3)Bu, ¨C(=0)N(CT13)Su, ¨ ²C(=0)N(CH3)Cyclopropyl, ¨C(=0)N(CH3)Cyclobuty1).²<DP=82>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²[02291 In some embodiments. R4 is -0C(=0)N(Ra4)2. In certain embodiments. R4 ²is - ²OC(=0)NH.R" (e.g., -0C(I)NHMe, -0C(=0)NHEt, -0C(=0)NHPr, -0C(0)NIPPr, - ²0C(=0)NHBu, --0C(=0)NWBu, -0C(=0)NHCyclopropyl, -0C(=0)NHCyclobuty1). In ²certain embodiments, R4 is -OC(=0)N(CH3)11a4 (e.g., -0C(...0)NMe2, -²0C(=0)N(CH3)Et, - ²0C(=0)N(CH3)Pr, -0C(=0)N(CH3) / Pr, -0C(=0)N(CH3)Bu, -0C(=0)N(CH3)Su, - ²0C(=0)N(CH3)Cyclopropyl, -0C(=0)N(CH3)Cyclobuty1).²102301 In some embodiments. R4 is -S(=0)R84. In certain embodiments, le is ²...S(0)alkyl ²(e.g., -S('=0)Me, -S(=0)Et, -S(=0)Pr, -S(=0)iPr). In certain embodiments, R4 ²is - ²S(=0)cycloalk-y1 (e.g., -S(=0)cyclopropyl, -S(=0)cyclobutyl, -²S(=0)cyclopentyl, - ²S(=0)cyclohexyl).²[02311 In some embodiments, R4 is -S(=0)211a4. In certain embodiments, R4 is - ²²S(=0)2alkyl (e.g., -S(A))2Me, -S(=0)2Et, -S(0)2Pr, -S(=0)2'13r). In certain ²embodiments, ²R4 is -S()2cycloalkyl (e.g, -S()2cyclopropyl, -S())2cyclobutyl, -²202cõ,clopentyl, - ²S(=0)2cyc1ohexy1). In some embodiments, R4 is S(=0)2aryl (e.g., S(=0)2pheny1).²In some embodiments, 114 is -SRa4. In certain embodiments, R4 is -Salkyl ²(e.g., -SMe, -SEt, ²-SPr, -S113r). In certain embodiments, R4 is -Scycloalkyl (e.g., -²Scyclopropyl, -Scyclobutyl, - ²Scyclopentyl, -Scyclohexyl). In certain embodiments, R4 is -Saryl (e.g, ²Sphenyl).²In some embodiments, R4 is -S(=0)(=NR94)1124. In certain embodiments, R4 is - ²S(=0)(=NH)Ra4 (e.g , -S(D)(=NH)Me, -S(=0)(=NH)Et, -S(=0)(=NH)Pr, -²S(=0)(=NH)iPr, - ²S(=0)(=NH)Bu, -S(=0)(=NH)t3u, -S(=0)(=NH)Cyclopropyl, -S(=0)(=NH)Cyclobuty1). ²In ²some embodiments, R4 is -S(=0)(=NCH3)1e4 (e.g. -S(=0)(=NCH3)Me, -²S(=0)(=NCH3)Et, - ²S(=0)(=NCT13)Pr, -S(=0)(=NCI-T3)iPr, -S(=0)(=NCT13)Bu, -S(:=0)(=NCH3)tBu, - ²S(=0)(=NCH3)Cyclopropyl, -S(=0)(=NCH3)Cyclobuty1).²(02321 In some embodiments, R4 is -NRa4S(=0)2Ra4. In certain embodiments, R4 ²is - ²NITS(=0)2alkyl (e.g., -NHS(=0)2Me, -NHS(=0)2Et, -NITS(=0)2Pr, ..4I-²IS(...0)2130. In ²certain embodiments, R4 is -NHS(=0)2cycloalkyl (e.g., -NHS(=0)2cyc1opropy1, - ²NHS(=0)2cyclobutyl, -NHS(=0)2cyclopentyl, -NHS(=0)2cyc1ohexy1). In certain ²embodiments, R4 is -N(CH3)S(=0)2allcyl (e.g, -N(CH3)S(=0)2Me, -N(CH3)S(=0)2Et, ²- ²N(CH3)S(=0)2Pr, -N(CH3)S(:=0)2'Pr). In certain embodiments, R4 is - ²N(CH3)S(=0)2cycloalkyl (e. g , -N(CH3)S(=0)2cyclopropyl, -²N(CH3)S(=0)2cyclobutyl, - ²N(CH3)S()2cõ,clopentyl, -N(CH3)S(=0)2cyc1ohexy1).²(02331 In some embodiments, R4 is -S(=0)2N(R24)2. (e.g., -S(...0)21%12, -²S(...0)2NTIRa4, - ²S(=0)2N(CH3)R"). In some embodiments, R4 is -S(0)2NH2. In some embodiments, R4 ²is -²81²<DP=83>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²S(=0)2NIFills04 (e.g., -S(=0)2NTIMe, -S(::::0)2NHEt, -S(:=0)2NHPr, -²S(:=0)2NIffr, - ²S(=0)2NHcyclopropyl, -S(=-0)2NHcyclobu1yl). In some embodiments, R4 is - ²S(=0)2N(CH3)Ra4 (e.g, -S())2NMe2, -S(=0)2N(CH3)Et, -S(=0)2N(CH3)Pr, - ²S(:=0)2N(CH3)113r, -S(:=0)2N(CH3)cyclopropyl, -S(:=0)2N(CH3)cyclobuty1).²102341 As generally described herein, each R6 is independently absent or ²selected from H, - ²D. halo, -CN, -0-C6 alkyl, -CI-C6 heteroalk-yl, -Ci-C6 haloalkyl, -C3-Cio ²carbocyclyl, 3-²membered heterocyclyl, heterocyclylalkyl, C6-C10 aryl, 5-10 member heteroaryl, ²²heteroarylalkyl, arylalkyl, cycloalkylalkyl, -0Ra6, -N(Ra6)2, -C(:=0)R", -²C(::0)0Ra', - ²NR'C(=0)e, -NR'C(=0)01V6, -C(20)N(Ra6)2, -0C(=0)N(Ra6)2,-S(=0)R", -S(=0)2Ra6,²...s(..,0)(=NRa6)Ra6, -NRa6S(=0)2Ra6 and -S(=0)2N(Ra6)2; wherein each alkyl, ²carbocyclyl, heterocyclyl, cycloalkylalkyl, heterocyclylalkyl, aryl, ²heteroaryl, arylalkyl and ²heteroarylalkyl is optionally substituted at any available position, wherein ²each R' is as ²described herein. In some embodiments, each R6 is independently selected from ²halo, -CN, - ²CI-C6 alkyl, -C1-C6 heteroalkyl, -CI-C6 haloalk-yl, -C3-Cio carbocyclyl, 3-10 ²membered ²heterocyclyl, heterocyclylalkyl, C6-Cio aryl, 5-10 member heteroaryl, ²heteroarylalkyl, ²arylalkyl, cycloalkylalkyl, -OR", -N(R6)2, -C(43)Ra6, -C(4:)0Ra6, -NRa6CK9Ra6, ²- ²NRa6C(=0)0Ra6, -g=0)1=1(Ra6)2, -0CNRa6)2,..s(=o)Ra6, -S(=0)2Ra6, -SRa6, - ²S(:=0)(=NRa6)Ra6, -NR36S(=0)2Ra6 and -S(=0)2N(11")2, wherein each alkyl, ²carbocyclyl, ²heterocyclyl, cycloalkylalkyl, heterocyclylalkyl, aryl, heterom,71, arylalkyl ²and ²heterofflylalkyl is optionally substituted at any available position, wherein ²each le' is as ²described herein. In some embodiments; each Ra6 is independently selected from ²H and -CI-²C6 alkyl (e.g., -Me, -Et, -Pr, -'Pr,-Bu, -93u, -sec-Bu, -iso-Bu).²102351 In some embodiments, each alkyl, cabocyclyl, heterocyclyl, aryl, ²heteroaryl, ²cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl of R6 is ²substituted at any ²available position with 0, 1, 2 or 3 instances of RI , wherein each RI is as ²described herein. ²In some embodiments, each 116 is independently selected from H, -CI-C6 alkyl, -²Ci-C6 ²heteroalkyl, -C1-C6 haloalkyl, -C3-Clo carbocyclyl, 3-10 membered ²heterocyclyl, ²heterocyclylalkyl, C6-Cio aryl, 5-10 member heteroaryl, heteroarylalkyl, ²arylalkyl and ²cycloalkylalkyl, wherein each alkyl, carbocyclyl, heterocyclyl, ²cycloalkylalkyl, ²heterocyclylalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl is ²optionally substituted at ²any available position (e.g, substituted at any available position with 0, 1, ²2 or 3 instances of ²RI , wherein each 11' is as described herein). In some embodiments, each R6 is²independently selected from -CI--C6 alkyl, -Ci-C6 heteroalkyl, baloalkyl, -²C3-Cio²82²<DP=84>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²carbocyclyl, 3-10 membered heterocyclyl, heterocyclylalkyl, C6-C10 aryl, 5-10 ²member ²heteroaryl, heteroarylalkyl, arylalkyi and cycloalkylalkyl, wherein each ²alkyl, carbocyclyl, ²heterocyclyl; cycloalkylak,r1, heterocyclylalkyl, aryl; heterowyl, atylalkyl ²and ²heteroarylalkyl is optionally substituted at any available position (e.g., ²substituted at any ²available position with 0, 1, 2 or 3 instances of R' , wherein each Rw is as ²described herein). ²102361 in some embodiments, R6 is independently selected from H, -CI-C6 alkyl, ²-Cl-C6²heteroalkyl, haloalkyl, -C3-Cio carbocyclyl, 3-10 membered heterocyclyl, ²heterocyclylalkyl, C6-C10 aryl, 5-10 member heteroaryl, heteroarylalkyl, ²arylalkyl and ²cycloallcylalk-yl, wherein each alkyl, carbocyclyl, heterocyclyl, ²cycloallcylalk-yl, ²heterocyclylalkyl, arvi, heteroaryl, arylalkyl and heteroarylalkyl is ²substituted at any²available position with 0, 1, 2 or 3 instances of 11' wherein RI is as ²described herein. In ²some embodiments. R6 is independently selected from -CI-C6 alkyl, -CI-C6 ²heteroa141, - ²Ci-C6 haloalkyl, -C3-Cio carbocyclyl, 3-10 membered heterocyclyl, ²heterocyclylalkyl, C6-²Clo aryl, 5-10 member heteroaryl, heteroarylalkyl, arylalkyl and ²cycloalkylallcyl, wherein ²each alkyl, carbocyclyl, heterocyclyl, cycloalkylalkyl, heterocyclylalkyl, ²aryl, heteroaryl, ²arylalkyl and heteroarylalkyl is substituted at any available position with 0, ²1, 2 or 3 instances ²of RI wherein R' is as described herein. In some embodiments, each R6 is ²unsubstituted. In ²some embodiments, each R6 is substituted with 1 instance of Rw. In some ²embodiments, ²each R6 is substituted with 2 instances of le. In some embodim.ents, each R6 ²is substituted ²with 3 instances of Rw.²102371 In some embodiments. R6 is independently selected from H, -Ci-C6 alkyl, ²-Cs-Cio ²monocyclic or bicyclic carbocyclyl (e.g., a -C3--Cio monocyclic or bicyclic ²cycloalkyl, a ²partially unsaturated -C3-C10 monocyclic or bicyclic carbocyclyl, a -C3-C7 ²monocyclic ²carbocyclyl fused with phenyl or a 5-6-member heterocyclyl or heteroaryl ring ²containing 1-3 ²atoms independently selected from N, 0, S or oxidized forms thereof), 3-10 ²membered mono ²or bicyclic heterocyclyl (e.g., a 3-8 member monocyclic heterocyclyl ²containing 1-3 ²heteroatoms selected from N, 0 and S or oxidized forms thereof, a 4-10 member ²bicyclic ²heterocyclyl containing 1-3 heteroatoms independently selected from N, 0 and S ²or oxidized ²forms thereof), -C6-Cio mono or bicyclic aryl (e.g., phenyl, fully aromatic 9-²10 member ²bicyclic aryl, bicyclic aryl containing a phenyl ring fused with a C5-C6 au-²bocycle, bicyclic ²aryl containing a phenyl ring fused with a 5-6 member heterocycle containing 1-²3 ²heteroatoms independently selected from N, 0 and S or oxidized forms thereof), ²5-6 member ²monocyclic heteroaryl. (e.g , containing 1-4 heteroatoms independently ²selected from N, 0²83²<DP=85>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²and S), 8-10 member bicyclic heteroaryl (e.g., containing 1-4 heteroatoms ²independently ²selected from N, 0 and S) wherein each alkyl, carbocyclyl, heterocyclyl, aryl ²and heteroaryl ²is optionally substituted (e.g., substituted with 0, 1, 2 or 3 instances of ²R1' wherein RI is as ²described herein). In some embodiments, R6 is independently selected from -C1-²C6 alkyl, - ²C3-C10 monocyclic or bicyclic carbocyclyl (e.g , a -C3-CIO monocyclic or ²bicyclic ²cycloalk-yl, a partially unsaturated -C3-Cio monocyclic or bicyclic ²carbocyclyl, a -C3-C7 ²monocyclic carbocyclyl fused with phenyl or a 5-6-member heterocyclyl or ²heteroaryl ring ²containing 1-3 atoms independently selected from N, 0, S or oxidized forms ²thereof), 3-10 ²membered mono or bicyclic heterocyclyl (e.g, a 3-8 member monocyclic ²heterocyclyl ²containing 1-3 heteroatoms selected from N, 0 and S or oxidized forms thereof, ²a 4-10 ²member bicyclic heterocyclyl containing 1-3 heteroatoms independently selected ²from N, 0 ²and S or oxidized forms thereof), -C6-Cio mono or bicyclic aryl (e.g., phenyl, ²fully aromatic ²9-10 member bicyclic aryl, bicyclic aryl containing a phenyl ring fused with a ²C5-C6 ²carbocycle, bicyclic aryl containing a phenyl ring fused with a 5-6 member ²heterocycle ²containing 1-3 heteroatoms independently selected from N, 0 and S or oxidized ²forms ²thereof), 5-6 member monocyclic heteroaryl (e.g , containing 1-4 heteroatoms ²independently ²selected from N, 0 and S), 8-10 member bicyclic heteroaryl (e.g., containing 1-²4 heteroatoms ²independently selected from N, 0 and S) wherein each alkyl, carbocyclyl, ²heterocyclyl, aryl ²and heteroaryl is optionally substituted (e.g., substituted with 0, 1, 2 or 3 ²instances of RI ²wherein Rw is as described herein)²102381 In some embodiments, each R6 is independently selected from H, -CI-C6 ²alkyl (e.g., ²-Me, -Et, -Pr, -EN, -13u, sec-Bu, 213u), -C3-C10 monocyclic or bicyclic ²carbocyclyl (e.g., ²cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, ²bicyclo[1.1.1]pentan-yl, ²4,5,6,7-tetrahydro-1H-indazobõ,I, spiro[3.3]heptanyl), 3-10 membered mono or ²bicyclic ²heterocyclyl (e.g., oxetanyl, azepa.nyl, piperidinyl, pyrorolidinyl, ²tetrahydrofuranyl, ²tetrahydropyranyl, 1,2-dihydropyridinyl, morpholinyl), Co-C io mono or ²bicyclic aryl (e.g., ²phenyl, naphthyl, 1,2,3,4-tetrahydronaphthalenyl, 2,3-dihydro-1H-indemõ,I, ²1,2,3,4 ²tetrahydroquinolinyl, 1,2 dihydroquinolinyl, 1,2-dihydroisoquinolinyl, 1,2,3,4 ²²tetrahydroisoquinolinyl, chromanyl, indolinyl, isoindolinyl, 3,4-dihydro-2H-²benzo[b][1,4]oxazinyl, 2,3-dihydrobenzofuranyl, benzo[d] [1,3] dioxolyl, 2,3-²dihydro-1H-²benzo[d]irnidazoly1), 5-6 member monocyclic heteroaryl (e.g, thiophenyl, ²thiazolyl, ²pyrazolyl, imidazolyl, oxazolyl, pyridinyl, pyrimidinyl), 8-10 member bicyclic ²heteroaryl ²(e.g., benzo[d]isothiazolyl, indolyl, benzofuranyl, 1H-indazolyl, 2-H-²indazolyl,²84²<DP=86>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²benzo[b]thiophenyl, quinolinyl, 1,5-naphthyridinyl, 1,2-dihydro-1,5-²naphthyridinyl, 1,2,3,4-²tetrahydro-1,8-naphthyridinyl, isoquinolinyl, benzo[d]imidazolyl, ²benzo[d]thiazolyl, ²benzo[d]oxazolyl, [1,2,4]triazolo[4,3-a]pyridinyl, imidazo[1,2-alpyridinyl, ²imidazo[1,5-²a]pyridinyl, 1H-pyrazolo[4,3-blpyridinyl), 1H- pyrazolo[3,4-b]pyridinyl, 1H-²thieno[2,3-²c]pyrazolyl, 1H-thieno[3,2-c]pyrazolyl, thiazolo[5,4-b]pyridinyl) wherein each ²alkyl, ²cycloalk-yl, heterocyclyl, aryl and heteroaryl is optionally substituted ²(e.g., substituted with 0, ²1, 2 or 3 instances of RH) wherein RI is as described herein). In some ²embodiments, each R6²is independently selected from -CI-Co alkyl (e.g., -Me, -Et, -Pr, -Tr, sec-²Bu, -13u), ¨²C3¨Cio monocyclic or bicyclic carbocyclyl (e.g., cyclopropyl, cyclobutyl, ²cyclopentyl, ²cyclohex-yl, cycloheptyl, bicyclo[1.1.1]pentan-yl, 4,5,6,7-tetrahydro-1H-²indazolyl, ²spiro[3.3Theptanyl), 3-10 membered mono or bicyclic heterocyclyl (e.g., ²oxetanyl, azepa.nyl, ²piperidinyl, pyrorolidinyl, tetrahydrofuranyl, tetrahydropyranyl, 1,2-²dihydropyridinyl, ²moipholinyl), Co-Cto mono or bicyclic aryl (e.g., phenyl, naphthyl, 1,2,3,4-²tetrahydronaphthalenyl, 2,3-dihydro-1H-indenyl, 1,2,3,4 tetrahydroquinolinyl, ²1,2 ²clihydroquinolinyl, 1,2-dihydroisoquinolinyl, 1,2,3,4 tetrahydroisoquinolinyl, ²chromanyl, ²indolinyl, isoindolinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, 2,3-²dihydrobenzofuranyl, ²benzo[d] [1,3] dioxobõ,1, 2,3-dihydro-1H-benzo[d]imidazoly1), 5-6 member ²monocyclic ²heteroaryl (e.g., thiophenyl, thiazolyl, pyrazolyl, imidazolyl, oxazolyl, ²pyridinyl, ²pyrimidinyl), 8-10 member bicyclic heteroaryl (e.g., benzo[d]isothiazolyl, ²indolyl, ²benzofuranyl, 1H-indazolyl, 2-H-indazolyl, benzo[b]thiophenyl, quinolinyl, 1,5-²²naphthyridinyl, 1,2-dihydro-1,5-naphthyridinyl, 1,2,3,4-tetrahydro-1,8-²naphthyridinyl,²isoquinolinyl, benzo midazolyl, benzokithiazolyl, benzo[d]oxazolyl, [1 ²,2,41triazo1o[4,3-²a]pyridinyl, imidazo[1,2-a]pyridinyl, imidazo[1,5-a]pyridinyl, 1H-pyrazolo[4,3-²b]pyridinyl), ²1H- pyrazolo[3,4-b]pyridinyl, 1H-thieno[2,3-c]pyrazolyl, 1H-thieno[3,2-²c]pyrazolyl, ²thiazolo[5,4-b]pyridinyl) wherein each alkyl, cycloalkyl, heterocyclyl, aryl ²and heteroaryl is ²optionally substituted (e.g , substituted with 0, 1, 2 or 3 instances of RI ²wherein RI is as ²described herein).²102391 In some embodiments, each R6 is independently selected from H, -Me, -²'Bu, ²sec-Bu, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[1.1.1]pentan-l-yl, ²spiro[3.31heptan-2-yl, ²4,5,6,7-tetrahydro-1H-indazol-6-yl, piperidin-4-yl, piperidin-3-yl, pyrrolidin-²3-yl, 1,2-²dihydropyridin-4-yl, phenyl, naphthalen-2-yl, 1,2,3,4 tetrahydroquinolin-6-yl, ²1,2,3,4-²tetrahydronaphthalen-6-yl, chroman-6-yl, 1,5-naphthyridin-6-yl, 1,2,3,4-²tetrahydro-1,8-²naphthyridin-6-yl, 2,3-dihydro-1H-inden-5-yl, indolin-5-yl, indolin-4-yl, 2,3-²dihydro-1H-²<DP=87>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²benzo[d]imidazol-5-yl, 2,3-dihydrobenzofuran-5-yl, 2,3-dihydroberizofuran-6-²yl, ²berizo[d][1,3] dioxo1-5-y1], isoindoliri-5-yl, 3,4-dihydro-2H-²benzo[b][1,4]oxazin-7-yl, 1,2-²dihydroquinolin-6-yl, 1,2-dihydroisoquinolin-7-yl, thiophen-2-yl, thiophen-3-²yl, thiazol-2-y1; ²thiazol-4-yl, thiazol-5-yl, pyrazol-1-yl, pyrazol-5-yl, pyrazol-3-yl, pyrazol-²4-yl,²pyridin-4-yl, indo1-4-yl, benzofuran-5-yl,²benzofuran-6-yl, 1H indazol-5-yl, 111 2H-indazol-511,²benzo4dlisothiazol-5-yl,²benzo[b]thiophen-3-yl, benzo[b]thiophen-5-yl, quinolin-6-yl, quinoline-3-yl,²isoquinolin-²6-yl, benzo[d]imidazo-5-yl, 1H-benzo[d]irnidazol-4-yl, benzo[d]thiazol-5-yl, ²benzo[d]thiazol-6-yl, benzo[d]thiazol-4-yl, benzo[d]oxazol-4-yl, ²benzo[d]oxazol-5-yl,²[1,2,41triazolo[4,3-a]pyridin-6-yl, ²pyrazolo[4,3-b]pyridin-6-yl,²1H-pyrazolo[3,4-b]pyridin-5-yl, 1H-pyrazolo[3,4-b]pyridin-5-yl, 1H-²pyrazolo[4,3-b]pyridin-²5-yl, 1H-pyrazolo[4,3-b]põ,ridin-6-yl, 1H-thieno[2,3-c]pyrazol-5-yl, 1H-²thieno[3õ2-²c]pyrazol-5-yl, thiazolo[5,4-b]pyridin-5-y1), each optionally substituted ²(e.g, substituted with ²0, 1, 2 or 3 instances of Rw wherein RI is as described herein). In some ²embodiments, each ²R6 is independently selected from -Me, -Tr, -'13u, see-Bu, cyclobutyl, ²cyclopentyl, ²cyclohexyl, bicyclo[1.1.1]pentan-l-yl, spiro[3.3]heptan-2-yl, 4,5,6,7-²tetrahydro-1H-indazol-²6-y1õ pyrrolidin-3-yl, 1,2-dihydropyridin-4-yl, phenyl, ²naphthalen-2-yl, 1,2,3,4 tetrahydroquinolin-6-yl, 1,2,3,4-tetrahydronaphthalen-²6-yl, chrom.an-²6-yl, 1,5-naphthyridin-611, 1,2,3,4-tetrahydro-1,8-naphthyridin-6-yl, 2,3-²dihydro-1H-inden-²5-yl, indolin-5-y1; indolin-4-y1; 2,3-dihydro-1H-benzoldlimidazol-5-yl, 2,3-²dihydrobenzofuran-5-yl, 2,3-dihydrobenzofuran-6-yl, benzo[d][1,3] dioxo1-5-²y1],²isoindolin-²5-yl, 3,4-dihydro-2H-benzo[b][1,4]oxazi n-7-yl, 1,2-dihydroquinolin-6-yl, 1,2-²dihydroisoquinolin-7-yl, thiophen-2-yl, thiophen-3-yl, thiazol-2-yl, thiazol-4-²yl, thiazol-5-yl,²pyrazol-1-yl, pyrazol-5-yl, pyrazol-3-yl, pyrazol-4-yl, pyridin-3-yl,²pyrimidin-5-yl, indo1-5-yl, benzofuran-5-yl, benzofuran-6-yl, 1 H IN²indazo1-4-õ,1, isoindolin-6-yl, benzo[d]isothiazol-5-yl,²benzo[bithiophen-3-yl,²berizo [b] thiopheri-5-yl, isoquinoli ²n-6-y 1, benzo[d] irnidazo-5-²yl, 1H-benzo[d]imidazol.-4-yl, benzo[d]thiazol-5-yl, benzo[d]thiazol-6-yl, ²benzo[d]thiazol-4-²yl, benzo[d]oxazol-4-yl, benzo[d]oxazol-5-yl, [1,2,4]triazolo[4,3-a]pyridin-6-²yl, imidazo[1,2-²a]pyridin-6-yl, pyrazolo[4,3-b]pyridin-6-yl, 1H-pyrazolo[3,4-blpyridin-5-yl, ²1H-²pyrazolo[3,4-b]pyridin-5-yl, 1H-pyrazolo[4,3-b]pyridin-5-yl, 1H-pyrazolo[4,3-²b]pyridin-6-yl,²86²<DP=88>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²1H-thieno[2,3-c]pyrazol-5-yl, IH-thieno13,2-6]pyrazol-5-yl, thiazolo(5,4-²bipyridin-6-y1), ²each optionally substituted (e.g., substituted with 0, 1, 2 or 3 instances of ²RI wherein RI is ²as described herein).²102401 In some embodiments, R6 is H. In some embodiments R6 is -D.²102411 In certain embodiments, R6 is halo (e.g., fluoro, chloro, bromo, iodo). ²In further ²embodiments, R6 is -Cl. In some embodiments, R6 is -F. In some embodiments, R6 ²is -Br. ²In some embodiments, R6 is --I.²102421 In some embodiments. R6 is -CN.²102431 In certain embodiments, R6 is -C1-C6 alkyl (e.g., -Me, -Et, -Pr, -Tr, -²'Bu, sec-Bu, ²--Su). In further embodiments, R6 is -Me. In some embodiments. R6 is -Et. In ²some ²embodiments R6 is propyl. In some embodiments, R6 is isopropyl. In some ²embodiments R6 ²is sec-Bu. In some embodiments, R6 is -Su.²102441 in some embodiments, R6 is -CI-C6 heteroakl. In further embodiments, R6 ²is ²methoxymethyl (-CH2OCH3). In some embodiments, R6 is hydroxymethyl (-CH2OH). ²In ²some embodiments, R6 is aminomethyl (e.g.,-CH2NH2, -CH2NHCH.3, -ClT2N(CH3)2. ²102451 In some embodiments. R6 is -CI-C6 haloakl. In further embodiments, R6 ²is ²trifluoromethyl (-CF3). In other embodiments, R6 is difluoromethyl (-CHF2).²102461 In some embodiments, R6 is -C3-Cio carbocyclyl. In some embodiments, ²the ²carbocyclyl is not further substituted. In some embodiments, the carbocyclyl ²is substituted ²with 0, 1, 2 or 3 instances of R"), wherein Rw is as described herein. In some ²embodiments, ²the carbocyclyl is substituted with 1 or 2 instances of halo (e.g., --F, --²Cl), -Me, -Et, -iPr, ²OH, =0 or -CN. In further embodiments, the carbocyclyl is a -C3-Cio mono or ²bicyclic ²cycloalkyl (e.g , a monocyclic cycloalkyl, a fused bicyclic cycloalkyl, a ²spiro cycloalkyl or a ²bridged cycloalkyl). In some embodiments, the carbocyclyl is a -C3-C7 ²monocyclic ²cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl). In some ²embodiments, ²R6 is cyclopropyl. In some embodiments R6 is cyclobutyl. In some embodiments, ²R6 is ²cyclopentyl. In some embodiments, R6 is cyclohexyl. In some embodiments, the ²carbocyclyl ²is a -C4-Cio bicyclic cycloalkyl. In some embodiments, R6 is a -C4-Cio fused ²cycloalkyl ²(e.g., decahydronaphtyl, octahydroindenyl). In some embodiments, R6 is a -C4-²C10 spiro ²cycloalkyl (e.g, spiro[4.5]decanyl, spiro[4.4]nonanyl, spiro[3.3]heptanyl, ²spiro[3.4]octany1). ²In further embodiments. R6 is spiro[3.3]heptanyl. In some embodiments, R6 is a ²bridged ²bicyclic cycloalkyl (e.g., bicyclo[1.1.1.1pentanyl, bicyclo[2.2. I Jheptanyl,²87²<DP=89>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²bicyclo[3.3.1]heptanyl, bicyclo[2.1.1Thexanyl, bicyclo[3.2.1]octanyl, ²bicyclo[3.3.1]nonanyl. ²In some embodiments, le is bicyclo[1.1.1]pentanyl.²102471 In some embodiments, the carbocyclyl is a=--=C3=--C7 monocyclic ²carbocyclyl fused ²with phenyl (e.g., 1,2,3,4-tetrahydronaphthalenyl, 2,3-dihydro-1H-indenyl ²wherein the ²attachment point is on the saturated ring). In some embodiments, R6 is a -C3-²C7 monocyclic ²carbocyclyl fused with a 5-6-member heterocyclyl ring containing 1-3 atoms ²independently ²selected from N, 0, S or oxidized forms thereof (e.g., octahydrochromenyl, ²decahydroisoquinolinyl, decahydroquinolinyl, octahydroindolyl, ²octabydroisoindoly1 ²hexahydro chromane, hexahydro isoquinoline, hexahydroquinoline, ²octahydrobenzofuran ²wherein the attachment point is on the carbocyclic ring). In some embodiments. ²R6 is a -Cs--²C7 monocyclic carbocyclyl fused with a 5-6-member heteroatyl ring containing 1-²3 atoms ²independently selected from N, 0, S or oxidized forms thereof (e.g., 4,5,6,7-²tetrahydro-1H-²indazoly1). In one embodiment, R6 is 4,5,6,7-tetrakõ,dro-1H-indazol-6-4.²102481 In certain embodiments, R6 is selected from:²,An.r²qL,NH²102491 In some embodiments, R6 is a 3-10 membered mono or bicyclic ²heterocyclyl. In ²some embodiments, R6 is a 3-8 member monocyclic heterocyclyl containing 1-3 ²heteroatoms ²selected from N, 0 and S or oxidized forms thereof (e.g., oxetanyl, ²tetrahydropyranyl, ²tetrahydrofuranyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, ²morpholinyl, azepanyl, ²tetrahydropyridinyl). In some embodiments, R6 is oxetanyl. In some ²embodiments, R6 is ²tetrahydropyranyl. In some embodiments, R6 is tetrahydrofuranyl. In some ²embodiments. R6 ²is azetidinyl. In some embodiments, R6 is pyrrolidinyl. In some embodiments, ²R6 is ²piperidinyl. In some embodiments, R6 is piperazinyl. In some embodiments, R6 ²is ²molpholinyl. In some embodiments, R6 is azepanyl. In some embodiments, R6 is ²tetrahydropyridinyl. In some embodiments. R6 is.a 4-10 member bicyclic ²heterocyclyl ²containing 1-3 heteroatoms independently selected from N, 0 and S or oxidized ²forms ²thereof. In some embodiments, the mono or bicyclic heterocyclyl is not further ²substituted. ²In some embodiments, the heterocyclyl is substituted with 1 or 2 instances of ²halo (e.g., -F,²CD, -Me, -Et, -iPr, ...0 or -²CN. In some instances, the heterocyclyl is substituted with²=0 (e.g., 2-oxo-1,2-dihydropyridin-4-y1).²88²<DP=90>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²In some embodiments, R6 is an optionally substituted 6-10 member mono or ²bicyclic aryl. ²In some embodiments, R6 is substituted with 0, 1, 2 or 3 instances of le, ²wherein Rw is as ²described herein.²102501 In some embodiments, R6 is optionally substituted phenyl. In some ²embodiments, ²R6 is phenyl substituted with 0, 1, 2 or 3 instances of RI , wherein each RI ²is independently ²as described herein. In some embodiments, the phenyl is unsubstituted. In some ²²embodiments, the phenyl is substituted with one instance of Rm. In some ²embodiments, the ²phenyl is substituted with 1 instance of Rw at the position para- to the ²attachment point to the ²piperidine.²1101²102511 In some embodiments, R6 is R" . In some embodiments, the phenyl is ²substituted ²with 2 instances of RI . In some embodiments, the phenyl is substituted with 3 ²instances of ²RI . In some embodiments, R6 is phenyl substituted with halo (e.g, fluor(); ²chloro, bromo). ²102521 In some embodiments, R6 is an optionally substituted 9-10 member ²bicyclic aryl ²(e.g., naphthyl). In some embodiments, R6 is an optionally substituted ²bicyclic aryl ²containing a phenyl ring fused with a Cs-Cs carbocycle (e.g , ²tetrahydronaphthyl, ²dihydroindenyl). In some embodiments, 126 is 1,2,3,4-tetrahydronaphthalenyl. ²In some ²embodiments. R6 is 2,3-dihydro-1H-indenyl. In some embodiments. R6 is an ²optionally ²substituted bicyclic aryl containing a phenyl ring fused with a 5-6 member ²heterocycle ²containing 1-3 heteroatoms independently selected from N, 0 and S or oxidized ²forms ²thereof (e.g., tetrahydronaphthalenyl, dihydroindenyl, 1,2,3,4 ²tetrahydroquinolinyl, 1,2 ²dihydroquinolinyl, 1,2-dihydroisoquinolinyl, tetrabydroisoquinolinyl, ²chromanyl, indolinyl, ²isoindolinyl, dihydrobenzoxazinyl, dihydrobenzofuranyl, benzodioxolyl, ²dihydrobenzimidazolyl. In some embodiments, R6 is 1,2,3,4 ²tetrahydroquinolinyl. In some ²embodiments, R6 is 1,2 dih,rdroquinolinyl. In some embodiments, R6 is 1,2-²dihydroisoquinolinyl. In some embodiments, R6 is 1,2,3,4 ²tetrabydroisoquinolinyl. In some ²embodiments, R6 is chromanyl. In some embodiments, R6 is indolinyl. In some ²embodiments, ²R6 is isoindolinyl. In some embodiments, R6 is 3,4-dihydro-2H-²benzo[b][1,41oxazinyl. In ²some embodiments, R6 is 2,3-dihydrobenzofuranyl. In some embodiments, R6 is²benzo[d] [ 1,3] dioxolyl. In some embodiments, R6 is 2,3-dihydro-1H-²benzo[d]imidazolyl. In ²some embodiments, R6 is selected from:²89²<DP=91>²CA 03176912 2022-09-23² WO 2022 / 026892 PCT / US2021 / 044004². ,,,,,,,²i²6..).,,. .. / ............... -% 'N,²= - - c - - ' - - , - - -- \ NH n ²--, 1 0 ___ / ²syst. 1 1 1²41:1,4 .A.A14 .². i²'1:::k Nn²--., '-sr;;N= I 1²H ..i ..,,,r'',......²0--- / HN l_¨NH²O.,, HN,,,,².,,,,,,²..neyv².,..sN.²HN..-)NNH²Lr------ I 1 ²Ki ,,²,²ils, ,, , -,,,,, , __________________________ -,,,,,, ,õ² L-N,N) HN õ,..) HN ..,..,..)j LIzs,,, NH 1.___N=H²H²102531 In some embodiments, the bicyclic my] is unsubstituted. In some ²embodiments, the ²bicyclic aryl is substituted with 0, 1, 2 or 3 instances of RI , wherein each ²10 is as described ²herein. In some embodiments, the bicyclic an is substituted with 1 instance of ²RI . In ²further embodiments, the bicyclic aryl is substituted with one instance of RI ²wherein R.' is ²selected from halo (e.g., F, CI, Br), -Me, =0. In some embodiments, RI is =0 ²and R6 is ²selected from:²,,,,²J 41 / ²õs1 f²...........\,, '''²NH .s.("Ns, ^........\., . / ..)::::k,...- / ....).s.²A ²\¨__N / H² HN¨i HN ,sir HN--- H²--1\cH²0²0 0²0²a 40 õ),,,..²1 ....L.,..²i²y.õ1²..,²N 0 ²HN..ir² 0...A.N..-- .-..,õ.. NH²H H²0²102541 In some embodiments, R6 is an optionally substituted 5-6 member ²monocyclic ²heteroaryl (e.g , a 5-member monocyclic heteroaryl containing 1-3 heteroatoms²independently selected from 0, N and S, a 6-member monocyclic heteroaryl ²containing 1-3 N ²heteroatoms).²In some embodiments, the 5-6 member monocyclic heteroaryl is unsubsfituted. In ²some ²embodiments, the 5-6 member monocyclic heteroaryl is substituted with 0, 1, 2 ²or 3 instances²<DP=92>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²of R.', wherein each Rm is as described herein. In some embodiments, the 5-6 ²member ²monocyclic heteroaryl is substituted with 1 instance of R In some embodiments, ²the 5-6 ²member monocyclic heteroaryl is substituted with 2 instances of le. In some ²embodiments, ²the 5-6 member monocyclic heteroaryl is substituted with 2 instances of RI . ²In some ²embodiments, the 5-6 member monocyclic heteroaryl is substituted with 3 ²instances of RI . ²In some embodiments, R6 is a 5-member monocyclic heteroaryl (e.g , pyrazolyl, ²pyrolyl, ²thiophenyl, furyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, imidazolyl, ²triazolyl, ²thiadiazolyl, oxadiazolyl). In some embodiments, R6 is thiophenyl (e.g., ²thiophen-2-yl, ²thiophen-3-y1). In some embodiments, R6 is pyrazolyl (e.g. pyrazol-1-yl, ²pyrazol-3-yl, ²pyrazol-5-y1). In some embodiments, R6 is thiazolyl (e.g., thiazol-2-yl, ²thiazol-4-yl, thiazol-²5-y1). In some embodiments. R6 is selected from:².,õ²Na " elk-N?²N¨ N¨N11 ²[02551 In some embodiments. R6 is a 6-member monocyclic heteroaryl (e.g., ²pyridyl, ²pyrimidinyl, triazinyl, pyrazinyl, pyridaziny1). In some embodiments, the 6-²member ²monocyclic heteroaryl is Imsubstituted. In some embodiments, the 6-member ²monocyclic ²heteroaryl is substituted with 0, 1, 2 or 3 instances of RI . In some ²embodiments, the 6-²member monocyclic heteroaryl is substituted with 1 instance of Rm. In some ²embodiments, ²the 6-member monocyclic heteroaryl is substituted with 1 instance of Rm at the ²position para ²to the attachment point to the piperidine. In some embodiments, the he 6-²member ²monocyclic heteroaryl is substituted with 2 instances of RI . In some ²embodiments, the 6-²member monocyclic heteroaryl is substituted with 3 instances of Rw. In some ²embodiments, ²R6 is pyridinyl (e.g., pyridin-2-yl, pyridin-3-yl, pyridin-4-y1). In some ²embodiments, R6 is ²pyrimidinyl (e.g, pyrimidin-211, pyrimidin-4-yl, pyrimidin-5-y1). In some ²embodiments, R6²NV I²VW²O r)-²is selected from: ==== ri = N²102561 In some embodiments. R6 is selected from:²avw²N²I h., I² LJ N²1² Rio R10 R10²In further embodiments, R6 is R1 ²91²<DP=93>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²[02571 In some embodiments. R6 is an 8-10 member bicyclic heteroaryl (e.g., a ²5,5 bicyclic ²heteroaryl (e.g. 1H-thieno[2,3-c]pyrazolyl, 1H-thieno[3,2-c]pyrazoly1), a 5,6 ²bicyclic ²heteroaly1 (e.g., indolyl, benzofuranyl, 1H-indazolyl, 2H-indazolyl, ²benzo[b]thiophenyl, ²benzo[d]imidazolyl, benzo[d]thiazolyl, benzo[d.loxazolyl, [1,2,4]triazo1o[4,3-²ajlpyridinyl, ²benzo[d]isothiazolyl, imidazo[1,2-a]pyridinyl, imidazo[1,2-c]pyridinyl, 1H-²pyrazolo[4,3-²b]pyridinyl),1H- pyrazolo[3,4-b]pyridinyl, thiazolo[5,4-b]pyridinyl),or a 6, 6 ²bicyclic ²heteroaryl (e.g , quinolinyl, 1,5-naphthyridiny1,1,2-dihydro-1,5-²naphthyridinyl, 1,2,3,4-²tetrahydro-1,8-naphthyridinyl,isoquinolinyl),wherein each bicyclic heteroaryl ²contains 1-3 ²heteroatoms independently selected from 0, N and S).²In some embodiments R6 is selected from indolyl, benzofuranyl, 1H-indazolyl, ²2H-indazolyl, ²benzo[b]thiophenyl, quinolinyl, 1,5-naphthyridinyl, 1,2-dihydro-1,5-²naphthyridinyl, 1,2,3,4-²tetrahydro-1,8-naphthyridinyl,isoquinolinyl, benzo[d]imidazolyl, ²benzo[d]thiazolyl, ²benzo[d]oxazolyl, [1,2,4]triazolo[4,3-a]pyridinyl, imidazo[1,2-c]pyridinyl,²benzo I dlisothiazolyl, imidazo[1,2-alpyridinyl, 1H-pyrazoloR3-²bilpyridinyl),1H-²pyrazolo[3,4-14yridinyl, 1H-thieno[2,3-4yrazolyl, 1H-thieno[3,2-elpyrazoly1, ²thiazolo[5,4-²b]pyridinyl, 1,2,3,4-tetrahydro-1,8-naphthyridinyl) wherein the bicyclic ²heteroaryl is ²optionally substituted (e.g., substituted with 0, 1, 2 or 3 instances of R")).²102581 In some embodiments R6 is an 8-10 member bicyclic heteroaryl selected ²from:²92²<DP=94>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²t²N².===.õ.f,,, N / ,40 isi .²411111 < / . 40 * 0² 1 . . 0²1,,,,ft1H HN.,....õ,- S / S--, i\P---- / 0 / ²-..,. N -... ,!4 11.²I² N 40 al , * N² I I HN--14 H HN / H².f81²i I²1 I i i 1²= S,² / N 411 1111\ ilk 0 1111 ²N' / N² / H 1 N 1 N Li 0 ssz / N 'TN²HN-N Ni-1 Nil N N-N²1p ?NH² S)., S., ,....r,,,,N I. \²N .1 Ni==., "=,. N..)²0²\ / HN, .,- \.NH²N-NH HN-N ---N N N²102591 In some embodiments, the 8-10 member bicyclic heteroaryl is ²unsubstituted. In ²some embodiments, the 8-10 member bicyclic heteroaryl is substituted with 0, ²1, 2 or 3 ²instances of fe, wherein each le is as described herein. In some embodiments, ²the 8-10 ²member bicyclic heteroaryl is substituted with I instance of R.' . In further ²embodiments, the ²8-10 member bicyclic heteroaryl is substituted with one instance of le wherein ²RI is ²selected from halo (e.g., F. Cl, Br), -Me, =0. In some embodiments, le is =0 ²and R6 is ²selected from:²JVW²I²NH HN²0 0²102601 In some embodiments 126 is cycloalkylalkyl (e.g., cyclopropylmethyl, ²cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cycloheptylmethyl). In ²some ²embodiments. R6 is heterocyclylalkyl (e.g., oxetanylmethyl, aziridinylinethylõ ²²tetrahydrofuranylmethyl, pyrolidinylmethyl, tetrahydropyranylmethyl, ²piperidinylmethyl, ²piperazinylmethyl, morpholinylmethyl, azepanylmethyl).²93²<DP=95>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²102611 In some embodiments, 126 is arylalkyl. In some embodiments, 116 is ²benzyl.²102621 In some embodiments, R6 is heteroarylalk-yl (e.g, pyridinylmethyl, ²thiazolylmethyl, ²triazolylmethyl, pyrazolylmethyl).²102631 In some embodiments, R6 is -0R36 (e.g., hydroxy (-OH), methoxy, ²difluoromethoxy ²(-0CHF2), trifluoromethoxy (-0CF3), ethoxy, propoxy, isopropoxy, ²cyclopropyloxy, ²cyclobutyloxy). In some embodiments, R6 is hydrox,,. In some embodiments, R6 ²is methoxy. ²In some embodiments, R6 is ethoxy. In some embodiments, R6 is propoxy. In some ²²embodiments, R6 is isopropoxy. In some embodiments R6 is difluoromethoxy. (-²0CHF2). ²In some embodiments, 116 is trifluoromethov (-0CF3).²102641 In some embodiments, R6 is -N(R6)2 (e.g, -NHRa6, -N(CH3)Ra6). In ²some ²embodiments, R6 is -NtI2. In some embodiments, R6 is -NHR86 (e.g, -NHMe, -²NHEt, - ²N'HPr, -NH / Pr, -NHcyclopropyl, -NHcyclobuty1). In some embodiments, 116 is -²N(CH3)Ra6 ²(e.g., -NMe2, -N(CH3)Et, -N(CH3)Pr, -N(CH3) / Pr, -N(CH3)cyclopropyl, - ²N(CH3)cyclobuty1).²In some embodiments, 116 is -C(:...0)R' or -C(=0)0Ra6. In some embodiments, R6 ²is - ²C(=0)Ra6 wherein 1V6 is as described herein. In some embodiments, R6 is -²C(0)alkyl. In ²some embodiments, R6 is -C(0)CH3, -C(0)cyclopropyl, -C(0)cyclobutyl, -²C(0)t13u, - ²C(0)113r, -C(0)Pr, -C(0) / Bu, or -C(=0)0Me. In some embodiments, R6 is acetyl (-²²C(=0)Me). In some embodiments. R6 is -C(D)ORa6. In some embodiments, R6 is - ²COOH. In some embodiments, R6 is COOMe.²102651 In some embodiments, R6 is -NRa6C(=0)Ra6. In certain embodiments, R6 is ²- ²NTIC(=0)11a6 (e.g, NITC(=0)Me, NTIC(=0)Et, NHC(:=0)Pr, NTIC(:=0)lPr, ²NHC(=0)Bu, ²NHC(=0)4314 NHC(0)Cyclopropyl, NHC(=0)Cyclobuty1). In some embodiments, R6 is -² ²N(CH3)C())Ra6 (e.g, N(CH3)C(=0)Me, N(CH3)C(=0)Et, N(CH3)C(D)Pr, ²N(CH3)C(=0)iPr, N(CH3)C(:=0)Bu, N(CH3)C(=0)q3u, N(CIT3)C(:=0)Cyclopropyl, ²N(CH3)C()Cyclobuty1).²In some embodiments, R6 is -NR96CKOORa6. In certain embodiments, R6 is - ²NHC(=0)0R36 (e.g., NHC(=0)0Me, NHC(=0)0Et, NHCD)0Pr, NHC(=0)0iPr, ²NTIC(:=0)0Bu, NHC(=0)0tBu, NHC(=0)0Cyclopropyl, NHC(=0)0Cyclobuty1). In some ²embodiments, R6 is -N(CH3)C(=0)0R96 (e.g., N(CH3)C(=0)0Me, N(CH3)C(=0)0Et, ²N(CH3)C(J)0Pr, N(CH3)C(=0)0iPr, N(CH3)C(=0)013u, N(CH3)C(=0)0'13u, ²N(CH3)C(:=0)0Cyclopropyl, N(CH3)C(=0)0Cyclobuty1).²94²<DP=96>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²WWI In some embodiments, R6 is -C(=0)N(11.a6)2 (e.g., -C(=0)N112, -²C(:=0)NEIRa6, - ²C(=0)N(CH3)Ra6). In some embodiments, R6 is -CK9NH2. In certain embodiments. ²1(6 is ²-C(=0)NHIV6 (e.g., -C(=0)NHMe, -C(=0)NHEt, -C(=0)NHPr, -C(=0)NHIPr, ²C(:=0)NFIBu, -g=0)N1-11311, -C(=0)NFICyclopropy1, -C(=0)NITCyclobu1y1). In ²certain ²embodiments, R6 is -C(=0)N(CH3)Ra6 (e.g., -C(=0)NMe2, -C(=0)N(CH3)Et, - ²C(31)N(CH3)Pr, -C(=0)N(CH3)1Pr, -C(=0)N(CH3)Bu, -C()N(CH3)'Bu, - ²C(=0)N(CH3)Cyclopropyl, -C(=0)N(CH3)Cyclobuty1).²102671 In some embodiments, R6 is -0C(=0)N(Ra6)2. In certain embodiments, 116 ²is - ²0C(=0)NHR6 (e.g, -0C(3)NHMe, -0C(C)NHEt, -0C(=0)NHPr, -0C(=0)NH'Pr, - ²0C(=0)NHBu, -0C(=0)NITBu, -0C(=0)NHCyclopropyl, -0C(=0)NHCyclobuty1). In ²certain embodiments, R6 is -OC(=0)N(CH3)11.a6 (e.g., -0C(...0)NMe2, -²0C(=0)N(CH3)Et, - ²OC(=0)N(CH3)Pr, -0C(=0)N(CH3) / Pr, -0C(=0)N(CH3)Bu, -0C(=0)N(CH3)Su, - ²0C(=0)N(CH3)Cyclopropyl, -0C(=0)N(CH3)Cyclobuty1).²102681 In some embodiments, R6 is -S(=0)R86. In certain embodiments, R6 is -²S(=0)alkyl ²(e.g., -S(=0)Me, -S(=0)Et, -S(=0)Pr, -S(=0)iPr). In certain embodiments, R6 is ²- ²S(=0)cycloalkyl (e.g., -S(=0)cyclopropyl, -S(=0)cyclobutyl, -S(=0)cyclopentyl, ²- ²S(=0)cyclohexyl).²102691 In some embodiments, R6 is -S(:=0)211a6. In certain embodiments, R6 is -² ²S(=0)2alkyl (e.g., -S(A))2Me, -S(=0)2Et, -S(00)2Pr, -S(=0)2iPr). In certain ²embodiments, ²R6 is -S()2cycloalkyl (e.g, -S(=0)2cyclopropyl, -S())2cyclobutyl, -²S()2cyclopentyl, - ²S(=0)2cyc1ohexy1). In some embodiments, R6 is S(=0)2aiy1 (e.g., S(=0)2pheny1). ²²102701 In some embodiments, R6 is -SR'. In certain embodiments, R6 is -Salkyl ²(e.g., - ²SMe, -SEt, -SPr, -S'Pr). In certain embodiments, R6 is -Scycloalkyl (e.g , -²Scyclopropyl, - ²Scyclobutyl, -Scyclopentyl, -Scyclohexyl). In certain embodiments, 1(6 is -²Sary1 (e.g, ²Spheny1).²102711 In some embodiments, R6 is -S(=0)(=NRa6)12.3ô. In certain embodiments, ²R6 is - ²S(=0)(=NH)Ra6 (e.g, -S(3)(=NH)Me, -S(=0)(=NH)Et, -S()(=NH)Pr, -S(=0)(=NH)IPr, -² ²S(=0)(=NH)Bu, -S(=0)(=NH)t3u, -S(=0)(=NH)Cyc1opropy1, -S(=0)(=NH)Cyclobuty1). ²In ²some embodiments, R6 is -S(=0)(=NCH3)R 6 (e.g, -S(=0)(=NCH3)Me, -²S(:=0)(=NCH3)Et, - ²S(=0)(=NCH3)Pr, -S(=0)(=NCH3)11)r, -S(D)(=NCH3)Bu, -S(=0)(=NCH3)Su, - ²S(=0)(=NCH3)Cyclopropyl, -S(=0)(=NCH3)Cyclobuty1).²102721 In some embodiments, R6 is -NR36S(=0)2Ra6. In certain embodiments, R6 ²is - ²N'HS(=0)2alkyl (e.g., -NHS(=0)2Me, -NHS(=0)2Et, -NHS(:))2Pr, -NHS(=0)2Tr). In²<DP=97>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²certain embodiments, R6 is -NITS(...0)2cyc10a1ky1 (e.g., -²NFIS(...0)2cyclopropyl, - ²NHS(=0)2cyclobutyl, -NHS(=0)2cyclopentyl, -NHS(=0)2cyclohexyl). In certain ²embodiments, R6 is ---N(CH3)S(=0)2alk-y1 (e.g., --N(CH3)8(=0)2Me, ---²N(CH3)S(=0)2Et, - ²N(CH3)8(...0)2Pr, -N(CI-1.3)8(...0)21130. In certain embodiments, R6 is - ²N(CH3)S(D)2cycloa1ky1 (e.g., -N(CH3)8(0)2cyc10pr0py1, -N(CH3)8(0)2cyc10buty1, -² ²N(CH3)S(=0)2cyc10pen1y1, -N(CH3)8(=0)2cyc10hexy1).²102731 In some embodiments. R6 is -8(=0)2N(R86)2. (e.g , -S(=0)2NH2, -²S(=0)2NHRa6 , - ²S(...0)2N(C1.i3)1226). In some embodiments. R6 is -S(...0)2N1-12. In some ²embodiments, R6 is - ²S(=0)2NHIV6 (e.g., -S(=0)2NHMe, -S(=0)2NHEt, -S())2NHPr, -8(=0)2NWPr, ²S(=0)2NHcyclopropyl, -8(=0)2NHcyclobuty1). In some embodiments, R6 is - ²S(".0)2N(CH3)12 6 (e.g. -S(".0)2NMe2, -S(".0)2N(CH3)Et, -S(".0)2N(CH3)Pr, - ²S(=0)2N(CH3) / Pr, -S(=0)2N(CH3)cyclopropyl, -S(=0)2N(CH3)cyclobuty1).²102741 As generally defined herein, each R7 is independently absent or ²selected from H, -D, ²halo, ---CN, ---CI---C6 alkyl, ---Cl--C6 hydroxyalkyl, ---CI---C6 haloalkyl, --²-C3---C9 cycloalkyl, 3-10 ²membered heterocyclyl, 5-6-membered monocyclic heteroaryl, heterocyclylalkyl,²heteroarylalkyl, arylakl, cycloalkylalkyl, -0R'7, -N(Ra7)2, -C(=0)Ra7, - ²NRa7C(=0)Ra7, -NR97g=0)0Ra7, -CCON(Ra7)2, -0C(=O)N(Ra7)2,-S(=0)Ra7, -²S(=0)2Ra7, ²-SR , -S(:=0)(=NR87)Ra7, -NRa7S(=0)2Ra7 and -S(:=0)2N(Ra7)2, wherein Ra7 is as ²defined ²herein.²102751 in some embodiments, each R7 is independently selected from H, halo ²(e.g, F, Cl), - ²CN, ---CI---C6 alkyl (e.g, --Me, --Et, --Pr, ---'Pr, -see-Bu, ---93u), 5-²membered heteroaryl (e.g, ²pyrazolyl), -CI-C6 haloalkyl (e.g., -CF3, -CI-1F2, -CH2CF3), -C1---C6 ²hydroxyalkyl (e.g., - ²CH2OH), -C3-C9 cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, ²cyclohexyl), -OR ²(e.g , -OH, -0Me, -OCHF2), -N(Ra7)2 and -C())N(Ra7)2 (e.g , -C(=0)NH2, - ²C(---0)NTIMe), wherein each R is as defined herein. In further embodiments, ²each Ra7 is ²independently selected from H and -CI-C6 alkyl (e.g., -Me, -Et, -Pr, -Tr,-"Bu, ²-Su, -sec-²Bu, -iso-Bu).²102761 In certain embodiments, each R7 is independently selected from H and ²methyl.²[02771 In some embodiments, R7 is In some embodiments R7 is -D.²102781 In certain embodiments, R7 is halo (e.g, fluor , chloro, bromo, iodo). ²In further²embodiments, R7 is -Cl. In some embodiments, R7 is -F. In some embodiments, R7 ²is -Br.²In some embodiments, R7 is -T.²102791 in some embodiments, le is -CN.²96²<DP=98>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²
[0280] In certain embodiments, 127 is -C1-C6 alkyl. In further embodiments. R7 ²is -Me. In ²some embodiments, R7 is -Et. In some embodiments R7 is -Pr or -iPr.²
[0281] In some embodiments, R7 is -CI-C6 heteroalkyl. In further embodiments, ²R7 is ²methoxymethyl (-CH2OCH3). In some embodiments, R7 is hydroxymethyl (-CH2OH). ²In ²some embodiments, R7 is aminomethyl (e.g.,-CH2NH2, -CH2NHCH3, -CH2N(CH3)2. ²102821 in some embodiments, R7 is -C]-C6 haloalkyl. In further embodiments, R7 ²is ²trifluoromethyl (-CF3). In other embodiments, R7 is difluoromethyl (-CHF2).²102831 In some embodiments. R7 is -C3-C9 carbocyclyl (e.g., cyclopropyl, ²cyclobutyl, ²cyclopentyl, cyclohexyl). In some embodiments, R7 is cyclopropyl. In some ²embodiments ²R7 is cyclobutyl. In some embodiments, R7 is cyclopentyl. In some embodiments, ²R7 is ²cyclohexyl.²102841 In some embodiments, R7 is 3-10 membered heterocyclyl (e.g., oxetanyl, ²tetrahydropyranyl, tetrahydrofuranyl, azetidinyl, pyrrolidinyl, piperidinyl, ²piperazinyl, ²morpholinyl, azepanyl). In some embodiments, R7 is oxetanyl. In some ²embodiments, R7 is ²tetrahydropyranyl. In some embodiments, R7 is tetrahydrofuranyl. In some ²embodiments, R7 ²is azetidinyl. In some embodiments, R7 is pyrrolidinyl. In some embodiments, ²R7 is ²piperidinyl. In some embodiments, R7 is piperazinyl. In some embodiments, R7 ²is ²morpholinyl. In some embodiments, R7 is azepanyl.²102851 In some embodiments, R7 is a 5-6 member monocyclic heteroaryl (e.g., a ²5-member ²monocyclic heteroaryl containing 1-3 heteroatoms independently selected from ²0. N and S. a ²6-member monocyclic heteroaryl containing 1-3 N heteroatoms). In some ²embodiments, R7 ²is a 5-member monocyclic heteroaryl (e.g., pyrazolyl, pyrolyl, thiophenyl, ²futyl, thiazolyl, ²isothiazolyl, oxazolyl, isoxazolyl, imidazolyl, triazolyl, thiadiazolyl, ²oxadiazolyl). In some ²embodiments, R7 is thiophenyl (e.g., thiophen-2-yl, thiophen-3-y1). In some ²embodiments, R7 ²is pyrazolyl (e.g pyrazol-l-yl, pyrazol-3-yl, pyrazol-5-y1). In some ²embodiments, R7 is ²thiazolyl (e.g., thiazol-2-yl, thiazol-4-yl, thiazol-5-y1). In some ²embodiments, R7 is a 6-²member monocyclic heteroaryl (e.g., pyridyl, pyrimidinyl, triazinyl, ²pyrazinyl, pyridazinyl). ²In some embodiments, R7 is pyridinyl (e.g., pyridin-2-yl, pyridin-3-yl, ²pyridin-4-y1). In some ²embodiments, R7 is pyrimidinyl (e.g, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-²5-y1). ²In some embodiments R7 is cycloalkylalkyl (e.g , cyclopropylmethyl, ²cyclobutylmethyl, ²cyclopentylmethyl, cyclohexylmethyl, cycloheptylmethyl). In some embodiments. ²R7 is ²heterocyclylalkyl (e.g., oxetanylmethyl, aziridinylmethyl, ²tetrahydrofuranylmethyl,²97²<DP=99>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²pyrolidinylmethyl, tetrahydropyranylmethyl, piperidinylmethyl, ²piperazinylmethyl, ²morpholinylmethyl, azepanylmetbyl).²10286j In some embodiments, R7 is aiyialkyl. In some embodiments, R7 is ²benzyl.²102871 In some embodiments, R7 is heteroarylalkyl (e.g., pyridinylmethyl, ²thiazolylmethyl, ²triazolylmethyl, pyrazolylmethyl).²102881 in some embodiments, R7 is _0R7 (e.g., hydroxy (-0H), methoxy, ²difluoromethoxy ²(-0CHF2), trifluoromethoxy (-0CF3), ethoxy, propoxy, isopropoxy, ²cyclopropyloxy, ²cyclobutyloxy). In some embodiments, R7 is hydroxy. In some embodiments, R7 is ²methoxy. ²In some embodiments, R7 is ethoxy. In some embodiments, R7 is propox-y. In ²some ²embodiments, R7 is isopropoxy. In some embodiments R7 is difluoromethoxy. (-²0CHF2). ²In some embodiments, R7 is trifluoromethoxy (-0CF3).²102891 In some embodiments, R7 is _N(Rai)2 (e.g., -NH2, -NHRa7, -N(CH3)1e7). ²In some ²embodiments, R7 is -NH2. In some embodiments, R7 is -NHRa7 (e.g, -NHMe, -NHEt, ²-²NI-11)r, -NHcyclopropyl, -NHcyc1obuty1). In some embodiments, R7 is -²N(CH3)Ra7 ²(e.g., -NMe2, -N(CH3)Et, -N(CH.3)Pr, -N(CT13)Tr, -N(CI-13)cyclopropyl, - ²N(CH3)cyclobuty1).²In some embodiments, R7 is -C(=0)Ra7or -C(=0)0Ra7. In some embodiments, R7 is -² ²C(=0)R37 wherein Ra7 is as described herein. In some embodiments. R7 is -²C(...0)alkyl. In ²some embodiments, R7 is -C(0)CH3, -C(0)cyclopropyl, -C(0)cyclobutyl, -²C(0)'13u, - ²C(0)113r, -C(0)Pr, -C(0)113u, or -C())0Me. In some embodiments, R7 is acetyl (-²²C(=0)Me). In some embodiments, R7 is -C(=0)01V7. In some embodiments, R7 is - ²COOH. In some embodiments. R7 is COOMe.²102901 In some embodiments. R7 is -NRa7C(=0)Ra7. In certain embodiments, R7 is ²- ²NHC(=0)Ra7 (e.g, NHC(=0)Me, NHC(=0)Et, NHC()Pr, NHC(=0)iPr, NHC(20)Bu, ²NITC(...0)43u, NHC(...0)Cyclopropyl, NITC(...0)Cyclobuty1). In some ²embodiments, R7 is - ²N(CH3)C(=3)Ra7 (e.g., N(CH3)C(=0)Me, N(CH3)C(=0)Et, N(CH3)C()Pr, ²N(CH3)CKOIPr, N(CH3)C(0)Bu, N(CH3)C(=0)43u, N(CH3)C(=0)Cyclopropyl, ²N(CH3)C(Cyclobuty1).²102911 In some embodiments. R7 is -NRa7C(=0)01127. In certain embodiments, R7 ²is - ²NHC(=0)011a7 (e.g., NH.C(=0)0Me, NHC(=0)0Et, NHC(20)0Pr, NHC(=0)0IPr, ²NHC(=0)0Bu, NHC(=0)0113u, NHC(=0)0Cyclopropyl, NHC(=0)0Cyc1obuty1). In some ²embodiments. R7 is -N(CH3)C(...0)0Ra7 (e.g., N(C113)C(=0)0Me, ²N(CH3)C(...0)0Et,²98²<DP=100>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²N(CI-1.3)C(=0)0Pr, N(CH3)C(=0)0'Pr, N(CH3)C(=O)0Bu, N(CI-1.3)C(=0)013u, ²N(CH3)CK90Cyclopropyl, N(CH3)¶=0)0Cyclobuty1).²10292j In some embodiments, R7 is -C(=0)N(Ra7)2(e.g., --C(=0)NH2, --²C(=0)NHRa7, - ²C(:=0)N(CH3)11.a7). In some embodiments. R7 is -C(=0)NH2. In certain ²embodiments, R7 is ²-C(=0)NHRa7 (e.g., -C(=D)NHMe, -C(00)NHEt, -C(00)NHPr, -C(00)NH'Pr, - ²C()NHBu, -C(=0)NWI3u, -C(=0)NHCyclopropyl, -C(=0)NHCyclobuty1). In certain ²embodiments, le is -C(=0)N(CH3)Ra7 (e.g., --C(=0)NMe2, -C(=0)N(CH3)Et, ²C(=0)N(CH3)Pr, -C(:=0)N(CH3):Pr, -C(=0)N(CT13)Bu, -C(=0)N(CI-T3)!Bu, - ²C(=0)N(CH3)Cyclopropyl, -C(=0)N(CH3)Cyclobuty1).²10293j In some embodiments, R7 is -0C(=0)N(Ra7)2. In certain embodiments, R7 ²is - ²0C(=0)NHRa7 (e.g., -0C(=0)NHMe, -0C(=0)NFIEt, -0C(=0)NHPr, -0C(=0)NH'Pr, - ²0C(=0)NHI3u, -0C(=0)NITI3u, -0C(=0)NHCyclopropyl, -0C(=0)NHCyclobuty1). In ²certain embodiments, R7 is -0C()N(CH3)12.a7 (e.g., -0C(=0)NMe2, -²0C(=0)N(CH3)Et, - ²OC(=0)N(CH3)Pr, -0C(=0)N(CH3):Pr, -0C(=0)N(CH3)1311, -0C(=0)N(CH3)t3u, - ²0C(=0)N(CH.3)Cyclopropyl, -0C(:=0)N(CH3)Cyclobuty1).²102941 In some embodiments, R7 is -S(=0)Ra7. In certain embodiments, R7 is -²S(=0)alkyl ²(e.g, -S(=0)Me, -S(=0)Et, -S(=0)Pr, -S(=0)1Pr). In certain embodiments, R7 is -² ²S(=0)cycloalkyl (e.g., -S(=0)cyclopropyl, -S(=0)cyclobutyl, -S(=0)cyclopentyl, ²- ²S(=0)cyclohexy1).²102951 in some embodiments, R7 is -S(=0)211a7. In certain embodiments, R7 is - ²²S(=0)2alkyl (e.g., -S(=0)2Me, -S(=0)2Et, -S(=0)2Pr, -S(=0)2'Pr). In certain ²embodiments, ²R7 is -S(=0)2cyc1oa1kyl (e.g., -S(=0)2cyclopropyl, -S(:=0)2cyc10buty1, -²S(=0)2cyclopentyl, - ²S(=0)2cyclohexyl). In some embodiments, R7 is S(=D)2aryl (e.g, S(=0)2pheny1).²In some embodiments, R7 is -SRa7. In certain embodiments, R7 is -Salkyl (e.g., ²-SMe, -SEt, ²-SPr, -S'Pr). In certain embodiments, R7 is -Scycloalkyl (e.g., -Scyclopropyl, ²-Scyclobutyl, ²Scyclopentyl, -Scyclohexyl). In certain embodiments, R7 is -Saryl (e.g., ²Spheny1).²In some embodiments, R7 is -S(=0)(=NRa7)Ra7. In certain embodiments, R7 is - ²S(=0)(=NH)Ra7 (e.g, -S(=3)(=NH)Me, -S(=0)(=NH)Et, -S(=0)(=NH)Pr, -²S(=0)(=NH)iPr, - ²SC=0)(=NH)Bu, -S(:=0)(=NH)13u, -S(=0)(=NFI)Cyclopropyl, -²S(=0)(=NH)Cyclobuty1). In ²some embodiments, R7 is -S(=0)(=NCH3)Ra7 (e.g., -S(=20)(=NCH3)Me, -²S(43)(=NCH3)Et, - ²S(=0)(=NCH3)Pr, -S(=0)(=NCH3Or, -S(=0)(=NCH3)Bu, -S(=0)(=NCH3)Su, - ²S(:=0)(=NCIT3)Cyclopropyl, -S(:=0)(=NCH3)Cyclobuty1).²99²<DP=101>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²
[0296] In some embodiments. R7 is -NR27S(...0)2Ra7. In certain embodiments, R7 ²is - ²NHS(=0)2alkyl (e.g., -NH.S(=0)2Me, -NHS(=0)2Et, -NHS(=D)2Pr, -NHS(=0)2'Pr). In ²²certain embodiments, R7 is -NHS(=0)2cycloalkyl (e.g, -NHS(=0)2cyclopropyl, - ²NITS(...0)2cyc10buty1, -NITS(...0)2cyclopentyl, -NHS(...0)2cyc10hexy1). In ²certain ²embodiments, R7 is -N(CH3)S(=0)2a1ky1 (e.g., -N(CH3)S(=0)214e, -²N(CH3)S(=0)2Et, - ²N(CH3)S(=0)2Pr, -N(CH3)S())2113r). In certain embodiments, R7 is - ²N(CH3)S(=0)2cycloalkyl (e.g., -N(CH3)S(=0)2cyc10pr0py1, -²N(CH3)S(=0)2cyclobutyl, - ²N(CH3)S('=0)2cyc10pen1y1, -N(CH3)S(...0)2cyc10hexy1).²102971 In some embodiments, R7 is -S(=0)2N(Ra7)2. (e.g., -S(=0)2NH2, -²S(=0)2NHRa7 , - ²S(=0)2N(CH3)1e7). In some embodiments, R7 is -S(=0)2NH2. In some embodiments, ²R7 is - ²S(...0)2NHRa7 (e.g , -S(=0)2NHMe, -S(=0)2NHEt, -S(...0)2NHPr, -S(...0)2N1-²1113r, - ²S(=0)2NHcyclopropyl, -S(=0)2NHcyclobuty1). In some embodiments, R7 is - ²S(=0)2N(CH3)Ra7 (e.g., -S())2NMe2, -S(=0)2N(CH3)Et, -S(=0)2N(CH3)Pr, - ²S(=0)2N(CH3):13r, -S(=0)2N(CH3)cyclopropyl, -S(=0)2N(CH3)cyclobuty1).²102981 As generally defined herein, each le is independently selected from H, -²D, =0, ²halo, -CN, -CI-C6 alkyl, -CI-Co heteroalkyl, -CI-C6 haloalkyl, -C3-C9 ²cycloalkyl, 3-10 ²membered heterocyclyl, heterocyclylalkyl, heteroarylalkyl, arylakl, ²cycloalkylallcyl, -0Ra8,²_N(Ras)2, _c(,,,o)oRas, _NRasc(,,,o)Ras, -NR38C(...0)0Ra8, -²CH2C(...0)N(Ra8)2²-C(=0)N(Ra8)2, -0C(=0)N(Ra8)2, -CH2C(=0)N(Ra8)2, -S20)Ra8, -S(=0)2R.08, -SRa8, ²- ²S(=0)(=NRa8)Ras, -NR88S(=0)2Ras and -S(3)2N(Ra8)2 wherein two instances of R8 ²together ²with the atom or atoms to which they are attached can be taken together to ²form a 3-10 ²member carbocyclyl (e.g. cycloalkyl) or heterocyclyl ring (e.g., a ring that ²together with the ²piperidine ring of Structure I can form a bridged, fused or Spiro bicyclic ²heterocyclic ring), ²wherein Ra8 is as defined herein.²102991 In some embodiments of Formula (I), two R8 groups are taken together ²with the ²atom to which they are attached to form a 3-10 member spiro cycloalkyl (e.g , ²cyclopropyl, ²cyclobutyl, cyclopentyl, cydohexyl, cycloheptyl) or Spiro heterocyclyl ring ²(e.g., oxetanyl, ²tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrolidinyl, piperidinyl, ²piperazinyl, ²morpholinyl, azepanyl, tetrahydrothiopyranyl, thiomorpholiny1).²103001 In some embodiments of Formula (I), two R8 groups are taken together ²with the ²adjacent atoms to which they are attached to form a 3-10 member fused ²cycloallcyl (e.g, ²cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl) or fused ²heterocyclyl ring²100²<DP=102>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²(e.g., oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, ²pyrolidinyl, piperidinyl, ²piperazinyl, morpholinyl, anpanyl, tetrahydrothiopyranyl, thiomorpholinyl).²103011 In some embodiments, the two le groups taken together with the atoms to ²which ²they are attached form a bridged piperidine-containing carbocyclyl or ²heterocyclyl ring (e.g., ²2-azabicyclo[2.2.1]heptane, 2-azabicyclo[2.2.2]octane, 3-azabicyclo[3.2. ²I]octane).²R7²riN1 me%².X.N y.j.......1" in²103021 In certain embodiments, the moiety represented as R6 in Formula ²(I) is²selected from:²(R8)n-2²\R7²: N.. 8 8² R6 (R )n2 R6 (R )n-2 R-6 (R )n-2 R6 .²- .²n-2(R8)²\ S,²77 r\-] 1²;,õ.N.y...A....,...,..) (R8)n..2 XN.,...r>"=,,, µN.,y,.... XN ²..s.r....²....' R8 R8²( )11.2² R6 R6 R6 R6²( )n-2², . , ,²R7"'. =.'-= ²r ''S²X¨(R8)õ..2² 1R8)n-2 R' 6 `(R8)n.2²R6 and R6 , wherein R6, ²R7, R8 and²,²n are as defined herein.²R7²(IN) s²103031 In further embodiments, the moiety represented as R6 in Formula ²(I) is²selected from:²(---;:,²E-1)²AN ,..,...\-) N², ,xµr...44;j1',N, A.N ..,..N.²R6 (R8)11-2 R6 (R )n2 R6 (R8) / 1-2, - \ 8²Fi6 (R )r,-2². .²101²<DP=103>²CA 03176912 2022-09-23²WO 2022 / 026892 PCT / US2021 / 044004²115, 4,²Re (R8)11-2, Re (R 8)n-2²Re (R8)n-2 , Re (R8).2²(R8)n-2 (R8)n-2 (R6).2 (R8)n-2²)....., \ µ²\.:.²v,....,., .,$.õN ;\ I.\ \\:,,I., / ....;::² Re , R6 , Re , R6 ,²(R8)n-2 (Re)1.1-2 (Re)2 (R8)n-2²\²c.....1.,, =²vy.²Re Re. Re , Re² . , . .²R7 R7 R7 R7² _____________ iR81 rts).,0-...,1 8²ril tp81 1')'-i-') , ,².._ rn-2 ;NLN,,.........).i ER )n-2 ;\N ,,.....õ..e.s4w,..3 .. - fn-2 ²A.N.õ.. / ..,),..) .R8,n4² R7 R7 R7 R7²____________________________________________ , ,õ __________ , õ,²__________ (R8) 2 1 ___ (R8) 2²n- "zzN AN..õ..) n- A.N ...,..õ-²1,..) ,R . n-2 "1 / 4N,...s.,2.,,.) .R , n-2²5²r1:²XN.......,...- (R8)n-2 ' t __ CO: )²1,N,,,-). 98 ¨(R )n-2 \N ¨(R8) (Re²n-2 \N n-2².'²5²(--(--)¨(R8) 2²and' ---2.-,, ' wherein R6. R7, le and n are as defined herein.². ²103041 in certain embodiments of the bicyclic and polycyclic moieties ²described above, n is ²2 (i.e., the rings do not bear any R8 substituents). In some embodiments of ²the bicyclic and ²polycyclic moieties described above, each R6 and R7 is independently selected ²from I-1 and ---²CI-I3. In some embodiments. R6 is H. In some embodiments. R6 is -CI-13. In ²certain²102²<DP=104>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²embodiments 117 is H. In other embodiments, le is -G3. In certain embodiments, ²both R6 ²and R.7 are H.²In other embodiments, the R8 groups are not taken together to form cycloalkyl ²or heterocyclyl ²rings (i.e., each R8 is independently selected from 1-I, -D, =0, halo, -CN, -²Ci-C6 alkyl, -CI-²Co heteroalk-yl, -Ci-C6 haloakl, -C3-C9 cycloalkyl, 3-10 membered ²heterocyclyl, ²heterocyclylalkyl, heteroarylalkyl, arylalkyl, cycloalk-ylalkyl, -OR, -²N(Ra8)2, -C(=0)Ra8, - ²C(=0)012.88, -NRa8C(=0)Ra8, -NRa8C(=0)0Ra8, -CH2C(=0)N(R88)2-C(=0)N(Ra8)2, -²0C(...0)N(Ra8)2, -CT-I2C(=0)N(Ra8)2, -S(...0)2Ra8, -SR", -²S(...0)(=NR08)R18, -²NRa8S(=0)2Ra8 and -S(=0)2N(Ra8)2), wherein Ras is as defined herein.²103051 In some embodiments, each R8 is independently selected from H, -D, halo ²(e.g, -F,²-Cl), -CN, -CI-Co alkyl (e.g., -Me, -Et, -Pr, -Tr, -sec-Bu, ²arylalkyl, (e.g., benzyl), -²C(=-0)Ra8 (e.g , -C(=0)Me, -C(=0)Et,-C(=0)Pr, -C(=0)'Pr), -N(Ra8)2 (e.g , -²NHMe, NH2, ²NMe2), ¨NRa8C())Ra8 (e.g , -NHC(=0)Me), -CH2C(C)N(Ra8)2 (e.g., -CH2C(=0)NH2) ²and -01k28 (e.g., -OH, -0Me, -0'Pr, -0CF3), wherein each Ra8 is as defined ²herein. In ²further embodiments, each Ra8 is independently selected from H, -CF3, and -C i-²Co alkyl²(e.g, -Me, -Et, -Pr, -1Pr,-nBu, -sec-Bu, -iso-Bu).²103061 In some embodiments, each le is independently selected from H, -D, -F, -²Me, -Et,²--CN, benzyl, -0Me, -0'Pr, -NHC(...0)Me, -NMe2,-CH2C(=0)NH2, -C(...0)113r ²and²-OH. In some embodiments, R8 is selected from H, -D, -F, -Me, -Et and -CN. In ²some²embodiments, R8 is selected from H, -D, -F and -Me.²103071 In some embodiments. R8 is H.²103081 In some embodiments, R8 is -D.²103091 In certain embodiments, R8 is =0.²103101 In certain embodiments, le is halo (e.g, fluoro, chloro, bromo, iodo). ²In further²embodiments, R8 is -Cl. In some embodiments, R8 is -F. In some embodiments. R8 ²is -Br.²In some embodiments, R8 is -I.²103111 in some embodiments, R8 is -CN.²103121 In certain embodiments, R8 is -C1-C6 alkyl. In further embodiments, le ²is -Me. In²some embodiments, R8 is -Et. In some embodiments R8 is -Pr or -iPr.²103131 In some embodiments. R8 is -Ci-Co heteroalkyl. In further embodiments, ²R8 is²methoxymethyl (-CH2OCH3). In some embodiments, R8 is hyroxymethyl (-CH2OH). In²some embodiments, R8 is aminomethyl (e.g.,-CH2NH2, -CH2NHCH3, -CT-I2N(CH3)2.²103²<DP=105>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²In some embodiments, R8 is -C1-C6 haloalkyl. In further embodiments, fe is ²trifluoromethyl (-CF3).²103141 In some embodiments, R8 is -C3-C9 carbocyclyi (e.g., cyclopropyi, ²cyclobutyl, ²cyclopentyl, cyclohexyl). In some embodiments, R8 is cyclopropyl. In some ²embodiments ²R8 is cyclobutyl. In some embodiments, R8 is cyclopentyl. In some embodiments, ²R8 is ²cyclohexi.²In some embodiments, R8 is 3-10 membered heterocyclyl (e.g., oxetanyl, ²tetrahydropyranyl, ²tetrahydrofuranyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, ²morpholinyl, azepanyl). ²In some embodiments, R8 is oxetanyl. In some embodiments, le is ²tetrahydropyranyl. In ²some embodiments, R8 is tetrahydrofuranyi. In some embodiments, R8 is ²azetidinyl. In some ²embodiments, R8 is pyrrolidinyl. In some embodiments, R8 is piperidinyl. In ²some ²embodiments, R8 is piperazinyl. In some embodiments, R8 is morpholinyl. In ²some ²embodiments, 12.8 is azepanyl.²103151 In some embodiments R8 is cycloakrialkyl (e.g., cyclopropylmethyl, ²cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cycloheptylmethyl). In ²some ²embodiments, le is heterocyclylalkyl (e.g., oxetanylm.ethyl, aziridinylmethyl, ²²tetrahydrofuranylmethyl, pyrolidinylmethyl, tetrahydropyranylmethyl, ²piperidinylmethyl, ²piperazinylmethyl, morpholinylmethyl, azepanylmethyl). In some embodiments, R8 ²is ²arylalk)71 (e.g benzyl). In some embodiments, R8 is heteroarylalkyl (e.g., ²pyridinylmethyl, ²thiazolylmethyl, triazolylmethyl, pyrazolylmethyl).²103161 In some embodiments. R8 is -CH2C(=0)N(Ra8)2 (e.g., ---CH2C(=0)N(Tes)2). ²²103171 In some embodiments, R8 is ¨ORa8 (e.g., -OH, methoxy, isopropoxy, ²difluoromethoxy (-0CHF2), trifluoromethoxy (-OM), ethoxy, propoxy, isopropexY, ²²cyclopropyloxy, cyclobutyloxy). In some embodiments le is -OH. In some ²embodiments, le ²is methoxy. In some embodiments, R8 is ethoxy. In some embodiments, R8 is ²propoxy. In ²some embodiments. R8 is isopropoxy. In some embodiments R8 is difluoromethoxy. ²(-²OCHF2). In some embodiments, R8 is trifluoromethoxy (-0CF3).²103181 In some embodiments. R8 is -N(Ra8)2 (e.g., ---NH2, -N(CH3)1e8). In ²some ²embodiments, R8 is -NH2. In some embodiments, R8 is -NH1128 (e.g., -NHMe, -²NHEt, - ²NHPr, -NH'Pr, -NHcyclopropyl, -NHcyclobuty1). In some embodiments, le is -²N(CH3)Ra8 ²(e.g , -NMe2, -N(CH3)Et, -N(CH3)Pr, -N(CH3YPr, -N(CH3)cyclopropyl, - ²N(CH3)cyclobuty1).²104²<DP=106>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²In some embodiments, R8 is -C(...0)R" wherein R" is as described herein. In ²some ²embodiments R8 is -C(=0)Ra8 wherein Ras is Ci-Co aikyl, C3-C9 carbocycly1 or 3-²10 ²membered heterocycly1 (e.g. -C(:=0)Me, -C(=0)Et, -C(0)q3u, -C(0)1Pr, -C(0)Pr, -²C(0)713u, ²--g=0)cyc1opropy1, -C(...0)cyc1obutyl, -C(...0)oxetany1, --²g=0)tetrahydropyrany1). In ²some embodiments. R8 is -C(=0)Me, -C(D)Et, -QUA:3u, -C(0)Pr, -C(0)Pr or -²C(0)'13u. ²In some embodiments, R8 is -C(=0)Pr.²103191 In some embodiments. R8 is -NRa8C(=0)Ra8. In certain embodiments; R8 is ²-²NTIC(:=0)Ras (e.g., NITC(...0)Me, MIC(:=0)Et, MIC(:=0)Pr, NHC(...0)Bu, ²NHC(=0)Su, NHC())Cyclopropyl, NHC(=0)Cyclobuty1). In certain embodiments, R8 ²is ²NHC(=0)Me. In some embodiments, R8 is -N(CH3)C(=0)1e8 (e.g., N(CH3)C(=0)Me,²N(CH3)C(...0)Et, N(C113)C(:=0)iPr, N(CH3)C(:=0)Bu, N(CI-²1.3)C(...0)43u, ²N(CH3)C(=:::0)Cyclopropyl, N(CH3)C(=0)Cyclobuty1).²103201 In some embodiments, R8 is -NRa8C(=0)0Ra8. In certain embodiments, R8 ²is - ²NHC(0)0R" (e.g., NHC(=0)0Me, NHC(=0)0Et, NHC())0Pr, NHC(=0)0'Pr, ²NTIC(:=0)0Bli, NTIC(:=0)0tBu, NFIC(-0)0Cyclopropyl, NITC(...0)0Cyclobuty1). In ²some ²embodiments, R8 is -N(CH3)C(=0)0Ras (e.g., N(CH3)C(=0)0Me, N(CH3)C(=0)0Et, ²N(CH3)C(J)0Pr, N(CH3)C(=0)0'Pr, N(CH3)C(=0)0BI4 N(CH3)C(=0)0'13u, ²N(CH3)C(...0)0Cyclopropyl, N(CH3)C(...0)0Cyclobuty1).²[03211 In some embodiments, R8 is -C(=0)N(R08)2 (e.g., -C.(=0)NH2, -²C(43)NHIV8, - ²C()N(CH3)12"). In some embodiments, R8 is -C(=D)NH2. In certain embodiments, ²R8 is²-C(=0)NHR" (e.g., --C())NHMe, -C(=0)NIPPr,²-C(...0)N1f13u, -C(...0)NHCyclopropyl, -g=0)NFICyc1obuty1). In certain ²embodiments, R8 is -C(=0)N(CH3)12." (e.g, -C(=0)NMe2, -C(=0)N(CH3)Et, - ²C(=0)N(CH3)Pr, -C(=0)N(CH3):Pr, -C(=0)N(CH3)Bu, -C(=0)N(CH3)tf3u, - ²C(=0)N(CH3)Cyclopropyl, -C(=0)N(CH3)Cy clobuty I).²103221 In some embodiments, R8 is -0C(=0)N(12a8)2. In certain embodiments, R8 ²is - ²0C(=0)NHIta8 (e.g, -0C())NHMe, -0C(=0)NHEt, -0C(=0)NHPr, -OCKONH'Pr, - ²0C(=0)NH1311, -0C(=0)NWI311, -0C(=0)NHCyclopropyl, -0C(=0)NHCyclobuty1). In ²certain embodiments. R8 is -0C(...0)N(CH3)Ra8 (e.g., -0C(4))NMe2, -²0C(...0)N(CH3)Et, - ²OC(=0)N(CH3)Pr, -0C(=0)N(CH3)113r, -0C(=0)N(CH3)Bu, -0C(=0)N(CH3)Su, - ²OC(=0)N(CH3)Cyclopropyl, -0C(=0)N(CH3)Cyclobuty1).²103231 In some embodiments, le is -S(...0)Ra8. In certain embodiments, R8 is -²S(=0)alkyl ²(e.g., -S(=0)Me, -S(=0)Et, -S(=0)Pr, -S(=0)'Pr). In certain embodiments. R.8 ²is -²105²<DP=107>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²S(=0)cycloalkyl (e.g., -S(=0)cyclopropyl, -S(=0)cyclobutyl, -²S(...0)cyclopentyl, -²S(=0)cyclohexyl).²103241 In some embodiments, R8 is -S(=0)21e8. In certain embodiments, R8 is -²S('=0)2alkyl (e.g., -S(=0)2Me, -S(=0)2Pr, -S(=0)2'Pr). In certain ²embodiments, ²R8 is -S(=0)2cycloalk-y1 (e.g , -S(=0)2cyclopropyl, -S(3)2cyclobutyl, -²S(=0)2cyclopentyl, - ²S(=0)2cyclohexyl). In some embodiments, 12.8 is S())2aryl (e.g., ²S(=0)2pheny1).²103251 In some embodiments. R8 is =SR8. In certain embodiments, R8 is -Salkyl ²(e.g., - ²SMe, -SEt, -SPr, -S'Pr). In certain embodiments. R8 is -Scycloalkyl (e.g., -²Scyclopropyl, ²Scyclobutyl, -Scyclopentyl, -Scyclohexyl). In certain embodiments, R8 is -²Saiy1 (e.g, ²Sphenyl).²In some embodiments, 11.8 is -S(=0)(=NRa8)1138. In certain embodiments, R8 is -² ²S(=0)(=NH)R.a8 (e.g , -S(3)(=NH)Me, -S(=0)(=NH)Et, -S(=0)(=NH)Pr, -S(A))(=N1-²10r, - ²S(=0)(=NH)Bu, -S(=0)(=NH)tBu, -S(=0)(=NH)Cyclopropyl, -S(=0)(=NH)Cyclobuty1). ²In ²some embodiments, le is -S(=0)(=NCH3)Ras (e.g. -S(A))(=NCH3)Me, -²S(=0)(=NCH3)Et, - ²S(...0)(=NCT13)Pr, -S(=0)(...NCI-13)iPr, -S(=0)(=NCT13)Bu, -²S(...0)(=NCH3)tElu, - ²S(=0)(=NCH3)Cyclopropyl, -S(=0)(=NCH3)Cyclobuty1).²103261 In some embodiments, R8 is -NR9sS(=0)2Ra8. In certain embodiments, R8 ²is - ²NITS(...0)2a1ky1 (e.g., -NtiS(...0)2Me, -NHS(=0)2Et, -NITS(...0)2Pr, ²..4HS(...0)213r). In ²certain embodiments, R8 is -NHS(=0)2cycloalkyl (e.g., -NHS(=0)2cyclopropyl, - ²NHS(=0)2cyc10bu1y1, -NHS(=0)2cyc10pen1y1, -NHS(=0)2cyclohexyl). In certain ²embodiments, R8 is -N(CH3)S(=0)2a1lcy1 (e.g, -N(CH3)S(=0)2Me, -N(CH3)S(=0)2Et, ²- ²N(CH3)S(=0)2Pr, -N(CH3)S('=0)2'Pr). In certain embodiments, R8 is - ²N(CH3)S(=0)2cycloalkyl (e.g , -N(CH3)S(=0)2cyclopropyl, -²N(CH3)S(=0)2cyclobutyl, - ²N(CH3)S(4,:)2cõ,clopentyl, -N(CH3)S(=0)2cyclohexyl).²103271 In some embodiments, le is -S(...0)2N(1138)2. (e.g., -S(=0)21\1112, -²S(...0)2NTIRas, - ²S(=0)2N(CH3)0). In some embodiments, le is -S(0)2NH2. In some embodiments, R8 ²is - ²S(=0)2NHRa8 (e.g, -S(31)2NHMe, -S(=0)2NHEt, -SKO2NHPr, -S(=0)2NI-PPr, - ²S(=0)2NHcyclopropyl, -S(=0)2NHcyclobuty1). In some embodiments, R8 is - ²R=0)2N(CI-1.3)Ra8 (e.g., -S(:=0)2NMe2, -S(:=0)2N(CH3)Et, -S(=0)2N(CH3)Pr, - ²S(=0)2N(CH3)113r, -S(=0)2N(CH3)cyc1opropyl, -S(=0)2N(CH3)cyc1obuty1).²103281 As generally described herein, each R' is independently selected from -²D, =0, - ²CN, halo, -CI-C6 alkyl, -Ci-C6 heteroalkyl, -Cl-C6 haloalkyl, -C3-C9 ²cycloalkyl, 3-10 ²membered heterocyclyl, Co-Cio aryl, 5-10 membered heterowyl, cycloalkylalkyl,²106²<DP=108>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²heterocyclylalkyl, atylalkyl, heteroarylalkyl, heterocyclylalkoxy, -011131 , -²N(Rb1 )2,²b²C(=0)Rb 10, _c(= h h in (=0)-10, NRb 1 C (=0)0Rb , -C(=0)N(Rb 1 )2, -²OC (=0)IC., 1)10,²-0C (=0)N(R")2,-S(=0)Rbi , ---²sc=o)(=NRbio)Rbio,²melos(=0)2Rbio and -S(=0)2N(Rb1 )2, wherein each alkyl, cycloalkyl, ²heteroalkyl, ²heterocyclyl, aryl, heteroatyl, cycloalkylalkyl, heterocyclylalkyl, ²heterocyclylalkoxy, ²arylakl and heteroarylalkyl of R1 is optionally substituted (e.g, with 0, 1, ²2, 3, 4, or 5 ²instances of -Me, -Et, ---1Pr, cyclopropyl, oxetan-3-yl, --OH, =0, ---P, ---²0Me, ---CH2CH2F, ---²CH2CHF2, -CH2CH2CF3, -C(=0)Me, -N(Me)2, -CH2N(CH3)2, -CH2N(CIT3)CIT2CH3, - ²N('Pr)(Et), -N('I3r)(Me), -N(Et)2, -N(CH3)(Et), -NHC()Me, or a combination ²thereof). ²10329I In some embodiments, each alkyl, cycloalkyl, heterocyclyl, atyl, ²heterowyl, ²cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl of R' is ²unsubstituted. In ²some embodiments, each alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, ²cycloalkylalkyl, ²heterocyclylalkyl, arylalk-y1 and heteroarylalkyl of R1 is independently ²substituted with 1²instance of-Me, -Et, cyclopropyl, ²oxetan-3-yl, --OH, =0, -F, ---0Me, ---CH2CH2F,²CH2CHF2, -CH2CH2CF3, -C(=0)Me, -N(Me)2, -CH2N(CH3)2, -CH2N(CIT3)CI-12C1-13, - ²N('Pr)(Et), -N('Pr)(Me), -N(Et)2, -N(CH3)(Et), -NHC.(=-0)Me, or a combination ²thereof). or ²a combination thereof. In some embodiments, each alkyl, cycloakl, ²heterocyclyl, atyl, ²heteroaryl, cycloalkylalkyl, heterocyclylalkyl, atylalkyl and heteroarylalkyl ²of Rw is ²independently substituted with 2 instances of-Me, -Et, -11?r, cyclopropyl, ²oxetan-3-yl, -OH, ²40, -F, -0Me, -CH2CH2F, -CH2CHP2, -CH2CH2CF3, -C(=0)Me, -N(Me)2, - ²CH2N(CH3)2, ---CH2N(CH3)CH2CH3, ---N('Pr)(Et), ---N('Pr)(Me), --N(Et)2, ---²N(CH3)(Et), ---²NTIC(=0)Me, or a combination thereof).. In some embodiments, each alkyl, ²cycloalkyl, ²heterocyclyl, aryl, heteroaryl, cycloalk-ylalkyl, heterocyclylalkyl, arylalkyl ²and ²heteroarylalkyl of Ri is independently substituted with 3 instances of-Me, -²Et, -'Pr,²cyclopropyl, oxetan-3-yl, -OFT, =0, -F, -0Me, -012CHP2, -CIT2C1-12CF3, - ²C(=0)Me, -N(Me)2, -CH2N(CH3)2, -CH2N(CH3)CH2CH3, -N('Pr)(Et), -N('Pr)(Me), - ²N(Et)2, -N(CH3)(Et), -NHC()Me, or a combination thereof). In some embodiments, ²each ²alkyl, cycloalkyl, heterocyclyl, aryl, heteroatyl, cycloalkylalkyl, ²heterocyclylalkyl, atylallc3;r1 ²and heteroarylalkyl of 111 is independently substituted with 4 instances of-²Me, -Et, -Pr, ²cyclopropyl, oxetan-3-yl, -OH, =0, -P, -0Me, -CH2CH2F, -CH2CHF2, -CH2CH2CF3, - ²²C(=0)Me, -N(Me)2, -CH2N(CH3)2, -CH2N(CH3)CH2CH3, -N('Pr)(Et), -N(Pr)(Me), - ²N(Et)2, -N(CI-1.3)(Et), -NTIC(:=0)Me, or a combination thereof).²107²<DP=109>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²
[0330] In some embodiments, each alkyl, cycloalkyl, heterocyclyl, aryl, ²heterouyl, ²cycloalkylakl, heterocyclylalkyl, arylalkyl and heteroarylalkyl of RI' is ²independently²substituted with 5 instances of-Me, --Et; --iPr, cyclopropyl, oxetan-3-yl, --²OH, --F,²OMe, --CII2C112F, -CT-I2CH2CF3, -N(Me)2, -CI-²12N(CT-13)2, -²CH2N(CH3)CH2CH3, -N(Pr)(Et), -N('Pr)(Me), -N(Et)2, -N(CH3)(Et), -NHC(=0)Me, or ²a ²combination thereof).²103311 In some embodiments, each IV is independently selected from ---D, =0, ²halo (e.g.,²F, Cl, Br), -CN, -C1-C6 alkyl (e.g., -Me, -Et, -Pr, -'Pr, -sec-Bu, ²CH2(CII3)(Pr)), - ²Ci-Co heteroalkyl (e.g, -CH(CH3)(NMe2), -CH2CH2N(Me)(oxetan-3-yI)), - ²CH2CH(CH3)(NMe2), --CH2OH, ---CH(OH)(CH3), ---C(OH)(CH3)2, ---CH2NH2),²haloalkyl (e.g., -CHF2, -CH2CF3, -C3-C9 cycloalkyl (e.g., cyclopropyl, ²cyclobutyl, ²cyclopentyl, cyclohexyl), 3-10 membered heterocyclyl (e.g. ,tetrahydrofuranyl, ²²tetrahydropyranyl, oxetanyl, morpholinyl, pyrolidinyl, piperidinyl, piperidin-²2-onyl, ²piperazinyl, piperazin-2-only, azetidinyl, decahydro-1,6-naphthyridinyl, 2-²azaspiro[3.311heptanyl, 5-oxa-2,8-diazzspiro[3.51nonanyl, 8-²azabicyclo[3.2.1loctanyl, 2-²azabicyclo[2.2.2]octanyl, 3-azabicyclo[3.2.0]heptanyl, 3-²azabicyclo[3.1.1]heptanyl, 3-²azabicyclo[3.1.0]hexanyl, 2-azabicyclo[2.1.1]hexanyl, 1-²azabicyclo[2.2.1]heptanyl, 3-²azabicyclo[3.2.0jheptanyl, 2,9-diazaspiro[5.5jundeca.nyl, ²bicyclo[1.1.1jpentanyl, ²octahydrocyclopenta[c]pynrolyl, decahydro-1,6-naphthyridinyl, octahydro-1H-²pyrrolo[3,4-²c]pyridinyl, decahydro-2,7-naphthyridinyl, 2,9-diazaspiro[5.5]undecanyl), 5-10 ²membered ²heteroaryl (e.g., pyridinyl, imidazo[1,2-alpyridiny1, imidazolyl, pyrazolyl, ²thiazolyl, ²thiophenyl), cycloalkylalkyl (e.g. -CH2-cyclopropyl), heterocyclylalkyl (e.g., ²-012-²morpholinyl, -(CH2)2-pyrolidinyl -(CH2)2-pyrolidinyl -CH2-pyrazolyl, ²-CH2-morpholinyl, --(CH2)2-morpholinyl), heterocyclylalkoxy (e.g., -0-²(CII2)2-pyrolidinyl, -0-CH2-oxetanyl, -0-CH2-tetrahydrofuranyl, ²CH2-tetrahydropyranyl), heterowylalkyl (e.g., -CH2-triazolyl, -CH2-imidazolyl, ²-CH2-²pyrazolyl), -0Rbio (e.g, -OH, -OMe, OEt, -0-tetrahydrofuranyl, -0-²tetrahydropyran-4-yl, - ²0CF3, -OCHF2),²tuo)2,²g., --NH2, -NHRbw, -NFIMe, -1=IMe2, -NHCH2CF3, -NH-²oxetan-3-yl, -N11-(N-Me-2-oxo-pyrolidin-3-y1), -NRbmC(...0)Rbi (e.g., -²NFIC(..0)Me), - ²C(=0)N(R1'10)2, (e.g., -C(=0)NH2, C(0)NHMe), -0C(=0)Rbm (e.g., -0C(=0)Me), - ²S(=0)Rbm (e.g., -S02Me), -NRbll'S(=0)2Rbl (e.g , NHSO2Me) and -S(=0)2N(Rb10)2 ²(e.g., ²S02NI-12, SO2N1-IMe), wherein each alkyl, cycloalkyl, heterocyclyl, aryl, ²heteromyl, ²cycloalkylalkyl, heterocyclylalkyl, arylalk-yl and heteroarylalk-yl is ²optionally' substituted²108²<DP=110>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²(e.g., with 0, 1, 2, 3, 4, or 5 instances of -Me, -Et, -Tr, cyclopropyl, ²oxetan-3-yl, -OH, 4),²-F, -0Me, -CH2CH2F, -CH2CHF2, -CH2CH2CF3, -C(=0)Me, -N(Me)2, -CH2N(CH3)2, - ²CH2N(CH3)CH2CH3, -NePr)(Et), --N('Pr)(Me), --N(E02, -N(CH3)(Et), -NHC(=0)Me, ²or a ²combination thereof), and wherein:²each el is independently selected from H, -C1-C6 alkyl, (e.g., -Me, -Et, -Pr, ²-Tr, -sec-Bu,²-Su), -Cl-C6 haloalkyl (e.g , -CF3, -CHF2, -CH2CF3), -CI-C6heteroalkyl ²substituted with ²0 or 1 instances of =0 (e.g , -CH2CH2NMe2, -CH2C(=0)NMe2, --CH(CH3)CH2NMe2, - ²CH(CH3)C(=0)NMe2), C3-C9 cycloalkyl, and 3-10 member heterocyclyl (e.g ²tetrahydrofuran-3-yl, tetrahydropyran-4-yl, oxetan-3-yl, N-Me-2-oxo-pyrolidin-²3-yl, ²piperidin-4-y1) substituted with 0 or 1 instances of =0, --Me or a combination ²thereof ²103321 As generally defined herein, each Ilbi is independently H; -C1-C6 ²alkyl; -C1-C6 ²haloalkyl; -CI-C6heteroalkyl substituted with 0 or 1 instance of =0 (e.g., ²unsubsfituted or ²substituted with one instance of 4)); C3-C9 cycloalky, 1; or 3-10 member ²heterocyclyl ²substituted with 0 or 1 instances of =0, -Me or a combination thereof (e.g., ²unsubstituted, ²substituted with one instance of =0, substituted with one instance of -Me or ²substituted with ²one instance of =0 and one instance of -Me). In certain embodiments of RI', ²each el' is²independently selected from H, -Me, -Et, -Pr, -Tr, -sec-Bu, -CF3, -CHF 2, -²CH2CF3, ²--CH2CII2NMe2, -CH2C(=0)NMe2, -CH(CH3)0I2NMe2, -CIACTI3)C(:=0)NMe2), ²tetrahydrofuran-3-yl, tetrahydropyran-4-yl, oxetan-4-y1 and N-Me-2-oxo-²pyrolidin-3-yl.²In some embodiments, W. is independently selected from -OH, -F, -Cl, -Br, -²²CN, --Me, -Et, --Pr, -Tr, --sec-Bu, --0Me, --0Et, -CHF2, -CH2CF3, --CF3, -²0CF3, ²OCTIF'2, -CI2011, -CII(OH)(CH3), -Cl20Me, -C(01.1)(CH3)2, -Cl12NIT2, - ²CH(CH3)(NMe2), -CH2CH(CH3)(NMe2), -CH2(CH3)(rPr), -NH2, -NI-IMe, -NHCH2CF3, - ²NMe2, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, thiazol-2-yl, thiazol-²5-yl, thiophen-²2-y1õ tetrahydrofuran-3-yl, tetrahydropyran-4-yl, oxetan-3-yl, morpholin-2-yl, ²-CH2-²-(CH2)2-morpholin-4-yl, imidazol-2-yl, 1H-pyrazol-5-yl, 1H-imidazol-4-yl, ²imidazo[1,2-a]pyridin-7-yl, pyrolidin-1-yl, pyrolidin-3-yl, piperidin-4-yl, ²piperidin-3-yl, ²piperidin-2-one-4-yl, piperazin-4-yl, piperazin-4-yl, piperazin-2-on-5-y1 ²pyridine-4-yl, ²pyridine-3-yl, pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, 1H-²pyrazol-5-yl, ²azeti din-3-yl, -(CH2)2-py roll din-1-y] -(CH2)2-pyrolidin-2-yl-CH2-imidazol-1-²yl, -CH2-²pyrazol-1-yl, -CH2-1,2,4-triazol-1-yl, -CH2-cyclopropyl, -0(CH2)2NMe2, -0-²tetrahydrofuran-3-yl, -0-tetrahydropyran-4-yl, -0-(N-Me-2-oxo-pyrolidin-3-y1), ²-0-²(CH2)2-pyrolidin-2-y1 -0-CH2-piperidin-4-y1 -0-CH2-oxetan-3-yl-NCH3-piperidin-²4-yl, -²109²<DP=111>²CA 03176912 2022-09-23²WO 2022 / 026892 PCT / US2021 / 044004²NH-oxetan-3-yl, -NFI-(N-Me-2-oxo-pyrolidin-3-y1), decahydro-1,6-naphthyridin-6-²yl, 2-²azaspiro[3.3]heptan-6-yl, 5-oxa-2,8-diazaspiro[3.5]nonan-8-yl, 8-²azabicyclo[3.2.1]octan-3-²yl, 2-azabicyclo[2.2.2loctan-4-yl, 3-azabicyclo[3.2.0Theptan-6-v!, 3-²azabicyclo[3.1.1]heptan-²l-yl, 3-azabicyclo[3.1.0]hexan-6-yl, 1-azabicyclo[2.2.1.1heptan-4-yl, 3-²azabicyclo[3.2.0]heptan-6-yl, 2-azabicyclo[2.1.1]hexan-4-yl, 2,9-²diazaspiro[5.5]undecane-9-²yl, bicyclo[1.1.1]pentan-2-yl, octahydrocyclopenta[c]pyrrol-5-yl, decahydro-²1,6-²naphthyridin-6-yl, octahydro-1H-pyrrolo[3,4-cipyridine-5-yl, decahydro-2,7-²naphthyridin-2-²yl, 2,9-diazaspiro[5.5jundeca.n-2-yl, -NlIC(=0)Me, -NtICTI2C(=0)NMe2, - ²NHCH(CH3)C(=0)NMe2, -C(=0)NH2, C(=0)NHMe, -0C()Me, -S02Me, -NHSO2Me,-²SO2NH2 and ---SO2NHMe, wherein each ---0Me, ---0Et, --Me, -Et, --Pr, ²cyclopropyl, ²cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuran-3-yl, oxetan-3-yl, ²pyrolidin-l-yl, ²pyrolidin-3-yl, piperidin-4-yl, piperidin-3-yl, piperidin-2-one-4-y1 piperazin-²4-yl, pyrazol-1-²yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, thiazol-2-yl, thiophen-2-yl, -²CH2-cyclopropyl, -²CH2-morpholin-4-yl, ---(CH2)2-morpholin-4-yl, --(CH2)2-pyrolidin-l-yl, ²CI-12- I ,2,4-tri azol-1-y I -CH2-imidazol- I -yl,²azetidin-3-yl, 2-azaspiro[3.3]heptan-6-yl, 2-m.ethy1-5-oxa-2,8-²diazaspiro[3.5]nonan-8-yl, 8-azabicyclo[3.2.1]octan-3-yl, and decakõ,dro-1,6-²naphthyridin-6-²yl, wherein each RI can be independently substituted with 0, I., 2, 3, 4, or ²5 instances of -Me, ²-Et, -Tr, cyclopropyl, oxetan-3-yl, -OH, =0, -F, -0Me, -CH2CH2F, -CH2CHF2, - ²CH2CH2CF3, -C(0)Me, -N(Me)2, -CH2N(CH3)2, -CH2N(CH3)CH2CH3, -N('Pr)(Et), - ²N('Pr)(Me), ---N(Et)2, --N(CH3)(Et), --NHC(=0)Me, or a combination thereof²103331 In some embodiments. RI is FL In some embodiments RI is -D.²103341 In certain embodiments, RI is halo (e.g, fluor , chloro, bromo, iodo). ²In further ²embodiments, RI is -Cl. In some embodiments, le' is -F. In some embodiments, ²RI is - ²Br. In some embodiments, RI is -I.²103351 In some embodiments, RI is -CN.²103361 in certain embodiments, RI is -0-C6 alkyl. In further embodiments, RI ²is -Me. ²In some embodiments, RI is --Et. In some embodiments RI is --Pr or ---'Pr. ²In some ²embodiments RI is -113u or -sec-Bu. In some embodiments RI is -CI-²12(CH.3)('Pr).²103371 In some embodiments. RI is -CI-C6 heteroalkyl. In further embodiments, ²RI is ²methoxõ,methyl (-CH2OCH3). In some embodiments, RI is hydroxymethyl (-CH2OH). ²In ²some embodiments. RI is -CHOI-Dab, C(OH)(CH3)2. In some embodiments. RI is ²aminomethyl (e.g.,-CH2NH2, -CH2NHCH3,-CH2NHCH2CH3 -CH2N(CH3)2. -²110²<DP=112>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²CH(CI-T3)(NMe2), ¨CI12CH2N(Me)(oxetan-3-y1), ¨CH2CH(CH3)(NMe2). In some ²embodiments, the heteroalkyl is further substituted with =0 (e.g , ²¨CH2NHC(=0)CH3). In ²some embodiments. RI is ¨CI¨C6 haloalkyl. In further embodiments, It' is ²trifluoromethyl ²(¨CF3). In other embodiments. RI is difluoromethyl (¨CITF2). In some ²embodiments RI is ²trifluoroethyl (¨CH2CF3)²In some embodiments, RI is ¨C3¨C9 carbocyclyl (e.g, cyclopropyl, cyclobutyl, ²cyclopentyl, ²cyclohexy1). In some embodiments, ItI is cyclopropyi. In some embodiments RI ²is ²cyclobutyl. In some embodiments, RI is cyclopentyl. In some embodiments, RI ²is ²cyclohexyl. In some embodiments, the carbocycly1 is substituted with ¨OH (e.g, ²²hydroxycyclobutyl)²103381 In some embodiments, RI is 3-10 membered heterocycly1 (e.g., oxetanyl, ²²tetrallydropyranyl, tetrahydrofuranyl, azetidinyl, pyrrolidinyl, piperidinyl, ²piperazinyl, ²morpholinyl, azepanyl, piperidin-2-onyl, piperazin-2-onyl, decakõ,dro-1,6-²naphthyridinyl, 2-²azaspiro[3.3Theptany1, 5-oxa-2,8-diazaspiro[3.51nonanyl, 8-²azabicyclo[3.2.11Ioctany1, 2-²azabicyc1o[2.2.2loctanyl, 3-azabicyclo[3.2.01heptany1, 3-²azabicyclo[3.1.11heptany1, 3-²azabicyclo[3.1.0]hexanyl, 2-azabicyclo[2.1.1]hexanyl, 1-²azabicyclo[2.2.1]heptanyl, 3-²azabicyclo[3.2.0]heptanyl, 2,9-diazaspiro[5.5]undecanyl, ²bicyclo[1.1.1]pentanyl, ²octahydrocyclopenta[C]pyrrolyl, decahydro-1,6-naphthyridinyl, octahydro-1I-T-²pyrro1o[3,4-²c]pyridinyl, decahydro-2,7-naphthyridinyl, 2,9-diazaspiro[5.5]undecany1).²In some embodiments, RI is oxetanyl. In some embodiments, R.I is ²tetrahydropyranyl. In ²some embodiments, RI is tetrahydrofuranyl. In some embodiments, Rw is ²azetidinyl. In ²some embodiments, R' is pyrrolidinyl. In some embodiments, R' is ²piperidinyl. In some ²embodiments, RI is piperazinyl. In some embodiments, RI is morpholinyl. In ²some ²embodiments, RI is azepanyl. In some embodiments, R.I is piperidinonyl.²103391 In some embodiments, RI is piperidin-2-onyl. In some embodiments, RI ²is ²piperazin-2-only. In some embodiments, RI is decahydro-1,6-naphthyridinyl. In ²some ²embodiments, RI is 2-azaspiro[3.3]heptanyl. In some embodiments, RI is 5-oxa-²2,8-²diazaspiro[3.5]nonanyl. In some embodiments, RI is 8-²azabicyclo[3.2.1loctanyl. In some ²embodiments, RI is 2-azabicyclo[2.2.2loctanyl. In some embodiments, RI is 3-²azabicyclo[3.2.0]heptanyl. In some embodiments, Rw is 3-²azabicyclo[3.1.1]heptanyl. In ²some embodiments, Itw is 3-azabicyclo[3.1.0]hexanyl. In some embodiments, RI ²is 2-²azabicyclo[2.1.1jhexany1. In some embodiments, RI is 1-²azabicyclo[2.2.1Jheptany1. In some ²embodiments, RI is 3-azabicyclo[3.2.0]heptanyl. In some embodiments, RI is ²2,9-²111²<DP=113>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²diazaspiro[5.51undecany1. In some embodiments, R' is bicyclo[1.1.11pentanyl. ²In some ²embodiments, RI is octahydrocyclopenta[c]pyrrolyl. In some embodiments, IV ²is ²decahydro-1,6-naphthyridinyl. In some embodiments, RI is octahydro-1H-²pyrrolo[3,4-²clpyridinyl. In some embodiments, RI is decahydro-2,7-naphthyridinyl. In some ²²embodiments, RI is 2,9-diazaspiro[5.5]undecanyl) In some embodiments, the ²heterocyclyl is ²substituted with 0, 1, 2 or 3 instances of -D, =0, -Me, -C()Me or -C()NHCH3. ²103401 In some embodiments. RI is a 5-10 member heteroaryl (e.g., a 5-6 ²member ²monocyclic heteroaryl or an 8-10 member bicyclic heteroaryl containing 1-3 ²heteroatoms ²independently selected from N, 0 and S).²10341j In some embodiments; IV is a 5-6 member monocyclic heteroaryl (e.g , a ²5-member ²monocyclic heteroaryl containing 1-3 heteroatoms independently selected from ²0, N and S. a ²6-member monocyclic heteroaryl containing 1-3 N heteroatoms).²In some embodiments, RI is a 5-member monocyclic heteroaryl (e.g, pyrazolyl, ²pyrolyl, ²thiophenyl, furyl; thiazolyl, isothiazolyl, oxazolyl; isoxazolyl, imidazolyl, ²triazolyl, ²thiadiazolyl, oxadiazolyl).²103421 In some embodiments, RH' is thiophenyl (e.g, thiophen-2-yl, thiophen-3-²y1). In ²some embodiments, RI is pyrazolyl (e.g pyrazol-1-yl, pyrazol-3-yl, pyrazol-5-²y1). In some ²embodiments, RI is thiazolyl (e.g., thiazol-2-yl, thiazol-4-yl, thiazol-5-²y1).²In some embodiments, RI is a 6-member monocyclic heteroaryl (e.g, pyridyl, ²pyrimidinyl, ²triazinyl, pyrazinyl, pyridazinyl).²103431 In some embodiments. RI is pyridinyl (e.g, pyridin-2-y1; pyridin-3-yl, ²pyridin-4-²yl). In some embodiments, RI is pyrimidinyl (e.g, pyrimidin-211, pyrimidin-4-²yl, ²pyrimidin-5-y1). In some embodiments, the heteroaryl is substituted with 0, 1 ²or 2 instances ²of -Me.²In some embodiments, RI is monocyclic heterocyclyl. In some embodiments, RI ²is ²monocyclic heteroaryl. In some embodiments, RI is tetrahydrofuran-3-yl. In ²some ²embodiments, RI is tetrahydropyran-4-yl. In some embodiments, RI is oxetan-3-²yl. In some ²embodiments, RI is morpholin-2-yl. In some embodiments, RI is -imidazol-2-²yl. In some ²embodiments, RI is 111-pyrazol-5-yl. In some embodiments, RI is 11-I-²imidazol-4-yl. In ²some embodiments, RI is imidazo[1,2-alpyridin-7-y1. In some embodiments, RI ²is pyrolidin-1-yl. In some embodiments, IV is pyrolidin-3-yl. In some ²embodiments, IV ²is piperidin-4-yl. In some embodiments, RI is piperidin-3-yl. In some ²embodiments, RI is ²piperidin-2-one-4-yl. In some embodiments, RI is piperazin-4-yl. In some ²embodiments, RI ²112²<DP=114>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²is piperazin-4-yl. In some embodiments, RI is piperazin-2-on-5-yl. In some ²embodiments, ²RI is pyridine-4-yl. In some embodiments, RI is pyridine-3-yl. In some ²embodiments, Rm ²is pyrazol-I-yl. In some embodiments, RI is pyrazol-3-yl. In some ²embodiments, RI is ²pyrazol-4-yl. In some embodiments, RI is pyrazol-5-yl. In some embodiments, ²RI is 1H-²pyrazol-5-yl. In some embodiments, RI is azetidin-3-yl.²In some embodiments, RI is heterocyclylalkoxy. In some embodiments, RI is - ²0(CH2)2NMe2. In some embodiments, RI is -0-tetrahydrofuran-3-yl. In some ²embodiments, ²RI is -0-tetrahydropyran-4-yl. In some embodiments, RI is -04N-Me-2-oxo-²pyrolidin-3-²34). In some embodiments, RI is -0-(CH2)2-pyrolidin-2-yl. In some ²embodiments, RI is -0-²CH2-piperidin-4-yl. In some embodiments. RI is -0-CH2-oxetan-3-y1.²103441 In some embodiments, RI is monocyclic heterocyclylalkyl (e.g., ²oxetanylmethyl, ²aziridinylmethyl, tetrahydrofuranylmethyl, pyrolidinylmethyl, ²tetrahydropyranylmethyl, ²piperidinylmethyl, piperazinylmethyl, morpholinylmethyl, azepanylmethyl). In ²some ²embodiments, RI is -CH2-morpholin-4-yl. In some embodiments, RI is -(CH2)2-²morpholin-²4-yl. In some embodiments, RI is -(CF12)2-pyrolidin-1-yl. In some ²embodiments, Rm is - ²(CH2)2-pyrolidin-2-yl.²103451 In some embodiments, RI is bicyclic 3-10 membered heterocõ,clyl. In ²some ²embodiments, RI is decahydro-1,6-naphthyridin-6-yl. In some embodiments, RI ²is 2-²azaspiro[3.3]heptan-6-yl. In some embodiments, RI is 5-oxa-2,8-²diazaspiro[3.5]nonan-8-yl. ²In some embodiments, RI is 8-azabicyclo[3.2.1]octan-3-yl. In some ²embodiments. RI is 2-²azabicyclo[2.2.2ioctan-4-yl. In some embodiments, RI is 3-²azabicyclo[3.2.01heptan-6-yl. In ²some embodiments, Rm is 3-azabicyclo[3.1.1Theptan-1-yl. In some embodiments, ²RI is 3-²azabicyclo[3.1.0]hexan-6-yl. In some embodiments, RI is 1-²azabicyclo[2.2.1]heptan-4-yl. In ²some embodiments, Itm is 3-azabicyclo[3.2.0]heptan-6-yl. In some embodiments, ²RI is 2-²azabicyclo[2.1.1]hexan-4-yl. In some embodiments, RI is 2,9-²diazaspiro[5.5Jundecane-9-yl. ²In some embodiments, RI is bicyclo[1.1.1]pentan-2-yl. In some embodiments, RI ² ²is octahydrocyclopenta[c]pyrrol-5-yl. In some embodiments, RI is decahydro-²1,6-²naphthyridin-6-yl. In some embodiments, RI is octahydro-1H-pyrrolo13,4-²elpyridine-5-y1. In ²some embodiments, RI is decahydro-2,7-naphthyridin-2-yl, 2,9-²diazaspiro[5.5Jundecan-211. ²In some embodiments Itm is cycloalkylalkyl (e.g, cyclopropylmethyl, ²cyclobutylmethyl, ²cyclopentylmethyl, cyclohexylmethyl, cycloheptylmethyl). In some embodiments. ²Rm is ²cyclopropylmethyl.²103461 In some embodiments, RI is arylalkyl. In some embodiments, RI is ²benzyl.²113²<DP=115>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²In some embodiments, le is heteroarylalkyl (e.g., -CH2-imidazole, -CH2-²pyrazole, -CH2-²pyridinyl). In some embodiments, RI is pyridinylmethyl (e.g , pyridiny1-4-²methyl). In some ²embodiments, RI is -CH2-1,2,4-triazo1-1-yl. In some embodiments, RI is -CH2-²imidazol-1-²yl. In some embodiments, RI is -CH2-pyrazol-1-yl.²103471 in some embodiments, RI is -0Rbl0 (e.g , hydroxy (-OH), methoxy, ²difluoromethoxy (-0CHF2), trifluoromethoxy (-0CF3), ethoxy, propoxy, ²isopropoxy, ²cyclopropyloxy, cyclobutyloxy). In some embodiments, RI is hydroxy. In some ²embodiments, le is methoxy. In some embodiments, IV is ethoxy. In some ²embodiments. ²IV is propoxy. In some embodiments, RI is isopropoxy. In some embodiments RI ² is ²difluoromethoxy. (-0CHF2). In some embodiments, RI is trifluoromethoxy (-²0CF3). ²103481 In some embodiments, Rio is _N(Rbio)2 (e.g., _NH2, _NH-Kbio,²N(CH.3)Rb1 ). In ²some embodiments. IV is -NH,. In some embodiments, RI is -NHRbI (e.g , -²NHMe, - ²NHEt, -NHPr, -NHCH2CF3, -NHIPr, -NHcyclopropyl, -NHcyclobuty1). In some ²embodiments, RI is NHCH2CF3. In some embodiments, RI is --N(CH3)Rbl (e.g., -²-NMe2, - ²N(CH3)Et, -N(CH3)Pr, -N(CH3)Pr, -N(CH3)cyclopropyl, -N(CH3)cyclobuty1).²In some embodiments, le is -C(=0)R,1 or -C(=0)0Rbm. In some embodiments, RI ²is - ²C(=0)Rw wherein Rbl is as described herein. In some embodiments, RI is -²C(=0)alkyl. ²In some embodiments, RI is -C(0)CH3, -C(0)cyclopropyl, -C(0)cyclobutyl, -²C(OYBu, - ²C(0) / Pr, -C(0)Pr, -C(OYBu, or -C(0)0Me. In some embodiments, RI is acetyl (-²C()Me). In some embodiments, le is -C(=0)0Rbla. In some embodiments. IV is - ²COOH. In some embodiments, le is COOMe.²103491 In some embodiments, le is -NRbwC(=0)Rm. In certain embodiments, RI is ²- ²NHC(=0)Rbi (e.g., -N'HC(=0)Me, -NHC(=0)Et, -NHC(=0)Pr, -NHC(=0)13r, - ²NHC(=0)Bu, -NHC(=OYBu, -NHC(=0)Cyclopropy1, -NHC(=0)Cyclobuty1). In some ²embodiments, RI is -NHC(...0)Me. In some embodiments, RI is -N(CH3)C(=0)Rbl ²(e.g., ²N(CH3)C()Me, N(CH3)C(20)Et, N(CH3)C(=0)Pr, N(CH3)C(=0)113r, N(CH3)C(=0)Bu, ²N(CH3)C()tBu, N(CH3)C(=0)Qõ,clopropyl, N(CH3)C(=0)Qõ,clobuty1).²103501 In some embodiments. RI is -NRbI C(=0)0Rb1 . In certain embodiments. ²RI is - ²NTIC(=0)0Rbl (e.g., NHC(..:0)0Me, NHC(...0)0Et, NTIC(=0)0Pr, NIIC(=0)0iPr, ²NHC(=0)0Bu, NHC(0)093u, NHC(=0)0Cyclopropyl, NHC(=0)0Cyclobuty1). In some ²embodiments, RI is -N(CH3)C()ORb' (e.g., N(CH3)C(=0)0Me, N(CH3)C(=0)0Et, ²N(CH3)C(...0)0Pr, N(CI-1.3)C(...0)0iPr, N(CH3)C(...0)0Bu, N(CI-13)C(...0)0`Bu, ²²N(CH3)C(=3)0Cyclopropyl, N(CH3)C(=0)0Cyclobuty1).²114²<DP=116>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²[03511 In some embodiments, 121 is -C(...0)N(Rb1 )2 (e.g., -C(....0)NH2, -²C(...0)NITRbw, - ²C(=0)N(CH3)R1"m). In some embodiments, 111 is -C(43)NH2. In certain ²embodiments, 111 ²is -C(=0)NHR1'1 (e.g., -C(=0)NHMe, -C(=0)NHEt, -C(=0)NHPr, -C(-0)NIPPr, -²C(:=0)NTIBu, -C(...0)NHCyclopropyl, -C(...0)NITCyclobuty1). In some ²embodiments, R1 is -C(=D)NHMe. In certain embodiments, le is -C(=0)N(CH3)Rbl ²²(e.g., -C(=0)NMe2, -C(=0)N(CH3)Et, -C(=0)N(CH3)Pr, -C(D)N(CH3)1Pr, - ²C(=0)N(CH3)Bu, --C(=0)N(CH3YBu, -C(=0)N(CH3)Cyclopropyl, - ²C(...0)N(CH3)Cyclobuty1).²103521 In some embodiments, 10 is -0C(=0)N(Rb1 )2. In certain embodiments, ²R.1 is - ²OC(=0)NHRbl (e.g., -0C(=0)NHMe, -0C(=0)NHEt, -0C(=0)NHPr, -0C(=0)NH'Pr, - ²0C(...0)N1Bu, -0C(...0)NITBu, -0C(...0)NHCyc1opropyl, -0C(...0)NITCyclobuty1). ²In ²certain embodiments, R1 is -0C(=0)N(CH3)Rbl (e.g., -0C(=0)NMe2, -²0C(=0)N(CH3)Et, ²-0C(=0)N(CH3)Pr, -0C(=0)N(CH3)`Pr, -0C(=0)N(CH3)Bu, -0C(I)N(CH3)'13u, - ²0C(=0)N(CH3)Cyc1opropyl, -0C(=0)N(CH3)Cyclobuty1).²103531 In some embodiments, 121 is -0C(...0)Rbw. (e.g., -0C(...0)Me, -²0C(=0)Et, - ²OC(=0)Pr, -0C(=0)Pr, -OC(0)Bu, -0C(D)Bu, -0C(=0)Cyclopropyl, - ²0C(=0)Cyclobuty1). In some embodiments, R.1 is -0C(=0)Me.²103541 In some embodiments, R1 is -S(...0)Rb1 . In certain embodiments, R1 ²is - ²S(=0)alkyl (e.g., -S(D)Me, -S(=0)Et, -S(=0)Pr, -S(0)'13r). In some embodiments ²R1 is - ²S(=0)Me. In certain embodiments, R1 is -S(=0)cycloalkyl (e.g, -²S()cyclopropyl, - ²S(=0)cyclobutyl, -S(=0)cyclopentyl, -S(=0)cyclohexyl).²103551 In some embodiments, 121 is -S(...0)2Rbw. In certain embodiments. R1 ²is - ²S(=0)2alkyl (e.g., -S(=0)2Me, -S(=0)2Et, -S(=0)2Pr, -S(=0)2'Pr). In some ²embodiments 111 ²is -S(=0)2Me. In certain embodiments, Rm is -S(D)2cycloalkyl (e.g , -²S(D)2cyclopropyl, - ²S(...0)2cyclobutyl, -S(...0)2cyc1opentyl, -S(...0)2cyc1ohexy1). In some ²embodiments, R1 is ²S(=0)2aryl (e.g., S(=0)2pheny1).²103561 in some embodiments, R1 is -SRb1 . In certain embodiments, R.1 is -²Salkyl (e.g, - ²SMe, -SEt, -SPr, -S1Pr). In certain embodiments, R1 is -Scycloalkyl (e.g., -²Scyclopropyl, - ²Scyclobutyl, -Scyclopentyl, -Scyclohexyl). In certain embodiments, R1 is -²Saryl (e.g., ²Spheny1).²103571 In some embodiments, R.1 is _s(=0)(NRbto)Rbio. In certain embodiments, ²R1 is - ²S(...0)(...NFORbl (e.g., -S(...0)(=NH)Me, -S(...0)(=NH)Et, -S(=0)(...NIT)Pr, -²S(:::0)04\11013r, ²-S(=0)(=NH)Bu, -S(=0)(=NH)%u, -S(43)(=NH)Cyclopropyl, -S(=0)(=NH)Cyclobuty1). ²In²115²<DP=117>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²some embodiments. R.' is -S(=0)(=NCH3)Rbi (e.g., -S(=0)(=NCH3)Me, - ²S(=0)(=NCH3)Et, -S(=0)(=NCH3)Pr, -S(=0)(=NCH3)93r, -S(=0)(=NCH3)Bu, - ²S(=0)(=NCH3)93u, -S(=0)(=NCH3)Cyclopropyl, -S(=0)(=NCH3)Cyclobuty1).²103581 In some embodiments, IR is -NRbIN(=0)2Rb1 . In certain embodiments, RI ² is - ²N'HS(=0)2alkyl (e.g, -NHS(=0)2Me, -NHS(=0)2Et, -NHS(:))2Pr, -NHS(=0)293r). In ²certain embodiments, RI is -NHS(=0)2cyc10a1ky1 (e.g., -NHS()2cyclopropyl, - ²NHS(=0)2cyclobutyl, -NHS(=0)2cyclopentyl, --NHS(=0)2c,rclohexyl). In certain ²embodiments, RI is -N(CH3)S(=0)2alkyl (e.g., -N(CH3)S(=0)2Me, -N(CI-²T3)S(=0)2Et, - ²N(CH3)S()2Pr, -N(CH3)S(3)21Pr). In certain embodiments, Rw is - ²N(CH3)S(0)2c,rc10a1ky1 (e.g, -N(CH3)S(=0)2cyclopropyl, -²N(CH3)S(=0)2cyclobutyl, ²N(CH.3)S(=0)2cyc10pen1y1, -N(CH3)S(=0)2cyclohexyl).²103591 In some embodiments, RI is -S(=0)2N(Rb10)2. (e.g., -S(=0)2NH2, -²S(=0)2NHRbio, ²S(=0)2N(CH3)Rbm). In some embodiments, RI is -S(=0)2NH2. In some embodiments, ²RI ²is -S(=0)2NHRbi (e.g, -S(=0)2NHMe, -S(=0)2NHEt, -S(=0)2NHPr, -S(=0)2N1-193r, -² ²S(=0)2NHcyclopropyl, -S(:=0)2Nlicyclobuty1). In some embodiments, Rw is - ²S(=0)2N(CH3)Rbm (e.g., -S(=0)2NMe2, -S(=0)2N(CH3)Et, -S(=0)2N(CH3)Pr, - ²S(=0)2N(CH3)1Pr, -S(=0)2N(CH3)cyclopropõ,I, -S(=0)2N(CH3)cyclobuty1).²103601 As generally defined herein, each Rai, Ra2, Ra3, Ra4, Rao, Re and Ras ²is²independently selected from H, Ci-Co alkyl, -C1-Co heteroakl, C3-C9 ²cycloalkyl, 3-7 ²membered heterocydyl, cycloalk-ylalkyl, heterocyclylalkyl, aryl, 5-6 membered ²heteroaryl, ²arylallcyl and heteroarylalkyl wherein each alkyl, cycloalkyl, heterocyclyl, ²cycloalkylalkyl, ²heterocyclylalkyl, aryl, heteromyl, arylalkyl and heteroarylalkyl is ²optionally substituted at ²any available position (e.g , substituted with 0, I, 2 or 3 instances of R9, ²wherein each R9 is ²independently selected from =0, halo, -CN, -CI-Co alkyl, -CI-Co heteroalkyl, -²C ²haloalkyl, -C3-C9 cycloalkyl, 3-10 membered heterocyclyl, Co-Clo aryl, 5-10 ²membered ²heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, -²ORb, -N(Rb)2, - ²C()Rb, -C(2)0Rb, -NRbC(=0)Rb, -NRbC(=0)0Rb, -C(=0)N(Rb)2, -0C(=0)N(Rb)2,-²S(=0)Rb, -S(=0)2Rb, -SRb, -S(=0)(=NRb)Rb, -NRbS(=0)2Rb and -S(0)2N(Rb)2, ²wherein ²each Rb is independently selected from Fl, -C1-C6 alkyl (e.g., -Me, -Et, -Pr, -²'Pr,-Bu, -93u, ²-sec-Bu, -iso-Bu). and C3-C9 cycloalkyl (e.g., cyclopropyl, cyclobutyl, ²cyclopentyl, ²cyclohexyl).²103611 In some embodiments, each Rai, Ra2, Ra3, Ra4, Rao, -a7²and Rag is independently²unsubstituted. In some embodiments, each Rai, Ra2, Ra3, Ra4, Ras, Ra7 and Raa ²is²116²<DP=118>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²independently substituted with 1 instance of R9. In some embodiments, each ²Re', R22, R23,²Ra4, Ra6, Re' and R" is independently substituted with 2 instances of R9. In ²some ²embodiments, each Rai, R, R3, Ra4,²K Ra7 and le' is independently substituted with 3²instances of R9.²In some embodiments, each Rai, R, Ro, Ra4,²R06, R" and R28 is independently selected from²H, -CI---C6 alkyl (e.g, -Me, -Et, -Pr, -Pr,-"Bu, -13u, -sec-Bu, -is o-Bu) and -²CJ--C6 ²haloalkyl (e.g., -CHF 2, ---CF3). In some embodiments, each Ral, ²Ra2,Ra3,Ra4,Ra6, Re' and Ra8²is independently selected from H and -CI-Cs alkyl (e.g., -Me, -Et, -Pr, -'13r,-²"Bu, -²sec-Bu, -iso-Bu).²[0362j In some embodiments; each RI, Ra2., Ra3, Ra4,²K R" and Re' is independently H.²In some embodiments, each Ral, R.2, Ro, Ra6, -o²and Wd8 is independently -Ci-C6 alkyl²(e. g. , -Me, -Et, -Pr, -'13r,-"Bu, -sec-Bu, -iso-Bu). In some embodiments, ²each RI,²Ra2, Ro, Ra4, -36,²tc. II" and le ²is independently -Me. In some embodiments, each Ra], Ra2,²Ra3, Ra4, Ra6, Ra7 and X" is independently --Et. In some embodiments, each ²Ral, Ra2, Ro, Ra4,²Ra6, K-o²and R" is independently -Pr or -Tr.²103631 In some embodiments, each RI, Ra2, Ra3, Ra4, Ra6, R.' and R" is ²independently -²CI-C6 heteroalkyl. In further embodiments, each Rai,R, R3. R4 Ro and Ra8 is ²²independently methoxymethyl (-CH2OCH.3). In some embodiments, each Rai, ²R.2,R.3,R.4, ²-.6,²K Ra7 and ²R" is independently hydroxymethyl (-CH2OH). In some embodiments, each Re',²Ra2, R., Ra4,²R6, Re' and le is independently is aminomethyl (e.g ,-CH2NH2, -CH2NHCH3,²-CH2N (CH3)2.²In some embodiments, each Re', Ra2, Ra3, Ra4, -a6,²K R27 and Ra8 is independently -CI-C6²haloalkyl. In further embodiments, each R1, Ra2, Ra3, Ra4, R,²Ra7 and Res is independently²trifluoromethyl (-CF3). In other embodiments, each Rat, Re, R3. R, R6,,²Ra7 and Re' is²independently difluoromethyl (-CHF2).²103641 In some embodiments, each Rai, Ra2, R03, Ra4, Ra6, Re and RS is ²independently - ²C3-C9 carbocyclyl (e.g cyclopropyl, cyclobutyl, cyclopentyl, cõ,clohexyl). In ²some ²embodiments, each Re], Ra2, Ro, Ra4, -a6,²K Ra7 and Ra8 is independently cyclopropyl. In ²some²embodiments each Rai, R22, Ra3, R R6,,²R27 and le is independently cyclobutyl. In some²embodiments, each Re', Ra2, Ra3, Ra4, Ra6, K-o²and R" is independently cyclopentyl. In some²embodiments, each Rai,Ra3, Ra4, K,rµa6,²Ra7 and Re' is independently cyclohexyl.²103651 In some embodiments, each Rai, Ra2, Ra3, Ra4, Ra6, Ra7 and , RS²is independently 3-10²membered heterocyclyl (e.g., oxetanyl, tetrahydropyranyl, tetrahydrofuranyl, ²azetidinyl,²117²<DP=119>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, azepanyl). In some ²embodiments,each ²Rai, R, R3, Ra4,²R, Ra7 and Ras is independently is oxetanyl. In some embodiments, each ²Rai, Ra2, Ra3, Ra4, K -a6,²Ra7 and Ras is independently tetrahydropyranyl. In some embodiments, ²each Ral, R. Ra3, Ra4, Ra6,²Rl and Ra$ is independently tetrahydrofuranyl. In some ²embodiments, each R. Ra2, R. Ra4, Ras,²R7 and Ras is independently azetidinyl. In some²embodiments, each le, Ra2, Ra3, Ra4, K=-=a6,²Ra7 and Ra8 is independently pyrrolidinyl. In some ²embodiments, each Re', Ra2, Ra3, Ra4, Ra6, lc -"a7²and Ra8 is independently piperidinyl. In some²embodiments, each Ral, R.2, Ra3, Ra4, R36, R7²and Ra8 is independently piperazinyl. In some²embodiments, each Rai, Ra2, Ra3, Ra4, Ra6,²R7 and Ras is independently morpholinyl. In some²embodiments, each Rai, Re, Ra3 Ra4,²K Ra7 and Ras is independently azepanyl.²103661 In some embodiments, R1. Ra2, Ra3, Ra4,²R6, Ra7 and Ra8 is independently²heteroaryl. In some embodiments, R", R, Ra3, Ra4, R06,²Ra7 and Ras is independently a 5-10 ²member heteroaryl (e.g., a 5-6 member monocyclic heteroaryl or an 8-10 member ²bicyclic ²heteroaryl containing 1-3 heteroatoms independently selected from N, 0 and S). ²In some ²embodiments, R", e, Ra3, Ra4, Ra6, Ra7 and Ras is independently a 5-6 member ²monocyclic ²heteroaryl (e.g., a 5-member monocyclic heteroaryl containing 1-3 heteroatoms²independently selected from 0, N and S, a 6-member monocyclic heteroaryl ²containing 1-3 N ²heteroatoms). In some embodiments, R", R, R3. Ra4, K.Na6,²Ra7 and Ras is independently a 5-²member monocyclic heteroaryl (e.g., pyrazolyl, pyrolyl, thiophenyl, furyl, ²thiazolyl, ²isothiazolyl, oxazolyl, isoxazobõ,1, irnidazolyl, triazolyl, thiadiazolyl, ²oxadiazolyl). In some ²embodiments, Ral, R.2,R.3,e,e, Ra7 and Ras is independently thiophenyl (e.g., ²thiophen-²2-yl, thiophen-3-y1). In some embodiments, R", Re, Ra3, Ra4, Rah, Ra7 and Ras ²is ²independently pyrazolyl (e.g. pyrazol-1-yl, pyrazol-3-yl, pyrazol-5-y1). In ²some ²embodiments, Rai, Ra2, Ra3, =s4²a,²K Ra6, Ra7 ²and Ras is independently thiazolyl (e.g, thiazol-2-yl,².thiazol-4-yl, thiazol-5-y1). In some embodiments, R1. Ra2, Ra3, R, R6,²Ra7 and Ras is²independently a 6-member monocyclic heteroaryl (e.g., pyridyl, pyrimidinyl, ²triazinyl, ²pyrazinyl, pyridazinyl). In some embodiments, Rai, RerRa3,R.4,-a6,²Ra7 and Ra$ is²independently pyridinyl (e.g., pyridin-2-y1; pyridin-3-yl, pyridin-4-y1). In ²some ²embodiments, Ral, R.2,R.3,e, Ra6, Ra7 and Ras is independently pyrimidinyl ²(e.g, ²pyrimidin-4-yl, pyrimidin-5-y1).²103671 In some embodiments, R", Re, Ror K-a4,²Ra6, Ra7 and Ras is independently atyl. In²some embodiments, R1, Ra2, Ra3, Ra4, Ra6,²R7 and Ras is independently 6-10 member mono ²or bicyclic aryl. In some embodiments, Rai, Ra2, Ra3, Ra4, R36,²R7 and Ras is independently²118²<DP=120>²CA 03176912 2022-09-23²WO 2022 / 026892 ²PCT / US2021 / 044004²phenyl. In some embodiments, the phenyl is substituted with 0, 1, 2 or 3 ²instances of R9 as²defined herein.²10368j In some embodiments; each RI, Ra2., Ra3, Ra4,²K Ra7 and Ras ²is independently²cycloalkylalkyl (e.g., cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, ²²cyclohexylmethyl, cycloheptylmethyl). In some embodiments, each Re', Ra2, Ra3, ²Ra4, Ra6, ²Re' and R" is independently heterocyclylalkyl (e.g, oxetanylmethyl, ²aziridinylmethyl, ²tetrahydrofuranylmethyl, pyrolidinylmethyl, tetrahydropyranylmethyl, ²piperidinylmek I, ²piperazinylmethyl, morpholinylmethyl, azepanylmethyl).²In some embodiments, each Re', Ra2, Ra3, Ra4, -a6.²K Re' and Ras is independently atylalk-yl. ²In²some embodiments, each RI, Raz, Ra3, Ra4,²R6, Re' and Re' is independently benzyl. ²In some embodiments, each Ral, R, R3, R. Ra6, Re' and Re' is independently ²heteroarylalkyl (e.g., pyridinylmethyl, thiazolylmethyl, triazolylmethyl, ²pyrazolylmethyl). ²103691 As generally defined herein, each R9 is independently selected from =0, ²halo, -CN, ²-Ct-C6 alkyl, -Ci--C6 heteroalkyl, -CI-C6 haloalkyl, -C3-C9 cycloalkyl, 3-10 ²membered ²heterocyclyl, C6-Cio aryl, 5-10 membered heteroatyl, cycloalkylalkyl, ²heterocyclylalkyl, ²arylalkyl, heteroarylalkyl, -ORb, -N(Rb)2, -C(0)R", -C(43)0Rb, -NRbC(=0)Rb, - ²NRbg=0)0Rb, -C(=0)N(Rb)2, -0C(=0)N(R1')2,-S(=0)R1', -SKO2Rbõ -SRbõ²N bR -b _²)t(, NRbS(:=0)2Rb and -S(=0)2N(R1')2, wherein each lib is independently ²se...
Claims
Claims 1. A compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein: [Image disponible dans le document PDF, Image available in the PDF document] each R<com:Sup>1< / com:Sup> is independently selected from H, -D, halo, -CN, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> heteroalkyl, –C<com:Sub>1< / com:Sub>–C<com:Sub>6< / com:Sub> haloalkyl, –C<com:Sub>3< / com:Sub>–C<com:Sub>9< / com:Sub> cycloalkyl, 3-10 membered heterocyclyl, heterocyclylalkyl, heteroarylalkyl, arylalkyl, cycloalkylalkyl, <com:Math><semantics>−ORa1<annotation encoding="application / x-tex">-OR^{a1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(Ra1)2<annotation encoding="application / x-tex">-N(R^{a1})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)Ra1<annotation encoding="application / x-tex">-C(=O)R^{a1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−<annotation encoding="application / x-tex">-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>C(=O)ORa1<annotation encoding="application / x-tex">C(=O)OR^{a1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRa1C(=O)Ra1<annotation encoding="application / x-tex">-NR^{a1}C(=O)R^{a1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRa1C(=O)ORa1<annotation encoding="application / x-tex">-NR^{a1}C(=O)OR^{a1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)N(Ra1)2<annotation encoding="application / x-tex">-C(=O)N(R^{a1})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(=O)N(Ra1)2<annotation encoding="application / x-tex">-OC(=O)N(R^{a1})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)Ra1<annotation encoding="application / x-tex">-S(=O)R^{a1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)Ra1<annotation encoding="application / x-tex">-S(=O)R^{a1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)Ra1<annotation encoding="application / x-tex">-S(=O)R^{a1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)Ra1<annotation encoding="application / x-tex">-S(=O)R^{a1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)Ra1<annotation encoding="application / x-tex">-S(=O)R^{a1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)Ra1<annotation encoding="application / x-tex">-S(=O)R^{a1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)Ra1<annotation encoding="application / x-tex">-S(=O)R^{a1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S<annotation encoding="application / x-tex">-S< / annotation>< / semantics>< / com:Math> <com:Math><semantics>S(=O)2Ra1<annotation encoding="application / x-tex">S(=O)_2R^{a1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−SRa1<annotation encoding="application / x-tex">-SR^{a1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)(=NRa1)Ra1<annotation encoding="application / x-tex">-S(=O)(=NR^{a1})R^{a1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRa1S(=O)2Ra1<annotation encoding="application / x-tex">-NR^{a1}S(=O)_2R^{a1}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>−S(=O)2N(Ra1)2<annotation encoding="application / x-tex">-S(=O)_2N(R^{a1})_2< / annotation>< / semantics>< / com:Math>; each R<com:Sup>2< / com:Sup> is independently selected from halo, -CN, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> heteroalkyl, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> haloalkyl, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> haloalkoxy, -C<com:Sub>3< / com:Sub>-C<com:Sub>9< / com:Sub> cycloalkyl, 3-10 membered heterocyclyl, heterocyclylalkyl, heteroarylalkyl, arylalkyl, cycloalkylalkyl, <com:Math><semantics>−ORa2<annotation encoding="application / x-tex">-OR^{a2}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(Ra2)2<annotation encoding="application / x-tex">-N(R^{a2})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)Ra2<annotation encoding="application / x-tex">-C(=O)R^{a2}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−<annotation encoding="application / x-tex">-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>C(=O)ORa2<annotation encoding="application / x-tex">C(=O)OR^{a2}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRa2C(=O)Ra2<annotation encoding="application / x-tex">-NR^{a2}C(=O)R^{a2}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRa2C(=O)ORa2<annotation encoding="application / x-tex">-NR^{a2}C(=O)OR^{a2}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)N(Ra2)2<annotation encoding="application / x-tex">-C(=O)N(R^{a2})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)N(ORa2)(Ra2)<annotation encoding="application / x-tex">-C(=O)N(OR^{a2})(R^{a2})< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)N(ORa2)(Ra2)<annotation encoding="application / x-tex">-C(=O)N(OR^{a2})(R^{a2})< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)N(ORa2)(Ra2)<annotation encoding="application / x-tex">-C(=O)N(OR^{a2})(R^{a2})< / annotation>< / semantics>< / com:Math> <com:Math><semantics>OC(=O)N(Ra2)2<annotation encoding="application / x-tex">OC(=O)N(R^{a2})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)Ra2<annotation encoding="application / x-tex">-S(=O)R^{a2}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)2Ra2<annotation encoding="application / x-tex">-S(=O)_2R^{a2}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−SRa2<annotation encoding="application / x-tex">-SR^{a2}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)(=NRa2)Ra2<annotation encoding="application / x-tex">-S(=O)(=NR^{a2})R^{a2}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRa2S(=O)2Ra2<annotation encoding="application / x-tex">-NR^{a2}S(=O)_2R^{a2}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>−S(=O)(=NRa2)Ra2<annotation encoding="application / x-tex">-S(=O)(=NR^{a2})R^{a2}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRa2S(=O)2Ra2<annotation encoding="application / x-tex">-NR^{a2}S(=O)_2R^{a2}< / annotation>< / semantics>< / com:Math> <com:Math><semantics>S(=O)2N(Ra2)2;<annotation encoding="application / x-tex">S(=O)_2N(R^{a2})_2;< / annotation>< / semantics>< / com:Math> each R<com:Sup>3< / com:Sup> is independently selected from H, -D, halo, -CN, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> heteroalkyl, –C<com:Sub>1< / com:Sub>–C<com:Sub>6< / com:Sub> haloalkyl, –C<com:Sub>3< / com:Sub>–C<com:Sub>9< / com:Sub> cycloalkyl, 3-10 membered heterocyclyl, heterocyclylalkyl, heteroarylalkyl, arylalkyl, cycloalkylalkyl, <com:Math><semantics>−ORa3<annotation encoding="application / x-tex">-OR^{a3}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(Ra3)2<annotation encoding="application / x-tex">-N(R^{a3})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)Ra3<annotation encoding="application / x-tex">-C(=O)R^{a3}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−<annotation encoding="application / x-tex">-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>C(=O)ORa3<annotation encoding="application / x-tex">C(=O)OR^{a3}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRa3C(=O)Ra3<annotation encoding="application / x-tex">-NR^{a3}C(=O)R^{a3}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRa3C(=O)ORa3<annotation encoding="application / x-tex">-NR^{a3}C(=O)OR^{a3}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)N(Ra3)2<annotation encoding="application / x-tex">-C(=O)N(R^{a3})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(=O)N(Ra3)2<annotation encoding="application / x-tex">-OC(=O)N(R^{a3})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)Ra3<annotation encoding="application / x-tex">-S(=O)R^{a3}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)Ra3<annotation encoding="application / x-tex">-S(=O)R^{a3}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)Ra3<annotation encoding="application / x-tex">-S(=O)R^{a3}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)Ra3<annotation encoding="application / x-tex">-S(=O)R^{a3}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)Ra3<annotation encoding="application / x-tex">-S(=O)R^{a3}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)Ra3<annotation encoding="application / x-tex">-S(=O)R^{a3}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)Ra3<annotation encoding="application / x-tex">-S(=O)R^{a3}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S<annotation encoding="application / x-tex">-S< / annotation>< / semantics>< / com:Math> <com:Math><semantics>S(=O)2Ra3<annotation encoding="application / x-tex">S(=O)_2R^{a3}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−SRa3<annotation encoding="application / x-tex">-SR^{a3}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)(=NRa3)Ra3<annotation encoding="application / x-tex">-S(=O)(=NR^{a3})R^{a3}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRa3S(=O)2Ra3<annotation encoding="application / x-tex">-NR^{a3}S(=O)_2R^{a3}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>−S(=O)2N(Ra3)2<annotation encoding="application / x-tex">-S(=O)_2N(R^{a3})_2< / annotation>< / semantics>< / com:Math>; each R<com:Sup>4< / com:Sup> is independently selected from H, –D, halo, –CN, –C<com:Sub>1< / com:Sub>–C<com:Sub>6< / com:Sub> alkyl, –C<com:Sub>1< / com:Sub>–C<com:Sub>6< / com:Sub> heteroalkyl, –C<com:Sub>1< / com:Sub>–C<com:Sub>6< / com:Sub> haloalkyl, –C<com:Sub>3< / com:Sub>–C<com:Sub>9< / com:Sub> cycloalkyl, 3-10 membered heterocyclyl, heterocyclylalkyl, heteroarylalkyl, arylalkyl, cycloalkylalkyl, <com:Math><semantics>−ORa4<annotation encoding="application / x-tex">-OR^{a4}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(Ra4)2<annotation encoding="application / x-tex">-N(R^{a4})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)Ra4<annotation encoding="application / x-tex">-C(=O)R^{a4}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−<annotation encoding="application / x-tex">-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>C(=O)ORa4<annotation encoding="application / x-tex">C(=O)OR^{a4}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRa4C(=O)Ra4<annotation encoding="application / x-tex">-NR^{a4}C(=O)R^{a4}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRa4C(=O)ORa4<annotation encoding="application / x-tex">-NR^{a4}C(=O)OR^{a4}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)N(Ra4)2<annotation encoding="application / x-tex">-C(=O)N(R^{a4})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(=O)N(Ra4)2<annotation encoding="application / x-tex">-OC(=O)N(R^{a4})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)Ra4<annotation encoding="application / x-tex">-S(=O)R^{a4}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)2Ra4<annotation encoding="application / x-tex">-S(=O)_2R^{a4}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−SRa4<annotation encoding="application / x-tex">-SR^{a4}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)(=NRa4)Ra4<annotation encoding="application / x-tex">-S(=O)(=NR^{a4})R^{a4}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRa4S(=O)2Ra4<annotation encoding="application / x-tex">-NR^{a4}S(=O)_2R^{a4}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>−S(=O)2N(Ra4)2<annotation encoding="application / x-tex">-S(=O)_2N(R^{a4})_2< / annotation>< / semantics>< / com:Math>; each R<com:Sup>6< / com:Sup> is independently absent or selected from H, –D, halo, –CN, –C<com:Sub>1< / com:Sub>–C<com:Sub>6< / com:Sub> alkyl, –C<com:Sub>1< / com:Sub>– C<com:Sub>6< / com:Sub> heteroalkyl, –C<com:Sub>1< / com:Sub>–C<com:Sub>6< / com:Sub> haloalkyl, –C<com:Sub>3< / com:Sub>–C<com:Sub>10< / com:Sub> carbocyclyl, 3-10 membered heterocyclyl, heterocyclylalkyl, C<com:Sub>6< / com:Sub>–C<com:Sub>10< / com:Sub> aryl, 5-10 member heteroaryl, heteroarylalkyl, arylalkyl, cycloalkylalkyl, <com:Math><semantics>−ORa6<annotation encoding="application / x-tex">-OR^{a6}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(Ra6)2<annotation encoding="application / x-tex">-N(R^{a6})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)Ra6<annotation encoding="application / x-tex">-C(=O)R^{a6}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)ORa6<annotation encoding="application / x-tex">-C(=O)OR^{a6}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRa6C(=O)Ra6<annotation encoding="application / x-tex">-NR^{a6}C(=O)R^{a6}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRa6C(=O)ORa6<annotation encoding="application / x-tex">-NR^{a6}C(=O)OR^{a6}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)N(Ra6)2<annotation encoding="application / x-tex">-C(=O)N(R^{a6})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(=O)N(Ra6)2<annotation encoding="application / x-tex">-OC(=O)N(R^{a6})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)Ra6<annotation encoding="application / x-tex">-S(=O)R^{a6}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)2Ra6<annotation encoding="application / x-tex">-S(=O)_2R^{a6}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−SRa6<annotation encoding="application / x-tex">-SR^{a6}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)(=NRa6)Ra6<annotation encoding="application / x-tex">-S(=O)(=NR^{a6})R^{a6}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)(=NRa6)Ra6<annotation encoding="application / x-tex">-S(=O)(=NR^{a6})R^{a6}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)(=NRa6)Ra6<annotation encoding="application / x-tex">-S(=O)(=NR^{a6})R^{a6}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)(=NRa6)Ra6<annotation encoding="application / x-tex">-S(=O)(=NR^{a6})R^{a6}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)(=NRa6)Ra6<annotation encoding="application / x-tex">-S(=O)(=NR^{a6})R^{a6}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−<annotation encoding="application / x-tex">-< / annotation>< / semantics>< / com:Math> NR<com:Sup>a6< / com:Sup>S(=O)<com:Sub>2< / com:Sub>R<com:Sup>a6< / com:Sup> and -S(=O)<com:Sub>2< / com:Sub>N(R<com:Sup>a6< / com:Sup>)<com:Sub>2< / com:Sub>, wherein each alkyl, carbocyclyl, heterocyclyl, cycloalkylalkyl, heterocyclylalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl is substituted at any available position with 0, 1, 2 or 3 instances of <com:Math><semantics>R10<annotation encoding="application / x-tex">R^{10}< / annotation>< / semantics>< / com:Math>; each R<com:Sup>7< / com:Sup> is independently absent or selected from H, –D, halo, –CN, –C<com:Sub>1< / com:Sub>–C<com:Sub>6< / com:Sub> alkyl, –C<com:Sub>1< / com:Sub>– C<com:Sub>6< / com:Sub> hydroxyalkyl, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> haloalkyl, -C<com:Sub>3< / com:Sub>-C<com:Sub>9< / com:Sub> cycloalkyl, 3-10 membered heterocyclyl, 5-6- membered monocyclic heteroaryl, heterocyclylalkyl, heteroarylalkyl, arylalkyl, cycloalkylalkyl, <com:Math><semantics>−ORa7<annotation encoding="application / x-tex">-OR^{a7}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(Ra7)2<annotation encoding="application / x-tex">-N(R^{a7})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)Ra7<annotation encoding="application / x-tex">-C(=O)R^{a7}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)ORa7<annotation encoding="application / x-tex">-C(=O)OR^{a7}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRa7C(=O)Ra7<annotation encoding="application / x-tex">-NR^{a7}C(=O)R^{a7}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRa7C(=O)ORa7<annotation encoding="application / x-tex">-NR^{a7}C(=O)OR^{a7}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)N(Ra7)2<annotation encoding="application / x-tex">-C(=O)N(R^{a7})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(=O)N(Ra7)2,−S(=O)Ra7,−S(=O)2Ra7,−SRa7,−S(=O)(=NRa7)Ra7,−NRa7S(=O)2Ra7and−NRa7S(=O)2Ra7,−NRa7S(=O)2Ra7and−NRa7S(=O)2Ra7,−NRa7S(=O)2Ra7,−NRa7S(=<annotation encoding="application / x-tex">-OC(=O)N(R^{a7})_2, -S(=O)R^{a7}, -S(=O)_2R^{a7}, -SR^{a7}, -S(=O)(=NR^{a7})R^{a7}, -NR^{a7}S(=O)_2R^{a7} \ and -NR^{a7}S(=O)_2R^{a7}, -NR^{a7}S(=O)_2R^{a7} \ and -NR^{a7}S(=O)_2R^{a7}, -NR^{a7}S(=O)_2R^{a7}, -NR^{a7}S(=< / annotation>< / semantics>< / com:Math> <com:Math><semantics>S(=O)2N(Ra7)2;<annotation encoding="application / x-tex">S(=O)_2N(R^{a7})_2;< / annotation>< / semantics>< / com:Math> each <com:Math><semantics>R8<annotation encoding="application / x-tex">R^8< / annotation>< / semantics>< / com:Math> is independently selected from H, -D, =O, halo, -CN, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> heteroalkyl, –C<com:Sub>1< / com:Sub>–C<com:Sub>6< / com:Sub> haloalkyl, –C<com:Sub>3< / com:Sub>–C<com:Sub>9< / com:Sub> cycloalkyl, 3-10 membered heterocyclyl, heterocyclylalkyl, heteroarylalkyl, arylalkyl, cycloalkylalkyl, <com:Math><semantics>−ORa8<annotation encoding="application / x-tex">-OR^{a8}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(Ra8)2<annotation encoding="application / x-tex">-N(R^{a8})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)Ra8<annotation encoding="application / x-tex">-C(=O)R^{a8}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−<annotation encoding="application / x-tex">-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>C(=O)ORa8<annotation encoding="application / x-tex">C(=O)OR^{a8}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRa8C(=O)Ra8<annotation encoding="application / x-tex">-NR^{a8}C(=O)R^{a8}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRa8C(=O)ORa8<annotation encoding="application / x-tex">-NR^{a8}C(=O)OR^{a8}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CH2C(=O)N(Ra8)2<annotation encoding="application / x-tex">-CH_2C(=O)N(R^{a8})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)N(Ra8)2<annotation encoding="application / x-tex">-C(=O)N(R^{a8})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)N(Ra8)2<annotation encoding="application / x-tex">-C(=O)N(R^{a8})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)N(Ra8)2<annotation encoding="application / x-tex">-C(=O)N(R^{a8})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)N(Ra8)2<annotation encoding="application / x-tex">-C(=O)N(R^{a8})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)N(Ra8)2<annotation encoding="application / x-tex">-C(=O)N(R^{a8})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)N(Ra8)2<annotation encoding="application / x-tex">-C(=O)N(R^{a8})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)<annotation encoding="application / x-tex">-C(=O)< / annotation>< / semantics>< / com:Math> <com:Math><semantics>OC(=O)N(Ra8)2<annotation encoding="application / x-tex">OC(=O)N(R^{a8})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CH2C(=O)N(Ra8)2<annotation encoding="application / x-tex">-CH_2C(=O)N(R^{a8})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)Ra8<annotation encoding="application / x-tex">-S(=O)R^{a8}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)2Ra8<annotation encoding="application / x-tex">-S(=O)_2R^{a8}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−SRa8<annotation encoding="application / x-tex">-SR^{a8}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)(=NRa8)Ra8<annotation encoding="application / x-tex">-S(=O)(=NR^{a8})R^{a8}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)(=NRa8)Ra8<annotation encoding="application / x-tex">-S(=O)(=NR^{a8})R^{a8}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)(=NRa8)Ra8<annotation encoding="application / x-tex">-S(=O)(=NR^{a8})R^{a8}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)(=NRa8)Ra8<annotation encoding="application / x-tex">-S(=O)(=NR^{a8})R^{a8}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)(=NRa8)Ra8<annotation encoding="application / x-tex">-S(=O)(=NR^{a8})R^{a8}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>NRa8S(=O)2Ra8<annotation encoding="application / x-tex">NR^{a8}S(=O)_2R^{a8}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>−S(=O)2N(Ra8)2<annotation encoding="application / x-tex">-S(=O)_2N(R^{a8})_2< / annotation>< / semantics>< / com:Math> wherein two instances of <com:Math><semantics>R8<annotation encoding="application / x-tex">R^8< / annotation>< / semantics>< / com:Math> together with the atom or atoms to which they are attached can be taken together to form a 3-10 member cycloalkyl or heterocyclyl ring; each R<com:Sup>a1< / com:Sup>, R<com:Sup>a2< / com:Sup>, R<com:Sup>a3< / com:Sup>, R<com:Sup>a4< / com:Sup>, R<com:Sup>a6< / com:Sup>, R<com:Sup>a7< / com:Sup> and R<com:Sup>a8< / com:Sup> is independently selected from H, C<com:Sub>1< / com:Sub>–C<com:Sub>6< / com:Sub> alkyl, – C<com:Sub>1< / com:Sub>–C<com:Sub>6< / com:Sub> heteroalkyl, C<com:Sub>3< / com:Sub>–C<com:Sub>9< / com:Sub> cycloalkyl, 3-7 membered heterocyclyl, cycloalkylalkyl, heterocyclylalkyl, aryl, 5-6 membered heteroaryl, arylalkyl and heteroarylalkyl wherein each alkyl, cycloalkyl, heterocyclyl, cycloalkylalkyl, heterocyclylalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl is independently substituted with 0, 1, 2 or 3 instances of R<com:Sup>9< / com:Sup>; each <com:Math><semantics>R9<annotation encoding="application / x-tex">R^9< / annotation>< / semantics>< / com:Math> is independently selected from =O, halo, -CN, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> heteroalkyl, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> haloalkyl, -C<com:Sub>3< / com:Sub>-C<com:Sub>9< / com:Sub> cycloalkyl, 3-10 membered heterocyclyl, C<com:Sub>6< / com:Sub>-C<com:Sub>10< / com:Sub> aryl, 5-10 membered heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, <com:Math><semantics>−ORb<annotation encoding="application / x-tex">-OR^b< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(Rb)2<annotation encoding="application / x-tex">-N(R^b)_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−<annotation encoding="application / x-tex">-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>C(=O)Rb<annotation encoding="application / x-tex">C(=O)R^b< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)ORb<annotation encoding="application / x-tex">-C(=O)OR^b< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRbC(=O)Rb<annotation encoding="application / x-tex">-NR^bC(=O)R^b< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRbC(=O)ORb<annotation encoding="application / x-tex">-NR^bC(=O)OR^b< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)N(Rb)2<annotation encoding="application / x-tex">-C(=O)N(R^b)_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(=O)N(Rb)2<annotation encoding="application / x-tex">-OC(=O)N(R^b)_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(=O)N(Rb)2<annotation encoding="application / x-tex">-OC(=O)N(R^b)_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(=O)N(Rb)2<annotation encoding="application / x-tex">-OC(=O)N(R^b)_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(=O)N(Rb)2<annotation encoding="application / x-tex">-OC(=O)N(R^b)_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(=O)N(Rb)2<annotation encoding="application / x-tex">-OC(=O)N(R^b)_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(=O)N(Rb)2<annotation encoding="application / x-tex">-OC(=O)N(R^b)_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(=O)N(Rb)2<annotation encoding="application / x-tex">-OC(=O)N(R^b)_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(=O)N<annotation encoding="application / x-tex">-OC(=O)N< / annotation>< / semantics>< / com:Math> <com:Math><semantics>S(=O)Rb<annotation encoding="application / x-tex">S(=O)R^{b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)2Rb<annotation encoding="application / x-tex">-S(=O)_{2}R^{b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−SRb<annotation encoding="application / x-tex">-SR^{b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)(=NRb)Rb<annotation encoding="application / x-tex">-S(=O)(=NR^{b})R^{b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRbS(=O)2Rb<annotation encoding="application / x-tex">-NR^{b}S(=O)_{2}R^{b}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>−S(=O)2N(Rb)2<annotation encoding="application / x-tex">-S(=O)_{2}N(R^{b})_{2}< / annotation>< / semantics>< / com:Math>; each R<com:Sup>b< / com:Sup> is independently selected from H, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, and C<com:Sub>3< / com:Sub>-C<com:Sub>9< / com:Sub> cycloalkyl; each R<com:Sup>10< / com:Sup> is independently selected from –D, =O, –CN, halo, –C<com:Sub>1< / com:Sub>–C<com:Sub>6< / com:Sub> alkyl, –C<com:Sub>1< / com:Sub>–C<com:Sub>6< / com:Sub> heteroalkyl, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> haloalkyl, -C<com:Sub>3< / com:Sub>-C<com:Sub>9< / com:Sub> cycloalkyl, 3-10 membered heterocyclyl, C<com:Sub>6< / com:Sub>-C<com:Sub>10< / com:Sub> aryl, 5- 10 membered heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, heterocyclylalkoxy, <com:Math><semantics>−ORb10<annotation encoding="application / x-tex">-OR^{b10}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(Rb10)2<annotation encoding="application / x-tex">-N(R^{b10})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)Rb10<annotation encoding="application / x-tex">-C(=O)R^{b10}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)ORb10<annotation encoding="application / x-tex">-C(=O)OR^{b10}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRb10C(=O)Rb10<annotation encoding="application / x-tex">-NR^{b10}C(=O)R^{b10}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−<annotation encoding="application / x-tex">-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>NRb10C(=O)ORb10<annotation encoding="application / x-tex">NR^{b10}C(=O)OR^{b10}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)N(Rb10)2<annotation encoding="application / x-tex">-C(=O)N(R^{b10})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(=O)Rb10<annotation encoding="application / x-tex">-OC(=O)R^{b10}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(=O)N(Rb10)2<annotation encoding="application / x-tex">-OC(=O)N(R^{b10})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)Rb10<annotation encoding="application / x-tex">-S(=O)R^{b10}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)2Rb10<annotation encoding="application / x-tex">-S(=O)_2R^{b10}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−SRb10<annotation encoding="application / x-tex">-SR^{b10}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)(=NRb10)Rb10<annotation encoding="application / x-tex">-S(=O)(=NR^{b10})R^{b10}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRb10S(=O)2Rb10<annotation encoding="application / x-tex">-NR^{b10}S(=O)_2R^{b10}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>−S(=O)2N(Rb10)2<annotation encoding="application / x-tex">-S(=O)_2N(R^{b10})_2< / annotation>< / semantics>< / com:Math>, wherein each alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, heterocyclylalkoxy, arylalkyl and heteroarylalkyl of R<com:Sup>10< / com:Sup> is substituted with 0, 1, 2, 3, 4, or 5 instances of –Me, –Et, –<com:Sup>i< / com:Sup>Pr, cyclopropyl, oxetan-3-yl, –OH, =O, –F, –OMe, –CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>F, – CH<com:Sub>2< / com:Sub>CHF<com:Sub>2< / com:Sub>, -CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>CF<com:Sub>3< / com:Sub>, -C(=O)Me, -N(Me)<com:Sub>2< / com:Sub>, -CH<com:Sub>2< / com:Sub>N(CH<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>, -CH<com:Sub>2< / com:Sub>N(CH<com:Sub>3< / com:Sub>)CH<com:Sub>2< / com:Sub>CH<com:Sub>3< / com:Sub>, - <com:Math><semantics>N(iPr)(Et)<annotation encoding="application / x-tex">N(^{i}Pr)(Et)< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(iPr)(Me)<annotation encoding="application / x-tex">-N(^{i}Pr)(Me)< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(Et)2<annotation encoding="application / x-tex">-N(Et)_{2}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(CH3)(Et)<annotation encoding="application / x-tex">-N(CH_{3})(Et)< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NHC(=O)Me<annotation encoding="application / x-tex">-NHC(=O)Me< / annotation>< / semantics>< / com:Math>, or a combination thereof; each <com:Math><semantics>Rb10<annotation encoding="application / x-tex">R^{b10}< / annotation>< / semantics>< / com:Math> is independently H; <com:Math><semantics>−C1−C6<annotation encoding="application / x-tex">-C_1-C_6< / annotation>< / semantics>< / com:Math> alkyl; <com:Math><semantics>−C1−C6<annotation encoding="application / x-tex">-C_1-C_6< / annotation>< / semantics>< / com:Math> haloalkyl; <com:Math><semantics>−C1−C6<annotation encoding="application / x-tex">-C_1-C_6< / annotation>< / semantics>< / com:Math> heteroalkyl substituted with 0 or 1 instance of =O; C<com:Sub>3< / com:Sub>–C<com:Sub>9< / com:Sub> cycloalkyl; or 3-10 member heterocyclyl substituted with 0 or 1 instances of =0, -Me or a combination thereof; and n is 0, 1, 2 or 3 provided that: (i) when <com:Math><semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics>< / com:Math> is H, <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is not halo, <com:Math><semantics>−OPr<annotation encoding="application / x-tex">-OPr< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(CH3)2<annotation encoding="application / x-tex">-N(CH_3)_2< / annotation>< / semantics>< / com:Math> or <com:Math><semantics>−CF3<annotation encoding="application / x-tex">-CF_3< / annotation>< / semantics>< / com:Math>; (ii) when <com:Math><semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>ORa1<annotation encoding="application / x-tex">OR^{a1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is not <com:Math><semantics>−ORa2<annotation encoding="application / x-tex">-OR^{a2}< / annotation>< / semantics>< / com:Math>; (iii) when R<com:Sup>1< / com:Sup> is H and R<com:Sup>2< / com:Sup> is –CH<com:Sub>3< / com:Sub>, R<com:Sup>8< / com:Sup> groups cannot be taken together to form a ring and R<com:Sup>6< / com:Sup> is not absent or H, and is not thiazolyl, furanyl or pyrrolyl; (iv) when <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is Me, <com:Math><semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics>< / com:Math> is not piperidine; and (v) the compound is not: A. 5-(2-(5-methyl-2-(p-tolyl)piperidin-1-yl)-2-oxoacetamido)nicotinamide or any of its enantiomers or diastereomers; B. 2-(2-(4-(2H-tetrazol-5-yl)phenyl)-5-methylpiperidin-1-yl)-N-(5,6-dimethylpyridin- 3-yl)-2-oxoacetamide or any of its enantiomers or diastereomers; C. 2-cyano-5-(2-(5-methyl-2-phenylpiperidin-1-yl)-2-oxoacetamido)nicotinamide or any of its enantiomers or diastereomers; and [Image disponible dans le document PDF, Image available in the PDF document] D. • 2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] moiety represented as is selected from: [Image disponible dans le document PDF, Image available in the PDF document] • 3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] moiety represented as is selected from: [Image disponible dans le document PDF, Image available in the PDF document] 4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] moiety represented as is selected from: [Image disponible dans le document PDF, Image available in the PDF document] .
5. A compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula (Ia) [Image disponible dans le document PDF, Image available in the PDF document] 6. A compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula (Ib) [Image disponible dans le document PDF, Image available in the PDF document] 7. A compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula (Ic) [Image disponible dans le document PDF, Image available in the PDF document] 8. A compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula (Id) [Image disponible dans le document PDF, Image available in the PDF document] 9 The compound of any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein each <com:Math><semantics>R8<annotation encoding="application / x-tex">R^8< / annotation>< / semantics>< / com:Math> is independently selected from H, -D, =O, halo, -CN, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> heteroalkyl, –C<com:Sub>1< / com:Sub>–C<com:Sub>6< / com:Sub> haloalkyl, –C<com:Sub>3< / com:Sub>–C<com:Sub>9< / com:Sub> cycloalkyl, 3-10 membered heterocyclyl, heterocyclylalkyl, heteroarylalkyl, arylalkyl, cycloalkylalkyl, <com:Math><semantics>−ORa8<annotation encoding="application / x-tex">-OR^{a8}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(Ra8)2<annotation encoding="application / x-tex">-N(R^{a8})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)Ra8<annotation encoding="application / x-tex">-C(=O)R^{a8}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−<annotation encoding="application / x-tex">-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>C(=O)ORa8<annotation encoding="application / x-tex">C(=O)OR^{a8}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRa8C(=O)Ra8<annotation encoding="application / x-tex">-NR^{a8}C(=O)R^{a8}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRa8C(=O)ORa8<annotation encoding="application / x-tex">-NR^{a8}C(=O)OR^{a8}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CH2C(=O)N(Ra8)2<annotation encoding="application / x-tex">-CH_2C(=O)N(R^{a8})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)N(Ra8)2<annotation encoding="application / x-tex">-C(=O)N(R^{a8})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)N(Ra8)2<annotation encoding="application / x-tex">-C(=O)N(R^{a8})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)N(Ra8)2<annotation encoding="application / x-tex">-C(=O)N(R^{a8})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)N(Ra8)2<annotation encoding="application / x-tex">-C(=O)N(R^{a8})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)N(Ra8)2<annotation encoding="application / x-tex">-C(=O)N(R^{a8})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)N(Ra8)2<annotation encoding="application / x-tex">-C(=O)N(R^{a8})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)<annotation encoding="application / x-tex">-C(=O)< / annotation>< / semantics>< / com:Math> <com:Math><semantics>OC(=O)N(Ra8)2<annotation encoding="application / x-tex">OC(=O)N(R^{a8})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CH2C(=O)N(Ra8)2<annotation encoding="application / x-tex">-CH_2C(=O)N(R^{a8})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)Ra8<annotation encoding="application / x-tex">-S(=O)R^{a8}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)2Ra8<annotation encoding="application / x-tex">-S(=O)_2R^{a8}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−SRa8<annotation encoding="application / x-tex">-SR^{a8}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)(=NRa8)Ra8<annotation encoding="application / x-tex">-S(=O)(=NR^{a8})R^{a8}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)(=NRa8)Ra8<annotation encoding="application / x-tex">-S(=O)(=NR^{a8})R^{a8}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)(=NRa8)Ra8<annotation encoding="application / x-tex">-S(=O)(=NR^{a8})R^{a8}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)(=NRa8)Ra8<annotation encoding="application / x-tex">-S(=O)(=NR^{a8})R^{a8}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)(=NRa8)Ra8<annotation encoding="application / x-tex">-S(=O)(=NR^{a8})R^{a8}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>NRa8S(=O)2Ra8<annotation encoding="application / x-tex">NR^{a8}S(=O)_2R^{a8}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>−S(=O)2N(Ra8)2<annotation encoding="application / x-tex">-S(=O)_2N(R^{a8})_2< / annotation>< / semantics>< / com:Math>.
10. A compound of any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein <com:Math><semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics>< / com:Math> is selected from H, halo, <com:Math><semantics>−CN<annotation encoding="application / x-tex">-CN< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C1−C6<annotation encoding="application / x-tex">-C_1-C_6< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>−C1−C6<annotation encoding="application / x-tex">-C_1-C_6< / annotation>< / semantics>< / com:Math> heteroalkyl, <com:Math><semantics>−C1−C6<annotation encoding="application / x-tex">-C_1-C_6< / annotation>< / semantics>< / com:Math> haloalkyl, <com:Math><semantics>−C3−C9<annotation encoding="application / x-tex">-C_3-C_9< / annotation>< / semantics>< / com:Math> cycloalkyl, 3-10 membered heterocyclyl, <com:Math><semantics>−ORa1<annotation encoding="application / x-tex">-OR^{a1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(Ra1)2<annotation encoding="application / x-tex">-N(R^{a1})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)Ra1<annotation encoding="application / x-tex">-C(=O)R^{a1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)ORa1<annotation encoding="application / x-tex">-C(=O)OR^{a1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)ORa1<annotation encoding="application / x-tex">-C(=O)OR^{a1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)ORa1<annotation encoding="application / x-tex">-C(=O)OR^{a1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)ORa1<annotation encoding="application / x-tex">-C(=O)OR^{a1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)ORa1<annotation encoding="application / x-tex">-C(=O)OR^{a1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)ORa1<annotation encoding="application / x-tex">-C(=O)OR^{a1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)ORa1<annotation encoding="application / x-tex">-C(=O)OR^{a1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)<annotation encoding="application / x-tex">-C(=O)< / annotation>< / semantics>< / com:Math> <com:Math><semantics>NRa1C(=O)Ra1<annotation encoding="application / x-tex">NR^{a1}C(=O)R^{a1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRa1C(=O)ORa1<annotation encoding="application / x-tex">-NR^{a1}C(=O)OR^{a1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)N(Ra1)2<annotation encoding="application / x-tex">-C(=O)N(R^{a1})_2< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>−OC(=O)N(Ra1)2<annotation encoding="application / x-tex">-OC(=O)N(R^{a1})_2< / annotation>< / semantics>< / com:Math>.
11. A compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein <com:Math><semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics>< / com:Math> is selected from H, halo, <com:Math><semantics>−CN<annotation encoding="application / x-tex">-CN< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C1−C6<annotation encoding="application / x-tex">-C_1-C_6< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>−C1−C6<annotation encoding="application / x-tex">-C_1-C_6< / annotation>< / semantics>< / com:Math> haloalkyl, <com:Math><semantics>−ORa1<annotation encoding="application / x-tex">-OR^{a1}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>−N(Ra1)2<annotation encoding="application / x-tex">-N(R^{a1})_2< / annotation>< / semantics>< / com:Math>.
12. A compound of any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, wherein <com:Math><semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics>< / com:Math> is selected from H, <com:Math><semantics>−C1−C6<annotation encoding="application / x-tex">-C_1-C_6< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>−C1−C6<annotation encoding="application / x-tex">-C_1-C_6< / annotation>< / semantics>< / com:Math> haloalkyl, <com:Math><semantics>−ORa1<annotation encoding="application / x-tex">-OR^{a1}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>−N(Ra1)2<annotation encoding="application / x-tex">-N(R^{a1})_2< / annotation>< / semantics>< / com:Math>.
13. A compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein each <com:Math><semantics>Ra1<annotation encoding="application / x-tex">R^{a1}< / annotation>< / semantics>< / com:Math> is independently selected from H, <com:Math><semantics>−C1−C6<annotation encoding="application / x-tex">-C_1-C_6< / annotation>< / semantics>< / com:Math> alkyl and <com:Math><semantics>−C1−C6<annotation encoding="application / x-tex">-C_1-C_6< / annotation>< / semantics>< / com:Math> haloalkyl.
14. A compound of any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, wherein <com:Math><semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics>< / com:Math> is selected from H, <com:Math><semantics>−C1−C6<annotation encoding="application / x-tex">-C_1-C_6< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>−C1−C6<annotation encoding="application / x-tex">-C_1-C_6< / annotation>< / semantics>< / com:Math> haloalkyl, <com:Math><semantics>−OH<annotation encoding="application / x-tex">-OH< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−O−(C1−C6<annotation encoding="application / x-tex">-O-(C_1-C_6< / annotation>< / semantics>< / com:Math> alkyl), <com:Math><semantics>−O−<annotation encoding="application / x-tex">-O-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>(C1−C6 haloalkyl)<annotation encoding="application / x-tex">(C_1-C_6 \text{ haloalkyl})< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NH2<annotation encoding="application / x-tex">-NH_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NH2<annotation encoding="application / x-tex">-NH_2< / annotation>< / semantics>< / com:Math> (<com:Math><semantics>C1−C6 alkyl<annotation encoding="application / x-tex">C_1-C_6 \text{ alkyl}< / annotation>< / semantics>< / com:Math>) and <com:Math><semantics>−N2<annotation encoding="application / x-tex">-N_2< / annotation>< / semantics>< / com:Math> (<com:Math><semantics>C1−C6 alkyl<annotation encoding="application / x-tex">C_1-C_6 \text{ alkyl}< / annotation>< / semantics>< / com:Math>)2.
15. A compound of any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, wherein R<com:Sup>1< / com:Sup> is selected from H, –Me, –Et, –CHF<com:Sub>2< / com:Sub>, –OMe, –OEt, –OCHF<com:Sub>2< / com:Sub>, –OCF<com:Sub>3< / com:Sub>, –OH and – <com:Math><semantics>NH2<annotation encoding="application / x-tex">NH_2< / annotation>< / semantics>< / com:Math>.
16. A compound of any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, wherein R<com:Sup>1< / com:Sup> is selected from H, –Et, –OMe, –OEt, –OCHF<com:Sub>2< / com:Sub>, –OCF<com:Sub>3< / com:Sub> and –OH.
17. A compound of any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, wherein R<com:Sup>1< / com:Sup> is selected from H and –OMe.
18. A compound of any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, wherein <com:Math><semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics>< / com:Math> is H.
19. A compound of any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, wherein <com:Math><semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>−OMe<annotation encoding="application / x-tex">-OMe< / annotation>< / semantics>< / com:Math>.
20. A compound of any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, wherein <com:Math><semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics>< / com:Math> is selected from H, <com:Math><semantics>−Me<annotation encoding="application / x-tex">-Me< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CHF2<annotation encoding="application / x-tex">-CHF_2< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>−NH2<annotation encoding="application / x-tex">-NH_2< / annotation>< / semantics>< / com:Math>.
21. A compound of any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, wherein <com:Math><semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics>< / com:Math> is selected from <com:Math><semantics>−Me<annotation encoding="application / x-tex">-Me< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>−NH2<annotation encoding="application / x-tex">-NH_2< / annotation>< / semantics>< / com:Math>.
22. A compound of any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, wherein <com:Math><semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>−Me<annotation encoding="application / x-tex">-Me< / annotation>< / semantics>< / com:Math>.
23. A compound of any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, wherein <com:Math><semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>−NH2<annotation encoding="application / x-tex">-NH_2< / annotation>< / semantics>< / com:Math>.
24. A compound of any one of claims 1 to 23, or a pharmaceutically acceptable salt thereof, wherein <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is selected from halo, <com:Math><semantics>−CN<annotation encoding="application / x-tex">-CN< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C1−C6<annotation encoding="application / x-tex">-C_1-C_6< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>−C1−C6<annotation encoding="application / x-tex">-C_1-C_6< / annotation>< / semantics>< / com:Math> heteroalkyl, <com:Math><semantics>−C1−C6<annotation encoding="application / x-tex">-C_1-C_6< / annotation>< / semantics>< / com:Math> haloalkyl, <com:Math><semantics>−<annotation encoding="application / x-tex">-< / annotation>< / semantics>< / com:Math> C<com:Sub>1< / com:Sub>–C<com:Sub>6< / com:Sub> haloalkoxy, –C<com:Sub>3< / com:Sub>–C<com:Sub>9< / com:Sub> cycloalkyl, 3-6 membered heterocyclyl, –OR<com:Sup>a2< / com:Sup>, –N(R<com:Sup>a2< / com:Sup>)<com:Sub>2< / com:Sub>, –C(=O)R<com:Sup>a2< / com:Sup>, <com:Math><semantics>−C(=O)ORa2<annotation encoding="application / x-tex">-C(=O)OR^{a2}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRa2C(=O)Ra2<annotation encoding="application / x-tex">-NR^{a2}C(=O)R^{a2}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRa2C(=O)ORa2<annotation encoding="application / x-tex">-NR^{a2}C(=O)OR^{a2}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)N(Ra2)2<annotation encoding="application / x-tex">-C(=O)N(R^{a2})_2< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>−OC(=O)N(Ra2)2<annotation encoding="application / x-tex">-OC(=O)N(R^{a2})_2< / annotation>< / semantics>< / com:Math>.
25. A compound of any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, wherein <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is selected from halo, <com:Math><semantics>−CN<annotation encoding="application / x-tex">-CN< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C1−C6<annotation encoding="application / x-tex">-C_1-C_6< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>−C1−C6<annotation encoding="application / x-tex">-C_1-C_6< / annotation>< / semantics>< / com:Math> haloalkyl, <com:Math><semantics>−C1−C6<annotation encoding="application / x-tex">-C_1-C_6< / annotation>< / semantics>< / com:Math> haloalkoxy, <com:Math><semantics>−<annotation encoding="application / x-tex">-< / annotation>< / semantics>< / com:Math> C<com:Sub>3< / com:Sub>–C<com:Sub>9< / com:Sub> cycloalkyl, 3-6 membered heterocyclyl, –OR<com:Sup>a2< / com:Sup>, –N(R<com:Sup>a2< / com:Sup>)<com:Sub>2< / com:Sub>, –C(=O)R<com:Sup>a2< / com:Sup>, – <com:Math><semantics>C(=O)N(ORa2)(Ra2)<annotation encoding="application / x-tex">C(=O)N(OR^{a2})(R^{a2})< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>−C(=O)N(Ra2)2<annotation encoding="application / x-tex">-C(=O)N(R^{a2})_2< / annotation>< / semantics>< / com:Math>.
26. A compound of any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, wherein <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is selected from halo, <com:Math><semantics>−C1−C6<annotation encoding="application / x-tex">-C_1-C_6< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>−C1−C6<annotation encoding="application / x-tex">-C_1-C_6< / annotation>< / semantics>< / com:Math> haloalkyl, <com:Math><semantics>−C1−C6<annotation encoding="application / x-tex">-C_1-C_6< / annotation>< / semantics>< / com:Math> haloalkoxy, <com:Math><semantics>−C3−C9<annotation encoding="application / x-tex">-C_3-C_9< / annotation>< / semantics>< / com:Math> cycloalkyl, 3-6 membered heterocyclyl, <com:Math><semantics>−ORa2<annotation encoding="application / x-tex">-OR^{a2}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)N(ORa2)(Ra2)<annotation encoding="application / x-tex">-C(=O)N(OR^{a2})(R^{a2})< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)Ra2<annotation encoding="application / x-tex">-C(=O)R^{a2}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>−<annotation encoding="application / x-tex">-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>C(=O)N(Ra2)2<annotation encoding="application / x-tex">C(=O)N(R^{a2})_2< / annotation>< / semantics>< / com:Math>.
27. A compound of any one of claims 1 to 26, or a pharmaceutically acceptable salt thereof, wherein <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is selected from halo, <com:Math><semantics>−C1−C6<annotation encoding="application / x-tex">-C_1-C_6< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>−C3−C9<annotation encoding="application / x-tex">-C_3-C_9< / annotation>< / semantics>< / com:Math> cycloalkyl, <com:Math><semantics>−C1−C6<annotation encoding="application / x-tex">-C_1-C_6< / annotation>< / semantics>< / com:Math> haloalkoxy, 3-6 membered heterocyclyl, <com:Math><semantics>−C1−C6<annotation encoding="application / x-tex">-C_1-C_6< / annotation>< / semantics>< / com:Math> haloalkyl, <com:Math><semantics>−ORa2<annotation encoding="application / x-tex">-OR^{a2}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>−C(=O)N(Ra2)2<annotation encoding="application / x-tex">-C(=O)N(R^{a2})_2< / annotation>< / semantics>< / com:Math>.
28. A compound of any one of claims 1 to 27, or a pharmaceutically acceptable salt thereof, wherein each R<com:Sup>a2< / com:Sup> is independently selected from H and -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl.
29. A compound of any one of claims 1 to 28, or a pharmaceutically acceptable salt thereof, wherein <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is selected from halo, <com:Math><semantics>−C1−C6<annotation encoding="application / x-tex">-C_1-C_6< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>−C1−C6<annotation encoding="application / x-tex">-C_1-C_6< / annotation>< / semantics>< / com:Math> haloalkyl, <com:Math><semantics>−C1−C6<annotation encoding="application / x-tex">-C_1-C_6< / annotation>< / semantics>< / com:Math> haloalkoxy, <com:Math><semantics>−C3−C9<annotation encoding="application / x-tex">-C_3-C_9< / annotation>< / semantics>< / com:Math> cycloalkyl, 3-6 membered heterocyclyl, <com:Math><semantics>−OMe<annotation encoding="application / x-tex">-OMe< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)H<annotation encoding="application / x-tex">-C(=O)H< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)NHOH<annotation encoding="application / x-tex">-C(=O)NHOH< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>−C(=O)NH2<annotation encoding="application / x-tex">-C(=O)NH_2< / annotation>< / semantics>< / com:Math>.
30. A compound of any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, wherein <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is selected from <com:Math><semantics>−C1<annotation encoding="application / x-tex">-C1< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−Me<annotation encoding="application / x-tex">-Me< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−Et<annotation encoding="application / x-tex">-Et< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−iPr<annotation encoding="application / x-tex">-iPr< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CF3<annotation encoding="application / x-tex">-CF_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CHF2<annotation encoding="application / x-tex">-CHF_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OCHF2<annotation encoding="application / x-tex">-OCHF_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OCF3<annotation encoding="application / x-tex">-OCF_3< / annotation>< / semantics>< / com:Math>, cyclopropyl, oxetan-3-yl, tetrahydrofuran-3-yl, <com:Math><semantics>−OMe<annotation encoding="application / x-tex">-OMe< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)H<annotation encoding="application / x-tex">-C(=O)H< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)NHOH<annotation encoding="application / x-tex">-C(=O)NHOH< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>−C(=O)NH2<annotation encoding="application / x-tex">-C(=O)NH_2< / annotation>< / semantics>< / com:Math>.
31. A compound of any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, wherein <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is selected from <com:Math><semantics>−C(=O)NH2<annotation encoding="application / x-tex">-C(=O)NH_2< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>−C(=O)H<annotation encoding="application / x-tex">-C(=O)H< / annotation>< / semantics>< / com:Math>.
32. A compound of any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, wherein <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>−C(=O)NH2<annotation encoding="application / x-tex">-C(=O)NH_2< / annotation>< / semantics>< / com:Math>.
33. A compound of any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, wherein <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is selected from <com:Math><semantics>−Cl<annotation encoding="application / x-tex">-Cl< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−Me<annotation encoding="application / x-tex">-Me< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−Et<annotation encoding="application / x-tex">-Et< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−iPr<annotation encoding="application / x-tex">-iPr< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CF3<annotation encoding="application / x-tex">-CF_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CHF2<annotation encoding="application / x-tex">-CHF_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OCHF2<annotation encoding="application / x-tex">-OCHF_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OCF3<annotation encoding="application / x-tex">-OCF_3< / annotation>< / semantics>< / com:Math>, oxetan-3-yl, tetrahydrofuran-3-yl and cyclopropyl.
34. A compound of any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, wherein R<com:Sup>2< / com:Sup> is selected from cyclopropyl, –Me and –Et.
35. A compound of any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein R<com:Sup>1< / com:Sup> is selected from H, –OMe, –OEt, –OCF<com:Sub>3< / com:Sub>, –OCHF<com:Sub>2< / com:Sub>, –CHF<com:Sub>2< / com:Sub>, –Me, –Et, –OH and – NH<com:Sub>2< / com:Sub> and R<com:Sup>2< / com:Sup> is selected from <com:Math><semantics>−Cl<annotation encoding="application / x-tex">-Cl< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−Me<annotation encoding="application / x-tex">-Me< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−Et<annotation encoding="application / x-tex">-Et< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−i<annotation encoding="application / x-tex">-i< / annotation>< / semantics>< / com:Math>Pr, <com:Math><semantics>−CF3<annotation encoding="application / x-tex">-CF_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CHF2<annotation encoding="application / x-tex">-CHF_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OCHF2<annotation encoding="application / x-tex">-OCHF_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OCF3<annotation encoding="application / x-tex">-OCF_3< / annotation>< / semantics>< / com:Math>, cyclopropyl, <com:Math><semantics>−<annotation encoding="application / x-tex">-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>C(=O)NH2<annotation encoding="application / x-tex">C(=O)NH_2< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>−C(=O)H<annotation encoding="application / x-tex">-C(=O)H< / annotation>< / semantics>< / com:Math>, provided that when <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>−Me<annotation encoding="application / x-tex">-Me< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>NH2<annotation encoding="application / x-tex">NH_2< / annotation>< / semantics>< / com:Math>.
36. A compound of any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein R<com:Sup>1< / com:Sup> is selected from H, -CHF<com:Sub>2< / com:Sub>, -Me and -NH<com:Sub>2< / com:Sub> and R<com:Sup>2< / com:Sup> is selected from -Cl, -Me, -Et, - <com:Math><semantics>CF3<annotation encoding="application / x-tex">CF_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CHF2<annotation encoding="application / x-tex">-CHF_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OCHF2<annotation encoding="application / x-tex">-OCHF_2< / annotation>< / semantics>< / com:Math> and cyclopropyl, provided that when <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>−Me<annotation encoding="application / x-tex">-Me< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>NH2<annotation encoding="application / x-tex">NH_2< / annotation>< / semantics>< / com:Math>.
37. A compound of any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein <com:Math><semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics>< / com:Math> is selected from <com:Math><semantics>−NH2<annotation encoding="application / x-tex">-NH_2< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>−Me<annotation encoding="application / x-tex">-Me< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is selected from cyclopropyl, <com:Math><semantics>−Me<annotation encoding="application / x-tex">-Me< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>−Et<annotation encoding="application / x-tex">-Et< / annotation>< / semantics>< / com:Math>.
38. A compound of claim 37, or a pharmaceutically acceptable salt thereof, wherein R<com:Sup>1< / com:Sup> is – NH<com:Sub>2< / com:Sub> and R<com:Sup>2< / com:Sup> is selected from cyclopropyl, –Me and –Et.
39. A compound of any one of claims 1 to 35, or a pharmaceutically acceptable salt thereof, wherein R<com:Sup>1< / com:Sup> is selected from H, –OMe, –OEt, –OCF<com:Sub>3< / com:Sub>, –OCHF<com:Sub>2< / com:Sub>, –Et and –OH and R<com:Sup>2< / com:Sup> is selected from <com:Math><semantics>−C(=O)NH2<annotation encoding="application / x-tex">-C(=O)NH_2< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>−C(=O)H<annotation encoding="application / x-tex">-C(=O)H< / annotation>< / semantics>< / com:Math>.
40. A compound of claim 39, or a pharmaceutically acceptable salt thereof, wherein R<com:Sup>1< / com:Sup> is selected from H and –OMe and <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is –C(=O)NH<com:Sub>2< / com:Sub>.
41. A compound of any one of claims 1 to 40, or a pharmaceutically acceptable salt thereof, wherein R<com:Sup>3< / com:Sup> is selected from H, halo, -CN, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> heteroalkyl, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> haloalkyl, -C<com:Sub>3< / com:Sub>-C<com:Sub>9< / com:Sub> cycloalkyl, 3-10 membered heterocyclyl, -OR<com:Sup>a3< / com:Sup>, -N(R<com:Sup>a3< / com:Sup>)<com:Sub>2< / com:Sub>, -C(=O)R<com:Sup>a3< / com:Sup>, -C(=O)OR<com:Sup>a3< / com:Sup>, - <com:Math><semantics>NRa3C(=O)Ra3<annotation encoding="application / x-tex">NR^{a3}C(=O)R^{a3}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRa3C(=O)ORa3<annotation encoding="application / x-tex">-NR^{a3}C(=O)OR^{a3}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)N(Ra3)2<annotation encoding="application / x-tex">-C(=O)N(R^{a3})_2< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>−OC(=O)N(Ra3)2<annotation encoding="application / x-tex">-OC(=O)N(R^{a3})_2< / annotation>< / semantics>< / com:Math>.
42. The compound of any one of claims 1 to 41, or a pharmaceutically acceptable salt thereof, wherein R<com:Sup>3< / com:Sup> is selected from H, halo, -CN, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> haloalkyl and -N(R<com:Sup>a3< / com:Sup>)<com:Sub>2< / com:Sub>.
43. The compound of any one of claims 1 to 42, or a pharmaceutically acceptable salt thereof, wherein R<com:Sup>a3< / com:Sup> is selected from H and C<com:Sub>1< / com:Sub>–C<com:Sub>6< / com:Sub> alkyl.
44. The compound of any one of claims 1 to 43, or a pharmaceutically acceptable salt thereof, wherein <com:Math><semantics>R3<annotation encoding="application / x-tex">R^3< / annotation>< / semantics>< / com:Math> is selected from <com:Math><semantics>−C1−C6<annotation encoding="application / x-tex">-C_1-C_6< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>−OH<annotation encoding="application / x-tex">-OH< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−O−(C1−C6<annotation encoding="application / x-tex">-O-(C_1-C_6< / annotation>< / semantics>< / com:Math> alkyl), <com:Math><semantics>−NH2<annotation encoding="application / x-tex">-NH_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NH−(C1−C6)<annotation encoding="application / x-tex">-NH-(C_1-C_6)< / annotation>< / semantics>< / com:Math> alkyl) and <com:Math><semantics>−N−(C1−C6 alkyl)2<annotation encoding="application / x-tex">-N-(C_1-C_6 \text{ alkyl})_2< / annotation>< / semantics>< / com:Math>.
45. The compound of any one of claims 1 to 44, or a pharmaceutically acceptable salt thereof, wherein R<com:Sup>3< / com:Sup> is selected from H, –Me and –NH<com:Sub>2< / com:Sub>.
46. The compound of any one of claims 1 to 44, or a pharmaceutically acceptable salt thereof, wherein <com:Math><semantics>R3<annotation encoding="application / x-tex">R^3< / annotation>< / semantics>< / com:Math> is selected from H and <com:Math><semantics>−Me<annotation encoding="application / x-tex">-Me< / annotation>< / semantics>< / com:Math>.
47. The compound of any one of claims 1 to 44, or a pharmaceutically acceptable salt thereof, wherein <com:Math><semantics>R3<annotation encoding="application / x-tex">R^3< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>−Me<annotation encoding="application / x-tex">-Me< / annotation>< / semantics>< / com:Math>.
48. A compound of any one of claims 1 to 47, or a pharmaceutically acceptable salt thereof, wherein <com:Math><semantics>R4<annotation encoding="application / x-tex">R^4< / annotation>< / semantics>< / com:Math> is selected from H, halo, <com:Math><semantics>−CN<annotation encoding="application / x-tex">-CN< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C1−C6<annotation encoding="application / x-tex">-C_1-C_6< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>−C1−C6<annotation encoding="application / x-tex">-C_1-C_6< / annotation>< / semantics>< / com:Math> heteroalkyl, <com:Math><semantics>−C1−C6<annotation encoding="application / x-tex">-C_1-C_6< / annotation>< / semantics>< / com:Math> haloalkyl, <com:Math><semantics>−C3−C9<annotation encoding="application / x-tex">-C_3-C_9< / annotation>< / semantics>< / com:Math> cycloalkyl, 3-10 membered heterocyclyl, <com:Math><semantics>−ORa4<annotation encoding="application / x-tex">-OR^{a4}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(Ra4)2<annotation encoding="application / x-tex">-N(R^{a4})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)Ra4<annotation encoding="application / x-tex">-C(=O)R^{a4}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)ORa4<annotation encoding="application / x-tex">-C(=O)OR^{a4}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)ORa4<annotation encoding="application / x-tex">-C(=O)OR^{a4}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)ORa4<annotation encoding="application / x-tex">-C(=O)OR^{a4}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)ORa4<annotation encoding="application / x-tex">-C(=O)OR^{a4}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)ORa4<annotation encoding="application / x-tex">-C(=O)OR^{a4}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)ORa4<annotation encoding="application / x-tex">-C(=O)OR^{a4}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)ORa4<annotation encoding="application / x-tex">-C(=O)OR^{a4}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)<annotation encoding="application / x-tex">-C(=O)< / annotation>< / semantics>< / com:Math> <com:Math><semantics>NRa4C(=O)Ra4<annotation encoding="application / x-tex">NR^{a4}C(=O)R^{a4}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRa4C(=O)ORa4<annotation encoding="application / x-tex">-NR^{a4}C(=O)OR^{a4}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)N(Ra4)2<annotation encoding="application / x-tex">-C(=O)N(R^{a4})_2< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>−OC(=O)N(Ra4)2<annotation encoding="application / x-tex">-OC(=O)N(R^{a4})_2< / annotation>< / semantics>< / com:Math>.
49. The compound of any one of claims 1 to 48, or a pharmaceutically acceptable salt thereof, wherein <com:Math><semantics>R4<annotation encoding="application / x-tex">R^4< / annotation>< / semantics>< / com:Math> is selected from H, halo, <com:Math><semantics>−CN<annotation encoding="application / x-tex">-CN< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C1−C6<annotation encoding="application / x-tex">-C_1-C_6< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>−C1−C6<annotation encoding="application / x-tex">-C_1-C_6< / annotation>< / semantics>< / com:Math> haloalkyl and <com:Math><semantics>−N(Ra4)2<annotation encoding="application / x-tex">-N(R^{a4})_2< / annotation>< / semantics>< / com:Math>.
50. The compound of any one of claims 1 to 49, or a pharmaceutically acceptable salt thereof, wherein each R<com:Sup>a4< / com:Sup> is independently selected from H and -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl.
51. The compound of any one of claims 1 to 50, or a pharmaceutically acceptable salt thereof, wherein R<com:Sup>4< / com:Sup> is selected from -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, -OH, -O-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl), -NH<com:Sub>2< / com:Sub>, -NH-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl) and <com:Math><semantics>−N−(C1−C6 alkyl)2<annotation encoding="application / x-tex">-N-(C_1-C_6 \text{ alkyl})_2< / annotation>< / semantics>< / com:Math>.
52. The compound of any one of claims 1 to 51, or a pharmaceutically acceptable salt thereof, wherein R<com:Sup>4< / com:Sup> is H.
53. The compound of any one of claims 1 to 52, or a pharmaceutically acceptable salt thereof, wherein each R<com:Sup>6< / com:Sup> is independently selected from H, halo, -CN, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> heteroalkyl, –C<com:Sub>1< / com:Sub>–C<com:Sub>6< / com:Sub> haloalkyl, –C<com:Sub>3< / com:Sub>–C<com:Sub>10< / com:Sub> carbocyclyl, 3-10 membered heterocyclyl, heterocyclylalkyl, C<com:Sub>6< / com:Sub>–C<com:Sub>10< / com:Sub> aryl, 5-10 member heteroaryl, heteroarylalkyl, arylalkyl, <com:Math><semantics>cycloalkylalkyl,−ORa6,−N(Ra6)2,−C(=O)Ra6,−C(=O)ORa6,−NRa6C(=O)Ra6,−NRa6C(=O)ORa6,<annotation encoding="application / x-tex">cycloalkylalkyl, -OR^{a6}, -N(R^{a6})_2, -C(=O)R^{a6}, -C(=O)OR^{a6}, -NR^{a6}C(=O)R^{a6}, -NR^{a6}C(=O)OR^{a6},< / annotation>< / semantics>< / com:Math> <com:Math><semantics>−C(=O)N(Ra6)2<annotation encoding="application / x-tex">-C(=O)N(R^{a6})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(=O)N(Ra6)2<annotation encoding="application / x-tex">-OC(=O)N(R^{a6})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)Ra6<annotation encoding="application / x-tex">-S(=O)R^{a6}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)2Ra6<annotation encoding="application / x-tex">-S(=O)_2R^{a6}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−SRa6<annotation encoding="application / x-tex">-SR^{a6}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)(=NRa6)Ra6<annotation encoding="application / x-tex">-S(=O)(=NR^{a6})R^{a6}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)(=NRa6)Ra6<annotation encoding="application / x-tex">-S(=O)(=NR^{a6})R^{a6}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)(=NRa6)Ra6<annotation encoding="application / x-tex">-S(=O)(=NR^{a6})R^{a6}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)(=NRa6)Ra6<annotation encoding="application / x-tex">-S(=O)(=NR^{a6})R^{a6}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)(=NRa6)Ra6<annotation encoding="application / x-tex">-S(=O)(=NR^{a6})R^{a6}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−<annotation encoding="application / x-tex">-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>NRa6S(=O)2Ra6<annotation encoding="application / x-tex">NR^{a6}S(=O)_2R^{a6}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>−S(=O)2N(Ra6)2<annotation encoding="application / x-tex">-S(=O)_2N(R^{a6})_2< / annotation>< / semantics>< / com:Math>, wherein each alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl is substituted at any available position with 0, 1, 2 or 3 instances of <com:Math><semantics>ℝ10<annotation encoding="application / x-tex">\mathbb{R}^{10}< / annotation>< / semantics>< / com:Math>.
54. The compound of any one of claims 1 to 52, or a pharmaceutically acceptable salt thereof, wherein each R<com:Sup>6< / com:Sup> is independently selected from halo, -CN, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> heteroalkyl, –C<com:Sub>1< / com:Sub>–C<com:Sub>6< / com:Sub> haloalkyl, –C<com:Sub>3< / com:Sub>–C<com:Sub>10< / com:Sub> carbocyclyl, 3-10 membered heterocyclyl, heterocyclylalkyl, C<com:Sub>6< / com:Sub>–C<com:Sub>10< / com:Sub> aryl, 5-10 member heteroaryl, heteroarylalkyl, arylalkyl, cycloalkylalkyl, <com:Math><semantics>−ORa6<annotation encoding="application / x-tex">-OR^{a6}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(Ra6)2<annotation encoding="application / x-tex">-N(R^{a6})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)Ra6<annotation encoding="application / x-tex">-C(=O)R^{a6}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)ORa6<annotation encoding="application / x-tex">-C(=O)OR^{a6}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRa6C(=O)Ra6<annotation encoding="application / x-tex">-NR^{a6}C(=O)R^{a6}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRa6C(=O)ORa6<annotation encoding="application / x-tex">-NR^{a6}C(=O)OR^{a6}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)N(Ra6)2<annotation encoding="application / x-tex">-C(=O)N(R^{a6})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(=O)N(Ra6)2<annotation encoding="application / x-tex">-OC(=O)N(R^{a6})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)Ra6<annotation encoding="application / x-tex">-S(=O)R^{a6}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)2Ra6<annotation encoding="application / x-tex">-S(=O)_2R^{a6}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−SRa6<annotation encoding="application / x-tex">-SR^{a6}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)(=NRa6)Ra6<annotation encoding="application / x-tex">-S(=O)(=NR^{a6})R^{a6}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)(=NRa6)Ra6<annotation encoding="application / x-tex">-S(=O)(=NR^{a6})R^{a6}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)(=NRa6)Ra6<annotation encoding="application / x-tex">-S(=O)(=NR^{a6})R^{a6}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)(=NRa6)Ra6<annotation encoding="application / x-tex">-S(=O)(=NR^{a6})R^{a6}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)(=NRa6)Ra6<annotation encoding="application / x-tex">-S(=O)(=NR^{a6})R^{a6}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−<annotation encoding="application / x-tex">-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>NRa6S(=O)2Ra6<annotation encoding="application / x-tex">NR^{a6}S(=O)_2R^{a6}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>−S(=O)2N(Ra6)2<annotation encoding="application / x-tex">-S(=O)_2N(R^{a6})_2< / annotation>< / semantics>< / com:Math>, wherein each alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl is substituted at any available position with 0, 1, 2 or 3 instances of <com:Math><semantics>ℝ10<annotation encoding="application / x-tex">\mathbb{R}^{10}< / annotation>< / semantics>< / com:Math>.
55. A compound of any one of claims 1 to 54, or a pharmaceutically acceptable salt thereof, wherein each R<com:Sup>a6< / com:Sup> is independently selected from H and –C<com:Sub>1< / com:Sub>–C<com:Sub>6< / com:Sub> alkyl.
56. The compound of any one of claims 1 to 52, or a pharmaceutically acceptable salt thereof, wherein each R<com:Sup>6< / com:Sup> is independently selected from H, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> heteroalkyl, - C<com:Sub>1< / com:Sub>–C<com:Sub>6< / com:Sub> haloalkyl, –C<com:Sub>3< / com:Sub>–C<com:Sub>10< / com:Sub> carbocyclyl, 3-10 membered heterocyclyl, heterocyclylalkyl, C<com:Sub>6< / com:Sub>–C<com:Sub>10< / com:Sub> aryl, 5-10 member heteroaryl, heteroarylalkyl, arylalkyl and cycloalkylalkyl, wherein each alkyl, cycloalkyl, heterocyclyl, cycloalkylalkyl, heterocyclylalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl is substituted at any available position with 0, 1, 2 or 3 instances of <com:Math><semantics>ℝ10<annotation encoding="application / x-tex">\mathbb{R}^{10}< / annotation>< / semantics>< / com:Math>.
57. The compound of any one of claims 1 to 52, or a pharmaceutically acceptable salt thereof, wherein each R<com:Sup>6< / com:Sup> is independently selected from -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> heteroalkyl, -C<com:Sub>1< / com:Sub>- C<com:Sub>6< / com:Sub> haloalkyl, –C<com:Sub>3< / com:Sub>–C<com:Sub>10< / com:Sub> carbocyclyl, 3-10 membered heterocyclyl, heterocyclylalkyl, C<com:Sub>6< / com:Sub>–C<com:Sub>10< / com:Sub> aryl, 5-10 member heteroaryl, heteroarylalkyl, arylalkyl and cycloalkylalkyl, wherein each alkyl, cycloalkyl, heterocyclyl, cycloalkylalkyl, heterocyclylalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl is substituted at any available position with <com:Math><semantics>0,1,2<annotation encoding="application / x-tex">0, 1, 2< / annotation>< / semantics>< / com:Math> or <com:Math><semantics>3<annotation encoding="application / x-tex">3< / annotation>< / semantics>< / com:Math> instances of <com:Math><semantics>R10<annotation encoding="application / x-tex">R^{10}< / annotation>< / semantics>< / com:Math>.
58. The compound of any one of claims 1 to 52, or a pharmaceutically acceptable salt thereof, wherein each R<com:Sup>6< / com:Sup> is independently selected from H, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, -C<com:Sub>3< / com:Sub>-C<com:Sub>10< / com:Sub> monocyclic or bicyclic carbocyclyl, 3-10 membered mono or bicyclic heterocyclyl, C<com:Sub>6< / com:Sub>–C<com:Sub>10< / com:Sub> mono or bicyclic aryl, 5-6 member monocyclic heteroaryl and 8-10 member bicyclic heteroaryl, wherein each alkyl, carbocyclyl, heterocyclyl, aryl and heteroaryl is substituted at any available position with <com:Math><semantics>0,1,2 or 3 instances of ℝ10<annotation encoding="application / x-tex">0, 1, 2 \text{ or } 3 \text{ instances of } \mathbb{R}^{10}< / annotation>< / semantics>< / com:Math>.
59. The compound of any one of claims 1 to 52, or a pharmaceutically acceptable salt thereof, wherein each R<com:Sup>6< / com:Sup> is independently selected from -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, -C<com:Sub>3< / com:Sub>-C<com:Sub>10< / com:Sub> monocyclic or bicyclic carbocyclyl, 3-10 membered mono or bicyclic heterocyclyl, C<com:Sub>6< / com:Sub>–C<com:Sub>10< / com:Sub> mono or bicyclic aryl, 5-6 member monocyclic heteroaryl and 8-10 member bicyclic heteroaryl, wherein each alkyl, carbocyclyl, heterocyclyl, aryl and heteroaryl is substituted at any available position with <com:Math><semantics>0,1,2<annotation encoding="application / x-tex">0, 1, 2< / annotation>< / semantics>< / com:Math> or 3 instances of <com:Math><semantics>ℝ10<annotation encoding="application / x-tex">\mathbb{R}^{10}< / annotation>< / semantics>< / com:Math>.
60. The compound of claim 58, or a pharmaceutically acceptable salt thereof, wherein R<com:Sup>6< / com:Sup> is an 8-10 member bicyclic heteroaryl, wherein the bicyclic heteroaryl is substituted at any available position with 0, 1, 2 or 3 instances of <com:Math><semantics>ℝ10<annotation encoding="application / x-tex">\mathbb{R}^{10}< / annotation>< / semantics>< / com:Math>.
61. The compound of any one of claims 1 to 52, or a pharmaceutically acceptable salt thereof, wherein each <com:Math><semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>< / com:Math> is independently selected from H, <com:Math><semantics>−Me<annotation encoding="application / x-tex">-Me< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−iPr<annotation encoding="application / x-tex">-^iPr< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−iBu<annotation encoding="application / x-tex">-^iBu< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>sec<annotation encoding="application / x-tex">sec< / annotation>< / semantics>< / com:Math>-Bu, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[1.1.1]pentan-1-yl, spiro[3.3]heptan-2-yl, 4,5,6,7-tetrahydro-1H- indazol-6-yl, piperidin-4-yl, piperidin-3-yl, pyrrolidin-3-yl, 1,2-dihydropyridin-4-yl, phenyl, naphthalen-2-yl, 1,2,3,4-tetrahydroquinolin-6-yl, 1,2,3,4-tetrahydronaphthalen-6-yl, chroman-6- yl, 1,5-naphthyridin-6-yl, 1,2,3,4-tetrahydro-1,8-naphthyridin-6-yl, 2,3-dihydro-1H-inden-5-yl, indolin-5-yl, indolin-4-yl, 2,3-dihydro-1H-benzo[d]imidazol-5-yl, 2,3-dihydrobenzofuran-5-yl, 2,3-dihydrobenzofuran-6-yl, benzo<com:Math><semantics>[d]<annotation encoding="application / x-tex">[d]< / annotation>< / semantics>< / com:Math>[1,3] dioxol-5-yl], isoindolin-5-yl, isoindolin-6-yl, 3,4- dihydro-2H-benzo[b][1,4]oxazin-7-yl, 1,2-dihydroquinolin-6-yl, 1,2-dihydroisoquinolin-7-yl, thiophen-2-yl, thiophen-3-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, pyrazol-1-yl, pyrazol-5-yl, pyrazol-3-yl, pyrazol-4-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-5-yl, indol-4-yl, indol-5-yl, benzofuran-5-yl, benzofuran-6-yl, 1H indazol-5-yl, 1H indazol-4-yl, 2H-indazol-6-yl, 2H-indazol-5-yl, benzo[b]thiophen-3-yl, benzo[b]thiophen-5-yl, quinolin-6-yl, quinoline-3-yl, isoquinolin-6-yl, benzo[d]imidazo-5-yl, 1H-benzo[d]imidazol-4-yl, benzo[d]thiazol-5-yl, benzo[d]thiazol-6-yl, benzo[d]thiazol-4-yl, benzo[d]isothiazol-5-yl, benzo[d]oxazol-4-yl, benzo[d]oxazol-5-yl, [1,2,4]triazolo[4,3-a]pyridin-6-yl, imidazo[1,2-a]pyridin-6-yl, imidazo[1,2- a]pyridin-7-yl, imidazo[1,5-a]pyridin-6-yl, pyrazolo[4,3-b]pyridin-6-yl, 1H-pyrazolo[3,4- b]pyridin-5-yl, 1H-pyrazolo[4,3-b]pyridin-5-yl, 1H-pyrazolo[4,3-b]pyridin-6-yl, 1H-thieno[2,3- c]pyrazol-5-yl, 1H-thieno[3,2-c]pyrazol-5-yl and thiazolo[5,4-b]pyridin-6-yl), each substituted at any available position with 0, 1, 2 or 3 instances of <com:Math><semantics>ℝ10<annotation encoding="application / x-tex">\mathbb{R}^{10}< / annotation>< / semantics>< / com:Math>.
62. The compound of any one of claims 1 to 52, or a pharmaceutically acceptable salt thereof, wherein each <com:Math><semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>< / com:Math> is independently selected from <com:Math><semantics>−Me<annotation encoding="application / x-tex">-Me< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−iPr<annotation encoding="application / x-tex">-^iPr< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−iBu<annotation encoding="application / x-tex">-^iBu< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>sec<annotation encoding="application / x-tex">sec< / annotation>< / semantics>< / com:Math>-Bu, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[1.1.1]pentan-1-yl, spiro[3.3]heptan-2-yl, 4,5,6,7-tetrahydro-1H- indazol-6-yl, piperidin-4-yl, piperidin-3-yl, pyrrolidin-3-yl, 1,2-dihydropyridin-4-yl, phenyl, naphthalen-2-yl, 1,2,3,4 tetrahydroquinolin-6-yl, 1,2,3,4-tetrahydronaphthalen-6-yl, chroman-6- yl, 1,5-naphthyridin-6-yl, 1,2,3,4-tetrahydro-1,8-naphthyridin-6-yl, 2,3-dihydro-1H-inden-5-yl, indolin-5-yl, indolin-4-yl, 2,3-dihydro-1H-benzo[d]imidazol-5-yl, 2,3-dihydrobenzofuran-5-yl, 2,3-dihydrobenzofuran-6-yl, benzo<com:Math><semantics>[d]<annotation encoding="application / x-tex">[d]< / annotation>< / semantics>< / com:Math>[1,3] dioxol-5-yl], isoindolin-5-yl, isoindolin-6-yl, 3,4- dihydro-2H-benzo[b][1,4]oxazin-7-yl, 1,2-dihydroquinolin-6-yl, 1,2-dihydroisoquinolin-7-yl, thiophen-2-yl, thiophen-3-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, pyrazol-1-yl, pyrazol-5-yl, pyrazol-3-yl, pyrazol-4-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-5-yl, indol-4-yl, indol-5-yl, benzofuran-5-yl, benzofuran-6-yl, 1H indazol-5-yl, 1H indazol-4-yl, 2H-indazol-6-yl, 2H-indazol-5-yl, benzo[b]thiophen-3-yl, benzo[b]thiophen-5-yl, quinolin-6-yl, quinoline-3-yl, isoquinolin-6-yl, benzo[d]imidazo-5-yl, 1H-benzo[d]imidazol-4-yl, benzo[d]thiazol-5-yl, benzo[d]thiazol-6-yl, benzo[d]thiazol-4-yl, benzo[d]isothiazol-5-yl, benzo[d]oxazol-4-yl, benzo[d]oxazol-5-yl, [1,2,4]triazolo[4,3-a]pyridin-6-yl, imidazo[1,2-a]pyridin-6-yl, imidazo[1,2- a]pyridin-7-yl, imidazo[1,5-a]pyridin-6-yl, pyrazolo[4,3-b]pyridin-6-yl, 1H-pyrazolo[3,4- b]pyridin-5-yl, 1H-pyrazolo[4,3-b]pyridin-5-yl, 1H-pyrazolo[4,3-b]pyridin-6-yl, 1H-thieno[2,3- c]pyrazol-5-yl, 1H-thieno[3,2-c]pyrazol-5-yl and thiazolo[5,4-b]pyridin-6-yl), each substituted at any available position with 0, 1, 2 or 3 instances of <com:Math><semantics>ℝ10<annotation encoding="application / x-tex">\mathbb{R}^{10}< / annotation>< / semantics>< / com:Math>.
63. The compound of any one of claims 1 to 52, or a pharmaceutically acceptable salt thereof, wherein R<com:Sup>6< / com:Sup> is selected from phenyl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl and pyrimidin-5-yl, substituted at any available position with 0, 1, 2 or 3 instances of <com:Math><semantics>ℝ10<annotation encoding="application / x-tex">\mathbb{R}^{10}< / annotation>< / semantics>< / com:Math>.
64. The compound of any one of claims 1 to 63, or a pharmaceutically acceptable salt thereof, wherein each <com:Math><semantics>R10<annotation encoding="application / x-tex">R^{10}< / annotation>< / semantics>< / com:Math> is independently selected from <com:Math><semantics>−D<annotation encoding="application / x-tex">-D< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>=O<annotation encoding="application / x-tex">=O< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CN<annotation encoding="application / x-tex">-CN< / annotation>< / semantics>< / com:Math>, halo, <com:Math><semantics>−C1−C6<annotation encoding="application / x-tex">-C_1-C_6< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>−C1−C6<annotation encoding="application / x-tex">-C_1-C_6< / annotation>< / semantics>< / com:Math> C<com:Sub>6< / com:Sub> heteroalkyl, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> haloalkyl, -C<com:Sub>3< / com:Sub>-C<com:Sub>9< / com:Sub> cycloalkyl, 3-10 membered heterocyclyl, C<com:Sub>6< / com:Sub>-C<com:Sub>10< / com:Sub> aryl, 5-10 membered heteroaryl, cycloalkylalkyl, arylalkyl, heteroarylalkyl, heterocyclylalkoxy, heterocyclylalkyl, <com:Math><semantics>−ORb10<annotation encoding="application / x-tex">-OR^{b10}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(Rb10)2<annotation encoding="application / x-tex">-N(R^{b10})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)Rb10<annotation encoding="application / x-tex">-C(=O)R^{b10}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)ORb10<annotation encoding="application / x-tex">-C(=O)OR^{b10}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRb10C(=O)Rb10<annotation encoding="application / x-tex">-NR^{b10}C(=O)R^{b10}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−<annotation encoding="application / x-tex">-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>NRb10C(=O)ORb10<annotation encoding="application / x-tex">NR^{b10}C(=O)OR^{b10}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)N(Rb10)2<annotation encoding="application / x-tex">-C(=O)N(R^{b10})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(=O)Rb10<annotation encoding="application / x-tex">-OC(=O)R^{b10}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(=O)N(Rb10)2<annotation encoding="application / x-tex">-OC(=O)N(R^{b10})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)Rb10<annotation encoding="application / x-tex">-S(=O)R^{b10}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)2Rb10<annotation encoding="application / x-tex">-S(=O)_2R^{b10}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−SRb10<annotation encoding="application / x-tex">-SR^{b10}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)(=NRb10)Rb10<annotation encoding="application / x-tex">-S(=O)(=NR^{b10})R^{b10}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRb10S(=O)2Rb10<annotation encoding="application / x-tex">-NR^{b10}S(=O)_2R^{b10}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>−S(=O)2N(Rb10)2<annotation encoding="application / x-tex">-S(=O)_2N(R^{b10})_2< / annotation>< / semantics>< / com:Math>, wherein each alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl of R<com:Sup>10< / com:Sup> is substituted with 0, 1, 2, 3, 4, or 5 instances of –Me, –Et, – <com:Sup>i< / com:Sup>Pr, cyclopropyl, oxetan-3-yl, -OH, =O, -F, -OMe, -CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>F, -CH<com:Sub>2< / com:Sub>CHF<com:Sub>2< / com:Sub>, -CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>CF<com:Sub>3< / com:Sub>, - <com:Math><semantics>C(=O)Me,−N(Me)2,−CH2N(CH3)2,−CH2N(CH3)CH2CH3,−N(iPr)(Et),−N(iPr)(Me),−N(Et)2,−<annotation encoding="application / x-tex">C(=O)Me, -N(Me)_2, -CH_2N(CH_3)_2, -CH_2N(CH_3)CH_2CH_3, -N(^iPr)(Et), -N(^iPr)(Me), -N(Et)_2, -< / annotation>< / semantics>< / com:Math> <com:Math><semantics>N(CH3)(Et)<annotation encoding="application / x-tex">N(CH_3)(Et)< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NHC(=O)Me<annotation encoding="application / x-tex">-NHC(=O)Me< / annotation>< / semantics>< / com:Math>, or a combination thereof, and wherein: each R<com:Sup>b10< / com:Sup> is independently selected from H, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> haloalkyl, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> heteroalkyl substituted with 0 or 1 instance of =O, C<com:Sub>3< / com:Sub>–C<com:Sub>9< / com:Sub> cycloalkyl and a 3-10 member heterocyclyl substituted with 0 or 1 instances of <com:Math><semantics>=0<annotation encoding="application / x-tex">=0< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−Me<annotation encoding="application / x-tex">-Me< / annotation>< / semantics>< / com:Math> or a combination thereof.
65. The compound of claim 63 or 64, or a pharmaceutically acceptable salt thereof, wherein R<com:Sup>6< / com:Sup> is selected from phenyl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, and pyrimidin-5-yl substituted with one instance of <com:Math><semantics>R10<annotation encoding="application / x-tex">R^{10}< / annotation>< / semantics>< / com:Math>.
66. The compound of claim 63 or 64, or a pharmaceutically acceptable salt thereof, wherein R<com:Sup>6< / com:Sup> is selected from: [Image disponible dans le document PDF, Image available in the PDF document] 67. The compound of claim 63 or 64, or a pharmaceutically acceptable salt thereof, wherein R<com:Sup>6< / com:Sup> is [Image disponible dans le document PDF, Image available in the PDF document] • 68. The compound of any one of claims 1 to 64, or a pharmaceutically acceptable salt thereof, wherein R<com:Sup>6< / com:Sup> is phenyl substituted at any available position with 0, 1, 2 or 3 instances of <com:Math><semantics>R10<annotation encoding="application / x-tex">R^{10}< / annotation>< / semantics>< / com:Math>.
69. The compound of claim 68, or a pharmaceutically acceptable salt thereof, wherein R<com:Sup>6< / com:Sup> is [Image disponible dans le document PDF, Image available in the PDF document] 70. The compound of any one of claims 1 to 59 and 64, or a pharmaceutically acceptable salt thereof, wherein R<com:Sup>6< / com:Sup> is a bicyclic heteroaryl substituted at any available position with 0, 1, 2 or 3 instances of <com:Math><semantics>R10<annotation encoding="application / x-tex">R^{10}< / annotation>< / semantics>< / com:Math>.
71. The compound of claim 70, or a pharmaceutically acceptable salt thereof, wherein R<com:Sup>6< / com:Sup> is selected from 1H-indazol-5-yl, 2H-indazol-5-yl, benzo[d]isothiazol-5-yl, benzo[d]thiazol-5-yl, benzo[b]thiophen-5-yl, benzo[d]oxazol-4-yl, benzo[d]oxazol-5-yl, quinoline-7-yl, 1H- thieno[2,3-c]pyrazol-5-yl, imidazo[1,2-a]pyridin-7-yl and imidazo[1,5-a]pyridin-6-yl substituted with <com:Math><semantics>0,1,2<annotation encoding="application / x-tex">0, 1, 2< / annotation>< / semantics>< / com:Math> or <com:Math><semantics>3<annotation encoding="application / x-tex">3< / annotation>< / semantics>< / com:Math> instances of <com:Math><semantics>ℝ10<annotation encoding="application / x-tex">\mathbb{R}^{10}< / annotation>< / semantics>< / com:Math>.
72. The compound of claim 70, or a pharmaceutically acceptable salt thereof, wherein R<com:Sup>6< / com:Sup> is benzo[d]thiazol-5-yl substituted with 0, 1, 2 or 3 instances of R<com:Sup>10< / com:Sup>.
73. The compound of claim 71, or a pharmaceutically acceptable salt thereof, wherein R<com:Sup>6< / com:Sup> is [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] , or 74. The compound of claim 71, or a pharmaceutically acceptable salt thereof, wherein R<com:Sup>6< / com:Sup> is [Image disponible dans le document PDF, Image available in the PDF document] 75. The compound of any one of claims 1-74, or a pharmaceutically acceptable salt thereof, wherein each R<com:Sup>10< / com:Sup> is independently selected from –D, =O, halo, –CN, –C<com:Sub>1< / com:Sub>–C<com:Sub>6< / com:Sub> alkyl, –C<com:Sub>1< / com:Sub>–C<com:Sub>6< / com:Sub> heteroalkyl, –C<com:Sub>1< / com:Sub>–C<com:Sub>6< / com:Sub> haloalkyl, –C<com:Sub>3< / com:Sub>–C<com:Sub>9< / com:Sub> cycloalkyl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl, heterocyclylalkyl, heterocyclylalkoxy, heteroarylalkyl, –OR<com:Sup>b10< / com:Sup>, –N(R<com:Sup>b10< / com:Sup>)<com:Sub>2< / com:Sub>, – <com:Math><semantics>NRb10C(=O)Rb10<annotation encoding="application / x-tex">NR^{b10}C(=O)R^{b10}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)N(Rb10)2<annotation encoding="application / x-tex">-C(=O)N(R^{b10})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(=O)Rb10<annotation encoding="application / x-tex">-OC(=O)R^{b10}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)Rb10<annotation encoding="application / x-tex">-S(=O)R^{b10}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRb10S(=O)2Rb10<annotation encoding="application / x-tex">-NR^{b10}S(=O)_2R^{b10}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>−<annotation encoding="application / x-tex">-< / annotation>< / semantics>< / com:Math> S(=O)<com:Sub>2< / com:Sub>N(R<com:Sup>b10< / com:Sup>)<com:Sub>2< / com:Sub>, wherein each alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl is substituted with 0, 1, 2, 3, 4 or 5 instances of – Me, -Et, -iPr, cyclopropyl, oxetan-3-yl, -OH, =O, -F, -OMe, -CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>F, -CH<com:Sub>2< / com:Sub>CHF<com:Sub>2< / com:Sub>, - <com:Math><semantics>CH2CH2CF3<annotation encoding="application / x-tex">CH_2CH_2CF_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)Me<annotation encoding="application / x-tex">-C(=O)Me< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(Me)2<annotation encoding="application / x-tex">-N(Me)_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CH2N(CH3)2<annotation encoding="application / x-tex">-CH_2N(CH_3)_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CH2N(CH3)CH2CH3<annotation encoding="application / x-tex">-CH_2N(CH_3)CH_2CH_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(iPr)(Et)<annotation encoding="application / x-tex">-N(^iPr)(Et)< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−<annotation encoding="application / x-tex">-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>N(iPr)(Me)<annotation encoding="application / x-tex">N(^{i}Pr)(Me)< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(Et)2<annotation encoding="application / x-tex">-N(Et)_{2}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(CH3)(Et)<annotation encoding="application / x-tex">-N(CH_{3})(Et)< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NHC(=O)Me<annotation encoding="application / x-tex">-NHC(=O)Me< / annotation>< / semantics>< / com:Math>, or a combination thereof, and wherein: each R<com:Sup>b10< / com:Sup> is independently selected from H, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> haloalkyl, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> heteroalkyl substituted with 0 or 1 instances of =O, C<com:Sub>3< / com:Sub>–C<com:Sub>9< / com:Sub> cycloalkyl, and 3-10 member heterocyclyl substituted with 0 or 1 instances of <com:Math><semantics>=0<annotation encoding="application / x-tex">=0< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−Me<annotation encoding="application / x-tex">-Me< / annotation>< / semantics>< / com:Math> or a combination thereof.
76. The compound of any one of claims 1-75, or a pharmaceutically acceptable salt thereof, wherein each <com:Math><semantics>Rb10<annotation encoding="application / x-tex">R^{b10}< / annotation>< / semantics>< / com:Math> is independently selected from H, -Me, -Et, -Pr, -iPr, -sec-Bu, -tBu, -CF<com:Sub>3< / com:Sub>, - <com:Math><semantics>CHF2<annotation encoding="application / x-tex">CHF_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CH2CF3<annotation encoding="application / x-tex">-CH_2CF_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CH2CH2NMe2<annotation encoding="application / x-tex">-CH_2CH_2NMe_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CH2C(=O)NMe2<annotation encoding="application / x-tex">-CH_2C(=O)NMe_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CH(CH3)CH2NMe2<annotation encoding="application / x-tex">-CH(CH_3)CH_2NMe_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−<annotation encoding="application / x-tex">-< / annotation>< / semantics>< / com:Math> CH(CH<com:Sub>3< / com:Sub>)C(=O)NMe<com:Sub>2< / com:Sub>), tetrahydrofuran-3-yl, tetrahydropyran-4-yl, oxetan-4-yl, N-Me-2-oxo- pyrolidin-3-yl and piperidine-4-yl.
77. The compound of any one of claims 1-74, or a pharmaceutically acceptable salt thereof, wherein each R<com:Sup>10< / com:Sup> is independently selected from the group consisting of: -D,_=O, -OH, -F, -Cl, <com:Math><semantics>−Br<annotation encoding="application / x-tex">-Br< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CN<annotation encoding="application / x-tex">-CN< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−Me<annotation encoding="application / x-tex">-Me< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−Et<annotation encoding="application / x-tex">-Et< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−Pr<annotation encoding="application / x-tex">-Pr< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−iPr<annotation encoding="application / x-tex">-iPr< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−sec<annotation encoding="application / x-tex">-sec< / annotation>< / semantics>< / com:Math>-Bu, <com:Math><semantics>−iBu<annotation encoding="application / x-tex">-iBu< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OMe<annotation encoding="application / x-tex">-OMe< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OEt<annotation encoding="application / x-tex">-OEt< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CHF2<annotation encoding="application / x-tex">-CHF_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CH2CF3<annotation encoding="application / x-tex">-CH_2CF_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CF3<annotation encoding="application / x-tex">-CF_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OCF3<annotation encoding="application / x-tex">-OCF_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CF3<annotation encoding="application / x-tex">-CF_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OCF3<annotation encoding="application / x-tex">-OCF_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OCF3<annotation encoding="application / x-tex">-OCF_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OCF3<annotation encoding="application / x-tex">-OCF_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OCF3<annotation encoding="application / x-tex">-OCF_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OCF3<annotation encoding="application / x-tex">-OCF_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OCF3<annotation encoding="application / x-tex">-OCF_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OCF3<annotation encoding="application / x-tex">-OCF_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OCF3<annotation encoding="application / x-tex">-OCF_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OCF3<annotation encoding="application / x-tex">-OCF_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−<annotation encoding="application / x-tex">-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>OCHF2<annotation encoding="application / x-tex">OCHF_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CH2OH<annotation encoding="application / x-tex">-CH_2OH< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CH(OH)(CH3)<annotation encoding="application / x-tex">-CH(OH)(CH_3)< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CH2OMe<annotation encoding="application / x-tex">-CH_2OMe< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(OH)(CH3)2<annotation encoding="application / x-tex">-C(OH)(CH_3)_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CH2NH2<annotation encoding="application / x-tex">-CH_2NH_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CH(CH3)(NMe2)<annotation encoding="application / x-tex">-CH(CH_3)(NMe_2)< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CH2NH2<annotation encoding="application / x-tex">-CH_2NH_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CH2NH2<annotation encoding="application / x-tex">-CH_2NH_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CH2NH2<annotation encoding="application / x-tex">-CH_2NH_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CH2NH2<annotation encoding="application / x-tex">-CH_2NH_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CH2NH2<annotation encoding="application / x-tex">-CH_2NH_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CH2NH2<annotation encoding="application / x-tex">-CH_2NH_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CH2NH2<annotation encoding="application / x-tex">-CH_2NH_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CH2NH2<annotation encoding="application / x-tex">-CH_2NH_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CH2NH2<annotation encoding="application / x-tex">-CH_2NH_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C<annotation encoding="application / x-tex">-C< / annotation>< / semantics>< / com:Math> CH<com:Sub>2< / com:Sub>CH(CH<com:Sub>3< / com:Sub>)(NMe<com:Sub>2< / com:Sub>), -CH<com:Sub>2< / com:Sub>(CH<com:Sub>3< / com:Sub>)(<com:Sup>i< / com:Sup>Pr), -NH<com:Sub>2< / com:Sub>, -NHMe, -NHCH<com:Sub>2< / com:Sub>CF<com:Sub>3< / com:Sub>, -NMe<com:Sub>2< / com:Sub>, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, thiazol-2-yl, thiazol-5-yl, thiophen-2-yl, tetrahydrofuran-3- yl, tetrahydropyran-4-yl, oxetan-3-yl, morpholin-2-yl, –CH<com:Sub>2< / com:Sub>-morpholin-4-yl, –(CH<com:Sub>2< / com:Sub>)<com:Sub>2< / com:Sub>- morpholin-4-yl, imidazol-2-yl, 1H-pyrazol-5-yl, 1H-imidazol-4-yl, imidazo[1,2-a]pyridin-7- yl, pyrrolidin-1-yl, pyrrolidin-3-yl, piperidin-4-yl, piperidin-3-yl, piperidin-2-one-4-yl, piperazin- 4-yl, piperazin-2-on-5-yl pyridine-4-yl, pyridine-3-yl, pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, 1H-pyrazol-5-yl, azetidin-3-yl, –(CH<com:Sub>2< / com:Sub>)<com:Sub>2< / com:Sub>-pyrolidin-1-yl –(CH<com:Sub>2< / com:Sub>)<com:Sub>2< / com:Sub>-pyrolidin-2-yl – CH<com:Sub>2< / com:Sub>-imidazol-1-yl, -CH<com:Sub>2< / com:Sub>-pyrazol-1-yl, -CH<com:Sub>2< / com:Sub>-1,2,4-triazol-1-yl, -CH<com:Sub>2< / com:Sub>-cyclopropyl, - O(CH<com:Sub>2< / com:Sub>)<com:Sub>2< / com:Sub>NMe<com:Sub>2< / com:Sub>, –O-tetrahydrofuran-3-yl, –O-tetrahydropyran-4-yl, –O-(N-Me-2-oxo-pyrrolidin- 3-yl), -O-(CH<com:Sub>2< / com:Sub>)<com:Sub>2< / com:Sub>-pyrrolidin-2-yl, -O-CH<com:Sub>2< / com:Sub>-piperidin-4-yl, -O-CH<com:Sub>2< / com:Sub>-oxetan-3-yl -NCH<com:Sub>3< / com:Sub>-CH<com:Sub>2< / com:Sub>- piperidin-4-yl, –NH-oxetan-3-yl, –NH-(N-Me-2-oxo-pyrolidin-3-yl), 2-azaspiro[3.3]heptan-6- yl, 5-oxa-2,8-diazaspiro[3.5]nonan-8-yl, 8-azabicyclo[3.2.1]octan-3-yl, 2- azabicyclo[2.2.2]octan-4-yl, 3-azabicyclo[3.1.1]heptan-1-yl, 3-azabicyclo[3.1.0]hexan-6-yl, 1- azabicyclo[2.2.1]heptan-4-yl, 3-azabicyclo[3.2.0]heptan-6-yl, 2-azabicyclo[2.1.1]hexan-4- yl, 2,9-diazaspiro[5.5]undecane-9-yl, bicyclo[1.1.1]pentan-2-yl, octahydrocyclopenta[c]pyrrol-5- yl, decahydro-1,6-naphthyridin-6-yl, octahydro-1H-pyrrolo[3,4-c]pyridine-5-yl, decahydro-2,7- naphthyridin-2-yl, 2,9-diazaspiro[5.5]undecan-2-yl, -NHC(=O)Me, -NHCH<com:Sub>2< / com:Sub>C(=O)NMe<com:Sub>2< / com:Sub>, - <com:Math><semantics>NHCH(CH3)C(=O)NMe2<annotation encoding="application / x-tex">NHCH(CH_3)C(=O)NMe_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)NH2<annotation encoding="application / x-tex">-C(=O)NH_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C(=O)NHMe<annotation encoding="application / x-tex">C(=O)NHMe< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(=O)Me<annotation encoding="application / x-tex">-OC(=O)Me< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−SO2Me<annotation encoding="application / x-tex">-SO_2Me< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NHSO2Me<annotation encoding="application / x-tex">-NHSO_2Me< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−<annotation encoding="application / x-tex">-< / annotation>< / semantics>< / com:Math> SO<com:Sub>2< / com:Sub>NH<com:Sub>2< / com:Sub> and –SO<com:Sub>2< / com:Sub>NHMe, wherein each R<com:Sup>10< / com:Sup> can be independently substituted with 0, 1, 2, 3, 4 or 5 instances of –Me, –Et, – <com:Sup>i< / com:Sup>Pr, cyclopropyl, oxetan-3-yl, -OH, =O, -F, -OMe, -CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>F, -CH<com:Sub>2< / com:Sub>CHF<com:Sub>2< / com:Sub>, -CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>CF<com:Sub>3< / com:Sub>, - <com:Math><semantics>C(=O)Me,−N(Me)2,−CH2N(CH3)2,−CH2N(CH3)CH2CH3,−N(iPr)(Et),−N(iPr)(Me),−N(Et)2,−N(Et)2,−N(Et)2,−N(Et)2,−N(Et)2,−N(Et)2,−N(Et)2,−N(Et)2,−N(Et)2,−N(Et)2,−N(Et)2,−N(Et)2,−N(Et)2,−N(Et<annotation encoding="application / x-tex">C(=O)Me, -N(Me)_2, -CH_2N(CH_3)_2, -CH_2N(CH_3)CH_2CH_3, -N(^iPr)(Et), -N(^iPr)(Me), -N(Et)_2, -N(Et)_2, -N(Et)_2, -N(Et)_2, -N(Et)_2, -N(Et)_2, -N(Et)_2, -N(Et)_2, -N(Et)_2, -N(Et)_2, -N(Et)_2, -N(Et)_2, -N(Et)_2, -N(Et< / annotation>< / semantics>< / com:Math> <com:Math><semantics>N(CH3)(Et)<annotation encoding="application / x-tex">N(CH_3)(Et)< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NHC(=O)Me<annotation encoding="application / x-tex">-NHC(=O)Me< / annotation>< / semantics>< / com:Math>, or a combination thereof.
78. The compound of any one of claims 1-74, or a pharmaceutically acceptable salt thereof, wherein R<com:Sup>10< / com:Sup> is a 3-6 membered monocyclic heterocyclyl or a 6-10 membered bicyclic heterocyclyl, substituted with 0, 1, 2, 3, 4 or 5 instances of –Me, –Et, –<com:Sup>i< / com:Sup>Pr, cyclopropyl, oxetan- 3-yl, -OH, =O, -F, -OMe, -CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>F, -CH<com:Sub>2< / com:Sub>CHF<com:Sub>2< / com:Sub>, -CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>CF<com:Sub>3< / com:Sub>, -C(=O)Me, -N(Me)<com:Sub>2< / com:Sub>, - <com:Math><semantics>CH2N(CH3)2<annotation encoding="application / x-tex">CH_2N(CH_3)_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CH2N(CH3)CH2CH3<annotation encoding="application / x-tex">-CH_2N(CH_3)CH_2CH_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(iPr)(Et)<annotation encoding="application / x-tex">-N(^iPr)(Et)< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(iPr)(Me)<annotation encoding="application / x-tex">-N(^iPr)(Me)< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(Et)2<annotation encoding="application / x-tex">-N(Et)_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(CH3)(Et)<annotation encoding="application / x-tex">-N(CH_3)(Et)< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(CH3)(Et)<annotation encoding="application / x-tex">-N(CH_3)(Et)< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(Et)2<annotation encoding="application / x-tex">-N(Et)_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(Et)2<annotation encoding="application / x-tex">-N(Et)_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(Et)2<annotation encoding="application / x-tex">-N(Et)_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(Et)2<annotation encoding="application / x-tex">-N(Et)_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(Et)2<annotation encoding="application / x-tex">-N(Et)_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(Et)2<annotation encoding="application / x-tex">-N(Et)_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(Et)2<annotation encoding="application / x-tex">-N(Et)_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(Et)2<annotation encoding="application / x-tex">-N(Et)_2< / annotation>< / semantics>< / com:Math>, <Formule mathématique disponible dans le document PDF, Math available in the PDF document>$-N(Et)_$ NHC(=O)Me, or a combination thereof.
79. The compound of any one of claims 1-74, or a pharmaceutically acceptable salt thereof, wherein <com:Math><semantics>R10<annotation encoding="application / x-tex">R^{10}< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>−D<annotation encoding="application / x-tex">-D< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−Cl<annotation encoding="application / x-tex">-Cl< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−F<annotation encoding="application / x-tex">-F< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−Me<annotation encoding="application / x-tex">-Me< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CH2<annotation encoding="application / x-tex">-CH_2< / annotation>< / semantics>< / com:Math>-OH, [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] 80. The compound of any one of claims 1 to 79, or a pharmaceutically acceptable salt thereof, wherein each R<com:Sup>7< / com:Sup> is independently selected from H, halo, -CN, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, 5- membered heteroaryl, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> haloalkyl, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> hydroxyalkyl, -C<com:Sub>3< / com:Sub>-C<com:Sub>9< / com:Sub> cycloalkyl, -OR<com:Sup>a7< / com:Sup>, - <com:Math><semantics>N(Ra7)2<annotation encoding="application / x-tex">N(R^{a7})_2< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>−C(=O)N(Ra7)2<annotation encoding="application / x-tex">-C(=O)N(R^{a7})_2< / annotation>< / semantics>< / com:Math>.
81. The compound of any one of claims 1 to 80, or a pharmaceutically acceptable salt thereof, wherein each R<com:Sup>a7< / com:Sup> is independently selected from H and -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl.
82. The compound of any one of claims 1 to 79, or a pharmaceutically acceptable salt thereof, wherein each R<com:Sup>7< / com:Sup> is independently selected from H and methyl.
83. The compound of any one of claims 1 to 79, or a pharmaceutically acceptable salt thereof, wherein each R<com:Sup>7< / com:Sup> is H.
84. The compound of any one of claims 1 to 79, or a pharmaceutically acceptable salt thereof, wherein each R<com:Sup>7< / com:Sup> is methyl.
85. The compound of any one of claims 1 to 84, or a pharmaceutically acceptable salt thereof, wherein each R<com:Sup>8< / com:Sup> is independently selected from H, –D, halo, –CN, –C<com:Sub>1< / com:Sub>–C<com:Sub>6< / com:Sub> alkyl, –C<com:Sub>1< / com:Sub>–C<com:Sub>6< / com:Sub> haloalkoxy, arylalkyl, <com:Math><semantics>−C(=O)Ra8<annotation encoding="application / x-tex">-C(=O)R^{a8}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(Ra8)2<annotation encoding="application / x-tex">-N(R^{a8})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRa8C(=O)Ra8<annotation encoding="application / x-tex">-NR^{a8}C(=O)R^{a8}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CH2C(=O)N(Ra8)2<annotation encoding="application / x-tex">-CH_2C(=O)N(R^{a8})_2< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>−ORa8<annotation encoding="application / x-tex">-OR^{a8}< / annotation>< / semantics>< / com:Math>.
86. The compound of any one of claims 1 to 85, or a pharmaceutically acceptable salt thereof, wherein each R<com:Sup>a8< / com:Sup> is independently selected from H, –CF<com:Sub>3< / com:Sub> and –C<com:Sub>1< / com:Sub>–C<com:Sub>6< / com:Sub> alkyl.
87. The compound of any one of claims 1 to 84, or a pharmaceutically acceptable salt thereof, wherein each R<com:Sup>8< / com:Sup> is independently selected from H, –D, –F, –Me,–Et, –sec-Bu, –CN, – OMe, <com:Math><semantics>−Oi<annotation encoding="application / x-tex">-O^i< / annotation>< / semantics>< / com:Math>Pr, <com:Math><semantics>−OCF3<annotation encoding="application / x-tex">-OCF_3< / annotation>< / semantics>< / com:Math>, benzyl, <com:Math><semantics>−NHC(=O)Me<annotation encoding="application / x-tex">-NHC(=O)Me< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NMe2<annotation encoding="application / x-tex">-NMe_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CH2C(=O)NH2<annotation encoding="application / x-tex">-CH_2C(=O)NH_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)i<annotation encoding="application / x-tex">-C(=O)^i< / annotation>< / semantics>< / com:Math>Pr and <com:Math><semantics>−OH<annotation encoding="application / x-tex">-OH< / annotation>< / semantics>< / com:Math>.
88. The compound of any one of claims 1 to 84, or a pharmaceutically acceptable salt thereof, wherein each R<com:Sup>8< / com:Sup> is independently selected from H, –D, –F, –Me, –Et and –CN.
89. The compound of any one of claims 1 to 84, or a pharmaceutically acceptable salt thereof, wherein each R<com:Sup>8< / com:Sup> is independently selected from H, –D, –F and –Me.
90. The compound of any one of claims 1 to 89, or a pharmaceutically acceptable salt thereof, wherein n is 0.
91. The compound of any one of claims 1 to 89, or a pharmaceutically acceptable salt thereof, wherein n is 1.
92. The compound of any one of claims 1 to 89, or a pharmaceutically acceptable salt thereof, wherein n is 2.
93. The compound of any one of claims 1 to 89, or a pharmaceutically acceptable salt thereof, wherein n is 3.
94. The compound of any one of claims 1, 12 to 89 and 92 to 93, or a pharmaceutically [Image disponible dans le document PDF, Image available in the PDF document] acceptable salt thereof, wherein the moiety represented as <com:Math><semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>< / com:Math> is selected from: [Image disponible dans le document PDF, Image available in the PDF document] rein the [Image disponible dans le document PDF, Image available in the PDF document] 96. The compound of claim 94 or 95, or a pharmaceutically acceptable salt thereof, wherein n is 2.
97. The compound of claim 94 or 95, or a pharmaceutically acceptable salt thereof, wherein each R<com:Sup>6< / com:Sup> and R<com:Sup>7< / com:Sup> is independently selected from H and –CH<com:Sub>3< / com:Sub>.
98. The compound of claim 94 or 95, or a pharmaceutically acceptable salt thereof, wherein <com:Math><semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>< / com:Math> is H.
99. The compound of claim 94 or 95, or a pharmaceutically acceptable salt thereof, wherein <com:Math><semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>< / com:Math> is –CH<com:Sub>3< / com:Sub>.
100. The compound of claim 94 or 95, or a pharmaceutically acceptable salt thereof, wherein R<com:Sup>7< / com:Sup> is H.
101. The compound of claim 94 or 95, or a pharmaceutically acceptable salt thereof, wherein <com:Math><semantics>R7<annotation encoding="application / x-tex">R^7< / annotation>< / semantics>< / com:Math> is –CH<com:Sub>3< / com:Sub>.
102. The compound of any one of claims 1 to 101, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] Ξ , [Image disponible dans le document PDF, Image available in the PDF document] _ - , [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] = . [Image disponible dans le document PDF, Image available in the PDF document] _ , 1 [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] _ , [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] <com:Math><semantics>O↘NH2<annotation encoding="application / x-tex">O_{\searrow}NH_2< / annotation>< / semantics>< / com:Math> [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] _ , [Image disponible dans le document PDF, Image available in the PDF document] _ [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] _ [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] 1 [Image disponible dans le document PDF, Image available in the PDF document] _ ı [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] 1 [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] _ [Image disponible dans le document PDF, Image available in the PDF document] 1 [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] - , [Image disponible dans le document PDF, Image available in the PDF document] 1 [Image disponible dans le document PDF, Image available in the PDF document] _ [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] • , [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] l . [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] - 0 [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] 103. A compound of Formula (I), or a pharmaceutically acceptable salt thereof; wherein: [Image disponible dans le document PDF, Image available in the PDF document] each R<com:Sup>1< / com:Sup> is independently selected from the group consisting of H, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, -OR<com:Sup>a1< / com:Sup> and - <com:Math><semantics>N(Ra1)2;<annotation encoding="application / x-tex">N(R^{a1})_2;< / annotation>< / semantics>< / com:Math> each R<com:Sup>a1< / com:Sup> is independently selected from the group consisting of H, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl and -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> haloalkyl; each R<com:Sup>2< / com:Sup> is independently selected from the group consisting of halo, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, - <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>–<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> haloalkyl, <com:Math><semantics>−C3<annotation encoding="application / x-tex">-C_3< / annotation>< / semantics>< / com:Math>–<com:Math><semantics>C9<annotation encoding="application / x-tex">C_9< / annotation>< / semantics>< / com:Math> cycloalkyl, 3-10 membered heterocyclyl, <com:Math><semantics>−ORa2<annotation encoding="application / x-tex">-OR^{a2}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>−C(=O)N(Ra2)2<annotation encoding="application / x-tex">-C(=O)N(R^{a2})_2< / annotation>< / semantics>< / com:Math>; each R<com:Sup>a2< / com:Sup> is independently selected from the group consisting of H and -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; each R<com:Sup>3< / com:Sup> is H; each R<com:Sup>4< / com:Sup> is H; [Image disponible dans le document PDF, Image available in the PDF document] , which is unsubstituted or substituted with 1 instance of <com:Math><semantics>R10<annotation encoding="application / x-tex">R^{10}< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>R7<annotation encoding="application / x-tex">R^7< / annotation>< / semantics>< / com:Math> is selected from the group consisting of <com:Math><semantics>−H<annotation encoding="application / x-tex">-H< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>−CH3<annotation encoding="application / x-tex">-CH_3< / annotation>< / semantics>< / com:Math>; each R<com:Sup>8< / com:Sup> is independently selected from the group consisting of halo, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl and - OR<com:Sup>a8< / com:Sup>; each R<com:Sup>a8< / com:Sup> is independently selected from the group consisting of H, -CF<com:Sub>3< / com:Sub> and -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; each <com:Math><semantics>R10<annotation encoding="application / x-tex">R^{10}< / annotation>< / semantics>< / com:Math> is independently selected from the group consisting of <com:Math><semantics>−D<annotation encoding="application / x-tex">-D< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C1−C6<annotation encoding="application / x-tex">-C_1-C_6< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>−C1−C6<annotation encoding="application / x-tex">-C_1-C_6< / annotation>< / semantics>< / com:Math> C<com:Sub>6< / com:Sub> heteroalkyl, -C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> haloalkyl, -C<com:Sub>3< / com:Sub>-C<com:Sub>9< / com:Sub> cycloalkyl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl, heterocyclylalkyl, and <com:Math><semantics>−N(Rb10)2<annotation encoding="application / x-tex">-N(R^{b10})_2< / annotation>< / semantics>< / com:Math>, wherein each alkyl, cycloalkyl, heteroalkyl, heterocyclyl, heteroaryl and heterocyclylalkyl of R<com:Sup>10< / com:Sup> is substituted with 0, 1, 2, 3, 4, or 5 instances of –Me, –Et, –<com:Sup>i< / com:Sup>Pr, cyclopropyl, oxetan-3-yl, –OH, =O, –F, –OMe, –CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>F, – <com:Math><semantics>CH2CHF2<annotation encoding="application / x-tex">CH_2CHF_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CH2CH2CF3<annotation encoding="application / x-tex">-CH_2CH_2CF_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)Me<annotation encoding="application / x-tex">-C(=O)Me< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(Me)2<annotation encoding="application / x-tex">-N(Me)_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CH2N(CH3)2<annotation encoding="application / x-tex">-CH_2N(CH_3)_2< / annotation>< / semantics>< / com:Math> or a combination thereof; each R<com:Sup>b10< / com:Sup> is independently selected from the group consisting of H and –C<com:Sub>1< / com:Sub>–C<com:Sub>6< / com:Sub> alkyl; and n is 0, 1 or 2; provided that: (vi) when <com:Math><semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics>< / com:Math> is H, <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is not halo, <com:Math><semantics>−OPr<annotation encoding="application / x-tex">-OPr< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(CH3)2<annotation encoding="application / x-tex">-N(CH_3)_2< / annotation>< / semantics>< / com:Math> or <com:Math><semantics>−CF3<annotation encoding="application / x-tex">-CF_3< / annotation>< / semantics>< / com:Math>; (vii) when <com:Math><semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>ORa1<annotation encoding="application / x-tex">OR^{a1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is not <com:Math><semantics>−ORa2<annotation encoding="application / x-tex">-OR^{a2}< / annotation>< / semantics>< / com:Math>.
104. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein R<com:Sup>1< / com:Sup> is selected from H, –Me, –OMe, –OCF<com:Sub>3< / com:Sub> and –NH<com:Sub>2< / com:Sub>.
105. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein R<com:Sup>2< / com:Sup> is selected from –Cl, –Me, –Et, –CF<com:Sub>3< / com:Sub>, –CHF<com:Sub>2< / com:Sub>, cyclopropyl, oxetan-3-yl, tetrahydrofuran-3-yl, – OMe and <com:Math><semantics>−C(=O)NH2<annotation encoding="application / x-tex">-C(=O)NH_2< / annotation>< / semantics>< / com:Math>.
106. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of: [Image disponible dans le document PDF, Image available in the PDF document] 107. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of: [Image disponible dans le document PDF, Image available in the PDF document] <com:Math><semantics>a¯<annotation encoding="application / x-tex">\overline{\phantom{a}}< / annotation>< / semantics>< / com:Math> , [Image disponible dans le document PDF, Image available in the PDF document] 108. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of: [Image disponible dans le document PDF, Image available in the PDF document] ) 109. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of: [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] 110. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of: [Image disponible dans le document PDF, Image available in the PDF document] • 111. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of: [Image disponible dans le document PDF, Image available in the PDF document] , , [Image disponible dans le document PDF, Image available in the PDF document] • , [Image disponible dans le document PDF, Image available in the PDF document] • 112. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of: [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] T. 0 [Image disponible dans le document PDF, Image available in the PDF document] - 113. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of: [Image disponible dans le document PDF, Image available in the PDF document] / [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] • 114. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of: [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] <com:Math><semantics>a¯<annotation encoding="application / x-tex">\overline{\phantom{a}}< / annotation>< / semantics>< / com:Math> 1 1 [Image disponible dans le document PDF, Image available in the PDF document] 115. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of: [Image disponible dans le document PDF, Image available in the PDF document] - 116. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of: [Image disponible dans le document PDF, Image available in the PDF document] - 117. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of: [Image disponible dans le document PDF, Image available in the PDF document] 118. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the compound is [Image disponible dans le document PDF, Image available in the PDF document] 119. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 120. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 121. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is • 122. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 123. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 124. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 125. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 126. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 127. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 128. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 129. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is • 130. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 131. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is .
132. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is • 133. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is • 134. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 135. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 136. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is • 137. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 138. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 139. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 140. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is .
141. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 142. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 1 143. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is , 144. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 145. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is , 146. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is ٠ 147. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is • 148. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is .
149. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 150. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 151. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 152. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is • 153. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 154. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 155. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 156. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 157. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 158. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 159. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 160. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 161. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 162. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is • 163. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 164. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 165. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is • 166. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 167. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 168. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 169. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 170. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 171. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 172. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 173. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 174. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 175. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 176. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 177. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 178. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 179. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 180. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 181. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 182. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 183. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 184. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is , 185. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is ٠ 186. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 187. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is , 188. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 189. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 190. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 191. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 192. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 193. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 194. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 195. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is .
196. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is • 197. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 198. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 199. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 200. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 201. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 202. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 203. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 204. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 205. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 206. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is .
207. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is , 208. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 209. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 210. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 211. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 212. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is , 213. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is • 214. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is .
215. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 216. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is .
217. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 218. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 219. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 220. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 221. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 222. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 223. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 224. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is , 225. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 226. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 227. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 228. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is .
229. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is , 230. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is .
231. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 232. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 233. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 234. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 235. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 236. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 237. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is .
238. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 239. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 240. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 241. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is .
242. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 243. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 244. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 245. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 246. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 247. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 248. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is , 249. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is , 250. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 251. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 252. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 253. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 254. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 255. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 256. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is - 257. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 258. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 259. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 260. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 261. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 262. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 263. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 264. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 265. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 266. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 267. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 268. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 269. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 270. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 271. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is .
272. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 273. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 274. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 275. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 276. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 277. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 278. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is • 279. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 280. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 281. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 282. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 283. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 284. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 285. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is .
286. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 287. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 288. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 289. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is • 290. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 1 291. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 292. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 293. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is • 294. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 295. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 296. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 297. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 298. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 299. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 300. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is , 301. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 302. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 303. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 304. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is • 305. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 306. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 307. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 308. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 309. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 310. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is ٠ 311. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 312. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 313. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 314. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 315. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 316. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 317. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] · _ compound is 318. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 319. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is .
320. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 321. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 322. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 323. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 324. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 325. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 326. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 327. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 328. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is .
329. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 330. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 331. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 332. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 333. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 334. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 335. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 336. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 337. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 338. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is 339. The compound of claim 103, or a pharmaceutically acceptable salt thereof, wherein the [Image disponible dans le document PDF, Image available in the PDF document] compound is [Image disponible dans le document PDF, Image available in the PDF document] 340. The compound of claim 103, wherein the compound is [Image disponible dans le document PDF, Image available in the PDF document] 341. The compound of claim 103, wherein the compound is • 342. A pharmaceutical composition comprising a compound of any one of claims 1 to 341, or a pharmaceutically acceptable salt thereof, as a first therapeutic agent and a pharmaceutically acceptable carrier.
343. The pharmaceutical composition of claim 342, further comprising a second therapeutic agent.
344. Use of a compound of any one of claims 1 to 341 or a pharmaceutically acceptable salt thereof, as a first therapeutic agent, or a pharmaceutical composition of claim 342 for treating an MTAP-deficient and / or an MTA-accumulating disease in a subject in need thereof.
345. The use of claim 344, wherein the compound or composition is administered in combination with a second therapeutic agent.
346. Use of a pharmaceutical composition of claim 343 for treating an MTAP-deficient and / or an MTA-accumulating disease in a subject in need thereof.
347. The use of any one of claims 344 to 346, wherein the disease is a proliferating disease.
348. The use of claim 347, wherein the disease is an MTAP-deficient and / or MTA- accumulating cancer.
349. The use of claim 348, wherein the cancer is glioblastoma, malignant peripheral nerve sheath tumors (MPNST), esophageal cancer, bladder cancer, pancreatic cancer, mesothelioma, melanoma, non-small cell lung cancer, astrocytoma, undifferentiated pleiomorphic sarcoma, diffuse large B-cell lymphoma (DLBCL), leukemia, head and neck cancer, stomach adenocarcinoma, myxofibrosarcoma, cholangiosarcoma, cancer of the brain, stomach cancer, kidney cancer, breast cancer, endometrium cancer, urinary tract cancer, liver cancer, soft tissue cancer, pleura cancer, large intestine cancer or sarcoma.
350. The use of claim 348, wherein the cancer is glioblastoma, malignant peripheral nerve sheath tumors (MPNST), esophageal squamous cell carcinoma, esophageal adenocarcinoma, bladder urothelial carcinoma, pancreatic adenocarcinoma, mesothelioma, melanoma, lung squamous cancer, lung adenocarcinoma, astrocytoma, undifferentiated pleiomorphic sarcoma, diffuse large B-cell lymphoma (DLBCL), leukemia, head and neck cancer, stomach adenocarcinoma, myxofibrosarcoma, cholangiosarcoma, cancer of the brain, stomach cancer, kidney cancer, breast cancer, endometrium cancer, urinary tract cancer, liver cancer, soft tissue cancer, pleura cancer, large intestine cancer or sarcoma.
351. A compound of any one of claims 1 to 341 for use in treating a cancer in a subject in need thereof, wherein the level of MTAP and / or MTA in a test sample obtained from said subject has been assessed, wherein the MTA level has been assessed directly or indirectly; and wherein the test sample has been compared with a reference, wherein MTAP deficiency and / or MTA accumulation in said test sample compared to the reference indicates the cancer in said subject will respond to the rapeutic treatment with a PRMT5 inhibitor.
352. A pharmaceutical composition of claim 342 for use in treating an MTAP-deficient and / or an MTA-accumulating disease in a subject in need thereof.
353. The pharmaceutical composition for use of claim 352, wherein the composition is configured to be administered in combination with a second therapeutic agent.
354. A pharmaceutical composition of claim 343 for use in treating an MTAP-deficient and / or an MTA-accumulating disease in a subject in need thereof.
355. The pharmaceutical composition for use of any one of claims 352 to 354, wherein the disease is a proliferating disease.
356. The pharmaceutical composition for use of claim 355, wherein the disease is an MTAP- deficient and / or MTA-accumulating cancer.
357. The pharmaceutical composition for use of claim 356, wherein the cancer is glioblastoma, malignant peripheral nerve sheath tumors (MPNST), esophageal cancer, bladder cancer, pancreatic cancer, mesothelioma, melanoma, non-small cell lung cancer, astrocytoma, undifferentiated pleiomorphic sarcoma, diffuse large B-cell lymphoma (DLBCL), leukemia, head and neck cancer, stomach adenocarcinoma, myxofibrosarcoma, cholangiosarcoma, cancer of the brain, stomach cancer, kidney cancer, breast cancer, endometrium cancer, urinary tract cancer, liver cancer, soft tissue cancer, pleura cancer, large intestine cancer or sarcoma.
358. A pharmaceutical composition of claim 342 or 343 for use in treating a cancer in a subject in need thereof, wherein the level of MTAP and / or MTA in a test sample obtained from said subject has been assessed, wherein the MTA level has been assessed directly or indirectly; and wherein the test sample has been compared with a reference, wherein MTAP deficiency and / or MTA accumulation in said test sample compared to the reference indicates the cancer in said subject will respond to the rapeutic treatment with a PRMT5 inhibitor.
359. A compound of any one of claims 1 to 341, or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for treating an MTAP-deficient and / or an MTA- accumulating disease in a subject in need thereof.
360. The compound for use of claim 359, wherein the medicament is configured to be administered in combination with a second therapeutic agent.
361. The compound for use of claim 359 or 360, wherein the disease is a proliferating disease.
362. The compound for use of claim 361, wherein the disease is an MTAP-deficient and / or MTA-accumulating cancer.
363. The compound for use of claim 362, wherein the cancer is glioblastoma, malignant peripheral nerve sheath tumors (MPNST), esophageal cancer, bladder cancer, pancreatic cancer, mesothelioma, melanoma, non-small cell lung cancer, astrocytoma, undifferentiated pleiomorphic sarcoma, diffuse large B-cell lymphoma (DLBCL), leukemia, head and neck cancer, stomach adenocarcinoma, myxofibrosarcoma, cholangiosarcoma, cancer of the brain, stomach cancer, kidney cancer, breast cancer, endometrium cancer, urinary tract cancer, liver cancer, soft tissue cancer, pleura cancer, large intestine cancer or sarcoma.
364. The compound for use of claim 362, wherein the cancer is glioblastoma, malignant peripheral nerve sheath tumors (MPNST), esophageal squamous cell carcinoma, esophageal adenocarcinoma, bladder urothelial carcinoma, pancreatic adenocarcinoma, mesothelioma, melanoma, lung squamous cancer, lung adenocarcinoma, astrocytoma, undifferentiated pleiomorphic sarcoma, diffuse large B-cell lymphoma (DLBCL), leukemia, head and neck cancer, stomach adenocarcinoma, myxofibrosarcoma, cholangiosarcoma, cancer of the brain, stomach cancer, kidney cancer, breast cancer, endometrium cancer, urinary tract cancer, liver cancer, soft tissue cancer, pleura cancer, large intestine cancer or sarcoma.
365. A pharmaceutical composition of claim 342 for use in the preparation of a medicament for treating an MTAP-deficient and / or an MTA-accumulating disease in a subject in need thereof.
366. The pharmaceutical composition for use of claim 365, wherein the composition is configured to be administered in combination with a second therapeutic agent.
367. A pharmaceutical composition of claim 343 for use in treating an MTAP-deficient and / or an MTA-accumulating disease in a subject in need thereof.
368. The pharmaceutical composition for use of any one of claims 365 to 367, wherein the disease is a proliferating disease.
369. The pharmaceutical composition for use of claim 368, wherein the disease is an MTAP- deficient and / or MTA-accumulating cancer.
370. The pharmaceutical composition for use of claim 369, wherein the cancer is glioblastoma, malignant peripheral nerve sheath tumors (MPNST), esophageal cancer, bladder cancer, pancreatic cancer, mesothelioma, melanoma, non-small cell lung cancer, astrocytoma, undifferentiated pleiomorphic sarcoma, diffuse large B-cell lymphoma (DLBCL), leukemia, head and neck cancer, stomach adenocarcinoma, myxofibrosarcoma, cholangiosarcoma, cancer of the brain, stomach cancer, kidney cancer, breast cancer, endometrium cancer, urinary tract cancer, liver cancer, soft tissue cancer, pleura cancer, large intestine cancer or sarcoma.
371. The pharmaceutical composition for use of claim 369 wherein the cancer is glioblastoma, malignant peripheral nerve sheath tumors (MPNST), esophageal squamous cell carcinoma, esophageal adenocarcinoma, bladder urothelial carcinoma, pancreatic adenocarcinoma, mesothelioma, melanoma, lung squamous cancer, lung adenocarcinoma, astrocytoma, undifferentiated pleiomorphic sarcoma, diffuse large B-cell lymphoma (DLBCL), leukemia, head and neck cancer, stomach adenocarcinoma, myxofibrosarcoma, cholangiosarcoma, cancer of the brain, stomach cancer, kidney cancer, breast cancer, endometrium cancer, urinary tract cancer, liver cancer, soft tissue cancer, pleura cancer, large intestine cancer or sarcoma.
372. A process for preparing a compound of formula (Ia) of any one of claims 5 and 9 to 341 [Image disponible dans le document PDF, Image available in the PDF document] (Ia) comprising a reaction between a compound of formula I-6 [Image disponible dans le document PDF, Image available in the PDF document] under amide bond coupling conditions to provide a compound of formula (I) [Image disponible dans le document PDF, Image available in the PDF document] wherein R<com:Sup>2a< / com:Sup> is R<com:Sup>2< / com:Sup> or NH-PG and R<com:Sup>1a< / com:Sup> is R<com:Sup>1< / com:Sup> or NH-PG, wherein PG is a nitrogen protecting group; and optionally further comprising (a) a chiral separation step, if the compound of formula (I) is a mixture of stereoisomers; and / or (b) a deprotection reaction to remove the nitrogen protective group, if R<com:Sup>2a< / com:Sup> or R<com:Sup>1a< / com:Sup> are NH- PG; wherein the chiral separation step can take place before, after, or in the absence of the deprotection reaction, and wherein the chiral separation step is not present if the compound of [Image disponible dans le document PDF, Image available in the PDF document] Formula I-6 is of formula I-6a (I-6a) and the amide bond coupling results in a compound of formula [Image disponible dans le document PDF, Image available in the PDF document] wherein: the reaction takes place at a temperature of 0 °C to room temperature; the reaction takes place in a solvent; the amide bond coupling conditions comprise a coupling agent and a base.
373. The process of claim 372, wherein the coupling agent is selected from the group consisting of CDI, HATU, HOBT, HBTU and PyBOP.
374. The process of claim 372, wherein the base is selected from a hydride base, an amine base, and a carbonate base.
375. The process of claim 372, wherein the base is selected from NaH, DBU, NEt<com:Sub>3< / com:Sub>, NEt(<com:Sup>i< / com:Sup>Pr)<com:Sub>2< / com:Sub>, Na<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub>, K<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub>, and Cs<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub>.
376. The process of claim 372, wherein the solvent is dimethylformamide (DMF) or methyl tert-butyl ether (MTBE).
377. The process of any one of claims 372 to 376, wherein the reaction takes place at a temperature of 70°C to 110°C.
378. A process for preparing a compound of formula (Ia) of any one of claims 8 to 341 [Image disponible dans le document PDF, Image available in the PDF document] (Ia) comprising a reaction between a compound of formula I-6 [Image disponible dans le document PDF, Image available in the PDF document] under amide bond coupling conditions to provide a compound of formula (I) [Image disponible dans le document PDF, Image available in the PDF document] ; wherein R<com:Sup>2a< / com:Sup> is R<com:Sup>2< / com:Sup> or NH-PG and R<com:Sup>1a< / com:Sup> is R<com:Sup>1< / com:Sup> or NH-PG, wherein PG is a nitrogen protecting group; and optionally further comprising (a) a chiral separation step, if the compound of formula (I) is a mixture of stereoisomers; and / or (b) a deprotection reaction to remove the nitrogen protective group, if R<com:Sup>2a< / com:Sup> or R<com:Sup>1a< / com:Sup> are NH- PG; wherein the chiral separation step can take place before, after, or in the absence of the deprotection reaction and wherein the chiral separation step is not present if the compound of [Image disponible dans le document PDF, Image available in the PDF document] Formula I-6 is of formula I-6a (I-6a) and the amide bond coupling results in a compound of formula [Image disponible dans le document PDF, Image available in the PDF document] wherein: the reaction takes place at a temperature of 0 °C to room temperature; the reaction takes place in an aprotic solvent; the amide bond coupling conditions comprise a base.
379. The process of claim 378, wherein the base is selected from an organolithium base, a hydride base, an amine base and a carbonate base.
380. The process of claim 378, wherein the base is selected from n-BuLi, t-BuLi, lithium diisopropylamide (LDA), lithium bis(trimethylsilyl)amide (LiHMDS), NaH, DBU, NEt<com:Sub>3< / com:Sub>, NEt(<com:Sup>i< / com:Sup>Pr)<com:Sub>2< / com:Sub>, Na<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub>, K<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub> and Cs<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub>.
381. The process of claim 378, wherein the base is an organolithium base.
382. The process of claim 381, wherein the organolithium base is selected from n-BuLi, t- BuLi, lithium diisopropylamide (LDA) and lithium bis(trimethylsilyl)amide (LiHMDS).
383. The process of claim 382, wherein the solvent is selected from tetrahydrofuran (THF), diethyl ether (Et<com:Sub>2< / com:Sub>O), tetramethylethylenediamine (TMEDA), dimethoxyethane (DME) and methyl tert-butyl ether (MTBE).
384. The process of any one of claims 378 to 383, wherein the reaction takes place at a temperature of 70°C to 110°C.
385. The process of any one of claims 372 to 384, wherein the compound of formula (I-6) is prepared through a reduction reaction from a compound of formula (I-3) [Image disponible dans le document PDF, Image available in the PDF document] (I-3) in the presence of a reducing agent.
386. The process of claim 385, wherein the reducing agent is a hydride reducing agent, a silicon reducing agent or H<com:Sub>2< / com:Sub> in the presence of a catalyst.
387. The process of claim 385, wherein the reducing agent is selected from NaBH<com:Sub>4< / com:Sub>, LiAlH<com:Sub>4< / com:Sub>, Cl<com:Sub>3< / com:Sub>SiH and hydrogen in the presence of an iridium (Ir) catalyst, a ruthenium (Ru) catalyst or a palladium (Pd) catalyst.
388. The process of claim 385, wherein the reducing agent is hydrogen in the presence of a Pd catalyst selected from palladium on carbon (Pd / C) and palladium acetate (Pd(OAc)<com:Sub>2< / com:Sub>).
389. The process of any one of claims 385 to 388, wherein the compound of formula (I-3) is prepared through a deprotection / double bond migration reaction from a compound of formula (I- 2) [Image disponible dans le document PDF, Image available in the PDF document] (I-2) in the presence of an acid in a solvent.
390. The process of claim 389, wherein the acid is selected from trifluoroacetic acid (TFA) and hydrochloric acid (HCl).
391. The process of claim 389 or 390, wherein the compound of formula (I-2) is prepared through a cross coupling reaction between a compound of formula (I-1) and a coupling partner: [Image disponible dans le document PDF, Image available in the PDF document] <com:Math><semantics>(I−1)<annotation encoding="application / x-tex">(I-1)< / annotation>< / semantics>< / com:Math>, wherein <com:Math><semantics>X1<annotation encoding="application / x-tex">X^1< / annotation>< / semantics>< / com:Math> is a leaving group, wherein: the coupling partner is R<com:Sup>6< / com:Sup>B(OH)<com:Sub>2< / com:Sub>, or R<com:Sup>6< / com:Sup>Bpin; the cross coupling reaction employs a base and a palladium catalyst and takes place in a solvent.
392. The process of claim 391, wherein <com:Math><semantics>X1<annotation encoding="application / x-tex">X^1< / annotation>< / semantics>< / com:Math> is halogen or -OSO<com:Sub>2< / com:Sub>CF<com:Sub>3< / com:Sub>.
393. The process of claim 391 or 392, wherein the base is Na<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub>.
394. The process of any one of claims 391 to 393, wherein the palladium catalyst is Pd(dppf)Cl<com:Sub>2< / com:Sub> DCM).
395. The process of any one of claims 391 to 394, wherein the solvent is selected from water and dioxane.
